[{"text": "The T790M mutation results in alteration of the topology of the ATP binding pocket not only interrupting the physicochemical binding of gefitinib/erlotinib , but also leading to much increased affinity of the EGFR protein to ATP resulting in resistance to EGFR-TKIs .", "entity_list": [{"name": "gefitinib/erlotinib", "ent_type": "drug", "char_span": [136, 155], "tok_span": [25, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [136, 155], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [25, 34]}], "umls_entity_list": []}, {"text": "H1975 cells , which also contain a second mutation ( T790M ) linked to gefitinib resistance , responded poorly to either agent .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [53, 58], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [53, 58], "obj_char_span": [71, 80], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "In particular , H1975 cells contain a second mutation ( T790M ) reported to be linked to gefitinib resistance , but we found that these cells also responded poorly to cetuximab .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [89, 98], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [56, 61], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [56, 61], "obj_char_span": [89, 98], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "In this study , we used a group of cancer cell lines with either overexpressed or tyrosine kinase domain mutated ( ΔE746-A750 or L858R ) EGFR to assess their responsiveness to cetuximab and gefitinib treatment and to evaluate HIF-1α as novel molecular marker for the therapeutic responses of the cancer cells to EGFR targeted therapy .", "entity_list": [{"name": "and gefitinib", "ent_type": "drug", "char_span": [186, 199], "tok_span": [45, 50]}, {"name": "or L858R", "ent_type": "variant", "char_span": [126, 134], "tok_span": [29, 34]}], "relation_list": [{"subject": "or L858R", "object": "and gefitinib", "sbj_char_span": [126, 134], "obj_char_span": [186, 199], "rel_type": "sensitivity", "sbj_tok_span": [29, 34], "obj_tok_span": [45, 50]}], "umls_entity_list": []}, {"text": "Therefore , in this study we explored the retained antitumor activity of gefitinib in resistant HCC827-GR5 and NCI-H1975 NSCLC cells , carrying MET amplification and T790M mutation , respectively .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [73, 82], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [166, 171], "tok_span": [38, 42]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [166, 171], "obj_char_span": [73, 82], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 42], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Of note , the continuous exposure of H1975 cells , carrying the T790M mutation , to gefitinib did not modify their migratory phenotype , possibly because of the low affinity of the mutated receptor for this drug .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [64, 69], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [64, 69], "obj_char_span": [84, 93], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "The most commonly identified mechanism of resistance is an EGFR mutation at position 790 ( T790M ) , resulting in substitution of a threonine residue with methionine , which abrogates the ability of gefitinib or erlotinib to inhibit EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [199, 208], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [91, 96], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [91, 96], "obj_char_span": [199, 208], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "Exon 19 deletions and L858R mutations have shown similar in vitro sensitivity to gefitinib ; however , erlotinib and gefitinib have shown different clinical efficacy depending on whether exon 19 deletions and L858R mutations are present .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [81, 90], "tok_span": [17, 21]}, {"name": "L858R", "ent_type": "variant", "char_span": [22, 27], "tok_span": [5, 9]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [117, 126], "tok_span": [29, 33]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [103, 112], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [22, 27], "obj_char_span": [81, 90], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [17, 21]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [22, 27], "obj_char_span": [117, 126], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [29, 33]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [22, 27], "obj_char_span": [103, 112], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "The G719S mutation renders the tumor less sensitive to gefitinib , while erlotinib and the second-generation TKI afatinib have proven to be effective in tumors characterized by this substitution . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [55, 64], "tok_span": [12, 16]}, {"name": "G719S", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "G719S", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [55, 64], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "This has been reported by several prospective trials of gefitinib and erlotinib in EGFR mutated NSCLC , which showed RRs exceeding 70 % in tumors with exon 19 deletions or the L858R mutation , with PFS intervals of 6-14 months and OS times beyond 20-24 months- .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [56, 65], "tok_span": [9, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [176, 181], "tok_span": [38, 42]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [176, 181], "obj_char_span": [56, 65], "rel_type": "sensitivity", "sbj_tok_span": [38, 42], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "An experiment using cell lines transfected concurrently with activating mutations and a T790M mutation also proved that resistance to gefitinib and erlotinib is evident when this mutation is present .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [88, 93], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [88, 93], "obj_char_span": [134, 143], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Inukai et al. hypothesized that gefitinib treatment may lead to the selection of T790M mutant cells and that even a small fraction of T790M positive tumor cells at the beginning of treatment could lead to clinical gefitinib resistance because of selective proliferation of T790M mutant cells .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [32, 41], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [81, 86], "tok_span": [19, 23]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [214, 223], "tok_span": [48, 52]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [81, 86], "obj_char_span": [32, 41], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [8, 12]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [81, 86], "obj_char_span": [214, 223], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "Although rare , T790M mutations exist as major clones irrespective of gefitinib administration in certain patients .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [70, 79], "tok_span": [14, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [16, 21], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [16, 21], "obj_char_span": [70, 79], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Ercan et al. established a resistant cell line for an irreversible EGFR-TKI by subjecting a reversible EGFR-TKI resistant cell line with a T790M mutation ( established by long-term exposure of exon 19 deletion mutant PC9 cells to gefitinib ) to long-term exposure to PF-00299804 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [230, 239], "tok_span": [52, 56]}, {"name": "T790M", "ent_type": "variant", "char_span": [139, 144], "tok_span": [31, 35]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [139, 144], "obj_char_span": [230, 239], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 35], "obj_tok_span": [52, 56]}], "umls_entity_list": []}, {"text": "In the gefitinib-resistant cell line , clones with amplified T790M mutant alleles existed in small quantities .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [7, 26], "tok_span": [2, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [61, 66], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [61, 66], "obj_char_span": [7, 26], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [2, 8]}], "umls_entity_list": []}, {"text": "Acquired resistance mechanism 1 ) Secondary T790M mutation of the EGFR gene Unfortunately , many of those patients who originally had responded eventually become insensitive to gefitinib or erlotinib therapy through acquired resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [44, 49], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [44, 49], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Interestingly , it was discovered that the T790M mutation does not confer resistance to gefitinib and erlotinib by preventing their binding as originally thought .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [88, 97], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [43, 48], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [43, 48], "obj_char_span": [88, 97], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "At present , the Genius study ( NCT01579630 ) is ongoing to compare the efficacy and safety of gefitinib/pemetrexed versus pemetrexed alone as maintenance therapy in patients EGFR mutation negative or T790M single mutation who responded to pemetrexed/platinum as first-line therapy .", "entity_list": [{"name": "gefitinib/pemetrexed", "ent_type": "drug", "char_span": [95, 115], "tok_span": [24, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [201, 206], "tok_span": [48, 52]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/pemetrexed", "sbj_char_span": [201, 206], "obj_char_span": [95, 115], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [24, 33]}], "umls_entity_list": []}, {"text": "However , the T790M mutation may exist in only a small fraction of tumor cells before drug treatment , and the tumor cells harboring this mutation may be enriched over time during treatment with gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [195, 204], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [208, 217], "tok_span": [42, 46]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [14, 19], "obj_char_span": [195, 204], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [37, 41]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [14, 19], "obj_char_span": [208, 217], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "MPR expression induced by gefitinib can facilitate NK cell cytotoxicity in human lung cancer cells with EGFR L858R + T790M resistance mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [117, 122], "tok_span": [26, 30]}, {"name": "L858R", "ent_type": "variant", "char_span": [109, 114], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [117, 122], "obj_char_span": [26, 35], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [5, 9]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [109, 114], "obj_char_span": [26, 35], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Our results suggest that making use of immunoregulatory property of gefitinib may be a potential new therapeutical option for lung cancer with EGFR L858 + T790M resistance mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [68, 77], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [155, 160], "tok_span": [34, 38]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [155, 160], "obj_char_span": [68, 77], "rel_type": "resistance or non-response", "sbj_tok_span": [34, 38], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Gefitinib enhanced cytotoxicity of NK cells in human lung cancer cells with EGFR L858R + T790M mutation", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "T790M", "ent_type": "variant", "char_span": [89, 94], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [81, 86], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [89, 94], "obj_char_span": [0, 9], "rel_type": "resistance or non-response", "sbj_tok_span": [20, 24], "obj_tok_span": [0, 3]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [81, 86], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Two gefitinib resistance NSCLC cell lines A549 ( EGFR wt ) and H1975 ( EGFR L858R + T790M ) were used .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [4, 13], "tok_span": [1, 5]}, {"name": "T790M", "ent_type": "variant", "char_span": [84, 89], "tok_span": [26, 30]}, {"name": "L858R", "ent_type": "variant", "char_span": [76, 81], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [84, 89], "obj_char_span": [4, 13], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [1, 5]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [76, 81], "obj_char_span": [4, 13], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "As to H1975 with L858R + T790M , gefitinib significantly improved NK cells cytotxicity ( Figure", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [33, 42], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [25, 30], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [17, 22], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [25, 30], "obj_char_span": [33, 42], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [16, 20]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [17, 22], "obj_char_span": [33, 42], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Those results suggested that gefitinib enhanced cytotoxicity of NK cells to human lung cancer with EGFR L858R + T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [29, 38], "tok_span": [4, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [112, 117], "tok_span": [24, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [104, 109], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [112, 117], "obj_char_span": [29, 38], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [4, 8]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [104, 109], "obj_char_span": [29, 38], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Our results suggested that gefitinib could enhance the ability of NK cell degradulation to lung cancer cells with EGFR L858R + T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [27, 36], "tok_span": [4, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [119, 124], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [127, 132], "obj_char_span": [27, 36], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [4, 8]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [119, 124], "obj_char_span": [27, 36], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Collectively , these results suggested that gefitinib and NK cells could up-regulate the MHC-I in human lung cells with wild type EGFR , while not significantly influence the MHC-I expression on human lung cells with wild type EGFR L858R + T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [44, 53], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [240, 245], "tok_span": [52, 56]}, {"name": "L858R", "ent_type": "variant", "char_span": [232, 237], "tok_span": [47, 51]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [240, 245], "obj_char_span": [44, 53], "rel_type": "resistance or non-response", "sbj_tok_span": [52, 56], "obj_tok_span": [6, 10]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [232, 237], "obj_char_span": [44, 53], "rel_type": "sensitivity", "sbj_tok_span": [47, 51], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Stat3 is a key factor in gefitinib-resistant EGFR T790M cells .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [25, 44], "tok_span": [7, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [50, 55], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [50, 55], "obj_char_span": [25, 44], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 13]}], "umls_entity_list": []}, {"text": "The functional relevance of restoration of NKG2D–NKG2DL interaction by gefitinib was demonstrated by the enhanced cytotoxicity , degranulation and IFN-γ production of NK cells in response to lung cancer cells with EGFR L858R + T790M resistance mutation .", "entity_list": [{"name": "by gefitinib", "ent_type": "drug", "char_span": [68, 80], "tok_span": [16, 21]}, {"name": "+ T790M", "ent_type": "variant", "char_span": [225, 232], "tok_span": [51, 56]}, {"name": "EGFR L858R", "ent_type": "variant", "char_span": [214, 224], "tok_span": [46, 51]}], "relation_list": [{"subject": "+ T790M", "object": "by gefitinib", "sbj_char_span": [225, 232], "obj_char_span": [68, 80], "rel_type": "resistance or non-response", "sbj_tok_span": [51, 56], "obj_tok_span": [16, 21]}, {"subject": "EGFR L858R", "object": "by gefitinib", "sbj_char_span": [214, 224], "obj_char_span": [68, 80], "rel_type": "sensitivity", "sbj_tok_span": [46, 51], "obj_tok_span": [16, 21]}], "umls_entity_list": []}, {"text": "Though gefitinib can also restore NKG2D ligands and NKG2D interaction , and inhibit stat3 expression , we did not find significant improvement on NK cells cytotoxicity to A549 cells with wild type EGFR , while there was significant enhancement to H1975 cells with EGFR L858R + T790M resistance mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [7, 16], "tok_span": [1, 5]}, {"name": "T790M", "ent_type": "variant", "char_span": [277, 282], "tok_span": [62, 66]}, {"name": "L858R", "ent_type": "variant", "char_span": [269, 274], "tok_span": [57, 61]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [277, 282], "obj_char_span": [7, 16], "rel_type": "resistance or non-response", "sbj_tok_span": [62, 66], "obj_tok_span": [1, 5]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [269, 274], "obj_char_span": [7, 16], "rel_type": "sensitivity", "sbj_tok_span": [57, 61], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "We find that gefitinib can enhance autophagy in the cell lines with L858R + T790M and up-regulate the cell surface MPR expression .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [13, 22], "tok_span": [3, 7]}, {"name": "T790M", "ent_type": "variant", "char_span": [76, 81], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [68, 73], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [76, 81], "obj_char_span": [13, 22], "rel_type": "resistance or non-response", "sbj_tok_span": [20, 24], "obj_tok_span": [3, 7]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [68, 73], "obj_char_span": [13, 22], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [19, 23]}, {"name": "L858R", "ent_type": "variant", "char_span": [173, 178], "tok_span": [33, 37]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [173, 178], "obj_char_span": [121, 130], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Although we could not perform an EGFR mutation test at the time of progression after gefitinib retreatment , the patient had another partial response with irreversible EGFR inhibitor , which is believed to overcome secondary resistance to reversible EGFR-TKI related with T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [15, 19]}, {"name": "T790M", "ent_type": "variant", "char_span": [272, 277], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [272, 277], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [50, 54], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "So , we suggest that the patient had acquired T790M mutation in addition to the original L858R/L861Q after gefitinib retreatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [107, 116], "tok_span": [29, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [46, 51], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [46, 51], "obj_char_span": [107, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 13], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "In this study , we show that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor is effective against tumor cell lines refractory to gefitinib by three different mechanisms : an EGFR gatekeeper T790M mutation , MET amplification , and KRAS/PIK3CA mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [152, 161], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [213, 218], "tok_span": [44, 48]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [213, 218], "obj_char_span": [152, 161], "rel_type": "resistance or non-response", "sbj_tok_span": [44, 48], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Gatekeeper mutations , the T790M mutation in EGFR associated with resistance to gefitinib , are common mechanisms by which tumor cells acquire resistance to molecularly targeted drugs .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [80, 89], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [27, 32], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [27, 32], "obj_char_span": [80, 89], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Although irreversible EGFR-TKIs , including BIBW2992 , have been developed to overcome T790M mediated resistance to gefitinib , recent clinical trials have failed to show that monotherapy with irreversible EGFR-TKIs has benefits in patients with NSCLC refractory to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [116, 125], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [87, 92], "tok_span": [18, 22]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [266, 275], "tok_span": [53, 57]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [87, 92], "obj_char_span": [116, 125], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [25, 29]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [87, 92], "obj_char_span": [266, 275], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [53, 57]}], "umls_entity_list": []}, {"text": "In addition , because HGF overexpression was frequently observed in tumors with the gatekeeper T790M mutation , monotherapy with a mutant-selective EGFR-TKI may not be sufficient to inhibit the growth of tumors with acquired resistance to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [239, 248], "tok_span": [47, 51]}, {"name": "T790M", "ent_type": "variant", "char_span": [95, 100], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [95, 100], "obj_char_span": [239, 248], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "We concluded that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor was effective in suppressing the growth of gefitinib-resistant tumors caused by EGFR T790M mutation , MET amplification , and KRAS/PIK3CA mutation .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [132, 151], "tok_span": [25, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [174, 179], "tok_span": [35, 39]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [174, 179], "obj_char_span": [132, 151], "rel_type": "resistance or non-response", "sbj_tok_span": [35, 39], "obj_tok_span": [25, 31]}], "umls_entity_list": []}, {"text": "Further studies revealed that just the tumor cell with EGFR-TK mutation ( L858R , del742-759 ) could match good response to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [124, 133], "tok_span": [31, 35]}, {"name": "L858R", "ent_type": "variant", "char_span": [74, 79], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [74, 79], "obj_char_span": [124, 133], "rel_type": "sensitivity", "sbj_tok_span": [14, 18], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "This hypothesis may explain the sensitivity to gefitinib of the patients with EGFR L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [7, 11]}, {"name": "L858R", "ent_type": "variant", "char_span": [83, 88], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [83, 88], "obj_char_span": [47, 56], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "In our study , carcinoma of esophagogastric junction rarely presents EGFR mutations , especially gefitinib associated mutations such as L858R and delE746-A750 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [97, 106], "tok_span": [16, 20]}, {"name": "L858R", "ent_type": "variant", "char_span": [136, 141], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [136, 141], "obj_char_span": [97, 106], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Adenocarcinoma of esophagogastric junction rarely presents EGFR mutation , especially gefitinib associated mutations such as L858R , or delE746-A750 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [86, 95], "tok_span": [13, 17]}, {"name": "L858R", "ent_type": "variant", "char_span": [125, 130], "tok_span": [21, 25]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [125, 130], "obj_char_span": [86, 95], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "This change leads to substitution of methionine for threonine at position 790 ( T790M ) and is associated with acquired resistance to gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [80, 85], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [80, 85], "obj_char_span": [134, 143], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "In terms of EGFR targeted therapy , resistant mechanisms ( eg , EGFR T790M mutation and MET amplification ) emerge as a result of the tumor evolution after EGFR inhibition by gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [175, 184], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [69, 74], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [69, 74], "obj_char_span": [175, 184], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "The first is the appearance of a `` resistance '' point mutation in the kinase domain ( T790M ) , observed in 50 % of the gefitinib-resistant patients .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [122, 141], "tok_span": [31, 37]}, {"name": "T790M", "ent_type": "variant", "char_span": [88, 93], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [88, 93], "obj_char_span": [122, 141], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [31, 37]}], "umls_entity_list": []}, {"text": "These systems each incorporate an EGFR kinase protein ( WT , L858R , delE746_A750 or delL747_P753insS ) and an inhibitor ( gefitinib or erlotinib ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [123, 132], "tok_span": [40, 44]}, {"name": "L858R", "ent_type": "variant", "char_span": [61, 66], "tok_span": [11, 15]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [136, 145], "tok_span": [45, 49]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [61, 66], "obj_char_span": [123, 132], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [40, 44]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [61, 66], "obj_char_span": [136, 145], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "The mechanism of H1975 resistance to gefitinib is due to T790M mutation , whereas that of PC9-IR , which was selected from parental PC9 cells that had been continuously exposed to increasing concentrations of gefitinib , could be associated with persistent activation of ERK pathway , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [57, 62], "tok_span": [15, 19]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [209, 218], "tok_span": [46, 50]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [37, 46], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [8, 12]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [209, 218], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "The human lung adenocarcinoma cell lines , A549 ( EGFR wild type ) , H1975 ( EGFR L858R/T790M , gefitinib-resistant ) , H1299 ( EGFR wild type , p53 null ) , and H3255 ( EGFR L858R ) were purchased from American Type Culture Collection ( ATCC ; Manassas , VA , USA ) .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [96, 115], "tok_span": [30, 36]}, {"name": "L858R", "ent_type": "variant", "char_span": [175, 180], "tok_span": [57, 61]}], "relation_list": [{"subject": "L858R", "object": "gefitinib-resistant", "sbj_char_span": [175, 180], "obj_char_span": [96, 115], "rel_type": "sensitivity", "sbj_tok_span": [57, 61], "obj_tok_span": [30, 36]}], "umls_entity_list": []}, {"text": "In conclusion , the current study reports a rare case of lung cancer harboring an L858R point mutation of exon 21 and a compound T790M EGFR substitution mutation following treatment with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [187, 196], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [129, 134], "tok_span": [27, 31]}, {"name": "L858R", "ent_type": "variant", "char_span": [82, 87], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [187, 196], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [37, 41]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [82, 87], "obj_char_span": [187, 196], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "However , following the detection of the T790M EGFR substitution mutation in the tumor cells , the patient exhibited poor curative effect when treatment with gefitinib was continued .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [158, 167], "tok_span": [28, 32]}, {"name": "T790M", "ent_type": "variant", "char_span": [41, 46], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [41, 46], "obj_char_span": [158, 167], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "( A ) L858R point mutation prior to the use of gefitinib , and ( B ) L858R and T790M point mutations following treatment with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [14, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [28, 32]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [126, 135], "tok_span": [37, 41]}, {"name": "L858R", "ent_type": "variant", "char_span": [6, 11], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [79, 84], "obj_char_span": [47, 56], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [14, 18]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [79, 84], "obj_char_span": [126, 135], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [37, 41]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [6, 11], "obj_char_span": [47, 56], "rel_type": "sensitivity", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 18]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [6, 11], "obj_char_span": [126, 135], "rel_type": "sensitivity", "sbj_tok_span": [3, 7], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "In the current study , the L858R point mutation of exon 21 was detected in the tumor cells , and an effective and curative outcome was observed following treatment with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [169, 178], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [27, 32], "tok_span": [6, 10]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [27, 32], "obj_char_span": [169, 178], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "Due to their ability to potently inhibit EGFR , both afatinib and neratinib have been assessed in lung cancer that has become resistant to gefitinib and erlotinib due to the T790M point mutation in the kinase domain .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [139, 148], "tok_span": [29, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [174, 179], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [174, 179], "obj_char_span": [139, 148], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 45], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Three out of five patients with T790M mutations who received gefitinib attained a partial response ( all three responders also had exon 19 deletions ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [61, 70], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [32, 37], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [32, 37], "obj_char_span": [61, 70], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Two patients harboring EGFR T790M mutation had received EGFR-TKI treatment : one received gefitinib and had an occurrence of brain metastasis in the sixth month ; the other received erlotinib to control the metastasis to the liver .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [28, 33], "obj_char_span": [90, 99], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Gefitinib sensitizing EGFR mutations , such as L858R and exon 19 in-frame deletions , selectively activate antiapoptosis signaling pathways .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [47, 52], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [47, 52], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "A secondary mutation of T790M in EGFR exon 20 was confirmed after progression on 15-month gefitinib treatment with subsequent lung wedge resection .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [24, 29], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [24, 29], "obj_char_span": [90, 99], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "One NSCLC patient with SD lasting ≥ 6 months , and who had a mutation in EGFR had progressed after 15-month gefitinib treatment ; he then subsequently developed a T790M mutation which was defined prior to entry to this study .", "entity_list": [{"name": "15-month gefitinib", "ent_type": "drug", "char_span": [99, 117], "tok_span": [20, 27]}, {"name": "a T790M", "ent_type": "variant", "char_span": [161, 168], "tok_span": [33, 38]}], "relation_list": [{"subject": "a T790M", "object": "15-month gefitinib", "sbj_char_span": [161, 168], "obj_char_span": [99, 117], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 38], "obj_tok_span": [20, 27]}], "umls_entity_list": []}, {"text": "However , the phosphorylation level of EGFR in EGFR T790M mutant cells ( H1975TM/LR ) was not suppressed by Gefitinib treatment .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [108, 117], "tok_span": [27, 30]}, {"name": "T790M", "ent_type": "variant", "char_span": [52, 57], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [52, 57], "obj_char_span": [108, 117], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 13], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 L858R point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [223, 232], "tok_span": [44, 48]}, {"name": "L858R", "ent_type": "variant", "char_span": [128, 133], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [128, 133], "obj_char_span": [223, 232], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "T790M ● erlotinib MET amplification ● gefitinib", "entity_list": [{"name": "● gefitinib", "ent_type": "drug", "char_span": [36, 47], "tok_span": [11, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}, {"name": "● erlotinib", "ent_type": "drug", "char_span": [6, 17], "tok_span": [4, 9]}], "relation_list": [{"subject": "T790M", "object": "● gefitinib", "sbj_char_span": [0, 5], "obj_char_span": [36, 47], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [11, 16]}, {"subject": "T790M", "object": "● erlotinib", "sbj_char_span": [0, 5], "obj_char_span": [6, 17], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [4, 9]}], "umls_entity_list": []}, {"text": "What is remarkable is that the H1975 cell line harbors the T790M and L858R mutations in the HER1 gene ( information obtained from the Sanger Institute website ) , which confer resistance to HER1 kinase inhibitors , Gefitinib and Erlotinib , responded to the irreversible HER1 kinase inhibitor BIBW-2992 .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [215, 224], "tok_span": [49, 52]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [14, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [69, 74], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [59, 64], "obj_char_span": [215, 224], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [49, 52]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [69, 74], "obj_char_span": [215, 224], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [49, 52]}], "umls_entity_list": []}, {"text": "Moreover , the irreversible HER1/2 kinase inhibitor , BIBW-2992 , was also able to potently inhibit the growth of the H1975 cell line , which harbored the T790M and L858R mutations in the HER1 gene and thus rendering the cells resistant to Gefitinib and Lapatinib treatment .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [240, 249], "tok_span": [60, 63]}, {"name": "T790M", "ent_type": "variant", "char_span": [155, 160], "tok_span": [38, 42]}, {"name": "L858R", "ent_type": "variant", "char_span": [165, 170], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [155, 160], "obj_char_span": [240, 249], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 42], "obj_tok_span": [60, 63]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [165, 170], "obj_char_span": [240, 249], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [60, 63]}], "umls_entity_list": []}, {"text": "Results of DNA Sanger sequencing of PCR products of exons 18–21 from H2170 and H358 parental and resistant cells showed no secondary erlotinib/gefitinib T790M or D761Y resistance point mutations .", "entity_list": [{"name": "secondary erlotinib/gefitinib", "ent_type": "drug", "char_span": [123, 152], "tok_span": [28, 38]}, {"name": "erlotinib/gefitinib T790M", "ent_type": "variant", "char_span": [133, 158], "tok_span": [29, 42]}], "relation_list": [{"subject": "erlotinib/gefitinib T790M", "object": "secondary erlotinib/gefitinib", "sbj_char_span": [133, 158], "obj_char_span": [123, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 42], "obj_tok_span": [28, 38]}], "umls_entity_list": []}, {"text": "The first example of a clinically relevant NSCLC driver oncogene was the identification of somatic mutations in the epidermal growth factor receptor (EGFR) gene ( – ) .Common EGFR alterations ( the L858R point mutation and exon 19 deletions ) are present in 10–30 % of patients with NSCLC and confer sensitivity to gefitinib , erlotinib , and afatinib .", "entity_list": [{"name": "to gefitinib", "ent_type": "drug", "char_span": [312, 324], "tok_span": [61, 66]}, {"name": "the L858R", "ent_type": "variant", "char_span": [194, 203], "tok_span": [35, 40]}, {"name": "and afatinib", "ent_type": "drug", "char_span": [339, 351], "tok_span": [72, 75]}], "relation_list": [{"subject": "the L858R", "object": "to gefitinib", "sbj_char_span": [194, 203], "obj_char_span": [312, 324], "rel_type": "sensitivity", "sbj_tok_span": [35, 40], "obj_tok_span": [61, 66]}, {"subject": "the L858R", "object": "and afatinib", "sbj_char_span": [194, 203], "obj_char_span": [339, 351], "rel_type": "sensitivity", "sbj_tok_span": [35, 40], "obj_tok_span": [72, 75]}], "umls_entity_list": []}, {"text": "Similarly , another CUP patient was identified as harboring a somatic EGFR L858R alteration via hotspot testing and responded to gefitinib , an EGFR targeted therapy .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [129, 138], "tok_span": [25, 29]}, {"name": "L858R", "ent_type": "variant", "char_span": [75, 80], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [75, 80], "obj_char_span": [129, 138], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Similarly , the gatekeeper mutation T790M in EGFR causes resistance to gefitinib and erlotinib , and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [36, 41], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [36, 41], "obj_char_span": [71, 80], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "In this present study , erlotinib- and gefitinib-resistant cell lines were established from two human lung cancer cell lines , PC9 cells harboring delE746-A750 mutation and 11–18 cells harboring L858R mutation , respectively .", "entity_list": [{"name": "erlotinib-", "ent_type": "drug", "char_span": [24, 34], "tok_span": [5, 10]}, {"name": "harboring L858R", "ent_type": "variant", "char_span": [185, 200], "tok_span": [47, 52]}], "relation_list": [{"subject": "harboring L858R", "object": "erlotinib-", "sbj_char_span": [185, 200], "obj_char_span": [24, 34], "rel_type": "sensitivity", "sbj_tok_span": [47, 52], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "To isolate erlotinib-resistant cell lines from PC9 cells harboring delE746-A750 , and from 11–18 cells harboring L858R , both cell lines were cultured in stepwise increasing doses of erlotinib from 0.05 to 10 µM , for approximately 6 months , as described previously .", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [11, 30], "tok_span": [2, 8]}, {"name": "harboring L858R", "ent_type": "variant", "char_span": [103, 118], "tok_span": [30, 35]}, {"name": "of erlotinib", "ent_type": "drug", "char_span": [180, 192], "tok_span": [45, 50]}], "relation_list": [{"subject": "harboring L858R", "object": "erlotinib-resistant", "sbj_char_span": [103, 118], "obj_char_span": [11, 30], "rel_type": "sensitivity", "sbj_tok_span": [30, 35], "obj_tok_span": [2, 8]}, {"subject": "harboring L858R", "object": "of erlotinib", "sbj_char_span": [103, 118], "obj_char_span": [180, 192], "rel_type": "sensitivity", "sbj_tok_span": [30, 35], "obj_tok_span": [45, 50]}], "umls_entity_list": []}, {"text": "Partial Loss of the Activating Mutant EGFR ( L858R ) Gene in Erlotinib- or Gefitinib-resistant Cell Lines from 11–18", "entity_list": [{"name": "Erlotinib-", "ent_type": "drug", "char_span": [61, 71], "tok_span": [17, 21]}, {"name": "L858R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib-", "sbj_char_span": [45, 50], "obj_char_span": [61, 71], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "In our present study , erlotinib-resistant cell lines were established ; PC9/ER1 from PC9 cells harboring delE746-A750 mutation , and 11–18/ER1-7 and 11–18/ER2-1 from 11–18 cells harboring L858R mutation .", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [23, 42], "tok_span": [5, 11]}, {"name": "harboring L858R", "ent_type": "variant", "char_span": [179, 194], "tok_span": [59, 64]}], "relation_list": [{"subject": "harboring L858R", "object": "erlotinib-resistant", "sbj_char_span": [179, 194], "obj_char_span": [23, 42], "rel_type": "sensitivity", "sbj_tok_span": [59, 64], "obj_tok_span": [5, 11]}], "umls_entity_list": []}, {"text": "Erlotinib blocked L858R induced pAkt at 10 nM , and caused relocation of the ectopic protein into fibrils at 100 nM . ", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [18, 23], "tok_span": [4, 8]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [18, 23], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "No fibrils were observed in the case of YFP-EGFR-ICD T790M or Ins774HV at any of the erlotinib concentrations tested . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [53, 58], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [53, 58], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "In line with previous observations the T790M mutation abrogated erlotinib sensitivity .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [64, 73], "tok_span": [14, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [39, 44], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [39, 44], "obj_char_span": [64, 73], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Images show that YFP-EGFR T790M did not effectively induce phosphorylation of endogenous Akt in MCF-7 cells , and did not relocate into fibrils upon erlotinib treatment .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [149, 158], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [26, 31], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [26, 31], "obj_char_span": [149, 158], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "Importantly , the wild type protein formed fibrils only at 10 μM erlotinib , whereas the TKI-sensitive mutants relocated to fibrils in the presence of 10–100 nM erlotinib , and this effect was fully abrogated by the erlotinib-resistant T790M mutation .", "entity_list": [{"name": "μM erlotinib", "ent_type": "drug", "char_span": [62, 74], "tok_span": [11, 17]}, {"name": "erlotinib-resistant T790M", "ent_type": "variant", "char_span": [216, 241], "tok_span": [53, 63]}, {"name": "nM erlotinib", "ent_type": "drug", "char_span": [158, 170], "tok_span": [37, 42]}, {"name": "the erlotinib-resistant", "ent_type": "drug", "char_span": [212, 235], "tok_span": [52, 59]}], "relation_list": [{"subject": "erlotinib-resistant T790M", "object": "μM erlotinib", "sbj_char_span": [216, 241], "obj_char_span": [62, 74], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [11, 17]}, {"subject": "erlotinib-resistant T790M", "object": "nM erlotinib", "sbj_char_span": [216, 241], "obj_char_span": [158, 170], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [37, 42]}, {"subject": "erlotinib-resistant T790M", "object": "the erlotinib-resistant", "sbj_char_span": [216, 241], "obj_char_span": [212, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [52, 59]}], "umls_entity_list": []}, {"text": "Mutations in exon 20 , most notably T790M , are usually associated with resistance to gefitinib and erlotinib ] .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [100, 109], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [36, 41], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [36, 41], "obj_char_span": [100, 109], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "For example , Caucasian patients harboring activating mutations in the EGFR kinase domain , such as a deletion in exon 19 or L858R , have shown significant responses to the EGFR tyrosine kinase inhibitor ( TKI ) erlotinib , including a 70 % response rate , 14-month progression-free survival , and 27-month median survival .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [212, 221], "tok_span": [41, 45]}, {"name": "L858R", "ent_type": "variant", "char_span": [125, 130], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [125, 130], "obj_char_span": [212, 221], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "T790M and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to gefitinib or erlotinib ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [118, 130], "tok_span": [26, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T790M", "object": "or erlotinib", "sbj_char_span": [0, 5], "obj_char_span": [118, 130], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [26, 31]}], "umls_entity_list": []}, {"text": "Consistent with the increased sensitivity to gefitinib and erlotinib of patient tumors harboring the missense mutations or exon 19 deletions , anchorage independent growth of cells expressing L858R , G719S , or L747_E749del A750P was inhibited by 100 nM erlotinib ( A and B ) or gefitinib ( B and unpublished data ) , although the G719S mutant may be somewhat more resistant to gefitinib ( A and unpublished data ) , consistent with other in vitro studies .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [59, 68], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [192, 197], "tok_span": [35, 39]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [254, 263], "tok_span": [63, 67]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [192, 197], "obj_char_span": [59, 68], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [11, 15]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [192, 197], "obj_char_span": [254, 263], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [63, 67]}], "umls_entity_list": []}, {"text": "( B ) Number of colonies formed in soft agar by clonal NIH-3T3 cells expressing L858R EGFR and D770_N771insNPG EGFR treated with the indicated concentrations of gefitinib or erlotinib immediately prior to suspension in soft agar .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [174, 183], "tok_span": [47, 51]}, {"name": "L858R", "ent_type": "variant", "char_span": [80, 85], "tok_span": [19, 23]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [80, 85], "obj_char_span": [174, 183], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "Transformation by cells expressing the L858R EGFR was inhibited by 0.1 μM gefitinib or erlotinib , whereas transformation by cells expressing the insertion mutant was resistant to low concentrations of these inhibitors .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [84, 96], "tok_span": [22, 27]}, {"name": "L858R", "ent_type": "variant", "char_span": [39, 44], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "or erlotinib", "sbj_char_span": [39, 44], "obj_char_span": [84, 96], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [22, 27]}], "umls_entity_list": []}, {"text": "This compound was previously found to be active against EGFR containing the exon 20 point mutation T790M , associated with resistance to gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [151, 160], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [99, 104], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [99, 104], "obj_char_span": [151, 160], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "The data suggest that low BRCA1 level may neutralize the negative effects of the EGFR T790M mutation on erlotinib sensitivity and that high BRCA1 expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [104, 113], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [86, 91], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [86, 91], "obj_char_span": [104, 113], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "In pretreated patients harboring a T790M mutation , low expression of BRCA1 mRNA is correlated with a prolonged progression-free survival to erlotinib treatment .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [141, 150], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [35, 40], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [35, 40], "obj_char_span": [141, 150], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Intriguingly , low expression of the NFκB inhibitor IκB was predictive of a poor clinical outcome in patients treated with erlotinib without a T790M mutation .", "entity_list": [{"name": "with erlotinib", "ent_type": "drug", "char_span": [118, 132], "tok_span": [25, 30]}, {"name": "a T790M", "ent_type": "variant", "char_span": [141, 148], "tok_span": [31, 36]}], "relation_list": [{"subject": "a T790M", "object": "with erlotinib", "sbj_char_span": [141, 148], "obj_char_span": [118, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 36], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "Similar to the EGFR T790M mutation , alteration of the drug contact residue T854 to a smaller hydrophobic alanine may increase the size of the selectivity pocket and negatively impact erlotinib binding .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [184, 193], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [20, 25], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [20, 25], "obj_char_span": [184, 193], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Second-generation irreversible EGFR inhibitors , which bind irreversibly in the ATP binding pocket of EGFR through a covalent bond at C797 , were shown to be more potent inhibitors of the second-site T790M mutation than erlotinib or gefitinib in pre-clinical models ( ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [220, 229], "tok_span": [45, 49]}, {"name": "T790M", "ent_type": "variant", "char_span": [200, 205], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [200, 205], "obj_char_span": [220, 229], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR T790M mutation . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [249, 254], "tok_span": [44, 48]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [119, 128], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [249, 254], "obj_char_span": [119, 128], "rel_type": "response", "sbj_tok_span": [44, 48], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "The T790M secondary mutation is not necessary for erlotinib resistance", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [50, 59], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Resistant cells did not display either the T790M or D761Y mutations , suggesting the use of an alternative signaling mechanism to overcome erlotinib susceptibility .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [139, 148], "tok_span": [29, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [43, 48], "tok_span": [8, 12]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [43, 48], "obj_char_span": [139, 148], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 12], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "In vitro studies demonstrated that the effective concentration of erlotinib in tumour cells harbouring both the L858R and T790M mutations has to be 300 times higher to induce apoptosis than in cells only with an activating mutation in codon 858 .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [9, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [112, 117], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [122, 127], "tok_span": [26, 30]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [112, 117], "obj_char_span": [66, 75], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [122, 127], "obj_char_span": [66, 75], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "In case of occurrence of both L858R and T790M mutations , the concentration of erlotinib should be three times higher in order to achieve a therapeutic effect .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [79, 88], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [30, 35], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [40, 45], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [30, 35], "obj_char_span": [79, 88], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [20, 24]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [40, 45], "obj_char_span": [79, 88], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Presence of T790M substitution may be an indication for treatment with irreversible EGFR TKI , such as neratinib , keratinib and especially afatinib , which is currently in the third phase of clinical trials . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [12, 17], "tok_span": [2, 6]}, {"name": "afatinib", "ent_type": "drug", "char_span": [140, 148], "tok_span": [30, 32]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [12, 17], "obj_char_span": [140, 148], "rel_type": "response", "sbj_tok_span": [2, 6], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Contrarily , a point mutation in the EGFR gene , which results in the substitution of methionine for threonine at position 790 ( T790M ) , decreases the ability of erlotinib or gefitinib to inhibit EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [164, 173], "tok_span": [36, 40]}, {"name": "T790M", "ent_type": "variant", "char_span": [129, 134], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [129, 134], "obj_char_span": [164, 173], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "T790M mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( EGFR-TKI ) —erlotinib and gefitinib in NSCLC patients . ", "entity_list": [{"name": "—erlotinib", "ent_type": "drug", "char_span": [202, 212], "tok_span": [36, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T790M", "object": "—erlotinib", "sbj_char_span": [0, 5], "obj_char_span": [202, 212], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [36, 41]}], "umls_entity_list": []}, {"text": "The possibility of detection of T790M mutation in EGFR-TKIs naive patients forces to expand the diagnostics of EGFR gene status during qualification for erlotinib or gefitinib treatment and to consider the new therapy modalities in carriers of this mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [153, 162], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [32, 37], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [32, 37], "obj_char_span": [153, 162], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Identification of a Novel Secondary Resistant EGFR Mutation , L747S ( A ) Sequencing chromatograms with the EGFR L747S exon 19 and L858R exon 21 by RT-PCR . ( B ) Amino acid alignments of the tyrosine kinase domain in EGFR , ErbB2 , and ABL1 . ( C ) Active conformation crystal structure of the kinase domain of EGFR in complex with erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [333, 342], "tok_span": [81, 85]}, {"name": "L858R", "ent_type": "variant", "char_span": [131, 136], "tok_span": [30, 34]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [131, 136], "obj_char_span": [333, 342], "rel_type": "sensitivity", "sbj_tok_span": [30, 34], "obj_tok_span": [81, 85]}], "umls_entity_list": []}, {"text": "Possible mechanisms of acquired or secondary resistance to erlotinib include second mutations in the EGFR gene such as T790M , activation of an alternative pathway including Met or HER2 amplification , histological transformation to small cell lung cancer ( SCLC ) and epithelial to mesenchymal transition .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [59, 68], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [119, 124], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [119, 124], "obj_char_span": [59, 68], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Second-generation TKIs that irreversibly inhibit the EGFR TKI domain may offer the potential for overcoming the resistance of T790M mutation to erlotinib and gefitinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [144, 153], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [126, 131], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [126, 131], "obj_char_span": [144, 153], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "All of the patients had the EGFR gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( L858R ) , and had received or were receiving gefitinib or erlotinib for treatment against advanced diseases at the blood sampling . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [147, 156], "tok_span": [43, 47]}, {"name": "L858R", "ent_type": "variant", "char_span": [89, 94], "tok_span": [26, 30]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [89, 94], "obj_char_span": [147, 156], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "At the same time , a secondary point mutation in exon 20 of EGFR ( T790M ) is associated with acquired resistance to EGFR inhibitors , including Erlotinib .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [145, 154], "tok_span": [30, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [67, 72], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [67, 72], "obj_char_span": [145, 154], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "For example , detecting the T790M mutation in blood samples would be useful for patient selection for treatment with new EGFR-TKIs for lung cancers that are resistant to gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [184, 193], "tok_span": [39, 43]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [28, 33], "obj_char_span": [184, 193], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "It is well known that the efficacy of targeted therapies such as gefitinib or erlotinib with NSCLC patients depends on the presence of EGFR activating mutations including in-frame deletion in exon 19 or L858R in exon 21 . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [78, 87], "tok_span": [17, 21]}, {"name": "L858R", "ent_type": "variant", "char_span": [203, 208], "tok_span": [41, 45]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [203, 208], "obj_char_span": [78, 87], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Cancer EGFR exon18 G719X Drug efficacy prediction of gefitinib and erlotinib exon19 deletion exon20 T790M exon21 L858R", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [67, 76], "tok_span": [17, 21]}, {"name": "L858R", "ent_type": "variant", "char_span": [113, 118], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [100, 105], "tok_span": [26, 30]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [113, 118], "obj_char_span": [67, 76], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [17, 21]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [100, 105], "obj_char_span": [67, 76], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "The T790M mutation is rarely found in tumors from patients not treated with either gefitinib or erlotinib , and could be discovered only in progressing tumors , in addition to a primary drug-sensitive mutation in EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [96, 105], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [96, 105], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "In addition , the presence of common activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene ( exon 19 deletion and exon 21 L858R mutation ) confers strong sensitivity to gefitinib and erlotinib , which are selective tyrosine kinase inhibitors of EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [232, 241], "tok_span": [46, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [171, 176], "tok_span": [31, 35]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [171, 176], "obj_char_span": [232, 241], "rel_type": "sensitivity", "sbj_tok_span": [31, 35], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "This event is analogous to replacement of threonine 790 with methionine ( T790M ) in erlotinib-resistant lung adenocarcinoma .", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [85, 104], "tok_span": [20, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "erlotinib-resistant", "sbj_char_span": [74, 79], "obj_char_span": [85, 104], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [20, 26]}], "umls_entity_list": []}, {"text": "Our biological model of sensitive and resistant cells consisted of two NSCLC cell lines , HCC827 and H1975 , with different sensitivities to the EGFR inhibitor erlotinib. ( ) The HCC827 cell line harbors a mutation in the EGFR tyrosine kinase domain ( E746–A750 ) that renders these cells sensitive to EGFR TKI therapies , whereas the H1975 cells harbor both the L858R and T790M mutations and are resistant to EGFR TKIs .", "entity_list": [{"name": "erlotinib.", "ent_type": "drug", "char_span": [160, 170], "tok_span": [30, 35]}, {"name": "the L858R", "ent_type": "variant", "char_span": [359, 368], "tok_span": [81, 86]}, {"name": "and T790M", "ent_type": "variant", "char_span": [369, 378], "tok_span": [86, 91]}], "relation_list": [{"subject": "the L858R", "object": "erlotinib.", "sbj_char_span": [359, 368], "obj_char_span": [160, 170], "rel_type": "sensitivity", "sbj_tok_span": [81, 86], "obj_tok_span": [30, 35]}, {"subject": "and T790M", "object": "erlotinib.", "sbj_char_span": [369, 378], "obj_char_span": [160, 170], "rel_type": "resistance or non-response", "sbj_tok_span": [86, 91], "obj_tok_span": [30, 35]}], "umls_entity_list": []}, {"text": "This behavior is consistent with clinical observations in which 100 % of patients who initially respond to erlotinib develop acquired resistance , often mediated by a T790M mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [107, 116], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [167, 172], "tok_span": [29, 33]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [167, 172], "obj_char_span": [107, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Somatic mutations included two different EGFR mutations : an activating mutation in a dominant tumor clone as well as a second T790M mutation present in an erlotinib-resistant subclone .", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [156, 175], "tok_span": [30, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [22, 26]}], "relation_list": [{"subject": "T790M", "object": "erlotinib-resistant", "sbj_char_span": [127, 132], "obj_char_span": [156, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [30, 36]}], "umls_entity_list": []}, {"text": "In this study , we report that BMS-690514 has in vivo efficacy on a panel of NSLCC xenografts , including those with T790M mutations , conferring resistance to EGFR therapies such as Erlotinib or Gefitinib .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [183, 192], "tok_span": [44, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [117, 122], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [117, 122], "obj_char_span": [183, 192], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [44, 47]}], "umls_entity_list": []}, {"text": "Sensitive detection methods have identified a proportion of tyrosin- kinase- naive tumors that carry T790M , a resistant tumor cell clones that may be selected during the exposure to gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [196, 205], "tok_span": [42, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [101, 106], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [101, 106], "obj_char_span": [196, 205], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "Moreover , interactions between Erlotinib and MYO2 or MYH9 have been described , and a MYH9 inhibitor synergizes with EGFR inhibitors to induce apoptosis in cells carrying the drug-resistant mutation T790M .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [32, 41], "tok_span": [4, 7]}, {"name": "T790M", "ent_type": "variant", "char_span": [200, 205], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [200, 205], "obj_char_span": [32, 41], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 45], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Kim and colleagues demonstrated that the combination of lapatinib with cetuximab overcame gefitinib resistance due to the secondary T790M mutation in NSCLC by inducing enhanced cytotoxicity both in vitro and in vivo .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [71, 80], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [132, 137], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [132, 137], "obj_char_span": [71, 80], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Furthermore , the association of cetuximab with afatinib has been shown to be effective to overcome T790M mediated drug resistance .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [33, 42], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [100, 105], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [100, 105], "obj_char_span": [33, 42], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Given the role of cetuximab in therapy of these cancers , initial efforts to identify activating EGFR mutations identified few such events , though potentially activating events such as G719S were seen .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [18, 27], "tok_span": [4, 8]}, {"name": "G719S", "ent_type": "variant", "char_span": [186, 191], "tok_span": [32, 36]}], "relation_list": [{"subject": "G719S", "object": "cetuximab", "sbj_char_span": [186, 191], "obj_char_span": [18, 27], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "To test whether G719S and G724S EGFR mutants are cetuximab-sensitive in vitro , we ectopically expressed these mutants in Ba/F3 cells , rendering these cells IL-3 independent but dependent on exogenous oncogenic EGFR signaling .", "entity_list": [{"name": "cetuximab-sensitive", "ent_type": "drug", "char_span": [49, 68], "tok_span": [15, 21]}, {"name": "G719S", "ent_type": "variant", "char_span": [16, 21], "tok_span": [3, 7]}, {"name": "G724S", "ent_type": "variant", "char_span": [26, 31], "tok_span": [8, 12]}], "relation_list": [{"subject": "G719S", "object": "cetuximab-sensitive", "sbj_char_span": [16, 21], "obj_char_span": [49, 68], "rel_type": "sensitivity", "sbj_tok_span": [3, 7], "obj_tok_span": [15, 21]}, {"subject": "G724S", "object": "cetuximab-sensitive", "sbj_char_span": [26, 31], "obj_char_span": [49, 68], "rel_type": "sensitivity", "sbj_tok_span": [8, 12], "obj_tok_span": [15, 21]}], "umls_entity_list": []}, {"text": "Ba/F3 cells expressing the colon-cancer derived G724S mutant and the lung/colon cancer derived G719S mutant showed sensitivity to cetuximab with an IC50 value of ~ 0.3 μg/ml ( Figure", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [130, 139], "tok_span": [31, 35]}, {"name": "G719S", "ent_type": "variant", "char_span": [95, 100], "tok_span": [23, 27]}, {"name": "G724S", "ent_type": "variant", "char_span": [48, 53], "tok_span": [11, 15]}], "relation_list": [{"subject": "G719S", "object": "cetuximab", "sbj_char_span": [95, 100], "obj_char_span": [130, 139], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [31, 35]}, {"subject": "G724S", "object": "cetuximab", "sbj_char_span": [48, 53], "obj_char_span": [130, 139], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Pharmacological effects of cetuximab against oncogenic G719S and G724S mutants in vitro and in vivo .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [27, 36], "tok_span": [5, 9]}, {"name": "G719S", "ent_type": "variant", "char_span": [55, 60], "tok_span": [11, 15]}, {"name": "G724S", "ent_type": "variant", "char_span": [65, 70], "tok_span": [16, 20]}], "relation_list": [{"subject": "G719S", "object": "cetuximab", "sbj_char_span": [55, 60], "obj_char_span": [27, 36], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [5, 9]}, {"subject": "G724S", "object": "cetuximab", "sbj_char_span": [65, 70], "obj_char_span": [27, 36], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "( A ) Cetuximab suppresses the growth of Ba/F3 cells dependent upon the G719S and G724S mutants , but not control cells .", "entity_list": [{"name": "Cetuximab", "ent_type": "drug", "char_span": [6, 15], "tok_span": [3, 6]}, {"name": "G719S", "ent_type": "variant", "char_span": [72, 77], "tok_span": [18, 22]}, {"name": "G724S", "ent_type": "variant", "char_span": [82, 87], "tok_span": [23, 27]}], "relation_list": [{"subject": "G719S", "object": "Cetuximab", "sbj_char_span": [72, 77], "obj_char_span": [6, 15], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [3, 6]}, {"subject": "G724S", "object": "Cetuximab", "sbj_char_span": [82, 87], "obj_char_span": [6, 15], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "The results are indicated as mean +/- SD of sextuplicate wells and are representative of three independent experiments ( B and C ) Cetuximab is effective against SW48 ( EGFR G719S mutant ) -induced tumors but not HCT8 ( KRAS G13D mutant ) induced-tumors in xenografted mice .", "entity_list": [{"name": "Cetuximab", "ent_type": "drug", "char_span": [131, 140], "tok_span": [27, 30]}, {"name": "G719S", "ent_type": "variant", "char_span": [174, 179], "tok_span": [37, 41]}, {"name": "G13D", "ent_type": "variant", "char_span": [225, 229], "tok_span": [53, 56]}], "relation_list": [{"subject": "G719S", "object": "Cetuximab", "sbj_char_span": [174, 179], "obj_char_span": [131, 140], "rel_type": "sensitivity", "sbj_tok_span": [37, 41], "obj_tok_span": [27, 30]}, {"subject": "G13D", "object": "Cetuximab", "sbj_char_span": [225, 229], "obj_char_span": [131, 140], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 56], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "Taken together , we found that G719S and G724S mutants are oncogenic in the absence of ligand stimulation and effectively respond to cetuximab in vivo and in vitro .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [133, 142], "tok_span": [28, 32]}, {"name": "G719S", "ent_type": "variant", "char_span": [31, 36], "tok_span": [6, 10]}, {"name": "G724S", "ent_type": "variant", "char_span": [41, 46], "tok_span": [11, 15]}], "relation_list": [{"subject": "G719S", "object": "cetuximab", "sbj_char_span": [31, 36], "obj_char_span": [133, 142], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [28, 32]}, {"subject": "G724S", "object": "cetuximab", "sbj_char_span": [41, 46], "obj_char_span": [133, 142], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Given that colon cancer derived G719S and G724S mutants are sensitive to cetuximab , we sought to examine whether oncogenic potential of these mutants are dependent on the asymmetric dimerization like lung cancer derived L858R mutant .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [73, 82], "tok_span": [18, 22]}, {"name": "G719S", "ent_type": "variant", "char_span": [32, 37], "tok_span": [5, 9]}, {"name": "G724S", "ent_type": "variant", "char_span": [42, 47], "tok_span": [10, 14]}], "relation_list": [{"subject": "G719S", "object": "cetuximab", "sbj_char_span": [32, 37], "obj_char_span": [73, 82], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [18, 22]}, {"subject": "G724S", "object": "cetuximab", "sbj_char_span": [42, 47], "obj_char_span": [73, 82], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "To test the hypothesis that cetuximab sensitivity of G719S and G724S mutants is a function of their dimerization dependence , we generated G719S and G724S mutants with compound substitution mutations at the dimerization interface in the N-lobe or C-lobe that disrupt the asymmetric dimerization of EGFR .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [28, 37], "tok_span": [5, 9]}, {"name": "G719S", "ent_type": "variant", "char_span": [53, 58], "tok_span": [11, 15]}, {"name": "G724S", "ent_type": "variant", "char_span": [63, 68], "tok_span": [16, 20]}], "relation_list": [{"subject": "G719S", "object": "cetuximab", "sbj_char_span": [53, 58], "obj_char_span": [28, 37], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [5, 9]}, {"subject": "G724S", "object": "cetuximab", "sbj_char_span": [63, 68], "obj_char_span": [28, 37], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Dimerization impairing cis mutations in EGFR , L704N and I941R , significantly reduced the ability of the cetuximab-sensitive G719S and G724S mutants to promote colony formation upon retroviral transduction ( Figure", "entity_list": [{"name": "cetuximab-sensitive", "ent_type": "drug", "char_span": [106, 125], "tok_span": [26, 32]}, {"name": "G719S", "ent_type": "variant", "char_span": [126, 131], "tok_span": [32, 36]}, {"name": "G724S", "ent_type": "variant", "char_span": [136, 141], "tok_span": [37, 41]}], "relation_list": [{"subject": "G719S", "object": "cetuximab-sensitive", "sbj_char_span": [126, 131], "obj_char_span": [106, 125], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [26, 32]}, {"subject": "G724S", "object": "cetuximab-sensitive", "sbj_char_span": [136, 141], "obj_char_span": [106, 125], "rel_type": "sensitivity", "sbj_tok_span": [37, 41], "obj_tok_span": [26, 32]}], "umls_entity_list": []}, {"text": "Recent data have suggested that tumors with specific KRAS mutations , especially the glycine-to-aspartate mutation in codon 13 ( G13D ) mutation , may be sensitive to cetuximab or panitumumab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [167, 176], "tok_span": [35, 39]}, {"name": "G13D", "ent_type": "variant", "char_span": [129, 133], "tok_span": [25, 28]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [129, 133], "obj_char_span": [167, 176], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 28], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "In vitro data has shown that cancer cell lines with the G13D mutation have a lower transforming potential and attenuated proliferation in the presence of cetuximab , compared to other KRAS mutations .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [154, 163], "tok_span": [27, 31]}, {"name": "G13D", "ent_type": "variant", "char_span": [56, 60], "tok_span": [11, 14]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [56, 60], "obj_char_span": [154, 163], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 14], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "The combination of afatinib and cetuximab can even overcome resistance due to the T790M mutation both preclinically as well as clinically .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [32, 41], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [82, 87], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [82, 87], "obj_char_span": [32, 41], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Strategies to improve EGFR inhibition in EGFR T790M cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "entity_list": [{"name": "antibody cetuximab", "ent_type": "drug", "char_span": [139, 157], "tok_span": [24, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [46, 51], "tok_span": [7, 11]}, {"name": "plus cetuximab", "ent_type": "drug", "char_span": [185, 199], "tok_span": [35, 40]}], "relation_list": [{"subject": "T790M", "object": "antibody cetuximab", "sbj_char_span": [46, 51], "obj_char_span": [139, 157], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [24, 29]}, {"subject": "T790M", "object": "plus cetuximab", "sbj_char_span": [46, 51], "obj_char_span": [185, 199], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [35, 40]}], "umls_entity_list": []}, {"text": "Materials and Methods 49 individual specimens of 21 metastatic CRCs and corresponding metastases collected before and after combined therapy with cetuximab were examined using CGH , certified PCR/DNA sequencing protocols ( KRAS exon 2 , Gl12/13 ; BRAF exon 15 , V600E ) as well as allele-specific PCR .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [146, 155], "tok_span": [21, 25]}, {"name": "V600E", "ent_type": "variant", "char_span": [262, 267], "tok_span": [52, 55]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [262, 267], "obj_char_span": [146, 155], "rel_type": "resistance or non-response", "sbj_tok_span": [52, 55], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "20 of 21 patients show concordance of the KRAS ( exon 2 , Gly 12/13 ) and BRAF ( exon 15 , V600E ) mutation status between samples of primary CRCs and/or corresponding metastases before and after combined cetuximab therapy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [205, 214], "tok_span": [46, 50]}, {"name": "V600E", "ent_type": "variant", "char_span": [91, 96], "tok_span": [25, 28]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [91, 96], "obj_char_span": [205, 214], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 28], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "Moreover , the presence of the V600E mutation in the BRAF gene is more and more frequently taken into consideration before patient targeted therapy qualification , because wild-type BRAF is required for a response to panitumumab or cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [232, 241], "tok_span": [44, 48]}, {"name": "V600E", "ent_type": "variant", "char_span": [31, 36], "tok_span": [6, 9]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [31, 36], "obj_char_span": [232, 241], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 9], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "Therefore , in pre-clinical studies , vemurafenib is strongly synergistic with EFGR inhibitors like cetuximab for colon cancers expressing BRAF V600E mutations ( Prahallad et al. , ) .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [100, 109], "tok_span": [21, 25]}, {"name": "V600E", "ent_type": "variant", "char_span": [144, 149], "tok_span": [30, 33]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [144, 149], "obj_char_span": [100, 109], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 33], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "The patient was offered off-label sorafenib ( to inhibit B-RAF V600E ) and cetuximab ( to inhibit ERBB1 signaling ) .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [75, 84], "tok_span": [21, 25]}, {"name": "V600E", "ent_type": "variant", "char_span": [63, 68], "tok_span": [16, 19]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [63, 68], "obj_char_span": [75, 84], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 19], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [17, 26], "tok_span": [5, 9]}, {"name": "V600E", "ent_type": "variant", "char_span": [117, 122], "tok_span": [29, 32]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [117, 122], "obj_char_span": [17, 26], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 32], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Cells of the colorectal cancer line HT-29 have a mutated BRAF gene ( V600E ) and are relatively resistant to cytotoxicity by anti-EGFR antibody cetuximab . ", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [144, 153], "tok_span": [30, 34]}, {"name": "V600E", "ent_type": "variant", "char_span": [69, 74], "tok_span": [15, 18]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [69, 74], "obj_char_span": [144, 153], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 18], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Others stabilise the active conformation of the receptor , which also prevents imatinib binding ( D820Y and N822K ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [79, 87], "tok_span": [13, 15]}, {"name": "D820Y", "ent_type": "variant", "char_span": [98, 103], "tok_span": [17, 21]}], "relation_list": [{"subject": "D820Y", "object": "imatinib", "sbj_char_span": [98, 103], "obj_char_span": [79, 87], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Some of these mutations alter specifically the configuration of the ATP binding kinase pocket ( V654A and T670I ) , inhibiting imatinib binding .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [127, 135], "tok_span": [27, 29]}, {"name": "V654A", "ent_type": "variant", "char_span": [96, 101], "tok_span": [15, 19]}, {"name": "T670I", "ent_type": "variant", "char_span": [106, 111], "tok_span": [20, 24]}], "relation_list": [{"subject": "V654A", "object": "imatinib", "sbj_char_span": [96, 101], "obj_char_span": [127, 135], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [27, 29]}, {"subject": "T670I", "object": "imatinib", "sbj_char_span": [106, 111], "obj_char_span": [127, 135], "rel_type": "resistance", "sbj_tok_span": [20, 24], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "GIST-T1R cells were generated by chronic , intermittent culture with imatinib , which resulted in the acquisition of an exon 13 mutation at KIT V654A .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [69, 77], "tok_span": [15, 17]}, {"name": "V654A", "ent_type": "variant", "char_span": [144, 149], "tok_span": [31, 35]}], "relation_list": [{"subject": "V654A", "object": "imatinib", "sbj_char_span": [144, 149], "obj_char_span": [69, 77], "rel_type": "resistance", "sbj_tok_span": [31, 35], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Some mutations ( L755S ) resulted in lapatinib resistance ; however this was not an activating mutation .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [10, 13]}, {"name": "L755S", "ent_type": "variant", "char_span": [17, 22], "tok_span": [3, 7]}], "relation_list": [{"subject": "L755S", "object": "lapatinib", "sbj_char_span": [17, 22], "obj_char_span": [37, 46], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Two of these mutations were located in the kinase domain and are known to mediate resistance to lapatinib ( L755S ) or to activate Her2 ( D769H ) .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [96, 105], "tok_span": [17, 20]}, {"name": "L755S", "ent_type": "variant", "char_span": [108, 113], "tok_span": [21, 25]}, {"name": "D769H", "ent_type": "variant", "char_span": [138, 143], "tok_span": [32, 36]}], "relation_list": [{"subject": "L755S", "object": "lapatinib", "sbj_char_span": [108, 113], "obj_char_span": [96, 105], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [17, 20]}, {"subject": "D769H", "object": "lapatinib", "sbj_char_span": [138, 143], "obj_char_span": [96, 105], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Bose et al. , noted that V777L mutation was associated with negative ERBB2 protein expression and resistance to lapatinib .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [112, 121], "tok_span": [25, 28]}, {"name": "V777L", "ent_type": "variant", "char_span": [25, 30], "tok_span": [8, 12]}], "relation_list": [{"subject": "V777L", "object": "lapatinib", "sbj_char_span": [25, 30], "obj_char_span": [112, 121], "rel_type": "sensitivity", "sbj_tok_span": [8, 12], "obj_tok_span": [25, 28]}], "umls_entity_list": []}, {"text": "The PDGFRA exon 18 D842V point mutant activates PDGFRA both in vitro and in vivo and is also imatinib resistant in vivo and in vitro , whereas other mutations affecting exon 18 ( D846Y , N848K , Y849K and HDSN845-848P ) are imatinib sensitive .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [93, 101], "tok_span": [23, 25]}, {"name": "D842V", "ent_type": "variant", "char_span": [19, 24], "tok_span": [5, 9]}, {"name": "imatinib", "ent_type": "drug", "char_span": [224, 232], "tok_span": [64, 66]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [19, 24], "obj_char_span": [93, 101], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [23, 25]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [19, 24], "obj_char_span": [224, 232], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [64, 66]}], "umls_entity_list": []}, {"text": "Lastly , knowledge of the predictive and prognostic value of mutational status could lead physicians to establish the dose of imatinib , identify those patients who would not benefit from imatinib treatment ( PDGFRA exon 18 D842V mutant tumors are imatinib resistant ) , chose a second line therapy , and evaluate the different risk of relapse during follow-up .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [126, 134], "tok_span": [21, 23]}, {"name": "D842V", "ent_type": "variant", "char_span": [224, 229], "tok_span": [40, 44]}, {"name": "imatinib", "ent_type": "drug", "char_span": [188, 196], "tok_span": [32, 34]}, {"name": "imatinib", "ent_type": "drug", "char_span": [248, 256], "tok_span": [47, 49]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [224, 229], "obj_char_span": [126, 134], "rel_type": "resistance or non-response", "sbj_tok_span": [40, 44], "obj_tok_span": [21, 23]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [224, 229], "obj_char_span": [188, 196], "rel_type": "resistance or non-response", "sbj_tok_span": [40, 44], "obj_tok_span": [32, 34]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [224, 229], "obj_char_span": [248, 256], "rel_type": "resistance or non-response", "sbj_tok_span": [40, 44], "obj_tok_span": [47, 49]}], "umls_entity_list": []}, {"text": "These data emphasize that mutational status must play a predominant role in the clinical management of patients and that new findings are necessary to establish the mechanisms responsible for imatinib resistance in specific subsets of tumors like PDGFRA D842V mutant and WT GIST .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [192, 200], "tok_span": [30, 32]}, {"name": "D842V", "ent_type": "variant", "char_span": [254, 259], "tok_span": [41, 45]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [254, 259], "obj_char_span": [192, 200], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 45], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "The most common PDGFRA mutation , D842V in exon 18 , is resistant to imatinib. , , In contrast , the substitution V561D in exon 12 results in an isoform of PDGFRA that is highly sensitive to imatinib. , Lasota et al. and Heinrich et al. reported imatinib sensitivities for a deletion/substitution ( SPDGHE566-571R ) and an in-frame insertion mutation ( ER561-562 ) in exon 12 .", "entity_list": [{"name": "imatinib.", "ent_type": "drug", "char_span": [69, 78], "tok_span": [18, 21]}, {"name": "D842V", "ent_type": "variant", "char_span": [34, 39], "tok_span": [7, 11]}, {"name": "imatinib.", "ent_type": "drug", "char_span": [191, 200], "tok_span": [47, 50]}, {"name": "imatinib", "ent_type": "drug", "char_span": [246, 254], "tok_span": [63, 65]}], "relation_list": [{"subject": "D842V", "object": "imatinib.", "sbj_char_span": [34, 39], "obj_char_span": [69, 78], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [18, 21]}, {"subject": "D842V", "object": "imatinib.", "sbj_char_span": [34, 39], "obj_char_span": [191, 200], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [47, 50]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [34, 39], "obj_char_span": [246, 254], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [63, 65]}], "umls_entity_list": []}, {"text": "Mutational analysis is helpful in detecting the development of secondary mutations in tumors that are responding poorly to tyrosine kinase inhibitors and in identifying the PDGFRA exon 18 codon D842V missense mutation , which is associated with a good prognosis , but conversely confers resistance to imatinib. , Exon 9 is reported to benefit from a high dose ( 800 mg/day ) of imatinib in some studies .", "entity_list": [{"name": "imatinib.", "ent_type": "drug", "char_span": [301, 310], "tok_span": [53, 56]}, {"name": "D842V", "ent_type": "variant", "char_span": [194, 199], "tok_span": [31, 35]}, {"name": "imatinib", "ent_type": "drug", "char_span": [378, 386], "tok_span": [75, 77]}], "relation_list": [{"subject": "D842V", "object": "imatinib.", "sbj_char_span": [194, 199], "obj_char_span": [301, 310], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 35], "obj_tok_span": [53, 56]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [194, 199], "obj_char_span": [378, 386], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 35], "obj_tok_span": [75, 77]}], "umls_entity_list": []}, {"text": "Imatinib has been found to be effective not only for GIST with C-KIT mutations but also for GIST with PDGFRA mutations and for wild-type GISTs. , However , no adjuvant treatment is recommended in GISTs with the D842V missense mutation in the PDGFRA exon 18 , which are known to be unresponsive to imatinib and showed very favorable outcome after surgery .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "D842V", "ent_type": "variant", "char_span": [211, 216], "tok_span": [49, 53]}, {"name": "imatinib", "ent_type": "drug", "char_span": [297, 305], "tok_span": [72, 74]}], "relation_list": [{"subject": "D842V", "object": "Imatinib", "sbj_char_span": [211, 216], "obj_char_span": [0, 8], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 53], "obj_tok_span": [0, 2]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [211, 216], "obj_char_span": [297, 305], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 53], "obj_tok_span": [72, 74]}], "umls_entity_list": []}, {"text": "As for PDGFRA mutated GIST , PDGFRA exon 18 generally benefits from adjuvant imatinib therapy , with the exception of PDGFRA exon 18 D842V mutated GIST .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [77, 85], "tok_span": [16, 18]}, {"name": "D842V", "ent_type": "variant", "char_span": [133, 138], "tok_span": [28, 32]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [133, 138], "obj_char_span": [77, 85], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "The PDGFR-α D842V mutant conferred resistance to imatinib as well as to sunitinib in in vitro experiments .", "entity_list": [{"name": "to imatinib", "ent_type": "drug", "char_span": [46, 57], "tok_span": [13, 16]}, {"name": "PDGFR-α D842V", "ent_type": "variant", "char_span": [4, 17], "tok_span": [1, 9]}], "relation_list": [{"subject": "PDGFR-α D842V", "object": "to imatinib", "sbj_char_span": [4, 17], "obj_char_span": [46, 57], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 9], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "T790M mutation occurs by substitution of the amino acid threonine by methionine in amino acid position 790 ( T790M ) on exon 20 and is similar to the KIT T670I gatekeeper mutation observed in imatinib-resistant gastrointestinal stromal tumor .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [192, 210], "tok_span": [48, 52]}, {"name": "T670I", "ent_type": "variant", "char_span": [154, 159], "tok_span": [38, 42]}], "relation_list": [{"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [154, 159], "obj_char_span": [192, 210], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "For example , crizotinib maintains activity against the R1275Q mutant , but drastically loses activity against F1174L , another frequently occurring mutant ( Wood et al. , ; Sakamoto et al. , ; Schönherr et al. , ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [14, 24], "tok_span": [3, 7]}, {"name": "F1174L", "ent_type": "variant", "char_span": [111, 117], "tok_span": [23, 27]}, {"name": "R1275Q", "ent_type": "variant", "char_span": [56, 62], "tok_span": [11, 15]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [111, 117], "obj_char_span": [14, 24], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [3, 7]}, {"subject": "R1275Q", "object": "crizotinib", "sbj_char_span": [56, 62], "obj_char_span": [14, 24], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "F1174L , which recapitulates the primary mutation found in neuroblastoma previously shown to render the enzyme insensitive to crizotinib , appears instead to induce a conformational change in the protein which results in increased affinity for ATP itself .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [126, 136], "tok_span": [25, 29]}, {"name": "F1174L", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [126, 136], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "In vivo efficacy was described only for the L1196M gatekeeper mutation , confirming a higher potency with respect to crizotinib in inhibiting the in vivo growth of ALK–L1196M driven Ba/F3 cells . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [117, 127], "tok_span": [24, 28]}, {"name": "L1196M", "ent_type": "variant", "char_span": [44, 50], "tok_span": [8, 12]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [44, 50], "obj_char_span": [117, 127], "rel_type": "resistance", "sbj_tok_span": [8, 12], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "X-396 was also evaluated on L1196M and C1156Y mutations and data suggest that it can potentially overcome at least these crizotinib resistance mutations .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [121, 131], "tok_span": [29, 33]}, {"name": "L1196M", "ent_type": "variant", "char_span": [28, 34], "tok_span": [8, 12]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [39, 45], "tok_span": [13, 17]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [28, 34], "obj_char_span": [121, 131], "rel_type": "resistance", "sbj_tok_span": [8, 12], "obj_tok_span": [29, 33]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [39, 45], "obj_char_span": [121, 131], "rel_type": "resistance", "sbj_tok_span": [13, 17], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "When tested in Ba/F3 cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than crizotinib in inhibiting the proliferation of L1196M ALK and C1156Y ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [63, 73], "tok_span": [15, 19]}, {"name": "L1196M", "ent_type": "variant", "char_span": [184, 190], "tok_span": [46, 50]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [138, 148], "tok_span": [37, 41]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [199, 205], "tok_span": [53, 57]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [184, 190], "obj_char_span": [63, 73], "rel_type": "resistance", "sbj_tok_span": [46, 50], "obj_tok_span": [15, 19]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [184, 190], "obj_char_span": [138, 148], "rel_type": "resistance", "sbj_tok_span": [46, 50], "obj_tok_span": [37, 41]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [199, 205], "obj_char_span": [63, 73], "rel_type": "resistance", "sbj_tok_span": [53, 57], "obj_tok_span": [15, 19]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [199, 205], "obj_char_span": [138, 148], "rel_type": "resistance", "sbj_tok_span": [53, 57], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "LDK378 appears very efficacious in vivo , inducing complete and durable tumor regression in an ALK positive NSCLC dependent model and was also described to be active in tumors bearing the C1156Y mutation that confers crizotinib resistance ( Li et al. , ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [217, 227], "tok_span": [43, 47]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [188, 194], "tok_span": [36, 40]}], "relation_list": [{"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [188, 194], "obj_char_span": [217, 227], "rel_type": "resistance", "sbj_tok_span": [36, 40], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "Two secondary mutations of ALK associated with crizotinib resistance – L1196M and C1156Y – were first detected in the same patient , who relapsed after achieving a partial response to the drug .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [47, 57], "tok_span": [8, 12]}, {"name": "– L1196M", "ent_type": "variant", "char_span": [69, 77], "tok_span": [13, 18]}, {"name": "and C1156Y", "ent_type": "variant", "char_span": [78, 88], "tok_span": [18, 23]}], "relation_list": [{"subject": "– L1196M", "object": "crizotinib", "sbj_char_span": [69, 77], "obj_char_span": [47, 57], "rel_type": "resistance", "sbj_tok_span": [13, 18], "obj_tok_span": [8, 12]}, {"subject": "and C1156Y", "object": "crizotinib", "sbj_char_span": [78, 88], "obj_char_span": [47, 57], "rel_type": "resistance", "sbj_tok_span": [18, 23], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "In contrast to crizotinib , alectinib also shows substantial inhibitory activity against the L1196M mutant of ALK , apparently because it is able to maintain an efficient ( CH/π ) interaction with position 1196 even after the substitution of methionine for leucine .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [15, 25], "tok_span": [3, 7]}, {"name": "L1196M", "ent_type": "variant", "char_span": [93, 99], "tok_span": [18, 22]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [93, 99], "obj_char_span": [15, 25], "rel_type": "resistance", "sbj_tok_span": [18, 22], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Studies of ALK rearranged lung cancers with acquired resistance to crizotinib have identified ALK fusion gene amplification and secondary ALK TK domain mutations ( L1196M and G1269A ) in about one third of cases .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [67, 77], "tok_span": [12, 16]}, {"name": "L1196M", "ent_type": "variant", "char_span": [164, 170], "tok_span": [31, 35]}, {"name": "G1269A", "ent_type": "variant", "char_span": [175, 181], "tok_span": [36, 40]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [164, 170], "obj_char_span": [67, 77], "rel_type": "resistance", "sbj_tok_span": [31, 35], "obj_tok_span": [12, 16]}, {"subject": "G1269A", "object": "crizotinib", "sbj_char_span": [175, 181], "obj_char_span": [67, 77], "rel_type": "resistance", "sbj_tok_span": [36, 40], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "However , while ceritinib is able to effectively suppress many crizotinib-resistant mutations , the G1202R and F1174V/C mutants are resistant to ceritinib .", "entity_list": [{"name": "crizotinib-resistant", "ent_type": "drug", "char_span": [63, 83], "tok_span": [12, 18]}, {"name": "G1202R", "ent_type": "variant", "char_span": [100, 106], "tok_span": [21, 25]}], "relation_list": [{"subject": "G1202R", "object": "crizotinib-resistant", "sbj_char_span": [100, 106], "obj_char_span": [63, 83], "rel_type": "resistance", "sbj_tok_span": [21, 25], "obj_tok_span": [12, 18]}], "umls_entity_list": []}, {"text": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated EGFR ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [38, 46], "tok_span": [12, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [180, 185], "tok_span": [49, 53]}, {"name": "afatinib", "ent_type": "drug", "char_span": [111, 119], "tok_span": [26, 28]}, {"name": "afatinib", "ent_type": "drug", "char_span": [201, 209], "tok_span": [56, 58]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [180, 185], "obj_char_span": [38, 46], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [12, 14]}, {"subject": "L858R", "object": "afatinib", "sbj_char_span": [180, 185], "obj_char_span": [111, 119], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [26, 28]}, {"subject": "L858R", "object": "afatinib", "sbj_char_span": [180, 185], "obj_char_span": [201, 209], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [56, 58]}], "umls_entity_list": []}, {"text": "Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant T790M mutation is concomitant to a sensitivity mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [11, 19], "tok_span": [2, 4]}, {"name": "T790M", "ent_type": "variant", "char_span": [106, 111], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [106, 111], "obj_char_span": [11, 19], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "In addition , afatinib should be active in patients with the T790M mutation and in those with HER2 amplification , representing 60 % –70 % of the resistant population .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [14, 22], "tok_span": [3, 5]}, {"name": "T790M", "ent_type": "variant", "char_span": [61, 66], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [61, 66], "obj_char_span": [14, 22], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Combined therapy with DzT and BIBW-2992 synergistically inhibited the growth of xenograft tumors derived from cells harboring the EGFR T790M mutant , suggesting that DzT may overcome T790M based TKI resistance in NSCLC .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [30, 39], "tok_span": [7, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [135, 140], "tok_span": [27, 31]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [135, 140], "obj_char_span": [30, 39], "rel_type": "response", "sbj_tok_span": [27, 31], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "Synergistic antitumor effect of combined treatment with cDzT and BIBW-2992 in vitro and in vivo cDzT could be used as single agent or as part of combination therapy with second generation TKIs to increase efficacy in the treatment of NSCLCs that harbor the EGFR T790M mutant .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [65, 74], "tok_span": [14, 19]}, {"name": "T790M", "ent_type": "variant", "char_span": [262, 267], "tok_span": [58, 62]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [262, 267], "obj_char_span": [65, 74], "rel_type": "response", "sbj_tok_span": [58, 62], "obj_tok_span": [14, 19]}], "umls_entity_list": []}, {"text": "The efficacy of combined treatment with cDzT and the TKI , BIBW-2992 , against EGFR T790M based drug resistance was evaluated in vitro and in vivo .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [59, 68], "tok_span": [15, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [84, 89], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [84, 89], "obj_char_span": [59, 68], "rel_type": "response", "sbj_tok_span": [23, 27], "obj_tok_span": [15, 20]}], "umls_entity_list": []}, {"text": "Both cDzT and BIBW-2992 alone inhibited growth and signaling in EGFR T790M mutant cells ( H1975TM/LR and CL97TM/GA ) , albeit through different mechanisms .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [14, 23], "tok_span": [6, 11]}, {"name": "T790M", "ent_type": "variant", "char_span": [69, 74], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [69, 74], "obj_char_span": [14, 23], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "cDzT specifically degraded EGFR T790M mRNA and decreased EGFR protein levels , whereas BIBW-2992 inhibited autophosphorylation of EGFR without affecting EGFR protein level .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [87, 96], "tok_span": [19, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [32, 37], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [32, 37], "obj_char_span": [87, 96], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [19, 24]}], "umls_entity_list": []}, {"text": "Taken together , these results indicate that the combination of cDzT and BIBW-2992 synergistically inhibits EGFR protein expression and downstream signaling , triggering T790M harboring cells to undergo apoptosis and suppressing xenograft tumor growth .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [73, 82], "tok_span": [15, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [170, 175], "tok_span": [31, 35]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [170, 175], "obj_char_span": [73, 82], "rel_type": "response", "sbj_tok_span": [31, 35], "obj_tok_span": [15, 20]}], "umls_entity_list": []}, {"text": "Furthermore , we showed a synergistic effect of cDzT and BIBW-2992 on growth inhibition in vitro and in vivo in cancer cells harboring the EGFR T790M mutant .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [57, 66], "tok_span": [13, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [144, 149], "tok_span": [32, 36]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [144, 149], "obj_char_span": [57, 66], "rel_type": "response", "sbj_tok_span": [32, 36], "obj_tok_span": [13, 18]}], "umls_entity_list": []}, {"text": "We also demonstrated that cDzT and BIBW-2992 functioned in a synergistic manner against EGFR signaling pathways to suppress the growth of EGFR T790M harboring NSCLC cells .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [35, 44], "tok_span": [9, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [143, 148], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [143, 148], "obj_char_span": [35, 44], "rel_type": "response", "sbj_tok_span": [30, 34], "obj_tok_span": [9, 14]}], "umls_entity_list": []}, {"text": "cDzT cleaves EGFR T790M mRNA , which leads to a decrease in EGFR protein levels , whereas BIBW-2992 is a second-line TKI that irreversibly binds to the intracellular kinase domain of EGFR and suppresses its downstream signaling .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [90, 99], "tok_span": [24, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [18, 23], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [18, 23], "obj_char_span": [90, 99], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [24, 29]}], "umls_entity_list": []}, {"text": "Combined treatment of cDzT and BIBW-2992 exerts a synergistic inhibitory effect on cell viability in cells harboring EGFR T790M mutants .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [31, 40], "tok_span": [8, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [122, 127], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [122, 127], "obj_char_span": [31, 40], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [8, 13]}], "umls_entity_list": []}, {"text": "Combined treatment of cDzT and BIBW-2992 exerts a synergistic inhibitory effect on cell viability in cells harboring EGFR T790M mutants .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [31, 40], "tok_span": [8, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [122, 127], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [122, 127], "obj_char_span": [31, 40], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [8, 13]}], "umls_entity_list": []}, {"text": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [216, 224], "tok_span": [63, 65]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [21, 25]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [57, 62], "obj_char_span": [216, 224], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [63, 65]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [74, 79], "obj_char_span": [216, 224], "rel_type": "response", "sbj_tok_span": [21, 25], "obj_tok_span": [63, 65]}], "umls_entity_list": []}, {"text": "The ability of irreversible pan-HER inhibitors such as afatinib and dacomitinib to overcome T790M mediated resistance to gefitinib has been demonstrated in some preclinical studies ; therefore , they are being actively investigated .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [55, 63], "tok_span": [10, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [92, 97], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [92, 97], "obj_char_span": [55, 63], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Kim et al. demonstrated a role for the IL-6R/JAK1/STAT3 signaling pathway , leading to STAT3 activation , in de novo resistance to irreversible EGFR-TKIs , such as afatinib , in NSCLC cells with EGFR T790M .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [164, 172], "tok_span": [41, 43]}, {"name": "T790M", "ent_type": "variant", "char_span": [200, 205], "tok_span": [49, 53]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [200, 205], "obj_char_span": [164, 172], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [41, 43]}], "umls_entity_list": []}, {"text": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR T790M models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "entity_list": [{"name": ", afatinib", "ent_type": "drug", "char_span": [48, 58], "tok_span": [13, 16]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [141, 151], "tok_span": [38, 43]}], "relation_list": [{"subject": "EGFR T790M", "object": ", afatinib", "sbj_char_span": [141, 151], "obj_char_span": [48, 58], "rel_type": "response", "sbj_tok_span": [38, 43], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Afatinib , an EGFR and HER2 irreversible inhibitor has been shown to reverse the effects of the T790M mutation in preclinical lung cancer studies .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "T790M", "ent_type": "variant", "char_span": [96, 101], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "Afatinib", "sbj_char_span": [96, 101], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "A subgroup analysis of progression-free survival in sporadic MTC patients suggested that RET M918T mutation positive patients had a higher response rate to vandetanib compared with RET M918T mutation negative patients. ,", "entity_list": [{"name": "vandetanib", "ent_type": "drug", "char_span": [156, 166], "tok_span": [29, 33]}, {"name": "M918T", "ent_type": "variant", "char_span": [93, 98], "tok_span": [16, 20]}], "relation_list": [{"subject": "M918T", "object": "vandetanib", "sbj_char_span": [93, 98], "obj_char_span": [156, 166], "rel_type": "response", "sbj_tok_span": [16, 20], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "A recent study compared the effect of four TKIs ( axitinib , sunitinib , vandetanib , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( M918T RET mutation ) , MTC-TT ( C634W RET mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "entity_list": [{"name": "vandetanib", "ent_type": "drug", "char_span": [73, 83], "tok_span": [19, 23]}, {"name": "M918T", "ent_type": "variant", "char_span": [234, 239], "tok_span": [54, 58]}, {"name": "C634W", "ent_type": "variant", "char_span": [266, 271], "tok_span": [67, 71]}], "relation_list": [{"subject": "M918T", "object": "vandetanib", "sbj_char_span": [234, 239], "obj_char_span": [73, 83], "rel_type": "response", "sbj_tok_span": [54, 58], "obj_tok_span": [19, 23]}, {"subject": "C634W", "object": "vandetanib", "sbj_char_span": [266, 271], "obj_char_span": [73, 83], "rel_type": "response", "sbj_tok_span": [67, 71], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Imatinib , masitinib and bafetinib are agents unable to block the kinase activity of KIT D816V , whereas midostaurin and dasatinib have clear inhibitory activity against KIT D816V .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [33, 35]}, {"name": "D816V", "ent_type": "variant", "char_span": [89, 94], "tok_span": [22, 26]}], "relation_list": [{"subject": "D816V", "object": "dasatinib", "sbj_char_span": [89, 94], "obj_char_span": [121, 130], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "We reasoned that if the same hypermethylator phenotype was caused by loss of TET2 in the KIT D816V positive HMC-1.2 cell line , resulting silencing of gene expression in these cells could potentially be reversed by treatment with epigenetic modifiers , providing an enhanced effect to dasatinib ( DASA ) .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [285, 294], "tok_span": [62, 64]}, {"name": "D816V", "ent_type": "variant", "char_span": [93, 98], "tok_span": [23, 27]}], "relation_list": [{"subject": "D816V", "object": "dasatinib", "sbj_char_span": [93, 98], "obj_char_span": [285, 294], "rel_type": "response", "sbj_tok_span": [23, 27], "obj_tok_span": [62, 64]}], "umls_entity_list": []}, {"text": "Dasatinib , to which KIT D816V is sensitive , may have a role in the therapy of these cases as evidenced by in vitro data as well as its in vivo activity of this drug in recent reports of SM , including a patient with SM-AML .", "entity_list": [{"name": "Dasatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "D816V", "ent_type": "variant", "char_span": [25, 30], "tok_span": [7, 11]}], "relation_list": [{"subject": "D816V", "object": "Dasatinib", "sbj_char_span": [25, 30], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "KIT W557R V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "entity_list": [{"name": "Nilotinib", "ent_type": "drug", "char_span": [97, 106], "tok_span": [44, 48]}, {"name": "L576P", "ent_type": "variant", "char_span": [18, 23], "tok_span": [12, 16]}], "relation_list": [{"subject": "L576P", "object": "Nilotinib", "sbj_char_span": [18, 23], "obj_char_span": [97, 106], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "Ponatinib is effective at nanomolar levels against T315I and other point mutations , .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [51, 56], "tok_span": [9, 13]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [51, 56], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [9, 13], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "In this study , we investigated ponatinib activity against Ph-positive leukemia cells carrying the T315I mutation .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [32, 41], "tok_span": [6, 10]}, {"name": "T315I", "ent_type": "variant", "char_span": [99, 104], "tok_span": [19, 23]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [99, 104], "obj_char_span": [32, 41], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Ponatinib inhibits growth and induces apoptosis in K562 and T315I mutant cells", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [60, 65], "tok_span": [12, 16]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [60, 65], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "It has been reported that ponatinib has potent activity against T315I mutant cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [5, 9]}, {"name": "T315I", "ent_type": "variant", "char_span": [64, 69], "tok_span": [13, 17]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [64, 69], "obj_char_span": [26, 35], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Thus , we examined ponatinib activity by using Ba/F3 BCR-ABL T315I mutant cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [19, 28], "tok_span": [4, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [61, 66], "tok_span": [19, 23]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [61, 66], "obj_char_span": [19, 28], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "In concordance with previously reported results , ponatinib inhibited growth in Ba/F3 T315I cells at low concentrations ( ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [7, 11]}, {"name": "T315I", "ent_type": "variant", "char_span": [86, 91], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [86, 91], "obj_char_span": [50, 59], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "( D ) Ba/F3 T315I cells were treated with ponatinib for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho ABL , anti-Crk-L , anti cleaved caspase 3 , anti-PARP , and anti-tubulin antibodies .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [42, 51], "tok_span": [15, 19]}, {"name": "T315I", "ent_type": "variant", "char_span": [12, 17], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [12, 17], "obj_char_span": [42, 51], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "We examined whether treatment with ponatinib and vorinostat induced cell death in T315I mutant cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [35, 44], "tok_span": [5, 9]}, {"name": "T315I", "ent_type": "variant", "char_span": [82, 87], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [82, 87], "obj_char_span": [35, 44], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "( B ) K562 or Ba/F3 T315I cells were treated with ponatinib and/or vorinostat for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho ABL , Crk-L , γH2A.X , cleaved caspase 3 , PARP , acetyl histone H4 , and tubulin antibodies .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [19, 23]}, {"name": "T315I", "ent_type": "variant", "char_span": [20, 25], "tok_span": [11, 15]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [20, 25], "obj_char_span": [50, 59], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "To confirm the effect of ponatinib and vorinostat on T315I mutant cells , we examined their activity in a mouse xenograft model .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [5, 9]}, {"name": "T315I", "ent_type": "variant", "char_span": [53, 58], "tok_span": [15, 19]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [53, 58], "obj_char_span": [25, 34], "rel_type": "response", "sbj_tok_span": [15, 19], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Thus , co-treatment with ponatinib and vorinostat inhibited tumor growth and induced apoptosis in T315I positive Ba/F3 cells in the xenograft .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [6, 10]}, {"name": "T315I", "ent_type": "variant", "char_span": [98, 103], "tok_span": [22, 26]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [98, 103], "obj_char_span": [25, 34], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "( B ) Immunohistochemical staining for hematoxylin and eosin ( HE ) at a magnification of 40× , Ki67 ( magnification , 400× ) , and TUNEL ( magnification , 400× ) in Ba/F3 T315I xenograft sections . ( C ) Tumor cells treated with or without ponatinib and vorinostat were examined by immunoblot analysis .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [241, 250], "tok_span": [59, 63]}, {"name": "Ba/F3 T315I", "ent_type": "variant", "char_span": [166, 177], "tok_span": [38, 46]}], "relation_list": [{"subject": "Ba/F3 T315I", "object": "ponatinib", "sbj_char_span": [166, 177], "obj_char_span": [241, 250], "rel_type": "response", "sbj_tok_span": [38, 46], "obj_tok_span": [59, 63]}], "umls_entity_list": []}, {"text": "Since vorinostat was effective against T315I mutant cells , we investigated whether ponatinib-resistant cells were inhibited by this HDACi .", "entity_list": [{"name": "ponatinib-resistant", "ent_type": "drug", "char_span": [84, 103], "tok_span": [18, 24]}, {"name": "T315I", "ent_type": "variant", "char_span": [39, 44], "tok_span": [8, 12]}], "relation_list": [{"subject": "T315I", "object": "ponatinib-resistant", "sbj_char_span": [39, 44], "obj_char_span": [84, 103], "rel_type": "response", "sbj_tok_span": [8, 12], "obj_tok_span": [18, 24]}], "umls_entity_list": []}, {"text": "We confirmed that ponatinib was effective against BCR-ABL wild-type and T315I mutant cells at low concentrations by cell proliferation and immunoblot assays .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [18, 27], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [72, 77], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [72, 77], "obj_char_span": [18, 27], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Vorinostat induced growth arrest and apoptosis , thus aggravating the apoptotic and cytotoxic effects of ponatinib on Ba/F3 T315I mutant cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [19, 23]}, {"name": "T315I", "ent_type": "variant", "char_span": [124, 129], "tok_span": [28, 32]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [124, 129], "obj_char_span": [105, 114], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Several strategies targeting T315I BCR-ABL including blockade of kinase-addiction by the third-generation of tyrosine kinase inhibitor ponatinib , down-modulation of BCR-ABL by inhibition of heat shock protein were documented .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [135, 144], "tok_span": [26, 30]}, {"name": "T315I", "ent_type": "variant", "char_span": [29, 34], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [29, 34], "obj_char_span": [135, 144], "rel_type": "response", "sbj_tok_span": [3, 7], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Although TKIs such as Ponatinib , with activity against the T315I mutation , have been developed , their application to CML therapy has been limited by concerns regarding toxicity .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [22, 31], "tok_span": [5, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [60, 65], "tok_span": [12, 16]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [60, 65], "obj_char_span": [22, 31], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "The L858R substitution ( an arginine for leucine substitution at amino acid 858 ) is one of the most frequently reported mutations and shows good responses to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [159, 168], "tok_span": [31, 35]}, {"name": "L858R", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [159, 168], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "However , no mechanistic explanation has been found for the contributions of these molecules to the gefitinib sensitivity of the L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [100, 109], "tok_span": [16, 20]}, {"name": "L858R", "ent_type": "variant", "char_span": [129, 134], "tok_span": [23, 27]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [100, 109], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The results indicate that the L858R model A , including Mig6 , successfully reproduced the inhibitory effect for ERK at higher concentrations of gefitinib , whereas model B , which included the effect of Cbl , failed to reproduce this response .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [145, 154], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [30, 35], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [30, 35], "obj_char_span": [145, 154], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "We confirmed that L858R model A with other parameter sets that have similar cost function values yields the same trends with regard to the role of Mig6 in gefitinib sensitivity ( data not shown ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [155, 164], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [18, 23], "tok_span": [3, 7]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [18, 23], "obj_char_span": [155, 164], "rel_type": "sensitivity", "sbj_tok_span": [3, 7], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "Yun et al showed that gefitinib directly binds more tightly to the L858R mutant than to the wild type EGFR in vitro , while Fabian et al indicated that EGFR with gefitinib sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [22, 31], "tok_span": [5, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [67, 72], "tok_span": [15, 19]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [162, 171], "tok_span": [38, 42]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [240, 249], "tok_span": [54, 58]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [67, 72], "obj_char_span": [22, 31], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [5, 9]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [67, 72], "obj_char_span": [162, 171], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [38, 42]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [67, 72], "obj_char_span": [240, 249], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [54, 58]}], "umls_entity_list": []}, {"text": "after 1st PS Response PFS to 2nd TKI OS from 2nd TKI 1 50 F Current Ad NA 9.8 G→E 7.9 CBDCA+GEM 1 PD 0.9 13.1 2 46 F Never Ad NA 11.8 G→G 4.5 DOC1 PR 6.4 24.6 3 58 F Ex Ad 19 deletion 38.4 G→G 2.8 DOC1 SD 7.3 24.1 4 70 F Never Sq NA 10.2 G→E12.8 GEM 1 SD 1.7 4.3 5 60 F Never Ad NA 13 G→G 5.4 GEM 1 PD1.6 2.1 6 63 F Never Ad NA 7.4 G→E 2.6 - 3 SD 3.6 7.8 7 52 M Never Ad L858R 5.8 G→E1 - 4 SD 6.4 6.4 8 51 M Current Ad NA 4.3 G→E1.6 AMR 3 PD 0.6 0.9 9 61 F Never Ad NA 8.5 G→E 2.3 VNR 3 SD 2.9 4 10 53 F Never Ad NA 12.9 G→E 0 - 4 SD 6.2 7.3 11 54 M Current Ad 19 deletion 3.8 G→E 7.3 VNR 1 SD 3.2 5 Response to the initial gefitinib treatment During the 1st EGFR-TKI treatment with gefitinib , 8 patients achieved PR as the best response ( 73 % , Table ) , and 3 patients ( 27 % ) were SD .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [683, 692], "tok_span": [306, 310]}, {"name": "Never Ad", "ent_type": "variant", "char_span": [362, 370], "tok_span": [171, 173]}], "relation_list": [{"subject": "Never Ad", "object": "gefitinib", "sbj_char_span": [362, 370], "obj_char_span": [683, 692], "rel_type": "sensitivity", "sbj_tok_span": [171, 173], "obj_tok_span": [306, 310]}], "umls_entity_list": []}, {"text": "These T790M mutation seemed to be the cause of gefitinib resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [6, 11], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [6, 11], "obj_char_span": [47, 56], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "While T790M is found in about half of patients with acquired resistance to erlotinib and gefitinib , the other mechanism of resistance – MET amplification – makes up about 5 % –10 % of these patients .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [89, 98], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [6, 11], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [6, 11], "obj_char_span": [89, 98], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "These missense ( G719S/C and L858R ) and deletion mutations ( in the region spanning codons 746-759 ) are located in exons 18 through 21 of EGFR and appear to confer tumor susceptibility to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [190, 199], "tok_span": [47, 51]}, {"name": "L858R", "ent_type": "variant", "char_span": [29, 34], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [29, 34], "obj_char_span": [190, 199], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "T790M and MET amplification , which can be detected in up to 20 % of EGFR NSCLCs secondarily refractory to EGFR TKIs , account for approximately 60–70 % of all known causes of acquired resistance to gefitinib/erlotinib .", "entity_list": [{"name": "to gefitinib/erlotinib", "ent_type": "drug", "char_span": [196, 218], "tok_span": [43, 53]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T790M", "object": "to gefitinib/erlotinib", "sbj_char_span": [0, 5], "obj_char_span": [196, 218], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [43, 53]}], "umls_entity_list": []}, {"text": "Intense research efforts over the past few years have identified two major mechanisms of acquired resistance to gefitinib/erlotinib : secondary resistance mutations ( e.g. , T790M ) and “oncogene kinase switch” systems ( e.g. , MET amplification and AXL activation ) .", "entity_list": [{"name": "gefitinib/erlotinib", "ent_type": "drug", "char_span": [112, 131], "tok_span": [18, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [174, 179], "tok_span": [37, 41]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib", "sbj_char_span": [174, 179], "obj_char_span": [112, 131], "rel_type": "resistance or non-response", "sbj_tok_span": [37, 41], "obj_tok_span": [18, 27]}], "umls_entity_list": []}, {"text": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or gefitinib would lead to a surge in the rate of EGFR T790M mutation which , in vitro , conferred resistance to treatment with erlotinib and gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [19, 23]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [315, 325], "tok_span": [67, 72]}, {"name": "or gefitinib", "ent_type": "drug", "char_span": [265, 277], "tok_span": [53, 58]}, {"name": "and gefitinib", "ent_type": "drug", "char_span": [403, 416], "tok_span": [88, 93]}], "relation_list": [{"subject": "EGFR T790M", "object": "gefitinib", "sbj_char_span": [315, 325], "obj_char_span": [90, 99], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [19, 23]}, {"subject": "EGFR T790M", "object": "or gefitinib", "sbj_char_span": [315, 325], "obj_char_span": [265, 277], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [53, 58]}, {"subject": "EGFR T790M", "object": "and gefitinib", "sbj_char_span": [315, 325], "obj_char_span": [403, 416], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [88, 93]}], "umls_entity_list": []}, {"text": "Contrarily , a point mutation in the EGFR gene , which results in the substitution of methionine for threonine at position 790 ( T790M ) , decreases the ability of erlotinib or gefitinib to inhibit EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [41, 45]}, {"name": "T790M", "ent_type": "variant", "char_span": [129, 134], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 L858R mutation. , Further studies then compared first-generation EGFR-TKIs ( erlotinib and gefitinib ) to chemotherapy in patients with EGFR activating mutations in advanced NSCLC .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [247, 256], "tok_span": [53, 57]}, {"name": "L858R", "ent_type": "variant", "char_span": [156, 161], "tok_span": [29, 33]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [156, 161], "obj_char_span": [247, 256], "rel_type": "sensitivity", "sbj_tok_span": [29, 33], "obj_tok_span": [53, 57]}], "umls_entity_list": []}, {"text": "The firstly described and the most common event responsible for resistance is the acquisition of the T790M missense mutation , which is found in ≈ 50 % of patients progressing after an initial response to erlotinib or gefitinib .", "entity_list": [{"name": "or gefitinib", "ent_type": "drug", "char_span": [215, 227], "tok_span": [44, 49]}, {"name": "T790M", "ent_type": "variant", "char_span": [101, 106], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "or gefitinib", "sbj_char_span": [101, 106], "obj_char_span": [215, 227], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [44, 49]}], "umls_entity_list": []}, {"text": "Neratinib is an oral , irreversible inhibitor of both EGFR and HER2 ; in preclinical studies conducted on cell lines with both an activating EGFR mutation and the T790M , neratinib was more effective at suppressing cell proliferation than gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [239, 248], "tok_span": [49, 53]}, {"name": "T790M", "ent_type": "variant", "char_span": [163, 168], "tok_span": [32, 36]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [163, 168], "obj_char_span": [239, 248], "rel_type": "resistance or non-response", "sbj_tok_span": [32, 36], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "In vitro studies showed that exon 19 deleted mutants and L858R mutant receptors appear to be more sensitive to gefitinib inhibition as compared to wild type receptors .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [111, 120], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [111, 120], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Patients with exon 19 harboring deletions were found to have longer survival following treatment with gefitinib or erlotinib compared with those having L858R mutations in NSCLC ; however , Marks et al. reported no difference in survival between exon 19 deletions and L858R mutations in the absence of EGFR targeted therapy .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [102, 111], "tok_span": [15, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [152, 157], "tok_span": [28, 32]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [152, 157], "obj_char_span": [102, 111], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [151, 160], "tok_span": [48, 52]}, {"name": "L858R", "ent_type": "variant", "char_span": [141, 146], "tok_span": [43, 47]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [282, 291], "tok_span": [110, 114]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [428, 437], "tok_span": [177, 181]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [477, 486], "tok_span": [201, 205]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [656, 665], "tok_span": [272, 276]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [1077, 1086], "tok_span": [456, 460]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [1123, 1132], "tok_span": [476, 480]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [1389, 1398], "tok_span": [577, 581]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [194, 203], "tok_span": [69, 73]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [237, 246], "tok_span": [89, 93]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [340, 349], "tok_span": [137, 141]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [384, 393], "tok_span": [157, 161]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [522, 531], "tok_span": [219, 223]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [567, 576], "tok_span": [237, 241]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [614, 623], "tok_span": [256, 260]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [701, 710], "tok_span": [292, 296]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [746, 755], "tok_span": [312, 316]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [791, 800], "tok_span": [330, 334]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [838, 847], "tok_span": [349, 353]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [881, 890], "tok_span": [367, 371]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [927, 936], "tok_span": [385, 389]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [973, 982], "tok_span": [408, 412]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1019, 1028], "tok_span": [429, 433]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1170, 1179], "tok_span": [496, 500]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1212, 1221], "tok_span": [509, 513]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1256, 1265], "tok_span": [527, 531]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1300, 1309], "tok_span": [544, 548]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1347, 1356], "tok_span": [563, 567]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1437, 1446], "tok_span": [595, 599]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1485, 1494], "tok_span": [613, 617]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1533, 1542], "tok_span": [633, 637]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1580, 1589], "tok_span": [656, 660]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [1627, 1636], "tok_span": [675, 679]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [141, 146], "obj_char_span": [151, 160], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [48, 52]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [141, 146], "obj_char_span": [282, 291], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [110, 114]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [141, 146], "obj_char_span": [428, 437], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [177, 181]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [141, 146], "obj_char_span": [477, 486], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [201, 205]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [141, 146], "obj_char_span": [656, 665], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [272, 276]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [141, 146], "obj_char_span": [1077, 1086], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [456, 460]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [141, 146], "obj_char_span": [1123, 1132], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [476, 480]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [141, 146], "obj_char_span": [1389, 1398], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [577, 581]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [194, 203], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [69, 73]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [237, 246], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [89, 93]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [340, 349], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [137, 141]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [384, 393], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [157, 161]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [522, 531], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [219, 223]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [567, 576], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [237, 241]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [614, 623], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [256, 260]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [701, 710], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [292, 296]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [746, 755], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [312, 316]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [791, 800], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [330, 334]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [838, 847], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [349, 353]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [881, 890], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [367, 371]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [927, 936], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [385, 389]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [973, 982], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [408, 412]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1019, 1028], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [429, 433]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1170, 1179], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [496, 500]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1212, 1221], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [509, 513]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1256, 1265], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [527, 531]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1300, 1309], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [544, 548]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1347, 1356], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [563, 567]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1437, 1446], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [595, 599]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1485, 1494], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [613, 617]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1533, 1542], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [633, 637]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1580, 1589], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [656, 660]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [1627, 1636], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [675, 679]}], "umls_entity_list": []}, {"text": "A retrospective study which investigated the frequency of complex mutations in 783 NSCLC patients found the majority was G719S plus L858R mutation ( n = 8 ) , the result also suggested poor response to gefitinib in patients with G719S plus L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [202, 211], "tok_span": [42, 46]}, {"name": "G719S", "ent_type": "variant", "char_span": [121, 126], "tok_span": [19, 23]}, {"name": "L858R", "ent_type": "variant", "char_span": [132, 137], "tok_span": [24, 28]}], "relation_list": [{"subject": "G719S", "object": "gefitinib", "sbj_char_span": [121, 126], "obj_char_span": [202, 211], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [42, 46]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [132, 137], "obj_char_span": [202, 211], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "Several studies have reported that advanced NSCLC patients with EGFR exon 19 deletion had a longer overall survival ( OS ) and/or progression-free survival ( PFS ) following treatment with gefitinib or erlotinib compared with those with the L858R mutation , , , but this result has not been shown in all reports , , , , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [189, 198], "tok_span": [34, 38]}, {"name": "L858R", "ent_type": "variant", "char_span": [241, 246], "tok_span": [48, 52]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [241, 246], "obj_char_span": [189, 198], "rel_type": "sensitivity", "sbj_tok_span": [48, 52], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "T790M mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( EGFR-TKI ) —erlotinib and gefitinib in NSCLC patients . ", "entity_list": [{"name": "and gefitinib", "ent_type": "drug", "char_span": [213, 226], "tok_span": [41, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T790M", "object": "and gefitinib", "sbj_char_span": [0, 5], "obj_char_span": [213, 226], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [41, 46]}], "umls_entity_list": []}, {"text": "The possibility of detection of T790M mutation in EGFR-TKIs naive patients forces to expand the diagnostics of EGFR gene status during qualification for erlotinib or gefitinib treatment and to consider the new therapy modalities in carriers of this mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [166, 175], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [32, 37], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [32, 37], "obj_char_span": [166, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Direct measurement of the binding affinity of gefitinib to the wild type and mutant kinases revealed that gefitinib binds the L858R mutant 20-fold more tightly than the wild-type kinase .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [46, 55], "tok_span": [7, 11]}, {"name": "L858R", "ent_type": "variant", "char_span": [126, 131], "tok_span": [26, 30]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [106, 115], "tok_span": [20, 24]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [126, 131], "obj_char_span": [46, 55], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [7, 11]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [126, 131], "obj_char_span": [106, 115], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "However , patients with wild-type EGFR and acquired mutation in EGFR T790M are eventually resistant to treatment with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [118, 127], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [69, 74], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [69, 74], "obj_char_span": [118, 127], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and EGFR mutant ( delE746-A750 , L858R ) NSCLC cells ( HCC827 ) and gefitinib-resistant and EGFR mutant ( T790M ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "entity_list": [{"name": "gefitinib-sensitive", "ent_type": "drug", "char_span": [100, 119], "tok_span": [22, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [226, 231], "tok_span": [64, 68]}, {"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [188, 207], "tok_span": [54, 60]}, {"name": "L858R", "ent_type": "variant", "char_span": [153, 158], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-sensitive", "sbj_char_span": [226, 231], "obj_char_span": [100, 119], "rel_type": "resistance or non-response", "sbj_tok_span": [64, 68], "obj_tok_span": [22, 28]}, {"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [226, 231], "obj_char_span": [188, 207], "rel_type": "resistance or non-response", "sbj_tok_span": [64, 68], "obj_tok_span": [54, 60]}, {"subject": "L858R", "object": "gefitinib-sensitive", "sbj_char_span": [153, 158], "obj_char_span": [100, 119], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [22, 28]}, {"subject": "L858R", "object": "gefitinib-resistant", "sbj_char_span": [153, 158], "obj_char_span": [188, 207], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [54, 60]}], "umls_entity_list": []}, {"text": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [197, 206], "tok_span": [48, 52]}, {"name": "T790M", "ent_type": "variant", "char_span": [109, 114], "tok_span": [27, 31]}, {"name": "L858R", "ent_type": "variant", "char_span": [38, 43], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [109, 114], "obj_char_span": [197, 206], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [48, 52]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [38, 43], "obj_char_span": [197, 206], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "The T790M mutation on exon 20 of the EGFR receptor has been reported as one of the driving mutations for the acquired resistance to gefitinib treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [132, 141], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [132, 141], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Approximately half of the patients that acquire resistance to gefitinib are found to harbor the T790M EGFR mutation , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [62, 71], "tok_span": [9, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [96, 101], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [96, 101], "obj_char_span": [62, 71], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Many of the patients that do relapse often harbor pre existing T790M EGFR mutation at very low levels within the original tumor population , leading to resistance after gefitinib treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [169, 178], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [63, 68], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [63, 68], "obj_char_span": [169, 178], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Screening patients for low level T790M EGFR mutations prior to administering gefitinib treatment may be useful for assessing the possibility of disease relapse .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [77, 86], "tok_span": [15, 19]}, {"name": "T790M", "ent_type": "variant", "char_span": [33, 38], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [33, 38], "obj_char_span": [77, 86], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "This method has recently been adapted for the detection of T790M EGFR mutation in gefitinib-refractory disease by the use of the PNA “clamp” to inhibit the amplification of wild type DNA , .", "entity_list": [{"name": "gefitinib-refractory", "ent_type": "drug", "char_span": [82, 102], "tok_span": [17, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-refractory", "sbj_char_span": [59, 64], "obj_char_span": [82, 102], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [17, 23]}], "umls_entity_list": []}, {"text": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the T790M mutation of EGFR and c-Met amplification are known mechanisms of acquired gefitinib ( TKI ) resistance in lung cancer .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [226, 235], "tok_span": [47, 51]}, {"name": "T790M", "ent_type": "variant", "char_span": [146, 151], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [146, 151], "obj_char_span": [226, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "PC9/ZD cells were established as a gefitinib-resistant clone from PC9 cells , and were shown to harbor the T790M mutation of EGFR .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [35, 54], "tok_span": [10, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [107, 112], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [107, 112], "obj_char_span": [35, 54], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [10, 16]}], "umls_entity_list": []}, {"text": "All of the patients had the EGFR gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( L858R ) , and had received or were receiving gefitinib or erlotinib for treatment against advanced diseases at the blood sampling . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [38, 42]}, {"name": "L858R", "ent_type": "variant", "char_span": [89, 94], "tok_span": [26, 30]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [89, 94], "obj_char_span": [134, 143], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "These exon 20 insertions were also found to be far less sensitive to irreversible TKIs ( neratinib and afatinib ) when compared to L858R and exon 19 mutations . ", "entity_list": [{"name": "L858R", "ent_type": "variant", "char_span": [131, 136], "tok_span": [28, 32]}, {"name": "afatinib", "ent_type": "drug", "char_span": [103, 111], "tok_span": [22, 24]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [131, 136], "obj_char_span": [103, 111], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "In the Taiwanese population , the treatment response to gefitinib was found to be 25 % , which was much lower when compared to exon 19 and L858R mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [56, 65], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [139, 144], "tok_span": [31, 35]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [139, 144], "obj_char_span": [56, 65], "rel_type": "sensitivity", "sbj_tok_span": [31, 35], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "The coexisting point mutations on exon 20 that rendered the patients resistant to gefitinib were G719A , V769L , W731 Stop , L858R , L 861Q and delE749_T751insVA .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [82, 91], "tok_span": [14, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [125, 130], "tok_span": [35, 39]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [125, 130], "obj_char_span": [82, 91], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR T790M models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . ", "entity_list": [{"name": "preclinical gefitinib-", "ent_type": "drug", "char_span": [94, 116], "tok_span": [25, 31]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [141, 151], "tok_span": [38, 43]}], "relation_list": [{"subject": "EGFR T790M", "object": "preclinical gefitinib-", "sbj_char_span": [141, 151], "obj_char_span": [94, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 43], "obj_tok_span": [25, 31]}], "umls_entity_list": []}, {"text": "Erlotinib is an orally bioavailable EGFR inhibitor , which is indicated for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 ( L858R ) substitution mutations . ", "entity_list": [{"name": "L858R", "ent_type": "variant", "char_span": [185, 190], "tok_span": [35, 39]}, {"name": "Erlotinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [185, 190], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "In our case , a biopsy ( ‘re-biopsy’ ) revealed the T790M mutation in the EGFR gene , which was widely known as a second mutation resistant to EGFR TKIs , such as gefitinib and erlotinib .", "entity_list": [{"name": "as gefitinib", "ent_type": "drug", "char_span": [160, 172], "tok_span": [40, 45]}, {"name": "the T790M", "ent_type": "variant", "char_span": [48, 57], "tok_span": [14, 19]}], "relation_list": [{"subject": "the T790M", "object": "as gefitinib", "sbj_char_span": [48, 57], "obj_char_span": [160, 172], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 19], "obj_tok_span": [40, 45]}], "umls_entity_list": []}, {"text": "Of note , according to our case , CBDCA + pemetrexed + bevacizumab and its maintenance chemotherapy is feasible and well tolerated for solitary breast metastasis from a lung adenocarcinoma which is resistant to gefitinib and possesses the secondary T790M mutation in the EGFR gene .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [211, 220], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [249, 254], "tok_span": [48, 52]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [249, 254], "obj_char_span": [211, 220], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "PC9GR cells ( gefitinib resistant ) were shown to harbor a secondary T790M mutation in EGFR , whereas HCC827ER cells ( erlotinib resistant ) demonstrated MET overexpression , as previously reported ( ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [69, 74], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [69, 74], "obj_char_span": [14, 23], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "It is well known that the efficacy of targeted therapies such as gefitinib or erlotinib with NSCLC patients depends on the presence of EGFR activating mutations including in-frame deletion in exon 19 or L858R in exon 21 . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [65, 74], "tok_span": [12, 16]}, {"name": "L858R", "ent_type": "variant", "char_span": [203, 208], "tok_span": [41, 45]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [203, 208], "obj_char_span": [65, 74], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Cancer EGFR exon18 G719X Drug efficacy prediction of gefitinib and erlotinib exon19 deletion exon20 T790M exon21 L858R", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [53, 62], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [100, 105], "tok_span": [26, 30]}, {"name": "L858R", "ent_type": "variant", "char_span": [113, 118], "tok_span": [32, 36]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [100, 105], "obj_char_span": [53, 62], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [12, 16]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [113, 118], "obj_char_span": [53, 62], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Introduction : Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors ( TKIs ) such as gefitinib are one of gold standard treatment options for non-small-cell lung cancer ( NSCLC ) patients , which eventually fail due to the acquired resistance and relapse because of the development of secondary activating mutations such as T790M in EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [99, 108], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [338, 343], "tok_span": [63, 67]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [338, 343], "obj_char_span": [99, 108], "rel_type": "resistance or non-response", "sbj_tok_span": [63, 67], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "In this study , we report that BMS-690514 has in vivo efficacy on a panel of NSLCC xenografts , including those with T790M mutations , conferring resistance to EGFR therapies such as Erlotinib or Gefitinib .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [196, 205], "tok_span": [48, 51]}, {"name": "T790M", "ent_type": "variant", "char_span": [117, 122], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [117, 122], "obj_char_span": [196, 205], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [48, 51]}], "umls_entity_list": []}, {"text": "The T790M EGFR mutant has increased affinity for ATP , which is the primary mechanism responsible for the development of resistance to small molecule tyrosine kinase inhibitors ( TKIs ) , such as gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [196, 205], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [196, 205], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Although several previous studies have suggested that tumors harboring mutations in the EGFR kinase domain were sensitive to TKIs such as gefitinib or erlotinib , others had reported an association between the T790M mutation in exon 20 and the resistance to TKIs .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [138, 147], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [210, 215], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [210, 215], "obj_char_span": [138, 147], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "In Vivo Correlation of BIM/Bim Expression and Mutant EGFR Activity ( A and B ) Lung tumor bearing mice that express a tetracycline-inducible L858R mutant ( EGFRL858R ) ( A ) or an exon 19 deletion mutant ( EGFRΔL747–S752 ) ( B ) were treated with a single dose of either vehicle control or 50 mg/kg erlotinib intraperitoneally .", "entity_list": [{"name": "mg/kg erlotinib", "ent_type": "drug", "char_span": [293, 308], "tok_span": [79, 86]}, {"name": "L858R", "ent_type": "variant", "char_span": [141, 146], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "mg/kg erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [293, 308], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [79, 86]}], "umls_entity_list": []}, {"text": "This change leads to substitution of methionine for threonine at position 790 ( T790M ) and is associated with acquired resistance to gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [148, 157], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [80, 85], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [80, 85], "obj_char_span": [148, 157], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "H1975 cells were insensitive to erlotinib due to the drug-resistant T790M mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [32, 41], "tok_span": [7, 11]}, {"name": "T790M", "ent_type": "variant", "char_span": [68, 73], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [68, 73], "obj_char_span": [32, 41], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "These results suggest that the T790M mutation may impair the ability of gefitinib or erlotinib to inhibit EGFR tyrosine kinase activity , even in EGFR mutants ( i.e. , L858R or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [168, 173], "tok_span": [41, 45]}, {"name": "T790M", "ent_type": "variant", "char_span": [31, 36], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [168, 173], "obj_char_span": [85, 94], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [20, 24]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [31, 36], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "In tumors from patients not treated with either gefitinib or erlotinib , the 2369 C→T mutation ( T790M ) appears to be extremely rare . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [61, 70], "tok_span": [13, 17]}, {"name": "( T790M", "ent_type": "variant", "char_span": [95, 102], "tok_span": [25, 30]}], "relation_list": [{"subject": "( T790M", "object": "erlotinib", "sbj_char_span": [95, 102], "obj_char_span": [61, 70], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 30], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Consistent with this , the H1975 NSCLC cell line reported here to contain both T790M and L858R did not to our knowledge undergo any prior treatment with gefitinib or erlotinib ; the doubly mutated cells must have become dominant over time through multiple passages in vitro .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [166, 175], "tok_span": [40, 44]}, {"name": "L858R", "ent_type": "variant", "char_span": [89, 94], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [89, 94], "obj_char_span": [166, 175], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [40, 44]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [79, 84], "obj_char_span": [166, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or erlotinib . ( D ) Cell line H1975 contains both an exon 21 L858R mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [314, 326], "tok_span": [78, 83]}, {"name": "L858R", "ent_type": "variant", "char_span": [376, 381], "tok_span": [97, 101]}, {"name": "T790M", "ent_type": "variant", "char_span": [34, 39], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "or erlotinib", "sbj_char_span": [376, 381], "obj_char_span": [314, 326], "rel_type": "sensitivity", "sbj_tok_span": [97, 101], "obj_tok_span": [78, 83]}, {"subject": "T790M", "object": "or erlotinib", "sbj_char_span": [34, 39], "obj_char_span": [314, 326], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [78, 83]}], "umls_entity_list": []}, {"text": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by Gefitinib or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [87, 96], "tok_span": [21, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [235, 240], "tok_span": [53, 57]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [6, 10]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [235, 240], "obj_char_span": [87, 96], "rel_type": "sensitivity", "sbj_tok_span": [53, 57], "obj_tok_span": [21, 24]}, {"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [28, 33], "obj_char_span": [87, 96], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "Collectively , our results suggest that the T790M mutation is associated with lesions that progress while on gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [122, 131], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [44, 49], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [44, 49], "obj_char_span": [122, 131], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Similar results were obtained using erlotinib against wild-type and del E747–L747 ; A750P EGFRs in comparison to the corresponding mutants containing the T790M mutation ( C ) . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [36, 45], "tok_span": [5, 9]}, {"name": "the T790M", "ent_type": "variant", "char_span": [150, 159], "tok_span": [36, 41]}], "relation_list": [{"subject": "the T790M", "object": "erlotinib", "sbj_char_span": [150, 159], "obj_char_span": [36, 45], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 41], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "To further explore the functional consequences of the T790M mutation , we determined the sensitivity of various NSCLC cells lines grown in the presence of either gefitinib or erlotinib , using an assay based upon Calcein AM .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [175, 184], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [54, 59], "tok_span": [8, 12]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [54, 59], "obj_char_span": [175, 184], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 12], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "We show here , through molecular analysis of tumor material from three patients and one NSCLC cell line , as well as additional biochemical studies , that acquired clinical drug resistance to gefitinib or erlotinib is indeed associated with the T790M mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [205, 214], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [245, 250], "tok_span": [46, 50]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [245, 250], "obj_char_span": [205, 214], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "This study revealed that the quinazoline rings of erlotinib and lapatinib interact differently with the EGFR kinase domain , suggesting that while the T790M mutation may affect inhibition by erlotinib and gefitinib , it may not affect inhibition of EGFR by compounds similar to lapatinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [151, 156], "tok_span": [30, 34]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [191, 200], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [151, 156], "obj_char_span": [50, 59], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [151, 156], "obj_char_span": [191, 200], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "Since tumor specimens from three additional patients with acquired resistance to EGFR tyrosine kinase inhibitors did not demonstrate the T790M mutation , this specific lesion does not account for all mechanisms of acquired resistance to gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [250, 259], "tok_span": [43, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [137, 142], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [137, 142], "obj_char_span": [250, 259], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "Analogously , the T790M mutation , in conjunction with the drug-responsive del L747–E749 ; A750P EGFR mutant , prevents inhibition of p-EGFR by erlotinib ( C ) . ", "entity_list": [{"name": "by erlotinib", "ent_type": "drug", "char_span": [141, 153], "tok_span": [39, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [18, 23], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "by erlotinib", "sbj_char_span": [18, 23], "obj_char_span": [141, 153], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [39, 44]}], "umls_entity_list": []}, {"text": "On the other hand , erlotinib could not inhibit EGFR phosphorylation in H1975 cells because the T790M mutation in EGFR causes a conformation change at the ATP binding pocket , thus decreasing the affinity between erlotinib and EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [20, 29], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [96, 101], "tok_span": [21, 25]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [213, 222], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [96, 101], "obj_char_span": [20, 29], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [5, 9]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [96, 101], "obj_char_span": [213, 222], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "The best therapy for those who have initially responded to erlotinib and have subsequently lost their response either through development of the T790M mutation or another resistance mechanism , remains another area of active research .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [59, 68], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [145, 150], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [145, 150], "obj_char_span": [59, 68], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Preclinical studies have shown superior activity of afatinib over first-generation TKIs , mainly due to ( 1 ) irreversible binding , which confers stronger binding affinity and potency , ( 2 ) ability to circumvent first-generation TKI resistance mechanism T790M mutation in exon 20 , and ( 3 ) effectiveness against multiple HER-endothelial growth factor receptors . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [257, 262], "tok_span": [48, 52]}, {"name": "afatinib", "ent_type": "drug", "char_span": [52, 60], "tok_span": [9, 11]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [257, 262], "obj_char_span": [52, 60], "rel_type": "response", "sbj_tok_span": [48, 52], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "One of the proposed mechanisms of resistance to gefitinib and erlotinib is the T790M mutation on exon 20 .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [62, 71], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [79, 84], "obj_char_span": [62, 71], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "As the theoretical advantage of afatinib versus the first-generation EGFR-TKI did not translate into progression-free survival gains , maybe the clinical relevance of possible inhibition of T790M is minimal , at least in the first-line setting , when T790M positive clones are rarely detected . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [190, 195], "tok_span": [34, 38]}, {"name": "afatinib", "ent_type": "drug", "char_span": [32, 40], "tok_span": [5, 7]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [190, 195], "obj_char_span": [32, 40], "rel_type": "response", "sbj_tok_span": [34, 38], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "A randomized phase II trial compared erlotinib to erlotinib plus bevacizumab in patients with activating EGFR mutations ( defined as exon 19 deletion and exon 21 L858R point mutations ) and advanced stage NSCLC ( n = 152 ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [6, 10]}, {"name": "L858R", "ent_type": "variant", "char_span": [162, 167], "tok_span": [33, 37]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [162, 167], "obj_char_span": [37, 46], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 10]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [162, 167], "obj_char_span": [50, 59], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "PFS was 4.4 months , whereas median overall survival was 19 months ; two patients with acquired T790M mutations had SD for 9 months and 1 month , respectively The most common afatinib related toxicities were diarrhea in all patients and rash/acne in 91.9 % of patients LUX-Lung 7 , NCT01466660 IIb Yes First-line Afatinib versus gefitinib PFS ; DCR – – LUX-Lung 8 , NCT01523587 III N/R Second-line after patient based chemotherapy ; squamous cell histology Afatinib versus erlotinib PFS – –", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [473, 482], "tok_span": [119, 123]}, {"name": "T790M", "ent_type": "variant", "char_span": [96, 101], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [96, 101], "obj_char_span": [473, 482], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [119, 123]}], "umls_entity_list": []}, {"text": "Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors gefitinib ( Iressa ) or erlotinib ( Tarceva ) , including in-frame deletions such as del L747–E749 ; A750P in exon 19 , or L858R in exon 21 .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [225, 234], "tok_span": [43, 47]}, {"name": "or L858R", "ent_type": "variant", "char_span": [321, 329], "tok_span": [77, 82]}, {"name": "Tarceva", "ent_type": "drug", "char_span": [237, 244], "tok_span": [48, 51]}], "relation_list": [{"subject": "or L858R", "object": "erlotinib", "sbj_char_span": [321, 329], "obj_char_span": [225, 234], "rel_type": "sensitivity", "sbj_tok_span": [77, 82], "obj_tok_span": [43, 47]}, {"subject": "or L858R", "object": "Tarceva", "sbj_char_span": [321, 329], "obj_char_span": [237, 244], "rel_type": "sensitivity", "sbj_tok_span": [77, 82], "obj_tok_span": [48, 51]}], "umls_entity_list": []}, {"text": "T790M in the context of either transiently expressed wild-type EGFR or the mutant alleles del L474–E749 ; A750P or L858R impairs inhibition by gefitinib or erlotinib as assessed by autophosphorylation .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [153, 165], "tok_span": [44, 49]}, {"name": "or L858R", "ent_type": "variant", "char_span": [112, 120], "tok_span": [32, 37]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "or L858R", "object": "or erlotinib", "sbj_char_span": [112, 120], "obj_char_span": [153, 165], "rel_type": "sensitivity", "sbj_tok_span": [32, 37], "obj_tok_span": [44, 49]}, {"subject": "T790M", "object": "or erlotinib", "sbj_char_span": [0, 5], "obj_char_span": [153, 165], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [44, 49]}], "umls_entity_list": []}, {"text": "A ribbon structure of erlotinib bound to the EGFR kinase domain ( ) shows the threonine residue at position 790 in green and the positions of the exon 19 and L858R gain-of-function mutations .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [22, 31], "tok_span": [5, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [158, 163], "tok_span": [36, 40]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [158, 163], "obj_char_span": [22, 31], "rel_type": "sensitivity", "sbj_tok_span": [36, 40], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "The mechanism of resistance in three patients was acquisition of a T790M substitution in EGFR that was not present at time of diagnosis , but was detected with progression of disease after initial response to gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [222, 231], "tok_span": [43, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [67, 72], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [67, 72], "obj_char_span": [222, 231], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "These observations provide convincing evidence that , at least in some patients with NSCLC , resistance to gefitinib or erlotinib can be attributed to acquisition of a T790M mutation in the context of EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [120, 129], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [168, 173], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [168, 173], "obj_char_span": [120, 129], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "However , three additional patients with clinical resistance to gefitinib or erlotinib did not have the T790M mutation , nor did they have mutant KRAS alleles that have previously been shown by these same authors to confer resistance to these inhibitors .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [77, 86], "tok_span": [14, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [104, 109], "tok_span": [22, 26]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [104, 109], "obj_char_span": [77, 86], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "In addition , only half of this small cohort of patients with NSCLC with clinical resistance to gefitinib or erlotinib had the T790M substitution .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [109, 118], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [127, 132], "obj_char_span": [109, 118], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "However , erlotinib did induce dose dependent cell death in Ba/F3 subclones expressing the EGFR ectodomain mutants ( missense and vIII truncation ) or EGFR kinase domain mutants ( L858R and L861Q ) ( A ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [10, 19], "tok_span": [2, 6]}, {"name": "L858R", "ent_type": "variant", "char_span": [180, 185], "tok_span": [40, 44]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [180, 185], "obj_char_span": [10, 19], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "A secondary point mutation in exon 20 of EGFR ( T790M ) is associated with acquired resistance to gefitinib or Erlotinib , but this can be overcome by the irreversible EGFR-tyrosine kinase inhibitor BIBW2992 ( BIBW ) .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [111, 120], "tok_span": [26, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [48, 53], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [48, 53], "obj_char_span": [111, 120], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 L858R point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [237, 246], "tok_span": [49, 53]}, {"name": "L858R", "ent_type": "variant", "char_span": [128, 133], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [128, 133], "obj_char_span": [237, 246], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "Through this approach , they showed that Src Family Kinases (SFKs) , as well as EGFR , are relevant targets for the Src inhibitor dasatinib and that acquired T790M mutations render cells resistant not only to erlotinib and gefitinib , but also to dasatinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [209, 218], "tok_span": [44, 48]}, {"name": "T790M", "ent_type": "variant", "char_span": [158, 163], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [158, 163], "obj_char_span": [209, 218], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "In fact , the patient with EGFR c.2573T & gt ; G ( L858R ) and EGFR c.2369C&gt ; T ( T790M ) was treated with erlotinib and a short-term improvement was observed .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [110, 119], "tok_span": [44, 48]}, {"name": "L858R", "ent_type": "variant", "char_span": [51, 56], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [85, 90], "tok_span": [36, 40]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [51, 56], "obj_char_span": [110, 119], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [44, 48]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [85, 90], "obj_char_span": [110, 119], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "NSCLC patients harboring exon 19 deletion or exon 21 L858R somatic mutations experience significant tumor regression when prescribed the reversible small molecular tyrosine kinase inhibitors ( TKIs ) such as gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [222, 231], "tok_span": [39, 43]}, {"name": "L858R", "ent_type": "variant", "char_span": [53, 58], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [53, 58], "obj_char_span": [222, 231], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "However , the acquired T790M mutation of EGFR leads to erlotinib resistance .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [55, 64], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [23, 28], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [23, 28], "obj_char_span": [55, 64], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "The first example of a clinically relevant NSCLC driver oncogene was the identification of somatic mutations in the epidermal growth factor receptor (EGFR) gene ( – ) .Common EGFR alterations ( the L858R point mutation and exon 19 deletions ) are present in 10–30 % of patients with NSCLC and confer sensitivity to gefitinib , erlotinib , and afatinib .", "entity_list": [{"name": ", erlotinib", "ent_type": "drug", "char_span": [325, 336], "tok_span": [66, 71]}, {"name": "the L858R", "ent_type": "variant", "char_span": [194, 203], "tok_span": [35, 40]}], "relation_list": [{"subject": "the L858R", "object": ", erlotinib", "sbj_char_span": [194, 203], "obj_char_span": [325, 336], "rel_type": "sensitivity", "sbj_tok_span": [35, 40], "obj_tok_span": [66, 71]}], "umls_entity_list": []}, {"text": "Indeed , in non-small cell lung cancers treated with gefitinib or erlotinib , sensitive patients have the EGFR T790M mutation in only a few cells , whereas resistant patients exhibit EGFR T790M in the majority of the tumour cells ( ; ) . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [111, 116], "obj_char_span": [66, 75], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The H1975 and H820 cell lines had EGFR T790M mutations in exon 20 , associated with gefitinib and erlotinib resistance .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [28, 32]}, {"name": "T790M", "ent_type": "variant", "char_span": [39, 44], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [39, 44], "obj_char_span": [98, 107], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Similarly , the gatekeeper mutation T790M in EGFR causes resistance to gefitinib and erlotinib , and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [36, 41], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [36, 41], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "In particular , H1975 cells contain a second mutation ( T790M ) reported to be linked to gefitinib resistance , but we found that these cells also responded poorly to cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [167, 176], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [56, 61], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [56, 61], "obj_char_span": [167, 176], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "Regarding KRAS , the same group reported in a pooled dataset of 579 cetuximab treated CRC patients that those with codon 13 KRAS mutant tumours ( G13D ) had better outcomes ( HR for death 0.50 ) compared to patients with other KRAS mutant tumours .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [68, 77], "tok_span": [15, 19]}, {"name": "G13D", "ent_type": "variant", "char_span": [146, 150], "tok_span": [32, 35]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [146, 150], "obj_char_span": [68, 77], "rel_type": "resistance or non-response", "sbj_tok_span": [32, 35], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Furthermore , we performed highly sensitive deep sequencing for mutations in KRAS ( exon 2 ) , PIK3CA ( exons 9 and 20 ) , BRAF ( V600E ) , and EGFR ( S492R mutation in patients who received cetuximab ) .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [191, 200], "tok_span": [48, 52]}, {"name": "S492R", "ent_type": "variant", "char_span": [151, 156], "tok_span": [39, 43]}, {"name": "V600E", "ent_type": "variant", "char_span": [130, 135], "tok_span": [31, 34]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [151, 156], "obj_char_span": [191, 200], "rel_type": "resistance", "sbj_tok_span": [39, 43], "obj_tok_span": [48, 52]}, {"subject": "V600E", "object": "cetuximab", "sbj_char_span": [130, 135], "obj_char_span": [191, 200], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 34], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "This is in keeping with an earlier study by Di Nicolantonio and colleagues , where the response to panitumumab or cetuximab was found to be impeded by the presence of BRAF V600E mutation and restored ( in a cellular model of CRC cells ) by BRAF inhibitor sorafenib .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [114, 123], "tok_span": [26, 30]}, {"name": "V600E", "ent_type": "variant", "char_span": [172, 177], "tok_span": [41, 44]}, {"name": "panitumumab", "ent_type": "drug", "char_span": [99, 110], "tok_span": [22, 25]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [172, 177], "obj_char_span": [114, 123], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 44], "obj_tok_span": [26, 30]}, {"subject": "V600E", "object": "panitumumab", "sbj_char_span": [172, 177], "obj_char_span": [99, 110], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 44], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "In a study by De Roock et al. , a pooled data set of 579 mCRC patients across various clinical trials treated with cetuximab plus/minus chemotherapy demonstrated that overall and progression-free survival was significantly longer in patients with G13D KRAS mutant tumors .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [115, 124], "tok_span": [28, 32]}, {"name": "G13D", "ent_type": "variant", "char_span": [247, 251], "tok_span": [50, 53]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [247, 251], "obj_char_span": [115, 124], "rel_type": "resistance or non-response", "sbj_tok_span": [50, 53], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Patients with G13D KRAS mutant tumors and treated with cetuximab/chemotherapy regimes had overall survival and progression free survival of average 7.6 and 4.0 mo vs. 5.7 and 1.9 mo in other KRAS mutant tumor subtypes .", "entity_list": [{"name": "cetuximab/chemotherapy", "ent_type": "drug", "char_span": [55, 77], "tok_span": [12, 18]}, {"name": "G13D", "ent_type": "variant", "char_span": [14, 18], "tok_span": [2, 5]}], "relation_list": [{"subject": "G13D", "object": "cetuximab/chemotherapy", "sbj_char_span": [14, 18], "obj_char_span": [55, 77], "rel_type": "resistance or non-response", "sbj_tok_span": [2, 5], "obj_tok_span": [12, 18]}], "umls_entity_list": []}, {"text": "This year at ASCO , Tejpar et al. further supported this finding by presenting retrospective analyses of two large phase III multicenter trials ( CRYSTAL and OPUS ) representing 83 patients with G13D KRAS mutant mCRC tumors who had longer overall survival and progression free survival on average post cetuximab treatment then other KRAS mutant subtypes .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [302, 311], "tok_span": [62, 66]}, {"name": "G13D", "ent_type": "variant", "char_span": [195, 199], "tok_span": [40, 43]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [195, 199], "obj_char_span": [302, 311], "rel_type": "resistance or non-response", "sbj_tok_span": [40, 43], "obj_tok_span": [62, 66]}], "umls_entity_list": []}, {"text": "Furthermore , De Roock and colleagues recently reported that chemotherapy-refractory metastatic colorectal cancers harboring a G13D KRAS mutation were more sensitive to treatment with the epidermal growth factor receptor (EGFR) inhibitor cetuximab compared to tumors with other KRAS mutations .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [238, 247], "tok_span": [39, 43]}, {"name": "G13D", "ent_type": "variant", "char_span": [127, 131], "tok_span": [18, 21]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [127, 131], "obj_char_span": [238, 247], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "This was confirmed in vitro , and G12V mutated cancer cells were resistant to cetuximab , whereas G13D mutated and KRAS wild-type cancer cells were sensitive .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [78, 87], "tok_span": [16, 20]}, {"name": "G13D", "ent_type": "variant", "char_span": [98, 102], "tok_span": [22, 25]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [98, 102], "obj_char_span": [78, 87], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 25], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Another approach for T790M mediated resistance is the dual inhibition of EGFR with afatinib and cetuximab , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [96, 105], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [21, 26], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [21, 26], "obj_char_span": [96, 105], "rel_type": "response", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "A single 25-mg/kg oral administration of S116836 in rats generated a maximal plasma concentration of 6205.0±731.4 ( Table ) , which may be sufficient to kill imatinib-resistant cells harboring gate-keeper mutant T674I PDGFRα , T315I BCR-ABL and D816V KIT .", "entity_list": [{"name": "kill imatinib-resistant", "ent_type": "drug", "char_span": [153, 176], "tok_span": [40, 45]}, {"name": "mutant T674I", "ent_type": "variant", "char_span": [205, 217], "tok_span": [51, 56]}], "relation_list": [{"subject": "mutant T674I", "object": "kill imatinib-resistant", "sbj_char_span": [205, 217], "obj_char_span": [153, 176], "rel_type": "resistance", "sbj_tok_span": [51, 56], "obj_tok_span": [40, 45]}], "umls_entity_list": []}, {"text": "Relapse in one patient was associated with the detection of the T674I mutation in PDGFRA that confers resistance to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [116, 124], "tok_span": [24, 26]}, {"name": "T674I", "ent_type": "variant", "char_span": [64, 69], "tok_span": [12, 16]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [64, 69], "obj_char_span": [116, 124], "rel_type": "resistance", "sbj_tok_span": [12, 16], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "The T674I mutation within the kinase domain of FIP1L1-PDGFRA ( adenosine-5′-triphosphate -binding region ) seems to be the most frequent mutation that appears under imatinib treatment and that causes resistance through steric hindrance mechanisms .", "entity_list": [{"name": "under imatinib", "ent_type": "drug", "char_span": [159, 173], "tok_span": [43, 46]}, {"name": "T674I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T674I", "object": "under imatinib", "sbj_char_span": [4, 9], "obj_char_span": [159, 173], "rel_type": "resistance", "sbj_tok_span": [1, 5], "obj_tok_span": [43, 46]}], "umls_entity_list": []}, {"text": "Treatment of two patients resistant to imatinib with nilotinib was successful. , Another patient intolerant to imatinib responded to nilotinib and dasatinib. , The sensitivity of the T674I mutation to second generation TKIs has been a matter of debate .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [39, 47], "tok_span": [6, 8]}, {"name": "T674I", "ent_type": "variant", "char_span": [183, 188], "tok_span": [38, 42]}, {"name": "imatinib", "ent_type": "drug", "char_span": [111, 119], "tok_span": [22, 24]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [183, 188], "obj_char_span": [39, 47], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [6, 8]}, {"subject": "T674I", "object": "imatinib", "sbj_char_span": [183, 188], "obj_char_span": [111, 119], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Dasatinib is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and FIP1L1-PDGFRA fusion but has no effect on imatinib-resistant FIP1L1-PDGFRA T674I and D842V mutants .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [111, 129], "tok_span": [32, 36]}, {"name": "T674I", "ent_type": "variant", "char_span": [144, 149], "tok_span": [44, 48]}, {"name": "D842V", "ent_type": "variant", "char_span": [154, 159], "tok_span": [49, 53]}], "relation_list": [{"subject": "T674I", "object": "imatinib-resistant", "sbj_char_span": [144, 149], "obj_char_span": [111, 129], "rel_type": "resistance", "sbj_tok_span": [44, 48], "obj_tok_span": [32, 36]}, {"subject": "D842V", "object": "imatinib-resistant", "sbj_char_span": [154, 159], "obj_char_span": [111, 129], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 53], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "Other small molecules have been tested against imatinib-resistant FIP1L1-PDGFRA T674I .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [47, 65], "tok_span": [7, 11]}, {"name": "T674I", "ent_type": "variant", "char_span": [80, 85], "tok_span": [19, 23]}], "relation_list": [{"subject": "T674I", "object": "imatinib-resistant", "sbj_char_span": [80, 85], "obj_char_span": [47, 65], "rel_type": "resistance", "sbj_tok_span": [19, 23], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "However , adjuvant imatinib was not recommended for patients with primary GISTs containing PDGFRA D842V mutations .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [19, 27], "tok_span": [3, 5]}, {"name": "D842V", "ent_type": "variant", "char_span": [98, 103], "tok_span": [17, 21]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [98, 103], "obj_char_span": [19, 27], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Mutation T798M at the gatekeeper residue and an ATP binding site mutation ( L755S and L755P ) showed reduced response to lapatinib , with IC50s of up to 50 times higher relative to wild-type HER2 .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [32, 35]}, {"name": "L755S", "ent_type": "variant", "char_span": [76, 81], "tok_span": [18, 22]}], "relation_list": [{"subject": "L755S", "object": "lapatinib", "sbj_char_span": [76, 81], "obj_char_span": [121, 130], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "GIST-T1-5R cells derived from GIST-T1 cells by prolonged in vitro exposure to imatinib and carrying a secondary , imatinib-resistant T670I mutation in exon 14 ( contributed by Dr. Anu Gupta and Dr. Brian P. Rubin ) were propagated in the presence of 1 µM imatinib mesylate ( LC Laboratories , Woburn , MA ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [78, 86], "tok_span": [23, 25]}, {"name": "T670I", "ent_type": "variant", "char_span": [133, 138], "tok_span": [34, 38]}, {"name": "imatinib-resistant", "ent_type": "drug", "char_span": [114, 132], "tok_span": [30, 34]}, {"name": "µM imatinib", "ent_type": "drug", "char_span": [252, 263], "tok_span": [66, 69]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [133, 138], "obj_char_span": [78, 86], "rel_type": "resistance", "sbj_tok_span": [34, 38], "obj_tok_span": [23, 25]}, {"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [133, 138], "obj_char_span": [114, 132], "rel_type": "resistance", "sbj_tok_span": [34, 38], "obj_tok_span": [30, 34]}, {"subject": "T670I", "object": "µM imatinib", "sbj_char_span": [133, 138], "obj_char_span": [252, 263], "rel_type": "resistance", "sbj_tok_span": [34, 38], "obj_tok_span": [66, 69]}], "umls_entity_list": []}, {"text": "These results suggest that acquired resistance to adjuvant imatinib was infrequent , especially since both arms included patients with mutations known to be less sensitive or resistant to imatinib ( e.g. , platelet derived growth factor receptor alpha [PDGFRA ] D842V ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [59, 67], "tok_span": [8, 10]}, {"name": "D842V", "ent_type": "variant", "char_span": [262, 267], "tok_span": [48, 52]}, {"name": "imatinib", "ent_type": "drug", "char_span": [188, 196], "tok_span": [30, 32]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [262, 267], "obj_char_span": [59, 67], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [8, 10]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [262, 267], "obj_char_span": [188, 196], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "KIT W557R V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [88, 96], "tok_span": [42, 44]}, {"name": "L576P", "ent_type": "variant", "char_span": [18, 23], "tok_span": [12, 16]}, {"name": "Imatinib", "ent_type": "drug", "char_span": [154, 162], "tok_span": [58, 60]}], "relation_list": [{"subject": "L576P", "object": "Imatinib", "sbj_char_span": [18, 23], "obj_char_span": [88, 96], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [42, 44]}, {"subject": "L576P", "object": "Imatinib", "sbj_char_span": [18, 23], "obj_char_span": [154, 162], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [58, 60]}], "umls_entity_list": []}, {"text": "Tumors that harbor BRAF V600E mutations display high radiographic response rates to mutant-specific inhibitors such as PLX4032/RG7204/vemurafinib ( Plexxikon/Roche ) , and GSK2118436 ( GlaxoSmithKline ) , while patients whose tumors have certain KIT mutations ( L576P , K642E , V559A ) have disease sensitive to the KIT inhibitor , imatinib ( ) , , , , , , , , .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [332, 340], "tok_span": [94, 96]}, {"name": "L576P", "ent_type": "variant", "char_span": [262, 267], "tok_span": [70, 74]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [262, 267], "obj_char_span": [332, 340], "rel_type": "resistance or non-response", "sbj_tok_span": [70, 74], "obj_tok_span": [94, 96]}], "umls_entity_list": []}, {"text": "For example , KIT exon 9 mutations and exon 11 deletions involving codons 557–558 are associated with poor outcome , and the PDGFRA mutation D842V is associated with resistance to imatinib .", "entity_list": [{"name": "to imatinib", "ent_type": "drug", "char_span": [177, 188], "tok_span": [38, 41]}, {"name": "mutation D842V", "ent_type": "variant", "char_span": [132, 146], "tok_span": [29, 34]}], "relation_list": [{"subject": "mutation D842V", "object": "to imatinib", "sbj_char_span": [132, 146], "obj_char_span": [177, 188], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 34], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "The PDGFRA mutation D842V , sporadic wild-type GISTs , mutations with succinate dehydrogenase or BRAF mutated GISTs are unlikely to respond to imatinib . ", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [143, 151], "tok_span": [31, 33]}, {"name": "D842V", "ent_type": "variant", "char_span": [20, 25], "tok_span": [4, 8]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [20, 25], "obj_char_span": [143, 151], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "The V600E B-RAF mutation appears in 4 % –15 % of CRC.– The possible relationship between of B-RAF mutational status and response to treatment with panitumumab in 48 patients with mCRC was investigated by Benvenuti et al . ", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [147, 158], "tok_span": [37, 40]}, {"name": "V600E", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 4]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [4, 9], "obj_char_span": [147, 158], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 4], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "Some of the second-generation TKI like dasatinib or PKC412 have been reported to override drug resistance in Kit D816V transformed cells ( – ) .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [39, 48], "tok_span": [9, 11]}, {"name": "D816V", "ent_type": "variant", "char_span": [113, 118], "tok_span": [25, 29]}], "relation_list": [{"subject": "D816V", "object": "dasatinib", "sbj_char_span": [113, 118], "obj_char_span": [39, 48], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Preclinical cell studies indicate that dasatinib may inhibit the KIT D816V mutation that is resistant to imatinib .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [39, 48], "tok_span": [7, 9]}, {"name": "D816V", "ent_type": "variant", "char_span": [69, 74], "tok_span": [14, 18]}], "relation_list": [{"subject": "D816V", "object": "dasatinib", "sbj_char_span": [69, 74], "obj_char_span": [39, 48], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Eight months after starting the treatment , when patients still responded to the dasatinib , authors sequenced kinase domain of DDR2 gene and identified the S768R mutation .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [81, 90], "tok_span": [13, 15]}, {"name": "S768R", "ent_type": "variant", "char_span": [157, 162], "tok_span": [28, 32]}], "relation_list": [{"subject": "S768R", "object": "dasatinib", "sbj_char_span": [157, 162], "obj_char_span": [81, 90], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "F1174L may therefore stabilize an active conformation that is both more oncogenic and less favored for crizotinib binding .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [103, 113], "tok_span": [19, 23]}, {"name": "F1174L", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [103, 113], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Consistent with this , we found that the introduction of R1275Q into EML4-ALK had no negative impact on sensitivity to crizotinib ( IC50 47 ± 8 nm ) . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [119, 129], "tok_span": [28, 32]}, {"name": "R1275Q", "ent_type": "variant", "char_span": [57, 63], "tok_span": [10, 14]}], "relation_list": [{"subject": "R1275Q", "object": "crizotinib", "sbj_char_span": [57, 63], "obj_char_span": [119, 129], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "The L1196M gatekeeper mutation likely sterically impedes crizotinib binding .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [57, 67], "tok_span": [14, 18]}, {"name": "L1196M", "ent_type": "variant", "char_span": [4, 10], "tok_span": [1, 5]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [4, 10], "obj_char_span": [57, 67], "rel_type": "resistance", "sbj_tok_span": [1, 5], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "In this patient who developed resistance to crizotinib after 5 months of treatment , molecular analyses showed the tumor had two acquired mutations within the kinase domain of EML4-ALK , C1156Y , and the gatekeeper mutation L1196M ( Katayama et al. , 2011 ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [44, 54], "tok_span": [7, 11]}, {"name": "L1196M", "ent_type": "variant", "char_span": [224, 230], "tok_span": [49, 53]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [187, 193], "tok_span": [38, 42]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [224, 230], "obj_char_span": [44, 54], "rel_type": "resistance", "sbj_tok_span": [49, 53], "obj_tok_span": [7, 11]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [187, 193], "obj_char_span": [44, 54], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "In vitro assays have also demonstrated L1196M gatekeeper mutation to be the major mechanism for crizotinib resistance ( Ou , 2011 ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [96, 106], "tok_span": [20, 24]}, {"name": "L1196M", "ent_type": "variant", "char_span": [39, 45], "tok_span": [6, 10]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [39, 45], "obj_char_span": [96, 106], "rel_type": "resistance", "sbj_tok_span": [6, 10], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "AP26113 has a fivefold greater potency than does crizotinib in inhibiting ALK as well as the L1196M gatekeeper mutation ( Katayama et al. , 2011 ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [49, 59], "tok_span": [11, 15]}, {"name": "L1196M", "ent_type": "variant", "char_span": [93, 99], "tok_span": [23, 27]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [93, 99], "obj_char_span": [49, 59], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "They had found a de novo secondary mutation G2032R in CD74-ROS1 , and this mutation conferred serious resistance to crizotinib .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [116, 126], "tok_span": [27, 31]}, {"name": "G2032R", "ent_type": "variant", "char_span": [44, 50], "tok_span": [8, 12]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [44, 50], "obj_char_span": [116, 126], "rel_type": "resistance", "sbj_tok_span": [8, 12], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "The mutated site G2032R , P-loop region , and crizotinib in WT-ROS1 and G2032R-ROS1 are shown in green surface , orange surface , green stick , and pink stick models , respectively , in panels A and B .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [46, 56], "tok_span": [14, 18]}, {"name": "G2032R", "ent_type": "variant", "char_span": [17, 23], "tok_span": [3, 7]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [17, 23], "obj_char_span": [46, 56], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Similar behavior of crizotinib was found in the G2032R mutated ROS1 tyrosine kinase .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [20, 30], "tok_span": [3, 7]}, {"name": "G2032R", "ent_type": "variant", "char_span": [48, 54], "tok_span": [11, 15]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [48, 54], "obj_char_span": [20, 30], "rel_type": "resistance", "sbj_tok_span": [11, 15], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "As shown in , the separation PMF in G2032R-ROS1 was much lower than that in WT-ROS1 , suggesting that serious crizotinib resistance could be induced by the mutation G2032R in the ROS1 tyrosine kinase .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [110, 120], "tok_span": [30, 34]}, {"name": "G2032R", "ent_type": "variant", "char_span": [165, 171], "tok_span": [41, 45]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [165, 171], "obj_char_span": [110, 120], "rel_type": "resistance", "sbj_tok_span": [41, 45], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Therefore , the P-loop was hard to be induced during the whole binding/unbinding process of crizotinib , and thus , an attenuated binding state was dominated between crizotinib and binding pocket of G2032R mutated ROS1 tyrosine kinase .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [92, 102], "tok_span": [20, 24]}, {"name": "G2032R", "ent_type": "variant", "char_span": [199, 205], "tok_span": [43, 47]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [166, 176], "tok_span": [35, 39]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [199, 205], "obj_char_span": [92, 102], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [20, 24]}, {"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [199, 205], "obj_char_span": [166, 176], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "In addition , we have analyzed the energetic contribution to crizotinib on residue level as well , which showed that the residue Leu18 ( located just in the P-loop region ) contributed the most to the attenuated binding of crizotinib to G2032R-ROS1 as shown in , therefore well supporting the issue that the P-loop conformation governs crizotinib resistance in G2032R mutated ROS1 tyrosine kinase .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [61, 71], "tok_span": [10, 14]}, {"name": "G2032R", "ent_type": "variant", "char_span": [361, 367], "tok_span": [80, 84]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [223, 233], "tok_span": [45, 49]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [336, 346], "tok_span": [74, 78]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [361, 367], "obj_char_span": [61, 71], "rel_type": "resistance", "sbj_tok_span": [80, 84], "obj_tok_span": [10, 14]}, {"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [361, 367], "obj_char_span": [223, 233], "rel_type": "resistance", "sbj_tok_span": [80, 84], "obj_tok_span": [45, 49]}, {"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [361, 367], "obj_char_span": [336, 346], "rel_type": "resistance", "sbj_tok_span": [80, 84], "obj_tok_span": [74, 78]}], "umls_entity_list": []}, {"text": "Therefore , by using the advanced metadynamics techniques , namely , well tempered metadynamics and funnel metadynamics , we explored the free energy surfaces of the crizotinib unbinding from WT and G2032R mutated ROS1 tyrosine kinase , which were designed to move against the ligand-receptor distance and P-loop conformational change ( open or close ) as described in the previous studies , .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [166, 176], "tok_span": [34, 38]}, {"name": "G2032R", "ent_type": "variant", "char_span": [199, 205], "tok_span": [43, 47]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [199, 205], "obj_char_span": [166, 176], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "The averaged structures ( derived from the equilibrium trajectories ) of WT and G2032R mutated crizotinib-ROS1 complexes were used as the initial structures for the metadynamics simulations .", "entity_list": [{"name": "crizotinib-ROS1", "ent_type": "drug", "char_span": [95, 110], "tok_span": [18, 25]}, {"name": "G2032R", "ent_type": "variant", "char_span": [80, 86], "tok_span": [13, 17]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib-ROS1", "sbj_char_span": [80, 86], "obj_char_span": [95, 110], "rel_type": "resistance", "sbj_tok_span": [13, 17], "obj_tok_span": [18, 25]}], "umls_entity_list": []}, {"text": "By using the combination of US , ABF , and Roux 's absolute binding free energy calculation scheme , we accurately characterized the one-dimensional ( 1D ) free energy profile of crizotinib separated from the binding sites of the WT and G2032R mutated ROS1 to the bulk .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [179, 189], "tok_span": [37, 41]}, {"name": "G2032R", "ent_type": "variant", "char_span": [237, 243], "tok_span": [50, 54]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [237, 243], "obj_char_span": [179, 189], "rel_type": "resistance", "sbj_tok_span": [50, 54], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "The same well equilibrated structures of WT and G2032R mutated crizotinib-ROS1 complexes as those used in metadynamics simulations were employed as the initial structures for the US and ABF simulations .", "entity_list": [{"name": "crizotinib-ROS1", "ent_type": "drug", "char_span": [63, 78], "tok_span": [14, 21]}, {"name": "G2032R", "ent_type": "variant", "char_span": [48, 54], "tok_span": [9, 13]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib-ROS1", "sbj_char_span": [48, 54], "obj_char_span": [63, 78], "rel_type": "resistance", "sbj_tok_span": [9, 13], "obj_tok_span": [14, 21]}], "umls_entity_list": []}, {"text": "The energetic difference between G2032R-ROS1 and WT-ROS1 are shown in panel C ( ΔΔG = ΔGG2032R−ΔGWT , a positive ΔG indicates a weaker binding affinity in the mutated protein , and a negative ΔG indicates a stronger binding affinity ) , where the residue Leu18 ( on the P-loop region ) contributes the most to the attenuated binding of crizotinib to G2032R mutated ROS1 , indicating that the P-loop conformation governs the binding of crizotinib .", "entity_list": [{"name": "binding of crizotinib", "ent_type": "drug", "char_span": [325, 346], "tok_span": [81, 87]}, {"name": "crizotinib to", "ent_type": "variant", "char_span": [336, 349], "tok_span": [83, 88]}, {"name": "binding of crizotinib", "ent_type": "drug", "char_span": [424, 445], "tok_span": [106, 112]}], "relation_list": [{"subject": "crizotinib to", "object": "binding of crizotinib", "sbj_char_span": [336, 349], "obj_char_span": [325, 346], "rel_type": "resistance", "sbj_tok_span": [83, 88], "obj_tok_span": [81, 87]}, {"subject": "crizotinib to", "object": "binding of crizotinib", "sbj_char_span": [336, 349], "obj_char_span": [424, 445], "rel_type": "resistance", "sbj_tok_span": [83, 88], "obj_tok_span": [106, 112]}], "umls_entity_list": []}, {"text": "Alternatively , it seems that the up-moved P-loop region in G2032R-ROS1 could attribute to the crizotinib resistance by attenuating the interactions between the drug and the enlarged binding pocket , which has also been observed in the C1156Y induced crizotinib resistance in the ALK tyrosine kinase .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [95, 105], "tok_span": [25, 29]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [236, 242], "tok_span": [51, 55]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [251, 261], "tok_span": [56, 60]}], "relation_list": [{"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [236, 242], "obj_char_span": [95, 105], "rel_type": "resistance", "sbj_tok_span": [51, 55], "obj_tok_span": [25, 29]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [236, 242], "obj_char_span": [251, 261], "rel_type": "resistance", "sbj_tok_span": [51, 55], "obj_tok_span": [56, 60]}], "umls_entity_list": []}, {"text": "The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 T790M “resistance” mutations .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [42, 50], "tok_span": [8, 10]}, {"name": "L858R", "ent_type": "variant", "char_span": [252, 257], "tok_span": [58, 62]}, {"name": "T790M", "ent_type": "variant", "char_span": [284, 289], "tok_span": [67, 71]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [252, 257], "obj_char_span": [42, 50], "rel_type": "sensitivity", "sbj_tok_span": [58, 62], "obj_tok_span": [8, 10]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [284, 289], "obj_char_span": [42, 50], "rel_type": "response", "sbj_tok_span": [67, 71], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Both in vivo and in vitro models have shown that afatinib has increased affinity for the EGFR L858R mutation compared to the first-generation EGFR-TKIs .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [49, 57], "tok_span": [10, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [94, 99], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [94, 99], "obj_char_span": [49, 57], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Among the 308 patients with the common mutations exon 19 deletion or exon 21 L858R mutation , the difference in PFS was even more striking : 13.6 months with afatinib compared to 6.9 months in the chemotherapy group ( HR 0.47 , P & lt ; 0.0001 ) . ", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [158, 166], "tok_span": [34, 36]}, {"name": "L858R", "ent_type": "variant", "char_span": [77, 82], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [77, 82], "obj_char_span": [158, 166], "rel_type": "sensitivity", "sbj_tok_span": [14, 18], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "Additionally , afatinib has higher potency than reversible EGFR-TKIs in reducing survival of NSCLC cell lines with the T790M resistance mutation ( ) and in cell lines with the less common secondary resistance mutation T854A .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [15, 23], "tok_span": [2, 4]}, {"name": "T790M", "ent_type": "variant", "char_span": [119, 124], "tok_span": [22, 26]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [119, 124], "obj_char_span": [15, 23], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Intermittent , high-dose afatinib ( NCT01647711 ) I Must have known T790M mutation 2nd/3rd line after progression on 1st-generation EGFR-TKI Afatinib at pulsatile , high doses MTD None , trial ongoing", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [25, 33], "tok_span": [7, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [68, 73], "tok_span": [22, 26]}, {"name": "Afatinib", "ent_type": "drug", "char_span": [141, 149], "tok_span": [44, 46]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [68, 73], "obj_char_span": [25, 33], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [7, 9]}, {"subject": "T790M", "object": "Afatinib", "sbj_char_span": [68, 73], "obj_char_span": [141, 149], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "Afatinib has shown activity in the treatment of patients with advanced lung adenocarcinoma with EGFR mutations , especially in patients with deletion 19 or L858R mutations .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "L858R", "ent_type": "variant", "char_span": [156, 161], "tok_span": [25, 29]}], "relation_list": [{"subject": "L858R", "object": "Afatinib", "sbj_char_span": [156, 161], "obj_char_span": [0, 8], "rel_type": "sensitivity", "sbj_tok_span": [25, 29], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "For example , the second generation of irreversible TKIs such as BIBW 2992 for patients with a T790M mutation and MET inhibitors combined with EGFR TKIs for MET amplification , – .", "entity_list": [{"name": "BIBW 2992", "ent_type": "drug", "char_span": [65, 74], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [95, 100], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "BIBW 2992", "sbj_char_span": [95, 100], "obj_char_span": [65, 74], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Ponatinib is a multi targeted kinase inhibitor that exhibits high activity against the T315I mutation but also other BCR-ABL kinase mutants in vitro .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [87, 92], "tok_span": [14, 18]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [87, 92], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "In addition , ponatinib has proven efficacy in mouse models of CML and was also found to be effective in a small cohort of patients with T315I mutations in two recent clinical trials ( phase 1 : NCT00660920 ; phase 2 : NCT01207440 ; http : //www.clinicaltrials.gov ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [137, 142], "tok_span": [29, 33]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [137, 142], "obj_char_span": [14, 23], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "As a whole our findings confirmed the efficacy of ponatinib on the T315I mutation , but also highlighted the notion that ponatinib is effective on all types of imatinib-resistant CML cells , whatever their mode of resistance .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [9, 13]}, {"name": "T315I", "ent_type": "variant", "char_span": [67, 72], "tok_span": [15, 19]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [27, 31]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [67, 72], "obj_char_span": [50, 59], "rel_type": "response", "sbj_tok_span": [15, 19], "obj_tok_span": [9, 13]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [67, 72], "obj_char_span": [121, 130], "rel_type": "response", "sbj_tok_span": [15, 19], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "In BaF3-WT-BCR-ABL and T315I cells , ponatinib efficiently inhibited BCR-ABL phosphorylation , but dephosphorylation of CRLK necessitated higher doses of ponatinib ( Figure ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [18, 22]}, {"name": "T315I", "ent_type": "variant", "char_span": [23, 28], "tok_span": [12, 16]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [154, 163], "tok_span": [45, 49]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [23, 28], "obj_char_span": [37, 46], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [18, 22]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [23, 28], "obj_char_span": [154, 163], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Interestingly , in our hands the cells carrying the G250E mutation seems less sensitive to the effect of ponatinib that the one carrying the T315I mutation .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [20, 24]}, {"name": "T315I", "ent_type": "variant", "char_span": [141, 146], "tok_span": [29, 33]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [141, 146], "obj_char_span": [105, 114], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Our results suggest that in addition to T315I patients , ponatinib could be widely used in resistant CML patients , whatever the supposed mode of resistance to first line ITKs .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [57, 66], "tok_span": [13, 17]}, {"name": "T315I", "ent_type": "variant", "char_span": [40, 45], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [40, 45], "obj_char_span": [57, 66], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Ponatinib is the only available drug that is designed to overcome T315I gatekeeper mutation and is efficient in inhibiting the mutant BCR-ABL. ", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [66, 71], "tok_span": [12, 16]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [66, 71], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Results showed that ponatinib has the highest binding affinity towards the T315I mutant BCR-ABL with a docking score of −11.050 kcal/mol while bosutinib , bafetinib , dasatinib , nilotinib and imatinib showed −5.513 kcal/mol , −4.689 kcal/mol , −4.702 kcal/mol , −3.772 kcal/mol , −3.593 kcal/mol and −3.78 kcal/mol , respectively ( ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [20, 29], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [75, 80], "tok_span": [14, 18]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [75, 80], "obj_char_span": [20, 29], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Ponatinib ( AP24534 ) is a novel pan–BCR-ABL inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native BCR-ABL and BCR-ABL mutants that can arise during treatment with other TKIs and cause resistance , including the T315I mutant .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "the T315I", "ent_type": "variant", "char_span": [273, 282], "tok_span": [61, 66]}, {"name": "AP24534", "ent_type": "drug", "char_span": [12, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "the T315I", "object": "Ponatinib", "sbj_char_span": [273, 282], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [61, 66], "obj_tok_span": [0, 2]}, {"subject": "the T315I", "object": "AP24534", "sbj_char_span": [273, 282], "obj_char_span": [12, 19], "rel_type": "response", "sbj_tok_span": [61, 66], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "In particular , the T315I gatekeeper mutant – the most commonly observed point mutation in clinical practice – confers universal resistance to these agents.– At present , the only TKI that is effective in patients with the T315I mutation is ponatinib ( ARIAD Pharmaceuticals , Inc. , Cambridge , MA , USA ) .", "entity_list": [{"name": "is ponatinib", "ent_type": "drug", "char_span": [238, 250], "tok_span": [50, 55]}, {"name": "T315I", "ent_type": "variant", "char_span": [20, 25], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "is ponatinib", "sbj_char_span": [20, 25], "obj_char_span": [238, 250], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [50, 55]}], "umls_entity_list": []}, {"text": "Ponatinib is a novel , synthetic , orally active , potent pan–BCR-ABL inhibitor and multi targeted TKI that was discovered using a computational and structure based drug design approach.– Ponatinib was specifically designed to inhibit native BCR-ABL and mutant forms that can arise during treatment with other TKIs and cause resistance , including the T315I gatekeeper mutant .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "the T315I", "ent_type": "variant", "char_span": [348, 357], "tok_span": [67, 72]}, {"name": "approach.– Ponatinib", "ent_type": "drug", "char_span": [177, 197], "tok_span": [35, 40]}], "relation_list": [{"subject": "the T315I", "object": "Ponatinib", "sbj_char_span": [348, 357], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [67, 72], "obj_tok_span": [0, 2]}, {"subject": "the T315I", "object": "approach.– Ponatinib", "sbj_char_span": [348, 357], "obj_char_span": [177, 197], "rel_type": "response", "sbj_tok_span": [67, 72], "obj_tok_span": [35, 40]}], "umls_entity_list": []}, {"text": "The T315I is a unique mutation because of its resistance to all approved Bcr-Abl inhibitors , prior to ponatinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [103, 112], "tok_span": [25, 29]}, {"name": "T315I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [4, 9], "obj_char_span": [103, 112], "rel_type": "response", "sbj_tok_span": [1, 5], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Ponatinib ( AP24534 ) an orally active Bcr-Abl Tyrosine Kinase Inhibitor effective against the T315I mutation had been approved for a phase II clinical trial .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [95, 100], "tok_span": [25, 29]}, {"name": "AP24534", "ent_type": "drug", "char_span": [12, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [95, 100], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [0, 2]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [95, 100], "obj_char_span": [12, 19], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Ponatinib contains an unique carbon–carbon triple bond linkage that avoids the steric hindrance to other drugs caused by the bulky isoleucine residue at position 315 in the T315I mutant .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "the T315I", "ent_type": "variant", "char_span": [169, 178], "tok_span": [34, 39]}], "relation_list": [{"subject": "the T315I", "object": "Ponatinib", "sbj_char_span": [169, 178], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [34, 39], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Ponatinib is a potent BCR-ABL inhibitor with activity against the T315I mutation. ", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [66, 71], "tok_span": [14, 18]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [66, 71], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "If the mutation is T315I , the choice will be always ponatinib , even if the first-line was imatinib. , ,,", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [53, 62], "tok_span": [14, 18]}, {"name": "T315I", "ent_type": "variant", "char_span": [19, 24], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [19, 24], "obj_char_span": [53, 62], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "In this respect , Ponatinib ( a third generation TKI ) has been recently shown to overcome the pharmacologic resistance mediated by some mutations of the BCR/ABL protein such as the T315I , and achieve impressive frequency of molecular CR .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [18, 27], "tok_span": [4, 6]}, {"name": "T315I", "ent_type": "variant", "char_span": [182, 187], "tok_span": [37, 41]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [182, 187], "obj_char_span": [18, 27], "rel_type": "response", "sbj_tok_span": [37, 41], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Ponatinib BCR-ABL with mutations , including T315I + + Sen et al", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [45, 50], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "For example , dasatinib is recommended for patients with F359V or Y253H , nilotinib for patients with F317L , and ponatinib for patients with T315I .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [114, 123], "tok_span": [32, 36]}, {"name": "T315I", "ent_type": "variant", "char_span": [142, 147], "tok_span": [39, 43]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [142, 147], "obj_char_span": [114, 123], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "The second-generation TKIs such as afatinib ( BIBW2992 ) described above irreversibly inhibit RTKs of EGFR family , as well as the T790M variant of EGFR .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [35, 43], "tok_span": [8, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [131, 136], "tok_span": [31, 35]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [131, 136], "obj_char_span": [35, 43], "rel_type": "response", "sbj_tok_span": [31, 35], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "We and others have recently demonstrated that the V600E mutation can also preclude responsiveness to panitumumab or cetuximab in mCRC patients and cellular models of CRC . ", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [101, 112], "tok_span": [18, 21]}, {"name": "V600E", "ent_type": "variant", "char_span": [50, 55], "tok_span": [8, 11]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [50, 55], "obj_char_span": [101, 112], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 11], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "A recently published experience found a correlation between BRAF V600E activating mutation , mutually exclusive with KRAS ones , and resistance to the treatment with cetuximab and panitumumab administered alone or in combination with chemotherapy ( ) .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [180, 191], "tok_span": [33, 36]}, {"name": "V600E", "ent_type": "variant", "char_span": [65, 70], "tok_span": [9, 12]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [65, 70], "obj_char_span": [180, 191], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 12], "obj_tok_span": [33, 36]}], "umls_entity_list": []}, {"text": "A recent report by Tol et al. found that the presence of the BRAF V600E mutation was a negative prognostic marker in 516 patients with metastatic colorectal cancer treated with capecitabine , oxaliplatin , and bevacizumab based regimens .", "entity_list": [{"name": "capecitabine", "ent_type": "drug", "char_span": [177, 189], "tok_span": [34, 39]}, {"name": "V600E", "ent_type": "variant", "char_span": [66, 71], "tok_span": [15, 18]}, {"name": "bevacizumab", "ent_type": "drug", "char_span": [210, 221], "tok_span": [45, 47]}], "relation_list": [{"subject": "V600E", "object": "capecitabine", "sbj_char_span": [66, 71], "obj_char_span": [177, 189], "rel_type": "sensitivity", "sbj_tok_span": [15, 18], "obj_tok_span": [34, 39]}, {"subject": "V600E", "object": "bevacizumab", "sbj_char_span": [66, 71], "obj_char_span": [210, 221], "rel_type": "sensitivity", "sbj_tok_span": [15, 18], "obj_tok_span": [45, 47]}], "umls_entity_list": []}, {"text": "Interestingly , vandetanib has been shown recently to be well tolerated and highly active in children with locally advanced or metastatic medullary thyroid cancer in the context of a RET M918T mutation .", "entity_list": [{"name": "vandetanib", "ent_type": "drug", "char_span": [16, 26], "tok_span": [2, 6]}, {"name": "M918T", "ent_type": "variant", "char_span": [187, 192], "tok_span": [34, 38]}], "relation_list": [{"subject": "M918T", "object": "vandetanib", "sbj_char_span": [187, 192], "obj_char_span": [16, 26], "rel_type": "response", "sbj_tok_span": [34, 38], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Thus , we tested the efficacy of these irreversible inhibitors CL-387785 and WZ-4002 ( ) on lapatinib-resistant ERBB2 point mutations ( L755S , L755P and T798M ) .", "entity_list": [{"name": "lapatinib-resistant", "ent_type": "drug", "char_span": [92, 111], "tok_span": [24, 29]}, {"name": "L755S", "ent_type": "variant", "char_span": [136, 141], "tok_span": [35, 39]}], "relation_list": [{"subject": "L755S", "object": "lapatinib-resistant", "sbj_char_span": [136, 141], "obj_char_span": [92, 111], "rel_type": "resistance or non-response", "sbj_tok_span": [35, 39], "obj_tok_span": [24, 29]}], "umls_entity_list": []}, {"text": "( A ) In the human colorectal adenocarcinoma cell line DLD-1 carrying tet-off inducible p53 wild-type (p53wt) or R175H mutant ( p53mut ) transgenes in a functionally p53 negative background the expression of transgenes was induced for 9 h. ( B ) mRNA expression of KIF23 transcript variants in D53wt cells after expression of p53wt was induced for 9 h. ( D+E ) HCT116 cells and HCT116 cells lacking ( D ) p53 or ( E ) p21 expression were treated with nutlin-3 and doxorubicin for 24 and 48 hours , respectively .", "entity_list": [{"name": "doxorubicin", "ent_type": "drug", "char_span": [464, 475], "tok_span": [120, 121]}, {"name": "R175H", "ent_type": "variant", "char_span": [113, 118], "tok_span": [30, 33]}], "relation_list": [{"subject": "R175H", "object": "doxorubicin", "sbj_char_span": [113, 118], "obj_char_span": [464, 475], "rel_type": "sensitivity", "sbj_tok_span": [30, 33], "obj_tok_span": [120, 121]}], "umls_entity_list": []}, {"text": "Mutations associated with resistance to dasatinib such as V299L , T315A and F317I may be sensitive to nilotinib , while the mutation V299L may be resistant to bosutinib ( - ) ( B ) .", "entity_list": [{"name": "bosutinib", "ent_type": "drug", "char_span": [159, 168], "tok_span": [42, 45]}, {"name": "T315A", "ent_type": "variant", "char_span": [66, 71], "tok_span": [14, 18]}], "relation_list": [{"subject": "T315A", "object": "bosutinib", "sbj_char_span": [66, 71], "obj_char_span": [159, 168], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [42, 45]}], "umls_entity_list": []}, {"text": "Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance , specifically the T790M EGFR mutation and MET amplification .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [65, 74], "tok_span": [9, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [190, 195], "tok_span": [29, 33]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [190, 195], "obj_char_span": [65, 74], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "The point mutation T790M of the EGFR gene and MET amplification are known to be involved in the majority of cases of acquired resistance to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [140, 149], "tok_span": [28, 32]}, {"name": "T790M", "ent_type": "variant", "char_span": [19, 24], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [19, 24], "obj_char_span": [140, 149], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "First , a secondary mutation in exon 20 , leading to a substitution of methionine for threonine at position 790 ( T790M ) in the kinase domain , is reported in 2 of 5 patients with acquired resistance to gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [204, 213], "tok_span": [44, 48]}, {"name": "T790M", "ent_type": "variant", "char_span": [114, 119], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [114, 119], "obj_char_span": [204, 213], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 27], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "The appearance of a second mutation represents a mechanism of resistance : in fact the authors demonstrate that the insertion of T790M into test cells renders them resistant to gefitinib in vitro .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [129, 134], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "Finally , a recent study shows not only that EGFR mutations are statistically associated with Asian ethnicity and never-smoker status , but also that patients with EGFR exon 19 deletions have significantly longer median survival than patients with EGFR L858R mutation ( 34 vs. 8 months , p=0.01 ) after treatment with gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [318, 327], "tok_span": [63, 67]}, {"name": "L858R", "ent_type": "variant", "char_span": [253, 258], "tok_span": [42, 46]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [253, 258], "obj_char_span": [318, 327], "rel_type": "sensitivity", "sbj_tok_span": [42, 46], "obj_tok_span": [63, 67]}], "umls_entity_list": []}, {"text": "T790M is mainly present in relapsed tumors after an initial response and secondary to EGFR-TKIs therapy , , and it accounts for about half of acquired resistance to gefitinib or elotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [165, 174], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [0, 5], "obj_char_span": [165, 174], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "The second-generation TKIs may overcome resistance to the treatment of erlotinib or gefitinib via the T790M gatekeeper mutation . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [102, 107], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [102, 107], "obj_char_span": [84, 93], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Phase II XL647 41 patients with relapsed or recurrent advanced NSCLC who progressed after ≥ 12 weeks of stable disease or response to erlotinib or gefitinib and/or those patients with a documented EGFR T790M Objective RR The objective RR was 3 % , 67 % of the patients harbored T790M had progression of disease , while14 % of those without this mutation , 11 patients ( 28 % ) had a dose reduction due to toxicity .", "entity_list": [{"name": "or gefitinib", "ent_type": "drug", "char_span": [144, 156], "tok_span": [30, 35]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [197, 207], "tok_span": [43, 48]}], "relation_list": [{"subject": "EGFR T790M", "object": "or gefitinib", "sbj_char_span": [197, 207], "obj_char_span": [144, 156], "rel_type": "resistance or non-response", "sbj_tok_span": [43, 48], "obj_tok_span": [30, 35]}], "umls_entity_list": []}, {"text": "This type of resistant cell with stem cell features was observed only after exposure to high concentrations of gefitinib , whereas the EGFR T790M mutation or MET amplification were found after the stepwise escalation method .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [111, 120], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [140, 145], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [140, 145], "obj_char_span": [111, 120], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated EGFR ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [7, 11]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [136, 145], "tok_span": [34, 38]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [226, 235], "tok_span": [64, 68]}, {"name": "L858R", "ent_type": "variant", "char_span": [180, 185], "tok_span": [49, 53]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [180, 185], "obj_char_span": [26, 35], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [7, 11]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [180, 185], "obj_char_span": [136, 145], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [34, 38]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [180, 185], "obj_char_span": [226, 235], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [64, 68]}], "umls_entity_list": []}, {"text": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [197, 206], "tok_span": [48, 52]}, {"name": "T790M", "ent_type": "variant", "char_span": [109, 114], "tok_span": [27, 31]}, {"name": "L858R", "ent_type": "variant", "char_span": [38, 43], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [109, 114], "obj_char_span": [197, 206], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [48, 52]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [38, 43], "obj_char_span": [197, 206], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "The T790M mutation in exon 20 of the EGFR gene was detected for the first time in tumour cells of a patient with progression after a few months of efficacious therapy with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [172, 181], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [172, 181], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "These results suggest that the addition of CX-4945 to EGFR-TKI may overcome T790M mediated resistance through the increased activity of EGFR-TKI to suppress EGFR signals by the down-regulation of EGFR . 10.1371/journal.pone.0114000.g004Addition of CX-4945 to EGFR-TKIs substantially suppressed the EGFR signaling pathway in gefitinib/erlotinib-resistant , PC-9 cells .", "entity_list": [{"name": "gefitinib/erlotinib-resistant", "ent_type": "drug", "char_span": [324, 353], "tok_span": [80, 91]}, {"name": "T790M", "ent_type": "variant", "char_span": [76, 81], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib-resistant", "sbj_char_span": [76, 81], "obj_char_span": [324, 353], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [80, 91]}], "umls_entity_list": []}, {"text": "Afatinib exhibits superior anticancer activity in lung cancer patients harboring gefitinib/erlotinib-resistant mutant EGFR ( including T790M , exon 20 insertion , and T790M/L858R double mutation ) .", "entity_list": [{"name": "gefitinib/erlotinib-resistant", "ent_type": "drug", "char_span": [81, 110], "tok_span": [11, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [135, 140], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib-resistant", "sbj_char_span": [135, 140], "obj_char_span": [81, 110], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [11, 22]}], "umls_entity_list": []}, {"text": "Furthermore , the only one patient with PSCCE identified for EGFR mutation was L858R missense mutation in exon 21 , termed as gefitinib associated mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [126, 135], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [79, 84], "tok_span": [15, 19]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [79, 84], "obj_char_span": [126, 135], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Furthermore , EGFR mutations in PSCCE are rare but do exist , especially gefitinib associated mutations such as L858R , therefore gefitinib based gene targeted therapy at EGFR but not KRAS and PIK3CA genes , probably should be included in this carcinoma treatment regimens for patients harboring L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [73, 82], "tok_span": [15, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [112, 117], "tok_span": [23, 27]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [130, 139], "tok_span": [29, 33]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [112, 117], "obj_char_span": [73, 82], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [15, 19]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [112, 117], "obj_char_span": [130, 139], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "On the other hand , a missense mutation in exon 20 , especially T790M , showed gefitinib resistance , as previously reported ( ; ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [79, 88], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [64, 69], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [64, 69], "obj_char_span": [79, 88], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "The T790M mutation detected in gefitinib-resistant tumours , was not found in any untreated tumours from the same patients .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [31, 50], "tok_span": [8, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [4, 9], "obj_char_span": [31, 50], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [8, 14]}], "umls_entity_list": []}, {"text": "In this regard , certain mutations , such as the T790M amino acid change , have been shown to confer resistance to gefitinib and erlotinib ] .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [115, 124], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [49, 54], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [49, 54], "obj_char_span": [115, 124], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Mutations in exon 20 , most notably T790M , are usually associated with resistance to gefitinib and erlotinib ] .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [86, 95], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [36, 41], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [36, 41], "obj_char_span": [86, 95], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "One patient with a T790M mutation caused by prior gefitinib treatment achieved SD after exposure to dacomitinib in the NCT00783328 trial .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [19, 24], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [19, 24], "obj_char_span": [50, 59], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "A similar theme exists in NSCLCs with a mutation in the EGFR – secondary mutations confer insensitivity to the EGFR tyrosine kinase inhibitor ( EGFR-TKI ) gefitinib , and have been identified in patients with clinical resistance to gefitinib , but also in untreated patients ( ) . analysed NSCLC samples for one such mutation in EGFR , the T790M mutation , from treatment-naïve patients , and from patients before and during treatment with EGFR-TKIs .", "entity_list": [{"name": ") gefitinib", "ent_type": "drug", "char_span": [153, 164], "tok_span": [30, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [340, 345], "tok_span": [70, 74]}, {"name": "to gefitinib", "ent_type": "drug", "char_span": [229, 241], "tok_span": [45, 50]}], "relation_list": [{"subject": "T790M", "object": ") gefitinib", "sbj_char_span": [340, 345], "obj_char_span": [153, 164], "rel_type": "resistance or non-response", "sbj_tok_span": [70, 74], "obj_tok_span": [30, 35]}, {"subject": "T790M", "object": "to gefitinib", "sbj_char_span": [340, 345], "obj_char_span": [229, 241], "rel_type": "resistance or non-response", "sbj_tok_span": [70, 74], "obj_tok_span": [45, 50]}], "umls_entity_list": []}, {"text": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [129, 138], "tok_span": [25, 29]}, {"name": "L858R", "ent_type": "variant", "char_span": [370, 375], "tok_span": [75, 79]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [370, 375], "obj_char_span": [129, 138], "rel_type": "sensitivity", "sbj_tok_span": [75, 79], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "For example , in glioblastoma and non-small-cell lung carcinoma ( NSCLC ) patients the presence of EGFRvIII or T790M EGFR was found to be associated with resistance to treatment with gefitinib and erlotinib , respectively ( ; ; ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [183, 192], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [111, 116], "obj_char_span": [183, 192], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "Epidermal growth factor receptor (EGFR) activating mutations , such as exon 19 deletion and exon 21 L858R point mutation , are found in a population of NSCLC , and are associated with a clinical response to the EGFR tyrosine kinase inhibitors ( EGF-TKIs ) , gefitinib and erlotinib – .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [258, 267], "tok_span": [54, 58]}, {"name": "L858R", "ent_type": "variant", "char_span": [100, 105], "tok_span": [19, 23]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [100, 105], "obj_char_span": [258, 267], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [54, 58]}], "umls_entity_list": []}, {"text": "XL647 has also showed to be active against cells containing the T790M mutation , which have been associated with emerging resistance to first-generation EGFR TKIs such as gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [171, 180], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [64, 69], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [64, 69], "obj_char_span": [171, 180], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "The drug resistance mutation T790M was detected in CTCs collected from patients with EGFR mutations that had received tyrosine kinase inhibitors Gefitinib ( Iressa ) or Erlotinib ( Tarceva ) .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [145, 154], "tok_span": [25, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [29, 34], "tok_span": [4, 8]}, {"name": "Iressa", "ent_type": "drug", "char_span": [157, 163], "tok_span": [29, 32]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [29, 34], "obj_char_span": [145, 154], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [25, 28]}, {"subject": "T790M", "object": "Iressa", "sbj_char_span": [29, 34], "obj_char_span": [157, 163], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "Immunofluorescence studies revealed that E-cadherin was associated with disorganized adhesive structures rather than restricted to the plasma membrane at areas of cell-cell contact in erlotinib-refractory H1975 cells , which express both the erlotinib sensitizing L858R mutation and the T790M resistant mutation .", "entity_list": [{"name": "erlotinib-refractory", "ent_type": "drug", "char_span": [184, 204], "tok_span": [32, 38]}, {"name": "L858R", "ent_type": "variant", "char_span": [264, 269], "tok_span": [53, 57]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [242, 251], "tok_span": [47, 51]}, {"name": "T790M", "ent_type": "variant", "char_span": [287, 292], "tok_span": [60, 64]}], "relation_list": [{"subject": "L858R", "object": "erlotinib-refractory", "sbj_char_span": [264, 269], "obj_char_span": [184, 204], "rel_type": "sensitivity", "sbj_tok_span": [53, 57], "obj_tok_span": [32, 38]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [264, 269], "obj_char_span": [242, 251], "rel_type": "sensitivity", "sbj_tok_span": [53, 57], "obj_tok_span": [47, 51]}, {"subject": "T790M", "object": "erlotinib-refractory", "sbj_char_span": [287, 292], "obj_char_span": [184, 204], "rel_type": "resistance or non-response", "sbj_tok_span": [60, 64], "obj_tok_span": [32, 38]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [287, 292], "obj_char_span": [242, 251], "rel_type": "resistance or non-response", "sbj_tok_span": [60, 64], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "NSCLC tumors carrying EGFR activating mutations ( e.g. , exon 19 deletions or L858R ) respond preferentially to the EGFR TKIs gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [140, 149], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [78, 83], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [78, 83], "obj_char_span": [140, 149], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "T790M and MET amplification , which can be detected in up to 20 % of EGFR NSCLCs secondarily refractory to EGFR TKIs , account for approximately 60–70 % of all known causes of acquired resistance to gefitinib/erlotinib .", "entity_list": [{"name": "gefitinib/erlotinib", "ent_type": "drug", "char_span": [199, 218], "tok_span": [44, 53]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib", "sbj_char_span": [0, 5], "obj_char_span": [199, 218], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [44, 53]}], "umls_entity_list": []}, {"text": "Development of EMT was observed in a NSCLC patient who acquired resistance to erlotinib in the absence of known resistance mechanisms , such as the EGFR T790M mutation and MET amplification .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [78, 87], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [153, 158], "tok_span": [29, 33]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [153, 158], "obj_char_span": [78, 87], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "In this scenario , it might appear reasonable to suggest that in addition to the presence of the T790M mutation , immunohistochemical and/or microarray based transcriptional profiling studies dedicated to specific alterations of EMT drivers ( e.g. , SLUG ) and/or effectors ( e.g. , vimentin ) may be helpful in monitoring for erlotinib responders and non-responders based on the loss of biomarkers associated with epithelial status and gain of biomarkers associated with mesenchymal status .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [327, 336], "tok_span": [70, 74]}, {"name": "T790M", "ent_type": "variant", "char_span": [97, 102], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [97, 102], "obj_char_span": [327, 336], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [70, 74]}], "umls_entity_list": []}, {"text": "The T790M mutation is known to mediate secondary resistance to EGFR TKIs , yet there is evidence that it can be detected even before treatment with erlotinib or gefitinib when a high sensitivity method of detection is applied .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [148, 157], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [148, 157], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 L858R mutation. , Further studies then compared first-generation EGFR-TKIs ( erlotinib and gefitinib ) to chemotherapy in patients with EGFR activating mutations in advanced NSCLC .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [233, 242], "tok_span": [48, 52]}, {"name": "L858R", "ent_type": "variant", "char_span": [156, 161], "tok_span": [29, 33]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [156, 161], "obj_char_span": [233, 242], "rel_type": "sensitivity", "sbj_tok_span": [29, 33], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "Inhibition of EGFR cell lines by afatinib compared to erlotinib as shown by EC50 values Wild-type L858R mutation L858R + T790M", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [54, 63], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [98, 103], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [121, 126], "tok_span": [33, 37]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [98, 103], "obj_char_span": [54, 63], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [121, 126], "obj_char_span": [54, 63], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "The T790M mutation accounts for approximately 50 % of cases in which acquired resistance to erlotinib or gefitinib occurs , , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [92, 101], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [92, 101], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Of note , mutations within ALK that lead to crizotinib resistance have already been described , analogous to the T790M mutation leading to erlotinib and gefitinib resistance in EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [139, 148], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [113, 118], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [113, 118], "obj_char_span": [139, 148], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 27], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "The L858R mutant was 10–100 fold more sensitive to erlotinib and gefitinib than the wild type kinase , .", "entity_list": [{"name": "to erlotinib", "ent_type": "drug", "char_span": [48, 60], "tok_span": [13, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "to erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [48, 60], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [13, 18]}], "umls_entity_list": []}, {"text": "The study showed that , among the 5 tumor samples collected at the time of XL647 failure , only one harbored the T790M mutation and that three patients treated with second line erlotinib derived additional long-term benefit from the EGFR TKI .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [113, 118], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [113, 118], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "BMS-690514 , a reversible oral inhibitor of EGFR , HER-2 and −4 , VEGFRs-1 to −3 , showed antitumour activity in tumour xenograft models and in cell lines containing the EGFR T790M mutation , suggesting a role against erlotinib-resistant tumours .", "entity_list": [{"name": "against erlotinib-resistant", "ent_type": "drug", "char_span": [210, 237], "tok_span": [53, 60]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [170, 180], "tok_span": [43, 48]}], "relation_list": [{"subject": "EGFR T790M", "object": "against erlotinib-resistant", "sbj_char_span": [170, 180], "obj_char_span": [210, 237], "rel_type": "resistance or non-response", "sbj_tok_span": [43, 48], "obj_tok_span": [53, 60]}], "umls_entity_list": []}, {"text": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with L858R mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [24, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [169, 174], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [169, 174], "obj_char_span": [134, 143], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Acquired resistance mechanism 1 ) Secondary T790M mutation of the EGFR gene Unfortunately , many of those patients who originally had responded eventually become insensitive to gefitinib or erlotinib therapy through acquired resistance .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [190, 199], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [44, 49], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [44, 49], "obj_char_span": [190, 199], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Interestingly , it was discovered that the T790M mutation does not confer resistance to gefitinib and erlotinib by preventing their binding as originally thought .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [102, 111], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [43, 48], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [43, 48], "obj_char_span": [102, 111], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "This figure is reprinted from the article by Giroux S. ( A ) Erlotinib bound to the epidermal growth factor receptor (EGFR) tyrosine kinase , the gatekeeper residue ( T790 ) is highlighted in green ; cysteine-797 , which forms a covalent bond with 2nd and 3rd generation irreversible EGFR inhibitors , is highlighted in green . ( B ) Structure of WZ-4002 covalently bound to EGFR T790M via cysteine-797 .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [61, 70], "tok_span": [16, 19]}, {"name": "T790M", "ent_type": "variant", "char_span": [380, 385], "tok_span": [88, 92]}], "relation_list": [{"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [380, 385], "obj_char_span": [61, 70], "rel_type": "resistance or non-response", "sbj_tok_span": [88, 92], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Patients with exon 19 harboring deletions were found to have longer survival following treatment with gefitinib or erlotinib compared with those having L858R mutations in NSCLC ; however , Marks et al. reported no difference in survival between exon 19 deletions and L858R mutations in the absence of EGFR targeted therapy .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [115, 124], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [152, 157], "tok_span": [28, 32]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [152, 157], "obj_char_span": [115, 124], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [24, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [173, 178], "tok_span": [33, 37]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [173, 178], "obj_char_span": [134, 143], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Since a secondary T790M mutation was found on a liver biopsy , but not in the CSF , the patient received erlotinib , and the brain metastasis responded well to treatment .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [24, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [18, 23], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [18, 23], "obj_char_span": [105, 114], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "As in that case report , our patient exhibited sensitivity to erlotinib in brain metastases , even though the cancer cells in the pleural effusion had acquired a resistant mutation to EGFR-TKI , T790M .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [62, 71], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [195, 200], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [195, 200], "obj_char_span": [62, 71], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "In a retrospective analysis of an erlotinib retrial , Becker et al. reported five cases of the T790M mutation and exon 19 deletions in rebiopsy specimens taken before the retrial of erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [34, 43], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [95, 100], "tok_span": [22, 26]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [182, 191], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [95, 100], "obj_char_span": [34, 43], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [6, 10]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [95, 100], "obj_char_span": [182, 191], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "For example , we detected the erlotinib resistance mutation , T790M , in tumor sample 10 ( 80 % tumor cell content ) obtained at the time of relapse ( Supplementary ) and this sample also harbored the L747_S752del_P753S deletion initially detected by dideoxy sequencing ( and ) . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [30, 39], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [62, 67], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [62, 67], "obj_char_span": [30, 39], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Tumor specimen 10b with a high allele frequency of T790M and clinical resistance to erlotinib treatment is not shown in this diagram .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [51, 56], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [51, 56], "obj_char_span": [84, 93], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Two patients harboring EGFR T790M mutation had received EGFR-TKI treatment : one received gefitinib and had an occurrence of brain metastasis in the sixth month ; the other received erlotinib to control the metastasis to the liver .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [182, 191], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [28, 33], "obj_char_span": [182, 191], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "This molecular change had been found in samples with gefitinib or erlotinib resistance in vivo or in vitro . c-MET amplification has also occasionally been found to coexist with EGFR T790M mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [14, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [183, 188], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [183, 188], "obj_char_span": [66, 75], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Patients with EGFR mutations have shown a positive response to therapy with erlotinib , although many of these patients relapse later , frequently due to a secondary EGFR mutation , T790M .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [76, 85], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [182, 187], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [182, 187], "obj_char_span": [76, 85], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "( B ) Drugs such as the 4-anilinoquinazolines gefitinib ( Iressa ) and erlotinib ( Tarceva ) can inhibit the activity of EGFR L858R mutant .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [24, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [126, 131], "tok_span": [39, 43]}, {"name": "Tarceva", "ent_type": "drug", "char_span": [83, 90], "tok_span": [29, 32]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [126, 131], "obj_char_span": [71, 80], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [24, 28]}, {"subject": "L858R", "object": "Tarceva", "sbj_char_span": [126, 131], "obj_char_span": [83, 90], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "In our case , a biopsy ( ‘re-biopsy’ ) revealed the T790M mutation in the EGFR gene , which was widely known as a second mutation resistant to EGFR TKIs , such as gefitinib and erlotinib .", "entity_list": [{"name": "and erlotinib", "ent_type": "drug", "char_span": [173, 186], "tok_span": [45, 50]}, {"name": "the T790M", "ent_type": "variant", "char_span": [48, 57], "tok_span": [14, 19]}], "relation_list": [{"subject": "the T790M", "object": "and erlotinib", "sbj_char_span": [48, 57], "obj_char_span": [173, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 19], "obj_tok_span": [45, 50]}], "umls_entity_list": []}, {"text": "We did not detect any V600E BRAF mutations in our study while the frequency of BRAF mutations was 12 % in the aforementioned study of cetuximab plus chemotherapy in advanced OGJ cancer patients .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [134, 143], "tok_span": [27, 31]}, {"name": "V600E", "ent_type": "variant", "char_span": [22, 27], "tok_span": [5, 8]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [22, 27], "obj_char_span": [134, 143], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 8], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Panitumumab can still bind to an EGFR mutant S492R to which cetuximab can not bind to .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [60, 69], "tok_span": [16, 20]}, {"name": "S492R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [45, 50], "obj_char_span": [60, 69], "rel_type": "resistance", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Patients with G13D respond better to cetuximab than patients with K-Ras codon 12 mutations .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [37, 46], "tok_span": [8, 12]}, {"name": "G13D", "ent_type": "variant", "char_span": [14, 18], "tok_span": [2, 5]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [14, 18], "obj_char_span": [37, 46], "rel_type": "resistance or non-response", "sbj_tok_span": [2, 5], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "On the other hand , there are a number of in vitro results that show that cells possessing the K-Ras G13D mutation are resistant to cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [132, 141], "tok_span": [29, 33]}, {"name": "G13D", "ent_type": "variant", "char_span": [101, 105], "tok_span": [22, 25]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [101, 105], "obj_char_span": [132, 141], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 25], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to cetuximab have acquired either K-Ras G12V or K-Ras G13D mutations .", "entity_list": [{"name": "cetuximab-resistant", "ent_type": "drug", "char_span": [70, 89], "tok_span": [13, 19]}, {"name": "G13D", "ent_type": "variant", "char_span": [174, 178], "tok_span": [42, 45]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [123, 132], "tok_span": [25, 29]}], "relation_list": [{"subject": "G13D", "object": "cetuximab-resistant", "sbj_char_span": [174, 178], "obj_char_span": [70, 89], "rel_type": "resistance or non-response", "sbj_tok_span": [42, 45], "obj_tok_span": [13, 19]}, {"subject": "G13D", "object": "cetuximab", "sbj_char_span": [174, 178], "obj_char_span": [123, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [42, 45], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "One mechanism to resistance was recently elucidated : cetuximab resistant cells contain an EGFR mutation in the extracellular domain ( S492R ) that impairs cetuximab , but not epidermal growth factor (EGF) binding .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [54, 63], "tok_span": [8, 12]}, {"name": "S492R", "ent_type": "variant", "char_span": [135, 140], "tok_span": [23, 27]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [156, 165], "tok_span": [30, 34]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [135, 140], "obj_char_span": [54, 63], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [8, 12]}, {"subject": "S492R", "object": "cetuximab", "sbj_char_span": [135, 140], "obj_char_span": [156, 165], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "A and D ) Detroit 562 cells ( harboring PIK3CA H1047R mutations ) and UMSCC17B cells ( expressing HRAS Q61L mutant oncogene ) were transplanted into athymic mice , and mice were treated with cetuximab or rapamycin alone , or cetuximab together with rapamycin , as indicated .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [191, 200], "tok_span": [52, 56]}, {"name": "H1047R", "ent_type": "variant", "char_span": [47, 53], "tok_span": [16, 20]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [225, 234], "tok_span": [61, 65]}], "relation_list": [{"subject": "H1047R", "object": "cetuximab", "sbj_char_span": [47, 53], "obj_char_span": [191, 200], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [52, 56]}, {"subject": "H1047R", "object": "cetuximab", "sbj_char_span": [47, 53], "obj_char_span": [225, 234], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [61, 65]}], "umls_entity_list": []}, {"text": "Indeed , Montagut et al. identified the S492R mutation in 2 out of 10 tumors from patients with cetuximab resistance , and those 2 tumors showed good response to panitumumab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [96, 105], "tok_span": [24, 28]}, {"name": "S492R", "ent_type": "variant", "char_span": [40, 45], "tok_span": [10, 14]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [40, 45], "obj_char_span": [96, 105], "rel_type": "resistance", "sbj_tok_span": [10, 14], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Briefly , they demonstrated the different effects of the G12 and G13 K-Ras alleles on response to cetuximab and found a significant association between the presence of a G13D mutation and survival benefit after cetuximab treatment in metastatic colorectal cancer patients . ", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [98, 107], "tok_span": [21, 25]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [211, 220], "tok_span": [43, 47]}, {"name": "G13D", "ent_type": "variant", "char_span": [170, 174], "tok_span": [35, 38]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [170, 174], "obj_char_span": [98, 107], "rel_type": "resistance or non-response", "sbj_tok_span": [35, 38], "obj_tok_span": [21, 25]}, {"subject": "G13D", "object": "cetuximab", "sbj_char_span": [170, 174], "obj_char_span": [211, 220], "rel_type": "resistance or non-response", "sbj_tok_span": [35, 38], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "However , they also noted that the addition of cetuximab to first-line chemotherapy may benefit patients with KRAS G13D mutation .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [47, 56], "tok_span": [9, 13]}, {"name": "G13D", "ent_type": "variant", "char_span": [115, 119], "tok_span": [24, 27]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [115, 119], "obj_char_span": [47, 56], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 27], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Montagut et al. reported an acquired EGFR ectodomain mutation ( S492R ) that prevented cetuximab binding , thus conferring resistance to this drug . ", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [87, 96], "tok_span": [22, 26]}, {"name": "S492R", "ent_type": "variant", "char_span": [64, 69], "tok_span": [15, 19]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [64, 69], "obj_char_span": [87, 96], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "One patient with cetuximab resistance and harboring the S492R mutation responded to treatment with panitumumab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [17, 26], "tok_span": [3, 7]}, {"name": "S492R", "ent_type": "variant", "char_span": [56, 61], "tok_span": [11, 15]}, {"name": "panitumumab", "ent_type": "drug", "char_span": [99, 110], "tok_span": [20, 23]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [56, 61], "obj_char_span": [17, 26], "rel_type": "resistance", "sbj_tok_span": [11, 15], "obj_tok_span": [3, 7]}, {"subject": "S492R", "object": "panitumumab", "sbj_char_span": [56, 61], "obj_char_span": [99, 110], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "This indicates that panitumumab may be effective in patients with the S492R mutation after failure of cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [102, 111], "tok_span": [21, 25]}, {"name": "S492R", "ent_type": "variant", "char_span": [70, 75], "tok_span": [13, 17]}, {"name": "panitumumab", "ent_type": "drug", "char_span": [20, 31], "tok_span": [3, 6]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [70, 75], "obj_char_span": [102, 111], "rel_type": "resistance", "sbj_tok_span": [13, 17], "obj_tok_span": [21, 25]}, {"subject": "S492R", "object": "panitumumab", "sbj_char_span": [70, 75], "obj_char_span": [20, 31], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Cancer EGFR exon18 G719X Drug efficacy prediction of gefitinib and erlotinib exon19 deletion exon20 T790M exon21 L858R KRAS codon12 , 13 Drug efficacy prediction of cetuximab", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [165, 174], "tok_span": [46, 50]}, {"name": "T790M", "ent_type": "variant", "char_span": [100, 105], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [100, 105], "obj_char_span": [165, 174], "rel_type": "response", "sbj_tok_span": [26, 30], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "There are suggestions that certain mutations ( e.g. , G13D ) do not confer resistance to Cetuximab , though these observations need to be confirmed by prospective trials and were not replicated in analysis of a recent panitumumab trial .", "entity_list": [{"name": "Cetuximab", "ent_type": "drug", "char_span": [89, 98], "tok_span": [21, 24]}, {"name": "G13D", "ent_type": "variant", "char_span": [54, 58], "tok_span": [12, 15]}], "relation_list": [{"subject": "G13D", "object": "Cetuximab", "sbj_char_span": [54, 58], "obj_char_span": [89, 98], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 15], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "Patients carrying KRAS G13D mutation could still benefit from cetuximab treatment .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [62, 71], "tok_span": [12, 16]}, {"name": "G13D", "ent_type": "variant", "char_span": [23, 27], "tok_span": [4, 7]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [23, 27], "obj_char_span": [62, 71], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 7], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "We didn’t observe that patients with KRAS G13D mutation had better response rate ( ) . 10.1371/journal.pone.0068022.t002Patients’ characteristics of the 35 patients receiving cetuximab .", "entity_list": [{"name": "receiving cetuximab", "ent_type": "drug", "char_span": [165, 184], "tok_span": [48, 53]}, {"name": "KRAS G13D", "ent_type": "variant", "char_span": [37, 46], "tok_span": [8, 13]}], "relation_list": [{"subject": "KRAS G13D", "object": "receiving cetuximab", "sbj_char_span": [37, 46], "obj_char_span": [165, 184], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 13], "obj_tok_span": [48, 53]}], "umls_entity_list": []}, {"text": "Clinically approved patient selection biomarkers for anti-EGFR treatments cetuximab and panitumumab include assessment of EGFR levels and KRAS G12D mutation status .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [74, 83], "tok_span": [11, 15]}, {"name": "G12D", "ent_type": "variant", "char_span": [143, 147], "tok_span": [27, 30]}], "relation_list": [{"subject": "G12D", "object": "cetuximab", "sbj_char_span": [143, 147], "obj_char_span": [74, 83], "rel_type": "sensitivity", "sbj_tok_span": [27, 30], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "It has been reported that the use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with G13D mutated tumors than patients with other KRAS mutated tumors .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [37, 46], "tok_span": [8, 12]}, {"name": "G13D", "ent_type": "variant", "char_span": [179, 183], "tok_span": [31, 34]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [179, 183], "obj_char_span": [37, 46], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 34], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , cetuximab and panitumumab , in metastatic colon cancer and BRAF V600E mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [123, 132], "tok_span": [19, 23]}, {"name": "V600E", "ent_type": "variant", "char_span": [187, 192], "tok_span": [34, 37]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [187, 192], "obj_char_span": [123, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [34, 37], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "However , acquired resistance to imatinib can occur because of point mutations in the ATP binding site ( e.g. , T674I and D842V ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [33, 41], "tok_span": [5, 7]}, {"name": "T674I", "ent_type": "variant", "char_span": [112, 117], "tok_span": [24, 28]}, {"name": "D842V", "ent_type": "variant", "char_span": [122, 127], "tok_span": [29, 33]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [112, 117], "obj_char_span": [33, 41], "rel_type": "resistance", "sbj_tok_span": [24, 28], "obj_tok_span": [5, 7]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [122, 127], "obj_char_span": [33, 41], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "The T674I gatekeeper mutation does not perturb the overall protein structure of PDGFRα , except that the large aliphatic side chain causes a steric hindrance that prevents the binding of imatinib but not ponatinib ( data not shown ) .", "entity_list": [{"name": "of imatinib", "ent_type": "drug", "char_span": [184, 195], "tok_span": [40, 43]}, {"name": "T674I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T674I", "object": "of imatinib", "sbj_char_span": [4, 9], "obj_char_span": [184, 195], "rel_type": "resistance", "sbj_tok_span": [1, 5], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "To examine whether ponatinib is active against T674I FIP1L1-PDGFRα , we exposed BaF3-T674I FIP1L1-PDGFRα cells to ponatinib , sorafenib and imatinib ( the latter two serving as positive and negative controls , respectively ) ; levels of phosphorylated and total PDGFRα were measured by immunoblotting .", "entity_list": [{"name": "and imatinib", "ent_type": "drug", "char_span": [136, 148], "tok_span": [52, 55]}, {"name": "T674I", "ent_type": "variant", "char_span": [47, 52], "tok_span": [10, 14]}], "relation_list": [{"subject": "T674I", "object": "and imatinib", "sbj_char_span": [47, 52], "obj_char_span": [136, 148], "rel_type": "resistance", "sbj_tok_span": [10, 14], "obj_tok_span": [52, 55]}], "umls_entity_list": []}, {"text": "The phosphorylation of T674I FIP1L1-PDGFRα was altered by sorafenib but not imatinib ( Figure 1A ) , which is consistent with a previous report .", "entity_list": [{"name": "not imatinib", "ent_type": "drug", "char_span": [72, 84], "tok_span": [22, 25]}, {"name": "T674I", "ent_type": "variant", "char_span": [23, 28], "tok_span": [3, 7]}], "relation_list": [{"subject": "T674I", "object": "not imatinib", "sbj_char_span": [23, 28], "obj_char_span": [72, 84], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "The in vivo antineoplastic activity of ponatinib as a single agent against imatinib-resistant T674I FIP1L1-PDGFRα expressing cells was evaluated in the nude mouse xenograft model .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [75, 93], "tok_span": [17, 21]}, {"name": "T674I", "ent_type": "variant", "char_span": [94, 99], "tok_span": [21, 25]}], "relation_list": [{"subject": "T674I", "object": "imatinib-resistant", "sbj_char_span": [94, 99], "obj_char_span": [75, 93], "rel_type": "resistance", "sbj_tok_span": [21, 25], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Ponatinib potently abrogates the growth of imatinib-resistant neoplastic cells expressing T674I FIP1L1-PDGFRα in nude mouse xenografts .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [43, 61], "tok_span": [10, 14]}, {"name": "T674I", "ent_type": "variant", "char_span": [90, 95], "tok_span": [17, 21]}], "relation_list": [{"subject": "T674I", "object": "imatinib-resistant", "sbj_char_span": [90, 95], "obj_char_span": [43, 61], "rel_type": "resistance", "sbj_tok_span": [17, 21], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Our molecular docking analysis revealed that ponatinib could target native or T674I FIP1L1-PDGFRα in the DFG-out ( inactive ) binding mode , similar to ponatinib docking in T315I Bcr-Abl . ", "entity_list": [{"name": "T674I", "ent_type": "variant", "char_span": [78, 83], "tok_span": [14, 18]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [45, 54], "tok_span": [6, 10]}, {"name": "in T315I", "ent_type": "variant", "char_span": [170, 178], "tok_span": [46, 51]}, {"name": "to ponatinib", "ent_type": "drug", "char_span": [149, 161], "tok_span": [40, 45]}], "relation_list": [{"subject": "in T315I", "object": "ponatinib", "sbj_char_span": [170, 178], "obj_char_span": [45, 54], "rel_type": "response", "sbj_tok_span": [46, 51], "obj_tok_span": [6, 10]}, {"subject": "in T315I", "object": "to ponatinib", "sbj_char_span": [170, 178], "obj_char_span": [149, 161], "rel_type": "response", "sbj_tok_span": [46, 51], "obj_tok_span": [40, 45]}], "umls_entity_list": []}, {"text": "Given the FDA approval of oral ponatinib in patients with refractory CML and Ph + ALL resistant to the first- and second-generation of TKIs , our findings warrant a clinical trial of ponatinib in imatinib-resistant CEL and other malignant disorders harboring T674I PDGFRα .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [196, 214], "tok_span": [44, 48]}, {"name": "T674I", "ent_type": "variant", "char_span": [259, 264], "tok_span": [55, 59]}], "relation_list": [{"subject": "T674I", "object": "imatinib-resistant", "sbj_char_span": [259, 264], "obj_char_span": [196, 214], "rel_type": "resistance", "sbj_tok_span": [55, 59], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "It showed to be 135-fold more potent than imatinib against primary gastrointestinal stromal tumors cells expressing PDGFRα with D842V deletion and IC50 of approximately 10 nmol/L .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [42, 50], "tok_span": [10, 12]}, {"name": "with D842V", "ent_type": "variant", "char_span": [123, 133], "tok_span": [23, 28]}], "relation_list": [{"subject": "with D842V", "object": "imatinib", "sbj_char_span": [123, 133], "obj_char_span": [42, 50], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 28], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "The most common PDGFRα mutation ( 62.6 % of PDGFRα mutations ) , the exon 18 D842V mutation , is insensitive to imatinib .", "entity_list": [{"name": "to imatinib", "ent_type": "drug", "char_span": [109, 120], "tok_span": [30, 33]}, {"name": "18 D842V", "ent_type": "variant", "char_span": [74, 82], "tok_span": [21, 26]}], "relation_list": [{"subject": "18 D842V", "object": "to imatinib", "sbj_char_span": [74, 82], "obj_char_span": [109, 120], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 26], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "Heinrich and associates reported on the effect of crenolanib on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [87, 105], "tok_span": [17, 21]}, {"name": "D842V", "ent_type": "variant", "char_span": [106, 111], "tok_span": [21, 25]}], "relation_list": [{"subject": "D842V", "object": "imatinib-resistant", "sbj_char_span": [106, 111], "obj_char_span": [87, 105], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "To explore potential target genes or mechanisms underlying imatinib resistance in wild-type GISTs , we integrated CGH and expression profiling in 32 gastric GISTs , including four wild-type GISTs and one imatinib-resistant PDGFRA D842V mutant GIST .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [59, 67], "tok_span": [8, 10]}, {"name": "D842V", "ent_type": "variant", "char_span": [230, 235], "tok_span": [46, 50]}, {"name": "imatinib-resistant", "ent_type": "drug", "char_span": [204, 222], "tok_span": [40, 44]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [230, 235], "obj_char_span": [59, 67], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [8, 10]}, {"subject": "D842V", "object": "imatinib-resistant", "sbj_char_span": [230, 235], "obj_char_span": [204, 222], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "To identify additional drivers or modifiers of GIST biology that can be targeted , we integrated array based analysis of DNA CN and gene expression results from tumors resistant to imatinib , i.e. wild-type and PDGFRA D842V GISTs ( summarized in ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [181, 189], "tok_span": [33, 35]}, {"name": "D842V", "ent_type": "variant", "char_span": [218, 223], "tok_span": [46, 50]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [218, 223], "obj_char_span": [181, 189], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "These observations were validated in clinical samples by qRT-PCR : CN gain of GSTT1 was detected in 90 % of wild-type and 100 % of PDGFRA D842V GISTs , and all cases with GSTT1 CN gain showed disease progression during imatinib therapy .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [219, 227], "tok_span": [53, 55]}, {"name": "D842V", "ent_type": "variant", "char_span": [138, 143], "tok_span": [33, 37]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [138, 143], "obj_char_span": [219, 227], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [53, 55]}], "umls_entity_list": []}, {"text": "Additionally , imatinib-resistant KIT exon 9 or PDGFRα exon 18 D842V mutations – or even no detectable mutation at all – could be the cause of the resistance. , It is also important that secondary mutations located on KIT exon 11 can cause low response to imatinib treatment.– Taking into consideration the fact that in 5 % –15 % of GISTs these mutations are absent , scientists consider it possible that there is an additional pathway that has not yet been discovered .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [15, 33], "tok_span": [2, 6]}, {"name": "18 D842V", "ent_type": "variant", "char_span": [60, 68], "tok_span": [15, 20]}, {"name": "to imatinib", "ent_type": "drug", "char_span": [253, 264], "tok_span": [56, 59]}], "relation_list": [{"subject": "18 D842V", "object": "imatinib-resistant", "sbj_char_span": [60, 68], "obj_char_span": [15, 33], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 20], "obj_tok_span": [2, 6]}, {"subject": "18 D842V", "object": "to imatinib", "sbj_char_span": [60, 68], "obj_char_span": [253, 264], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 20], "obj_tok_span": [56, 59]}], "umls_entity_list": []}, {"text": "PDGFRA exon 18 mutations ( D842V ) , which affect the activation loop of the PDGFRα kinase , are biochemically less sensitive to imatinib than the more common KIT exon 11 mutations .", "entity_list": [{"name": "to imatinib", "ent_type": "drug", "char_span": [126, 137], "tok_span": [29, 32]}, {"name": "D842V", "ent_type": "variant", "char_span": [27, 32], "tok_span": [6, 10]}], "relation_list": [{"subject": "D842V", "object": "to imatinib", "sbj_char_span": [27, 32], "obj_char_span": [126, 137], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "For example , patients can be screened readily for KRAS and V600E mutations to assess their eligibility to be treated with cetuximab or vermurafenib .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [123, 132], "tok_span": [24, 28]}, {"name": "V600E", "ent_type": "variant", "char_span": [60, 65], "tok_span": [12, 15]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [60, 65], "obj_char_span": [123, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 15], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Di Nicolantonio et al. ( ) also demonstrated that introduction of the BRAF V600E allele could confer resistance to either cetuximab or panitumumab in wild-type BRAF colorectal cancer cells .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [135, 146], "tok_span": [32, 35]}, {"name": "V600E", "ent_type": "variant", "char_span": [75, 80], "tok_span": [18, 21]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [75, 80], "obj_char_span": [135, 146], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "The effect of BRAF V600E mutation on cetuximab or panitumumab response was also assessed using cellular models of CRC .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [50, 61], "tok_span": [14, 17]}, {"name": "V600E", "ent_type": "variant", "char_span": [19, 24], "tok_span": [4, 7]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [19, 24], "obj_char_span": [50, 61], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 7], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "The introduction of BRAF V600E allele impaired the therapeutic effect of cetuximab or panitumumab .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [86, 97], "tok_span": [18, 21]}, {"name": "V600E", "ent_type": "variant", "char_span": [25, 30], "tok_span": [4, 7]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [25, 30], "obj_char_span": [86, 97], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 7], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [46, 57], "tok_span": [13, 16]}, {"name": "V600E", "ent_type": "variant", "char_span": [117, 122], "tok_span": [29, 32]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [117, 122], "obj_char_span": [46, 57], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 32], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Dasatinib is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and FIP1L1-PDGFRA fusion but has no effect on imatinib-resistant FIP1L1-PDGFRA T674I and D842V mutants . ", "entity_list": [{"name": "Dasatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "D842V", "ent_type": "variant", "char_span": [154, 159], "tok_span": [49, 53]}], "relation_list": [{"subject": "D842V", "object": "Dasatinib", "sbj_char_span": [154, 159], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Targeting the oncogenic fusion protein echinoderm microtubule associated protein-like 4-anaplastic lymphoma kinase ( EML4-ALK ) with TKIs such as crizotinib has also been shown to be negatively affected by the development of secondary gate keeper residue mutations such as L1196M , and the emergence of fusion negative tumors that render the disease insensitive to the drug .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [146, 156], "tok_span": [34, 38]}, {"name": "L1196M", "ent_type": "variant", "char_span": [273, 279], "tok_span": [58, 62]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [273, 279], "obj_char_span": [146, 156], "rel_type": "resistance", "sbj_tok_span": [58, 62], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "In vitro NSCLC cell lines selected for resistance to crizotinib also show amplification of the ALK fusion gene as well as kinase domain mutations such as L1196M ( ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [53, 63], "tok_span": [9, 13]}, {"name": "L1196M", "ent_type": "variant", "char_span": [154, 160], "tok_span": [30, 34]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [154, 160], "obj_char_span": [53, 63], "rel_type": "resistance", "sbj_tok_span": [30, 34], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "In the Crizotinib-resistant DFCI076 cell line , a unique L1152R ALK secondary mutation and concurrent coactivation of epidermal growth factor receptor (EGFR) signaling imparted resistance .", "entity_list": [{"name": "Crizotinib-resistant", "ent_type": "drug", "char_span": [7, 27], "tok_span": [2, 8]}, {"name": "L1152R", "ent_type": "variant", "char_span": [57, 63], "tok_span": [17, 21]}], "relation_list": [{"subject": "L1152R", "object": "Crizotinib-resistant", "sbj_char_span": [57, 63], "obj_char_span": [7, 27], "rel_type": "resistance", "sbj_tok_span": [17, 21], "obj_tok_span": [2, 8]}], "umls_entity_list": []}, {"text": "Relapse of hypereosinophilia during treatment with imatinib has been reported in two F/P+ patients , and was associated with appearance of a T674I point mutation in the ATP binding site of the PDGFRA moiety , similar to the T315I mutation observed in patients with CML that become refractory to treatment .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [51, 59], "tok_span": [10, 12]}, {"name": "T674I", "ent_type": "variant", "char_span": [141, 146], "tok_span": [30, 34]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [141, 146], "obj_char_span": [51, 59], "rel_type": "resistance", "sbj_tok_span": [30, 34], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Two other compounds , PKC412 which is structurally unrelated to imatinib , and sorafenib , are able to inhibit kinase activity of both wild-type F/P and its imatinib -resistant T674I mutant form .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [64, 72], "tok_span": [12, 14]}, {"name": "T674I", "ent_type": "variant", "char_span": [177, 182], "tok_span": [39, 43]}, {"name": "imatinib", "ent_type": "drug", "char_span": [157, 165], "tok_span": [35, 37]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [177, 182], "obj_char_span": [64, 72], "rel_type": "resistance", "sbj_tok_span": [39, 43], "obj_tok_span": [12, 14]}, {"subject": "T674I", "object": "imatinib", "sbj_char_span": [177, 182], "obj_char_span": [157, 165], "rel_type": "resistance", "sbj_tok_span": [39, 43], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "Afatinib is an irreversible HER2/ErbB-family blocker that shows high affinity for EGFR T790M mutation .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "T790M", "ent_type": "variant", "char_span": [87, 92], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "Afatinib", "sbj_char_span": [87, 92], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Afatinib ( BIBW 2992 , Boehringer Ingelheim GmbH ) , is an irreversible inhibitor of both EGFR , HER2 and HER4 kinases and retains some activity in tumors with T790M mutations , but at doses that are a log higher than what is needed for cancers harboring sensitizing mutations , , , , , .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "T790M", "ent_type": "variant", "char_span": [160, 165], "tok_span": [38, 42]}, {"name": "BIBW 2992", "ent_type": "drug", "char_span": [11, 20], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "Afatinib", "sbj_char_span": [160, 165], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [38, 42], "obj_tok_span": [0, 2]}, {"subject": "T790M", "object": "BIBW 2992", "sbj_char_span": [160, 165], "obj_char_span": [11, 20], "rel_type": "response", "sbj_tok_span": [38, 42], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "In the LUX-Lung 2 Phase II trial , afatinib showed activity in the treatment of patients with advanced lung ADC with EGFR mutations , especially in patients with deletion 19 or L858R mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [35, 43], "tok_span": [11, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [177, 182], "tok_span": [35, 39]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [177, 182], "obj_char_span": [35, 43], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "The treatment effect of afatinib was more pronounced when comparing progression-free survival in the pre defined subgroup of patients with the common Del-19 or Point 21 L858R EGFR mutations .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [24, 32], "tok_span": [4, 6]}, {"name": "L858R", "ent_type": "variant", "char_span": [169, 174], "tok_span": [31, 35]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [169, 174], "obj_char_span": [24, 32], "rel_type": "sensitivity", "sbj_tok_span": [31, 35], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR T790M mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [73, 81], "tok_span": [12, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [249, 254], "tok_span": [44, 48]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [249, 254], "obj_char_span": [73, 81], "rel_type": "response", "sbj_tok_span": [44, 48], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Preclinical data have demonstrated that afatinib is a potent irreversible inhibitor of EGFR/HER1/ErbB1 receptors including the T790M variant .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [40, 48], "tok_span": [7, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [127, 132], "obj_char_span": [40, 48], "rel_type": "response", "sbj_tok_span": [26, 30], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Second generation EGFR TKIs e.g. , BIBW 2992 ( afatinib ) and PF00299804 ( dacomitinib ) , and third generation EGFR TKIs e.g. , CO-1686 and AZD9291 are irreversible inhibitors that could overcome the AR caused by T790M .", "entity_list": [{"name": "BIBW 2992", "ent_type": "drug", "char_span": [35, 44], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [214, 219], "tok_span": [61, 65]}, {"name": "afatinib", "ent_type": "drug", "char_span": [47, 55], "tok_span": [15, 17]}], "relation_list": [{"subject": "T790M", "object": "BIBW 2992", "sbj_char_span": [214, 219], "obj_char_span": [35, 44], "rel_type": "response", "sbj_tok_span": [61, 65], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [214, 219], "obj_char_span": [47, 55], "rel_type": "response", "sbj_tok_span": [61, 65], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Interestingly , in patients with sporadic MTC , a subgroup analysis of PFS by M918T somatic mutation suggested that the patients who were mutation positive had a higher response rate to vandetanib compared with M918T mutation negative patients .", "entity_list": [{"name": "vandetanib", "ent_type": "drug", "char_span": [186, 196], "tok_span": [35, 39]}, {"name": "M918T", "ent_type": "variant", "char_span": [78, 83], "tok_span": [15, 19]}], "relation_list": [{"subject": "M918T", "object": "vandetanib", "sbj_char_span": [78, 83], "obj_char_span": [186, 196], "rel_type": "response", "sbj_tok_span": [15, 19], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Verbeek and coworkers set out to compare the efficiency of four recently developed TK inhibitors , XL184 , Vandetanib , Sunitinib and Axitinib , using three cell lines : the first derived from sporadic MTC expressing a C634W RET mutation , the second derived from metastatic sporadic MTC expressing a M918T RET mutation .", "entity_list": [{"name": "Vandetanib", "ent_type": "drug", "char_span": [107, 117], "tok_span": [22, 26]}, {"name": "M918T", "ent_type": "variant", "char_span": [301, 306], "tok_span": [66, 70]}, {"name": "C634W", "ent_type": "variant", "char_span": [219, 224], "tok_span": [49, 53]}], "relation_list": [{"subject": "M918T", "object": "Vandetanib", "sbj_char_span": [301, 306], "obj_char_span": [107, 117], "rel_type": "response", "sbj_tok_span": [66, 70], "obj_tok_span": [22, 26]}, {"subject": "C634W", "object": "Vandetanib", "sbj_char_span": [219, 224], "obj_char_span": [107, 117], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Patients with mutations linked to resistance with dasatinib ( F317L ) and nilotinib ( Y253H and F359C/I/V ) were among those who responded to bosutinib ( Khoury et al. , 2012 ) .", "entity_list": [{"name": "bosutinib", "ent_type": "drug", "char_span": [142, 151], "tok_span": [40, 43]}, {"name": "Y253H", "ent_type": "variant", "char_span": [86, 91], "tok_span": [20, 24]}], "relation_list": [{"subject": "Y253H", "object": "bosutinib", "sbj_char_span": [86, 91], "obj_char_span": [142, 151], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "The ponatinib molecule is designed to interact with T315I in a different manner than the existing kinase inhibitors .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [4, 13], "tok_span": [1, 5]}, {"name": "T315I", "ent_type": "variant", "char_span": [52, 57], "tok_span": [11, 15]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [52, 57], "obj_char_span": [4, 13], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "In contrast , ponatinib was designed to avoid binding with the side chain of T315I in native BCR-ABL , and instead forms beneficial van der Waals interactions with the isoleucine side chain of the T315I mutant .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [77, 82], "tok_span": [17, 21]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [77, 82], "obj_char_span": [14, 23], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Ponatinib inhibited native ABL with an IC50 of 0.37 nM and clinically relevant BCR-ABL mutations T315I , G252H , T253P , M351T , and H396A with IC50 values of 2.0 nM , 0.44 nM , 0.30 nM , 0.30 nM , and 0.35 nM , respectively .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [97, 102], "tok_span": [23, 27]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [97, 102], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [23, 27], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "In summary , preclinical data supports the conclusion that ponatinib is an orally active , pan-TKI that inhibits native BCR-ABL and most BCR-ABL mutants , including the clinically relevant T315I mutant , with high potency .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [59, 68], "tok_span": [9, 13]}, {"name": "T315I", "ent_type": "variant", "char_span": [189, 194], "tok_span": [41, 45]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [189, 194], "obj_char_span": [59, 68], "rel_type": "response", "sbj_tok_span": [41, 45], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "In vitro screening assay has demonstrated that ponatinib , the first TKI effective against T315I Bcr-Abl , is also a potent inhibitor of KIT , PDGFRα , Flt3 , Src , VEGFR and FGFR .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [7, 11]}, {"name": "T315I", "ent_type": "variant", "char_span": [91, 96], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [91, 96], "obj_char_span": [47, 56], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "These findings were similar to those observed in the complex between ponatinib and T315I Abl .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [69, 78], "tok_span": [11, 15]}, {"name": "T315I", "ent_type": "variant", "char_span": [83, 88], "tok_span": [16, 20]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [83, 88], "obj_char_span": [69, 78], "rel_type": "response", "sbj_tok_span": [16, 20], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Ponatinib ( AP24534 ) is an orally administered TKI designed to inhibit BCR-ABL with mutations , especially T315I , which confers resistance to other TKI such as imatinib , dasatinib , nilotinib , and bosutinib ( reviewed in ) . ", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [108, 113], "tok_span": [25, 29]}, {"name": "AP24534", "ent_type": "drug", "char_span": [12, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [108, 113], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [0, 2]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [108, 113], "obj_char_span": [12, 19], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Ponatinib and imatinib mechanisms of binding to BCR-ABL are comparable except for the presence of Ponatinib 's characteristic carbon-carbon triple bond , between the methylphenyl and purine groups , which allows it to bind to the T315I mutation without steric interference .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [230, 235], "tok_span": [47, 51]}, {"name": "Ponatinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [20, 22]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [230, 235], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [47, 51], "obj_tok_span": [0, 2]}, {"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [230, 235], "obj_char_span": [98, 107], "rel_type": "response", "sbj_tok_span": [47, 51], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "The PACE ( Ponatinib Ph+ ALL and CML Evaluation ) trial has been set up to evaluate the effect of Ponatinib on CML patients that were either resistant or intolerant to dasatinib or nilotinib or with T315I mutation .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [11, 20], "tok_span": [4, 6]}, {"name": "T315I", "ent_type": "variant", "char_span": [199, 204], "tok_span": [45, 49]}, {"name": "Ponatinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [23, 25]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [199, 204], "obj_char_span": [11, 20], "rel_type": "response", "sbj_tok_span": [45, 49], "obj_tok_span": [4, 6]}, {"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [199, 204], "obj_char_span": [98, 107], "rel_type": "response", "sbj_tok_span": [45, 49], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "These results showed the advantage that Ponatinib holds against other TKI , which were unable to tackle the T315I mutation .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [40, 49], "tok_span": [6, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [108, 113], "tok_span": [20, 24]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [108, 113], "obj_char_span": [40, 49], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Ponatinib2 Iclusig® Ariad BCR-ABL Patients with CML for which Imatinib , Nilotinib , and Dasatinib are not appropriate ( or patients carrying a T315I single-point-mutation ) 1st July 2013 CML , ALL", "entity_list": [{"name": "Iclusig®", "ent_type": "drug", "char_span": [11, 19], "tok_span": [3, 8]}, {"name": "a T315I", "ent_type": "variant", "char_span": [142, 149], "tok_span": [38, 43]}], "relation_list": [{"subject": "a T315I", "object": "Iclusig®", "sbj_char_span": [142, 149], "obj_char_span": [11, 19], "rel_type": "response", "sbj_tok_span": [38, 43], "obj_tok_span": [3, 8]}], "umls_entity_list": []}, {"text": "For example , patients with T315I mutation respond only on treatment with third generation TKI Ponatinib , which was specifically designed as a treatment option for these populations .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [19, 21]}, {"name": "T315I", "ent_type": "variant", "char_span": [28, 33], "tok_span": [5, 9]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [28, 33], "obj_char_span": [95, 104], "rel_type": "response", "sbj_tok_span": [5, 9], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Ponatinib has a potent activity towards BCR-ABL1 , as well as numerous imatinib-resistant BCR-ABL1 kinase domain mutants , including the T315I mutation .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [137, 142], "tok_span": [32, 36]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [137, 142], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [32, 36], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The choice of the second-line therapy is also dictated by whether the patient has a T315I mutation or not – ponatinib being the most promising agent in such a case .", "entity_list": [{"name": "– ponatinib", "ent_type": "drug", "char_span": [106, 117], "tok_span": [25, 30]}, {"name": "T315I", "ent_type": "variant", "char_span": [84, 89], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "– ponatinib", "sbj_char_span": [84, 89], "obj_char_span": [106, 117], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "These patients may respond to investigational agents , such as AP24534 or omacetaxine , and should pursue allogeneic stem cell transplantation.– There has been some concern about selecting for T315I with the increased use of second-generation TKIs . ", "entity_list": [{"name": "AP24534", "ent_type": "drug", "char_span": [63, 70], "tok_span": [11, 15]}, {"name": "for T315I", "ent_type": "variant", "char_span": [189, 198], "tok_span": [37, 42]}], "relation_list": [{"subject": "for T315I", "object": "AP24534", "sbj_char_span": [189, 198], "obj_char_span": [63, 70], "rel_type": "response", "sbj_tok_span": [37, 42], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Ponatinib is a pan-BCR-ABL inhibitor with activity against all IM-resistant mutants , including the T315I mutation .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [100, 105], "tok_span": [22, 26]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [100, 105], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The E884K mutation represents the first mutation reported to show an apparent differential response to the two EGFR kinase inhibitors erlotinib and gefitinib , while L858R was known to be sensitizing to both .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [148, 157], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [166, 171], "tok_span": [34, 38]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [23, 27]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [166, 171], "obj_char_span": [148, 157], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [28, 32]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [166, 171], "obj_char_span": [134, 143], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Conversely , E884K worked in concert with L858R in-cis to further enhance the sensitivity of the mutant receptor to gefitinib inhibition ( ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [116, 125], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [42, 47], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [42, 47], "obj_char_span": [116, 125], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "R958D mutation , when in-cis with L858R , decreased the sensitivity of the mutant receptor to erlotinib inhibition , while increasing the sensitivity to gefitinib in a dominant fashion ( ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [153, 162], "tok_span": [35, 39]}, {"name": "L858R", "ent_type": "variant", "char_span": [34, 39], "tok_span": [11, 15]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [94, 103], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [34, 39], "obj_char_span": [153, 162], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [35, 39]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [34, 39], "obj_char_span": [94, 103], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "The E884K mutation negatively modulated the effect of L858R to erlotinib inhibition in a dominant fashion but enhanced sensitivity of the mutant receptor to gefitinib inhibition .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [157, 166], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [54, 59], "tok_span": [11, 15]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [63, 72], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [54, 59], "obj_char_span": [157, 166], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [33, 37]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [54, 59], "obj_char_span": [63, 72], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "( B ) Densitometric quantitation of the p-EGFR levels showing differential alteration of sensitivity to erlotinib ( more resistant ) and gefitinib ( more sensitive ) by the E884K mutation when in-cis with L858R .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [137, 146], "tok_span": [30, 34]}, {"name": "L858R", "ent_type": "variant", "char_span": [205, 210], "tok_span": [50, 54]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [104, 113], "tok_span": [21, 25]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [205, 210], "obj_char_span": [137, 146], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [30, 34]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [205, 210], "obj_char_span": [104, 113], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "( D ) COS-7 cells with stable transduced expression of L858R or L858R+E884K mutant EGFR were tested in cellular cytotoxicity assay in vitro under drug treatment with either erlotinib or gefitinib at indicated concentrations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [186, 195], "tok_span": [46, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [55, 60], "tok_span": [12, 16]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [173, 182], "tok_span": [41, 45]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [55, 60], "obj_char_span": [186, 195], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [46, 50]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [55, 60], "obj_char_span": [173, 182], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "however , it significantly increased the sensitivity of cell viability inhibition by gefitinib compared with L858R alone .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [12, 16]}, {"name": "L858R", "ent_type": "variant", "char_span": [109, 114], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [109, 114], "obj_char_span": [85, 94], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Conversely , in gefitinib inhibition , E884K further sensitized L858R in-cis , leading to significantly higher cytotoxicity ( 63.5 ±6.86 % decreased viable cells after inhibition at 5 μM , P=0.0013 ) compared with L858R alone .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [16, 25], "tok_span": [3, 7]}, {"name": "L858R", "ent_type": "variant", "char_span": [64, 69], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [64, 69], "obj_char_span": [16, 25], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "R958D mutation modulated the effect of L858R on inhibitor sensitivity resulting in desensitization of the mutant receptor to erlotinib inhibition but modestly enhanced sensitivity to gefitinib inhibition .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [183, 192], "tok_span": [36, 40]}, {"name": "L858R", "ent_type": "variant", "char_span": [39, 44], "tok_span": [9, 13]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [125, 134], "tok_span": [25, 29]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [39, 44], "obj_char_span": [183, 192], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [36, 40]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [39, 44], "obj_char_span": [125, 134], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "( B ) Densitometric quantitation of the p-EGFR levels showing that R958D mutation differentially altered L858R mutant receptor sensitivity to erlotinib ( more resistant ) and gefitinib ( more sensitive ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [175, 184], "tok_span": [41, 45]}, {"name": "L858R", "ent_type": "variant", "char_span": [105, 110], "tok_span": [24, 28]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [142, 151], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [105, 110], "obj_char_span": [175, 184], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [41, 45]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [105, 110], "obj_char_span": [142, 151], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "T790M is a secondary mutation which endows gefitinib resistance to the L858R lesion .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [43, 52], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}, {"name": "L858R", "ent_type": "variant", "char_span": [71, 76], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [0, 5], "obj_char_span": [43, 52], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [11, 15]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [71, 76], "obj_char_span": [43, 52], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Assuming similar levels of transgenic expression , the observed difference in activity is likely due to a decrease in drug sensitivity conferred by the L858R mutation . 10.1371/journal.pone.0042441.g002The Muv phenotype of jgIs6 and jgIs25 reflects similar responses as human cancers have against the anti-cancer drugs , gefitinib and elrotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [321, 330], "tok_span": [76, 80]}, {"name": "L858R", "ent_type": "variant", "char_span": [152, 157], "tok_span": [25, 29]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [152, 157], "obj_char_span": [321, 330], "rel_type": "sensitivity", "sbj_tok_span": [25, 29], "obj_tok_span": [76, 80]}], "umls_entity_list": []}, {"text": "Pretreatment with Iressa ( 100 mg/kg 1 h before administration of morpholino- IPQA ) results in 53 % and 38 % decrease in the accumulation of radiotracer in L858R and E746-A750 del tumors , respectively ( Figures - right panels , ) .", "entity_list": [{"name": "Iressa", "ent_type": "drug", "char_span": [18, 24], "tok_span": [3, 6]}, {"name": "L858R", "ent_type": "variant", "char_span": [157, 162], "tok_span": [39, 43]}], "relation_list": [{"subject": "L858R", "object": "Iressa", "sbj_char_span": [157, 162], "obj_char_span": [18, 24], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Predominant accumulations of morpholino- IPQA in EGFR expressing L858R and E746-A750 del carcinoma tumor xenografts reflect the high level of phosphorylated EGFR expression and activity in those tumor cells , which are known to be responsive to therapy with small molecular inhibitors of EGFR ( e.g. , Gefitinib ) .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [302, 311], "tok_span": [68, 71]}, {"name": "L858R", "ent_type": "variant", "char_span": [65, 70], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [65, 70], "obj_char_span": [302, 311], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [68, 71]}], "umls_entity_list": []}, {"text": "Tracy et al. also proved that gefitinib induced apoptosis in the L858R mutant lead dramatic response to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [30, 39], "tok_span": [8, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [65, 70], "tok_span": [16, 20]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [104, 113], "tok_span": [25, 29]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [65, 70], "obj_char_span": [30, 39], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [8, 12]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [65, 70], "obj_char_span": [104, 113], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "The authors also concluded that the affinity for the L858R mutant to gefitinib was 20-fold higher than that for wild type , which could be explained by its tighter binding to active conformation of the tyrosine kinase domain .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [69, 78], "tok_span": [15, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [53, 58], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [53, 58], "obj_char_span": [69, 78], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Further study could be the mono/combinations of chemotherapy with gefitinib or inhibitors of the AKT pathway which should be tested in vitro in cell lines and in vivo in tumor xenografts with EGFR L858R mutations to determine whether these may be additive or synergistic .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [197, 202], "tok_span": [39, 43]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [197, 202], "obj_char_span": [66, 75], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Cell culture IC50 Gefitinib μM Exon 19 Del L858R ( ex21 ) L861Q ( ex21 ) T790M", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [18, 27], "tok_span": [4, 7]}, {"name": ") T790M", "ent_type": "variant", "char_span": [71, 78], "tok_span": [28, 33]}, {"name": "Del L858R", "ent_type": "variant", "char_span": [39, 48], "tok_span": [12, 17]}], "relation_list": [{"subject": ") T790M", "object": "Gefitinib", "sbj_char_span": [71, 78], "obj_char_span": [18, 27], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 33], "obj_tok_span": [4, 7]}, {"subject": "Del L858R", "object": "Gefitinib", "sbj_char_span": [39, 48], "obj_char_span": [18, 27], "rel_type": "sensitivity", "sbj_tok_span": [12, 17], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "To assess the effect of anti-ErbB3 monoclonals as sensitizers to gefitinib , we focused on MPEDCC Pe e/10 , which has high expression of ErbB3/ high resistance to the drug ( IC50=9,3 μM ) and PC9ZD resistant cell line which contains the Del exon and harbors the T790M mutation ( IC50 = 14,4 μM ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [65, 74], "tok_span": [17, 21]}, {"name": "the T790M", "ent_type": "variant", "char_span": [258, 267], "tok_span": [73, 78]}], "relation_list": [{"subject": "the T790M", "object": "gefitinib", "sbj_char_span": [258, 267], "obj_char_span": [65, 74], "rel_type": "resistance or non-response", "sbj_tok_span": [73, 78], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "In order to address this aspect we focused our attention on one of the high surface expressing cells , Pe e/10 and as controls on two stable NSCLC cell lines , the gefitinib sensitive PC9 and its resistant counterpart PC9ZD bearing the T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [164, 173], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [236, 241], "tok_span": [51, 55]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [236, 241], "obj_char_span": [164, 173], "rel_type": "resistance or non-response", "sbj_tok_span": [51, 55], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "EGFR L858R , one of the most common activating mutations , allows gefitinib to move deeper into the binding pocket , enhancing the interaction between gefitinib and the receptor . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [15, 19]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [151, 160], "tok_span": [31, 35]}, {"name": "L858R", "ent_type": "variant", "char_span": [5, 10], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [5, 10], "obj_char_span": [66, 75], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [15, 19]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [5, 10], "obj_char_span": [151, 160], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "For example , although somatic T790M mutations in patients who never received gefitinib or erlotinib are rare , they can occasionally be found in tumors with primary drug resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [78, 87], "tok_span": [15, 19]}, {"name": "T790M", "ent_type": "variant", "char_span": [31, 36], "tok_span": [5, 9]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [91, 100], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [31, 36], "obj_char_span": [78, 87], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [15, 19]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [31, 36], "obj_char_span": [91, 100], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "In both cases , this event seems to be due to selection of tumor cells that harbor the T790M mutation or that have amplification of MET at the diagnosis.– Because new agents that are able to block the activation of the T790M mutant EGFR or of MET will soon be available for clinical use , it will be important to develop techniques for the molecular monitoring of NSCLC patients who are treated with gefitinib .", "entity_list": [{"name": "with gefitinib", "ent_type": "drug", "char_span": [395, 409], "tok_span": [80, 85]}, {"name": "T790M", "ent_type": "variant", "char_span": [87, 92], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "with gefitinib", "sbj_char_span": [87, 92], "obj_char_span": [395, 409], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [80, 85]}], "umls_entity_list": []}, {"text": "The remarkable association between certain EGFR mutations , especially exon 19 deletions or L858R mutation in exon 21 and clinical benefit in patients with NSCLC treated with EGFR tyrosine kinase inhibitors ( TKIs ) , such as Gefitinib and Erlotinib , is well established .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [226, 235], "tok_span": [41, 44]}, {"name": "L858R", "ent_type": "variant", "char_span": [92, 97], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [92, 97], "obj_char_span": [226, 235], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [41, 44]}], "umls_entity_list": []}, {"text": "Doody and colleagues studied the activity of cetuximab with NSCLC lines bearing both wild-type EGFR and those with activating mutations in the intracellular kinase domain : not only those known to confer sensitivity to gefitinib and erlotinib ( L858R and delL747-T753insS ) but also the TKI-resistant mutation T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [219, 228], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [310, 315], "tok_span": [74, 78]}, {"name": "L858R", "ent_type": "variant", "char_span": [245, 250], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [310, 315], "obj_char_span": [219, 228], "rel_type": "resistance or non-response", "sbj_tok_span": [74, 78], "obj_tok_span": [40, 44]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [245, 250], "obj_char_span": [219, 228], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "In the EGFR gene , for example , we detected L858R ( in II-18 and H1975 ) and E746_A750del mutations ( in PC-9 and H1650 ) , which are known to be sensitive to the anti-cancer drugs , gefitinib and erlotinib . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [184, 193], "tok_span": [58, 62]}, {"name": "L858R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [45, 50], "obj_char_span": [184, 193], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [58, 62]}], "umls_entity_list": []}, {"text": "The resistance of PC9/AB2 cells to gefitinib has been proved to maintain for at least one year in the medium without gefitinib and there is no T790M in PC9/AB2 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [35, 44], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [143, 148], "tok_span": [36, 40]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [117, 126], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [143, 148], "obj_char_span": [35, 44], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [143, 148], "obj_char_span": [117, 126], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) – mainly either deletion at exon 19 or L858R mutation at exon 21 – respond to small molecule tyrosine kinase inhibitors ( gefitinib and erlotinib ) , , , with a recently reported median survival to gefitinib of 17.5 months .", "entity_list": [{"name": "( gefitinib", "ent_type": "drug", "char_span": [211, 222], "tok_span": [39, 44]}, {"name": "or L858R", "ent_type": "variant", "char_span": [127, 135], "tok_span": [22, 27]}, {"name": "to gefitinib", "ent_type": "drug", "char_span": [286, 298], "tok_span": [59, 64]}], "relation_list": [{"subject": "or L858R", "object": "( gefitinib", "sbj_char_span": [127, 135], "obj_char_span": [211, 222], "rel_type": "sensitivity", "sbj_tok_span": [22, 27], "obj_tok_span": [39, 44]}, {"subject": "or L858R", "object": "to gefitinib", "sbj_char_span": [127, 135], "obj_char_span": [286, 298], "rel_type": "sensitivity", "sbj_tok_span": [22, 27], "obj_tok_span": [59, 64]}], "umls_entity_list": []}, {"text": "H1975 NSCLC , harboring T790M mutation in the EGFR which renders gefitinib ineffective , appeared to be sensitive to AMA treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [65, 74], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [24, 29], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [24, 29], "obj_char_span": [65, 74], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Activating mutations such as L858R or delL747-P753insS that have previously been reported to be associated with Iressa sensitivity were not found .", "entity_list": [{"name": "Iressa", "ent_type": "drug", "char_span": [112, 118], "tok_span": [29, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [29, 34], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "Iressa", "sbj_char_span": [29, 34], "obj_char_span": [112, 118], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "EGFR M+ NSCLC cells ( HCC-827 , PC-9 ) were markedly more sensitive to growth inhibition by an EGFR TKI ( gefitinib ) as well as the AKT inhibitor MK2206 , compared with EGFR wild-type cells ( A549 ) and EGFR T790M cells ( H1975 ) ( Table ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [106, 115], "tok_span": [28, 32]}, {"name": "T790M", "ent_type": "variant", "char_span": [209, 214], "tok_span": [56, 60]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [209, 214], "obj_char_span": [106, 115], "rel_type": "resistance or non-response", "sbj_tok_span": [56, 60], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "For example , the T790M mutation of the EGFR gene retains the ability of the receptor to activate the downstream pathway but simultaneously decreases binding of gefitinib and erlotinib to the receptor and thus leads to drug resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [161, 170], "tok_span": [29, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [18, 23], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [18, 23], "obj_char_span": [161, 170], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Deletion of exon 19 and the point mutation L858R in EGFR are associated with elevated phosphorylated AKT and sensitivity to the EGFR tyrosine kinase inhibitor gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [159, 168], "tok_span": [30, 34]}, {"name": "L858R", "ent_type": "variant", "char_span": [43, 48], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [43, 48], "obj_char_span": [159, 168], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Compared to L858R alone , the L858R+E884K dual mutant was less sensitive to erlotinib in the inhibition of tyrosine phosphorylation of EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [76, 85], "tok_span": [24, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [12, 17], "tok_span": [2, 6]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [12, 17], "obj_char_span": [76, 85], "rel_type": "sensitivity", "sbj_tok_span": [2, 6], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Finally , we mapped the locations of the L858R and E884K mutations onto the three-dimensional structure of the EGFR kinase domain complexed with erlotinib and with lapatinib ( ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [145, 154], "tok_span": [32, 36]}, {"name": "L858R", "ent_type": "variant", "char_span": [41, 46], "tok_span": [8, 12]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [41, 46], "obj_char_span": [145, 154], "rel_type": "sensitivity", "sbj_tok_span": [8, 12], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "In the case of erlotinib , E884K was desensitizing to L858R , leading to lower cytotoxicity ( 56.3 ±2.68 % increased viable cells after inhibition at 5 μM , P=0.0004 ) compared with L858R alone .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [15, 24], "tok_span": [4, 8]}, {"name": "L858R", "ent_type": "variant", "char_span": [54, 59], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [54, 59], "obj_char_span": [15, 24], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "While drug-sensitive L858R bearing lungs showed degenerating tumor after erlotinib ( ) , EGFRL858R+T790M bearing tumors contained virtually all viable cells with no treatment effect ( and ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [73, 82], "tok_span": [15, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [21, 26], "tok_span": [4, 8]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [21, 26], "obj_char_span": [73, 82], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "We further tested whether T790M expressing lung tumors would respond to the kinase inhibitor , erlotinib , or an hsp90 inhibitor , 17-allylamino-17-demethoxygeldanamycin ( 17-AAG ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [26, 31], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [26, 31], "obj_char_span": [95, 104], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes PR 26.1 erlotinib , cetuximab PD1 5 Adenocarcinoma L858R ( exon 21 ) , G873E ( exon 21 ) Sensitive , Sensitive PIK3CA : E542K ( exon 9 )", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [28, 37], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [71, 76], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [71, 76], "obj_char_span": [28, 37], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes SD 4.0 cetuximab , sirolimus SD 4 7 Adenocarcinoma L858R ( exon 21 ) Sensitive PIK3CA : No KRAS : No TP53 : Not done Yes PR 8.1 erlotinib , bortezomib SD 2 8 Adenocarcinoma T790M ( exon 20 ) , deletion in exon 19 Resistant , Sensitive PIK3CA : Not done", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [148, 157], "tok_span": [52, 56]}, {"name": "L858R", "ent_type": "variant", "char_span": [71, 76], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [71, 76], "obj_char_span": [148, 157], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [52, 56]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes PR1.9 erlotinib , cetuximab PD2 9 Adenocarcinoma L858R ( exon 21 ) Sensitive PIK3CA : No", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [69, 74], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [69, 74], "obj_char_span": [26, 35], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes SD 11.5 erlotinib , dasatinib PD2 10 Adenocarcinoma L858R ( exon 21 ) Sensitive PIK3CA : Not done", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [28, 37], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [72, 77], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [72, 77], "obj_char_span": [28, 37], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "A second patient ( case # 5 , Table ) with two known EGFR-sensitive mutations ( L858R and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) had a PR ( 55 % decrease ; duration=9+ months ) on erlotinib/cetuximab/bevacizumab .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [202, 233], "tok_span": [62, 74]}, {"name": "L858R", "ent_type": "variant", "char_span": [80, 85], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [80, 85], "obj_char_span": [202, 233], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [62, 74]}], "umls_entity_list": []}, {"text": "A third patient ( case # 10 , Table ) with a known EGFR-sensitive mutation ( L858R ) in exon 21 attained SD for 10+ months on erlotinib/bortezomib .", "entity_list": [{"name": "erlotinib/bortezomib", "ent_type": "drug", "char_span": [126, 146], "tok_span": [33, 43]}, {"name": "L858R", "ent_type": "variant", "char_span": [77, 82], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "erlotinib/bortezomib", "sbj_char_span": [77, 82], "obj_char_span": [126, 146], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [33, 43]}], "umls_entity_list": []}, {"text": "Computed tomography ( CT ) scans of a NSCLC patient ( case # 5 , Table ) with two sensitive EGFR mutations ( L858R in exon 21 and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) a ) CT at baseline , and b ) CT taken 5 months after treatment initiation with erlotinib/cetuximab/bevacizumab demonstrating a PR ( -55 % ) .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [270, 301], "tok_span": [73, 85]}, {"name": "L858R", "ent_type": "variant", "char_span": [109, 114], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [109, 114], "obj_char_span": [270, 301], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [73, 85]}], "umls_entity_list": []}, {"text": "Of the two EGFR mutation positive patients with a simultaneous PIK3CA mutation , one patient ( case # 5 , Table ) with an E542K mutation in exon 9 of the PIK3CA gene in addition to two sensitive EGFR mutations ( L858R and G873E in exon 21 ) , achieved a PR ( -55 % ) for 9+ months on erlotinib/cetuximab/bevacizumab .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [284, 315], "tok_span": [77, 89]}, {"name": "L858R", "ent_type": "variant", "char_span": [212, 217], "tok_span": [50, 54]}], "relation_list": [{"subject": "L858R", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [212, 217], "obj_char_span": [284, 315], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [77, 89]}], "umls_entity_list": []}, {"text": "A third patient ( case # 10 , Table ) with a known EGFR-sensitive mutation ( L858R ) , with previous response to single agent erlotinib and subsequent resistance , has ongoing SD ( 26 % decrease ) for 10+ months on erlotinib and bortezomib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [126, 135], "tok_span": [30, 34]}, {"name": "L858R", "ent_type": "variant", "char_span": [77, 82], "tok_span": [18, 22]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [215, 224], "tok_span": [51, 55]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [77, 82], "obj_char_span": [126, 135], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [30, 34]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [77, 82], "obj_char_span": [215, 224], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [51, 55]}], "umls_entity_list": []}, {"text": "Most responses to erlotinib occur in patients with EGFR mutations , and both resistant ( e.g. , L861Q ) and sensitive ( e.g. , exon 18 G719S , exon 19 deletion or exon 21 L858R point mutation ) mutations have been identified .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [18, 27], "tok_span": [3, 7]}, {"name": "L858R", "ent_type": "variant", "char_span": [171, 176], "tok_span": [49, 53]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [171, 176], "obj_char_span": [18, 27], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Thus , the T790M variant reduces the relative efficacy of gefitinib and causes the development of acquired resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [58, 67], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [11, 16], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [11, 16], "obj_char_span": [58, 67], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Balak et al reported that the T790M variant was found in ~50 % of NSCLC patients with acquired resistance to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [109, 118], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [30, 35], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [30, 35], "obj_char_span": [109, 118], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "However , the T790M variant was also found in some patients who were not treated with gefitinib , and the presence of the T790M mutation was reported to be significantly higher in advanced tumors than in early-stage tumors .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [86, 95], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [14, 19], "obj_char_span": [86, 95], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Thus , Inukai et al proposed that , although the detection of T790M positive tumor cells may be useful for predicting the clinical efficacy of gefitinib , gefitinib treatment might result in the selection of T790M mutant cells and that even a small fraction of T790M positive tumor cells at the beginning of treatment could lead to clinical resistance as a result of the selective proliferation of T790M mutant cells .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [62, 67], "tok_span": [14, 18]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [155, 164], "tok_span": [35, 39]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [62, 67], "obj_char_span": [143, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [30, 34]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [62, 67], "obj_char_span": [155, 164], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "In addition to the presence of the T790M variation , L747S , D761Y , and G796A variations were identified in NSCLC patients with acquired resistance to gefitinib ; the G796A variant is especially known to cause strong resistance to EGFR-TKIs .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [152, 161], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [35, 40], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [35, 40], "obj_char_span": [152, 161], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "However , analysis of DNA from cells in the pleural effusion that developed after treatment with gefitinib showed the C→T mutation at nucleotide 2369 in exon 20 ( C , lower panels ; ) , corresponding to the T790M mutation described above .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [97, 106], "tok_span": [16, 20]}, {"name": "the T790M", "ent_type": "variant", "char_span": [203, 212], "tok_span": [43, 48]}], "relation_list": [{"subject": "the T790M", "object": "gefitinib", "sbj_char_span": [203, 212], "obj_char_span": [97, 106], "rel_type": "resistance or non-response", "sbj_tok_span": [43, 48], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The mutant 2369 T peak was small , possibly because gefitinib had been discontinued in this patient for 4 mo at the time pleural fluid tumor cells were collected ; thus , there was no selective advantage conferred upon cells bearing the T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [52, 61], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [237, 242], "tok_span": [47, 51]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [237, 242], "obj_char_span": [52, 61], "rel_type": "resistance or non-response", "sbj_tok_span": [47, 51], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Collectively , our results suggest that the T790M mutation is associated with lesions that progress while on gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [109, 118], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [44, 49], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [44, 49], "obj_char_span": [109, 118], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Gefitinib inhibited the activity of wild-type and L858R EGFRs progressively with increasing concentrations of drug , as demonstrated by a reduction of tyrosine phosphorylated proteins ( A ) and a decrease in p-EGFR : t-EGFR ratios ( B ) . ", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [50, 55], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [50, 55], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "The T790M mutation was shown in vitro in the context of wild-type EGFR to confer resistance to gefitinib and a related quinazoline inhibitor , PD153035 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [95, 104], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "We show here , through molecular analysis of tumor material from three patients and one NSCLC cell line , as well as additional biochemical studies , that acquired clinical drug resistance to gefitinib or erlotinib is indeed associated with the T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [192, 201], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [245, 250], "tok_span": [46, 50]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [245, 250], "obj_char_span": [192, 201], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "How tumor cells bearing the T790M mutation emerge within gefitinib- or erlotinib treated patients is a matter of investigation .", "entity_list": [{"name": "gefitinib-", "ent_type": "drug", "char_span": [57, 67], "tok_span": [12, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-", "sbj_char_span": [28, 33], "obj_char_span": [57, 67], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [12, 17]}], "umls_entity_list": []}, {"text": "This study revealed that the quinazoline rings of erlotinib and lapatinib interact differently with the EGFR kinase domain , suggesting that while the T790M mutation may affect inhibition by erlotinib and gefitinib , it may not affect inhibition of EGFR by compounds similar to lapatinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [205, 214], "tok_span": [44, 48]}, {"name": "T790M", "ent_type": "variant", "char_span": [151, 156], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [151, 156], "obj_char_span": [205, 214], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "Since tumor specimens from three additional patients with acquired resistance to EGFR tyrosine kinase inhibitors did not demonstrate the T790M mutation , this specific lesion does not account for all mechanisms of acquired resistance to gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [237, 246], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [137, 142], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [137, 142], "obj_char_span": [237, 246], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or erlotinib . ( D ) Cell line H1975 contains both an exon 21 L858R mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) .", "entity_list": [{"name": "either gefitinib", "ent_type": "drug", "char_span": [297, 313], "tok_span": [73, 78]}, {"name": "T790M", "ent_type": "variant", "char_span": [34, 39], "tok_span": [5, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [376, 381], "tok_span": [97, 101]}], "relation_list": [{"subject": "T790M", "object": "either gefitinib", "sbj_char_span": [34, 39], "obj_char_span": [297, 313], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [73, 78]}, {"subject": "L858R", "object": "either gefitinib", "sbj_char_span": [376, 381], "obj_char_span": [297, 313], "rel_type": "sensitivity", "sbj_tok_span": [97, 101], "obj_tok_span": [73, 78]}], "umls_entity_list": []}, {"text": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by Gefitinib or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [74, 83], "tok_span": [17, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [6, 10]}, {"name": "L858R", "ent_type": "variant", "char_span": [235, 240], "tok_span": [53, 57]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [28, 33], "obj_char_span": [74, 83], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [17, 20]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [235, 240], "obj_char_span": [74, 83], "rel_type": "sensitivity", "sbj_tok_span": [53, 57], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "The EGFR T790M mutation , in conjunction with either wild-type EGFR or the drug-sensitive L858R EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [183, 192], "tok_span": [44, 48]}, {"name": "T790M", "ent_type": "variant", "char_span": [9, 14], "tok_span": [2, 6]}, {"name": "L858R", "ent_type": "variant", "char_span": [90, 95], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [9, 14], "obj_char_span": [183, 192], "rel_type": "resistance or non-response", "sbj_tok_span": [2, 6], "obj_tok_span": [44, 48]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [90, 95], "obj_char_span": [183, 192], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "This cell line had previously been shown by others to contain a 2573 T→G mutation in exon 21 ( L858R ) , which we confirmed ( D , upper panel ) ; in addition , H1975 was reported to be more sensitive to gefitinib inhibition than other lung cancer cell lines bearing wild-type EGFR .", "entity_list": [{"name": "to gefitinib", "ent_type": "drug", "char_span": [200, 212], "tok_span": [50, 55]}, {"name": "( L858R", "ent_type": "variant", "char_span": [93, 100], "tok_span": [21, 26]}], "relation_list": [{"subject": "( L858R", "object": "to gefitinib", "sbj_char_span": [93, 100], "obj_char_span": [200, 212], "rel_type": "sensitivity", "sbj_tok_span": [21, 26], "obj_tok_span": [50, 55]}], "umls_entity_list": []}, {"text": "Actually , the response rate was 78 % and 59 % for patients carrying L858R mutation and exon 19 deletion , respectively , which are activating mutations , predictive for response to gefitinib , whereas it was 0 % in patients with atypical mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [182, 191], "tok_span": [35, 39]}, {"name": "L858R", "ent_type": "variant", "char_span": [69, 74], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [69, 74], "obj_char_span": [182, 191], "rel_type": "sensitivity", "sbj_tok_span": [14, 18], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "As shown in , out of 11 patients who first received gefitinib after lung surgery and then showed recurrence , 8 patients had the delE746-A750 mutation and 3 had L858R mutation in their primary lung tumors . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [52, 61], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [161, 166], "tok_span": [39, 43]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [161, 166], "obj_char_span": [52, 61], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Partial Loss of the Activating Mutant EGFR ( L858R ) Gene in Erlotinib- or Gefitinib-resistant Cell Lines from 11–18", "entity_list": [{"name": "Gefitinib-resistant", "ent_type": "drug", "char_span": [75, 94], "tok_span": [22, 27]}, {"name": "L858R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib-resistant", "sbj_char_span": [45, 50], "obj_char_span": [75, 94], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [22, 27]}], "umls_entity_list": []}, {"text": "Patients who responded to gefitinib and subsequently relapsed were found to have T790M secondary mutations , also in exon 20 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [4, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [81, 86], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [81, 86], "obj_char_span": [26, 35], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "This compound was previously found to be active against EGFR containing the exon 20 point mutation T790M , associated with resistance to gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [137, 146], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [99, 104], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [99, 104], "obj_char_span": [137, 146], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Insertion mutant autophosphorylation is less sensitive to inhibition by gefitinib than that of L858R , but CL-387,785 is more effective than gefitinib at inhibiting insertion mutant ( and L858R ) autophosphorylation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [72, 81], "tok_span": [12, 16]}, {"name": "L858R", "ent_type": "variant", "char_span": [95, 100], "tok_span": [19, 23]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [141, 150], "tok_span": [36, 40]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [95, 100], "obj_char_span": [72, 81], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [12, 16]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [95, 100], "obj_char_span": [141, 150], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "( B ) Number of colonies formed in soft agar by clonal NIH-3T3 cells expressing L858R EGFR and D770_N771insNPG EGFR treated with the indicated concentrations of gefitinib or erlotinib immediately prior to suspension in soft agar .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [161, 170], "tok_span": [42, 46]}, {"name": "L858R", "ent_type": "variant", "char_span": [80, 85], "tok_span": [19, 23]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [80, 85], "obj_char_span": [161, 170], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "Cells expressing wild-type , L858R , or D770_N771insNPG EGFR were treated for 2 h with the indicated concentrations of gefitinib or CL-387,785 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [119, 128], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [29, 34], "tok_span": [6, 10]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [29, 34], "obj_char_span": [119, 128], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "An objective response rate of 25 % for gefitinib treatment was reported in 16 patients with exon 20 mutations , and it was much lower than the response rate of patients with deletions in exon 19 and L858R mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [39, 48], "tok_span": [8, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [199, 204], "tok_span": [40, 44]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [199, 204], "obj_char_span": [39, 48], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "However , treatment with gefitinib and erlotinib will eventually fail because of the development of acquired drug resistance resulting from amplification of the MET proto-oncogene or the threonine-to-methionine amino acid substitution at position 790 ( T790M ) of EGFR , which is detected in 50 % of clinically resistant patients , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [4, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [253, 258], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [253, 258], "obj_char_span": [25, 34], "rel_type": "resistance or non-response", "sbj_tok_span": [50, 54], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "We found a gefitinib mimetic , N- ( 2-bromo-5- ( trifluoromethyl ) phenyl ) -6-methoxy-7- ( 3- ( piperidin-1-yl ) propoxy ) quinazolin-4-amine ( hereafter , V1801 ) , moderately inhibited EGFR kinase activity but significantly suppressed cell proliferation and induced apoptosis in T790M EGFR harboring non-small cell lung cancer ( NSCLC ) cells in vitro and in vivo .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [11, 20], "tok_span": [3, 7]}, {"name": "T790M", "ent_type": "variant", "char_span": [282, 287], "tok_span": [80, 84]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [282, 287], "obj_char_span": [11, 20], "rel_type": "resistance or non-response", "sbj_tok_span": [80, 84], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Compared with the parental compound gefitinib , V1801 is a relatively weak EGFR inhibitor which bears a much more potent cytotoxicity in T790M EGFR harboring NCI-H1975 cells ( ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [36, 45], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [137, 142], "tok_span": [27, 31]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [137, 142], "obj_char_span": [36, 45], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "One of the proposed mechanisms of resistance to gefitinib and erlotinib is the T790M mutation on exon 20 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [48, 57], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [79, 84], "obj_char_span": [48, 57], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "However , subsequent resistance to gefitinib is inevitable even among the initial good responders , mostly related to acquired EGFR mutation ( T790M ) or c-met amplification . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [35, 44], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [143, 148], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [143, 148], "obj_char_span": [35, 44], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "An acquired EGFR mutation ( T790M ) has been reported to occur upon failure of gefitinib and is also predictive of resistance to erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [79, 88], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [5, 9]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [129, 138], "tok_span": [29, 33]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [28, 33], "obj_char_span": [79, 88], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [18, 22]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [28, 33], "obj_char_span": [129, 138], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [19, 23]}, {"name": "L858R", "ent_type": "variant", "char_span": [169, 174], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [169, 174], "obj_char_span": [121, 130], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "These preclinical models suggest that dacomitinib may be quite effective against lung cancer that becomes resistant to gefitinib or erlotinib via acquisition of a T790M mutation in EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [119, 128], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [163, 168], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [163, 168], "obj_char_span": [119, 128], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of EGFR and its affinity toward gefitinib , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) -EGFR and three oncogenic mutants : G719S , T790M , and DM in complex with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [131, 140], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [264, 269], "tok_span": [55, 59]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [295, 304], "tok_span": [65, 69]}, {"name": "G719S", "ent_type": "variant", "char_span": [256, 261], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [264, 269], "obj_char_span": [131, 140], "rel_type": "resistance or non-response", "sbj_tok_span": [55, 59], "obj_tok_span": [22, 26]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [264, 269], "obj_char_span": [295, 304], "rel_type": "resistance or non-response", "sbj_tok_span": [55, 59], "obj_tok_span": [65, 69]}, {"subject": "G719S", "object": "gefitinib", "sbj_char_span": [256, 261], "obj_char_span": [131, 140], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [22, 26]}, {"subject": "G719S", "object": "gefitinib", "sbj_char_span": [256, 261], "obj_char_span": [295, 304], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [65, 69]}], "umls_entity_list": []}, {"text": "To further characterize the effect of the T790M mutation on the conformational distribution of structural elements , we calculated the time dependent distance between the mass centers of gefitinib and the active site residue M793 for the WT and the mutant proteins .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [187, 196], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [42, 47], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [42, 47], "obj_char_span": [187, 196], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Histogram plot showing the time dependent distance between the mass centers of gefitinib and residue M793 for G719S , T790M , and DM at different time intervals over the 50 ns of the trajectory .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [79, 88], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [118, 123], "tok_span": [28, 32]}, {"name": "G719S", "ent_type": "variant", "char_span": [110, 115], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [118, 123], "obj_char_span": [79, 88], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [13, 17]}, {"subject": "G719S", "object": "gefitinib", "sbj_char_span": [110, 115], "obj_char_span": [79, 88], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant .", "entity_list": [{"name": "for Gefitinib", "ent_type": "drug", "char_span": [323, 336], "tok_span": [82, 86]}, {"name": "T790M", "ent_type": "variant", "char_span": [11, 16], "tok_span": [4, 8]}, {"name": "for Gefitinib", "ent_type": "drug", "char_span": [434, 447], "tok_span": [104, 108]}, {"name": "for Erlotinib", "ent_type": "drug", "char_span": [126, 139], "tok_span": [35, 39]}, {"name": "L858R", "ent_type": "variant", "char_span": [64, 69], "tok_span": [18, 22]}, {"name": "for Erlotinib", "ent_type": "drug", "char_span": [229, 242], "tok_span": [56, 60]}], "relation_list": [{"subject": "T790M", "object": "for Gefitinib", "sbj_char_span": [11, 16], "obj_char_span": [323, 336], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [82, 86]}, {"subject": "T790M", "object": "for Gefitinib", "sbj_char_span": [11, 16], "obj_char_span": [434, 447], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [104, 108]}, {"subject": "L858R", "object": "for Erlotinib", "sbj_char_span": [64, 69], "obj_char_span": [126, 139], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [35, 39]}, {"subject": "L858R", "object": "for Erlotinib", "sbj_char_span": [64, 69], "obj_char_span": [229, 242], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [56, 60]}, {"subject": "T790M", "object": "for Erlotinib", "sbj_char_span": [11, 16], "obj_char_span": [126, 139], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [35, 39]}, {"subject": "T790M", "object": "for Erlotinib", "sbj_char_span": [11, 16], "obj_char_span": [229, 242], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [56, 60]}], "umls_entity_list": []}, {"text": "( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR L861Q activated more than T790M but less than L858R .", "entity_list": [{"name": "for Gefitinib", "ent_type": "drug", "char_span": [37, 50], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [242, 247], "tok_span": [59, 63]}, {"name": "for Gefitinib", "ent_type": "drug", "char_span": [148, 161], "tok_span": [30, 34]}, {"name": "EGFR L858R", "ent_type": "variant", "char_span": [59, 69], "tok_span": [13, 18]}], "relation_list": [{"subject": "T790M", "object": "for Gefitinib", "sbj_char_span": [242, 247], "obj_char_span": [37, 50], "rel_type": "resistance or non-response", "sbj_tok_span": [59, 63], "obj_tok_span": [8, 12]}, {"subject": "T790M", "object": "for Gefitinib", "sbj_char_span": [242, 247], "obj_char_span": [148, 161], "rel_type": "resistance or non-response", "sbj_tok_span": [59, 63], "obj_tok_span": [30, 34]}, {"subject": "EGFR L858R", "object": "for Gefitinib", "sbj_char_span": [59, 69], "obj_char_span": [37, 50], "rel_type": "sensitivity", "sbj_tok_span": [13, 18], "obj_tok_span": [8, 12]}, {"subject": "EGFR L858R", "object": "for Gefitinib", "sbj_char_span": [59, 69], "obj_char_span": [148, 161], "rel_type": "sensitivity", "sbj_tok_span": [13, 18], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "The mechanism of resistance in three patients was acquisition of a T790M substitution in EGFR that was not present at time of diagnosis , but was detected with progression of disease after initial response to gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [209, 218], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [67, 72], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [67, 72], "obj_char_span": [209, 218], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "T790M in the context of either transiently expressed wild-type EGFR or the mutant alleles del L474–E749 ; A750P or L858R impairs inhibition by gefitinib or erlotinib as assessed by autophosphorylation .", "entity_list": [{"name": "by gefitinib", "ent_type": "drug", "char_span": [140, 152], "tok_span": [39, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}, {"name": "or L858R", "ent_type": "variant", "char_span": [112, 120], "tok_span": [32, 37]}], "relation_list": [{"subject": "T790M", "object": "by gefitinib", "sbj_char_span": [0, 5], "obj_char_span": [140, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [39, 44]}, {"subject": "or L858R", "object": "by gefitinib", "sbj_char_span": [112, 120], "obj_char_span": [140, 152], "rel_type": "sensitivity", "sbj_tok_span": [32, 37], "obj_tok_span": [39, 44]}], "umls_entity_list": []}, {"text": "Furthermore , the NSCLC cell line H1975 harbors both the L858R and T790M mutations , and is resistant to inhibition by gefitinib or erlotinib , unlike cell lines that express the L858R allele alone .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [119, 128], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [67, 72], "tok_span": [18, 22]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [67, 72], "obj_char_span": [119, 128], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [30, 34]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [119, 128], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "These observations provide convincing evidence that , at least in some patients with NSCLC , resistance to gefitinib or erlotinib can be attributed to acquisition of a T790M mutation in the context of EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [107, 116], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [168, 173], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [168, 173], "obj_char_span": [107, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "In addition , only half of this small cohort of patients with NSCLC with clinical resistance to gefitinib or erlotinib had the T790M substitution .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [96, 105], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [127, 132], "obj_char_span": [96, 105], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Resistance mutations identified via in vitro screens have shown a high degree of correlation with those that develop in vivo , as shown in screens for imatinib-resistant BCR-ABL mutants and PKC412-resistant FLT3 mutants , as well as the T790M resistance mutation to gefitinib in the context of EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [266, 275], "tok_span": [57, 61]}, {"name": "T790M", "ent_type": "variant", "char_span": [237, 242], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [237, 242], "obj_char_span": [266, 275], "rel_type": "resistance or non-response", "sbj_tok_span": [50, 54], "obj_tok_span": [57, 61]}], "umls_entity_list": []}, {"text": "Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors gefitinib ( Iressa ) or erlotinib ( Tarceva ) , including in-frame deletions such as del L747–E749 ; A750P in exon 19 , or L858R in exon 21 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [201, 210], "tok_span": [33, 37]}, {"name": "or L858R", "ent_type": "variant", "char_span": [321, 329], "tok_span": [77, 82]}, {"name": "Iressa", "ent_type": "drug", "char_span": [213, 219], "tok_span": [38, 41]}], "relation_list": [{"subject": "or L858R", "object": "gefitinib", "sbj_char_span": [321, 329], "obj_char_span": [201, 210], "rel_type": "sensitivity", "sbj_tok_span": [77, 82], "obj_tok_span": [33, 37]}, {"subject": "or L858R", "object": "Iressa", "sbj_char_span": [321, 329], "obj_char_span": [213, 219], "rel_type": "sensitivity", "sbj_tok_span": [77, 82], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "H1975 cell line was chosen because it expresses the ‘gatekeeper'-resistant T790M-EGFR mutation ( in-cis with L858R ) in the receptor kinase domain hydrophobic pocket , representing a major mechanism of resistance to reversible EGFR-TKI ( erlotinib/gefitinib ) ( ; ) .", "entity_list": [{"name": "erlotinib/gefitinib", "ent_type": "drug", "char_span": [238, 257], "tok_span": [56, 65]}, {"name": "with L858R", "ent_type": "variant", "char_span": [104, 114], "tok_span": [29, 34]}, {"name": "( erlotinib/gefitinib", "ent_type": "drug", "char_span": [236, 257], "tok_span": [55, 65]}], "relation_list": [{"subject": "with L858R", "object": "erlotinib/gefitinib", "sbj_char_span": [104, 114], "obj_char_span": [238, 257], "rel_type": "sensitivity", "sbj_tok_span": [29, 34], "obj_tok_span": [56, 65]}, {"subject": "with L858R", "object": "( erlotinib/gefitinib", "sbj_char_span": [104, 114], "obj_char_span": [236, 257], "rel_type": "sensitivity", "sbj_tok_span": [29, 34], "obj_tok_span": [55, 65]}], "umls_entity_list": []}, {"text": "Of note , mutations within ALK that lead to crizotinib resistance have already been described , analogous to the T790M mutation leading to erlotinib and gefitinib resistance in EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [153, 162], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [113, 118], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [113, 118], "obj_char_span": [153, 162], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 27], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "The ability of irreversible pan-HER inhibitors such as afatinib and dacomitinib to overcome T790M mediated resistance to gefitinib has been demonstrated in some preclinical studies ; therefore , they are being actively investigated .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [26, 30]}, {"name": "T790M", "ent_type": "variant", "char_span": [92, 97], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [92, 97], "obj_char_span": [121, 130], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Thus , the patient began to take gefitinib at 250 mg/day because EGFR gene analysis in this patient showed a deletion mutation in exon 19 and point mutation L858R in exon 21 by direct sequence method ( ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [33, 42], "tok_span": [7, 11]}, {"name": "L858R", "ent_type": "variant", "char_span": [157, 162], "tok_span": [33, 37]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [157, 162], "obj_char_span": [33, 42], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "The research article by Pao et al. provides important new information addressing three patients with acquired resistance to gefitinib or erlotinib in progressing tumors containing a secondary mutation , leading to the substitution of methionine for threonine at position 790 ( T790M ) in exon 20 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [124, 133], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [277, 282], "tok_span": [52, 56]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [277, 282], "obj_char_span": [124, 133], "rel_type": "resistance or non-response", "sbj_tok_span": [52, 56], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "The tumor progressed and developed an additional T790M mutation after nine months of gefitinib treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [49, 54], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [49, 54], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The T790M mutation is rarely found in tumors from patients not treated with either gefitinib or erlotinib , and could be discovered only in progressing tumors , in addition to a primary drug-sensitive mutation in EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [83, 92], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [83, 92], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "In the case of our patient , the patient received no prior systemic chemotherapy , and we identified an initial gefitinib sensitizing L858R EGFR mutation , followed by a T790M mutation concomitantly with L858R in the biopsy taken from the growing tumor nine months after gefitinib use .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [112, 121], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [170, 175], "tok_span": [36, 40]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [271, 280], "tok_span": [59, 63]}, {"name": "L858R", "ent_type": "variant", "char_span": [134, 139], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [170, 175], "obj_char_span": [112, 121], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [20, 24]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [170, 175], "obj_char_span": [271, 280], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [59, 63]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [134, 139], "obj_char_span": [112, 121], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [20, 24]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [134, 139], "obj_char_span": [271, 280], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [59, 63]}], "umls_entity_list": []}, {"text": "We describe a chemonaive patient with gefitinib-sensitive lung adenocarcinoma harboring L858R .", "entity_list": [{"name": "gefitinib-sensitive", "ent_type": "drug", "char_span": [38, 57], "tok_span": [8, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [88, 93], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "gefitinib-sensitive", "sbj_char_span": [88, 93], "obj_char_span": [38, 57], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [8, 14]}], "umls_entity_list": []}, {"text": "Gefitinib responsiveness results in large part from the drug 's effective inhibition of essential antiapoptotic signals transduced by the mutant receptor , and L858R is the most commonly detected mutation .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [160, 165], "tok_span": [27, 31]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [160, 165], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [27, 31], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Citation : Gow CH , Shih JY , Chang YL , Yu CJ ( 2005 ) Acquired gefitinib-resistant mutation of epidermal growth factor receptor in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [65, 84], "tok_span": [22, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [205, 210], "tok_span": [49, 53]}, {"name": "gefitinib-sensitive", "ent_type": "drug", "char_span": [176, 195], "tok_span": [42, 48]}], "relation_list": [{"subject": "L858R", "object": "gefitinib-resistant", "sbj_char_span": [205, 210], "obj_char_span": [65, 84], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [22, 28]}, {"subject": "L858R", "object": "gefitinib-sensitive", "sbj_char_span": [205, 210], "obj_char_span": [176, 195], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [42, 48]}], "umls_entity_list": []}, {"text": "Another second-generation irreversible EGFR TKI , dacomitinib , demonstrated preclinical efficacy in NSCLC tumours harbouring the T790M gatekeeper mutation , , which is present in ∼50 % of NSCLCs that have acquired resistance to erlotinib or gefitinib , .", "entity_list": [{"name": "or gefitinib", "ent_type": "drug", "char_span": [239, 251], "tok_span": [53, 58]}, {"name": "T790M", "ent_type": "variant", "char_span": [130, 135], "tok_span": [24, 28]}, {"name": "to erlotinib", "ent_type": "drug", "char_span": [226, 238], "tok_span": [48, 53]}], "relation_list": [{"subject": "T790M", "object": "or gefitinib", "sbj_char_span": [130, 135], "obj_char_span": [239, 251], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [53, 58]}, {"subject": "T790M", "object": "to erlotinib", "sbj_char_span": [130, 135], "obj_char_span": [226, 238], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [48, 53]}], "umls_entity_list": []}, {"text": "In addition , the presence of common activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene ( exon 19 deletion and exon 21 L858R mutation ) confers strong sensitivity to gefitinib and erlotinib , which are selective tyrosine kinase inhibitors of EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [218, 227], "tok_span": [41, 45]}, {"name": "L858R", "ent_type": "variant", "char_span": [171, 176], "tok_span": [31, 35]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [171, 176], "obj_char_span": [218, 227], "rel_type": "sensitivity", "sbj_tok_span": [31, 35], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "In NSCLC , resistance to the EGFR TKI gefitinib is associated with the positive selection of cells harbouring the gatekeeper T790M mutation known to confer insensitivity to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [38, 47], "tok_span": [9, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [125, 130], "tok_span": [28, 32]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [173, 182], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [125, 130], "obj_char_span": [38, 47], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [125, 130], "obj_char_span": [173, 182], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "For example , gefitinib resistance in patients with EGFR mutant non-small cell lung cancers has been shown to be mediated in some cases by the selection of cancer cells harboring the EGFR ( T790M ) gatekeeper mutation and/or MET gene amplification .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [3, 7]}, {"name": "T790M", "ent_type": "variant", "char_span": [190, 195], "tok_span": [38, 42]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [190, 195], "obj_char_span": [14, 23], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 42], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "As previously demonstrated , cells with the deletion mutant and the point mutation L858R were inhibited by the TKIs gefitinib and erlotinib , while the exon 20 insertion mutation was resistant . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [116, 125], "tok_span": [23, 27]}, {"name": "L858R", "ent_type": "variant", "char_span": [83, 88], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [83, 88], "obj_char_span": [116, 125], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "The co-crystallized ligand ( IRESSA ) was first extracted from the catalytic site of L858R EGFR mutant ( PDB ID: 2ITZ ) and re-docked to calculate the root mean square difference ( RMSD ) between the top docking pose and original crystallographic geometry .", "entity_list": [{"name": "IRESSA", "ent_type": "drug", "char_span": [29, 35], "tok_span": [7, 10]}, {"name": "L858R", "ent_type": "variant", "char_span": [85, 90], "tok_span": [19, 23]}], "relation_list": [{"subject": "L858R", "object": "IRESSA", "sbj_char_span": [85, 90], "obj_char_span": [29, 35], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Male 70 Moderately differentiated adenocarcinoma 0 Gefitinib SD 8 29 delE746-A750 , T790M", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [51, 60], "tok_span": [7, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [84, 89], "tok_span": [22, 26]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [84, 89], "obj_char_span": [51, 60], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Female 48 Moderately differentiated adenocarcinoma 0 Gefitinib SD 10 18+ T790M , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [53, 62], "tok_span": [7, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [73, 78], "tok_span": [14, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [81, 86], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [73, 78], "obj_char_span": [53, 62], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 10]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [81, 86], "obj_char_span": [53, 62], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Male 74 Moderately and poorly differentiated adenocarcinoma 0 Gefitinib SD 8 8+ delE746-A750 , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [62, 71], "tok_span": [9, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [95, 100], "tok_span": [25, 29]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [95, 100], "obj_char_span": [62, 71], "rel_type": "sensitivity", "sbj_tok_span": [25, 29], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Female 47 Moderately differentiated papilla adenocarcinoma 10 Gefitinib SD 21 39 P753S , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [62, 71], "tok_span": [9, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [89, 94], "tok_span": [20, 24]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [89, 94], "obj_char_span": [62, 71], "rel_type": "sensitivity", "sbj_tok_span": [20, 24], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Female 53 Moderately differentiated squamous carcinoma adenosquamous carcinoma and fine counts 0 Gefitinib PR 15 58+ delE746-A750 , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [97, 106], "tok_span": [16, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [132, 137], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [132, 137], "obj_char_span": [97, 106], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Male 70 Moderately and poorly differentiated adenocarcinoma 20 Gefitinib SD 6 6.5 S768I , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [63, 72], "tok_span": [9, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [90, 95], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [90, 95], "obj_char_span": [63, 72], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Male 68 Moderately differentiated adenocarcinoma little fine counts 80 Gefitinib SD 10 26 E709K , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [10, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [98, 103], "tok_span": [21, 25]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [98, 103], "obj_char_span": [71, 80], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "The EGFR mutations are distributed throughout the kinase domain , but a deletion in exon 19 and the point mutation L858R in exon 21 account for approximately 90 % , which confer a greater response to gefitinib treatment , compared with other types of EGFR mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [200, 209], "tok_span": [39, 43]}, {"name": "L858R", "ent_type": "variant", "char_span": [115, 120], "tok_span": [20, 24]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [115, 120], "obj_char_span": [200, 209], "rel_type": "sensitivity", "sbj_tok_span": [20, 24], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "The interaction between TM4SF5 and EGFR is observed by a co-immunoprecipitation approach using NSCLC expressing TM4SF5 , where the interaction is positively correlated with the gefitinib resistance even without EGFR mutation ( e.g. , T790M ) following TM4SF5 overexpression .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [234, 239], "tok_span": [49, 53]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [234, 239], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 53], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "Examples include the T790M mutation in the gefitinib binding pocket of EGFR ; the T164I mutation within the epinephrine binding pocket of β2-adrenergic receptor ; and the polymorphism within binding pocket of STI-571 to c-Abl .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [43, 52], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [21, 26], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [21, 26], "obj_char_span": [43, 52], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Antitumor effects were shown against tumors with EGFR activating mutations , found in 30–50 % of Asian patients with lung cancer , and also against tumors with T790M , a mutation detected in the tumors of approximately 50 % of patients with lung adenocarcinoma who develop acquired resistance to gefitinib or erlotinib .", "entity_list": [{"name": "to gefitinib", "ent_type": "drug", "char_span": [293, 305], "tok_span": [54, 59]}, {"name": "with T790M", "ent_type": "variant", "char_span": [155, 165], "tok_span": [29, 34]}, {"name": "or erlotinib", "ent_type": "drug", "char_span": [306, 318], "tok_span": [59, 64]}], "relation_list": [{"subject": "with T790M", "object": "to gefitinib", "sbj_char_span": [155, 165], "obj_char_span": [293, 305], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 34], "obj_tok_span": [54, 59]}, {"subject": "with T790M", "object": "or erlotinib", "sbj_char_span": [155, 165], "obj_char_span": [306, 318], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 34], "obj_tok_span": [59, 64]}], "umls_entity_list": []}, {"text": "Furthermore , the association of cetuximab with afatinib has been shown to be effective to overcome T790M mediated drug resistance . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [100, 105], "tok_span": [20, 24]}, {"name": "afatinib", "ent_type": "drug", "char_span": [48, 56], "tok_span": [10, 12]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [100, 105], "obj_char_span": [48, 56], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Median PFS and OS for the 217 patients who received erlotinib were 14 and 27 months , patients with L858R had longer PFS than patients with exon 19 deletions and outcomes did not seem to differ whether erlotinib was given in the first or second-line setting .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [52, 61], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [100, 105], "tok_span": [22, 26]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [202, 211], "tok_span": [43, 47]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [100, 105], "obj_char_span": [52, 61], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [10, 14]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [100, 105], "obj_char_span": [202, 211], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "As compared to the large number of secondary resistance mutations noted in acquired imatinib resistance in CML , in the case of EGFR-TK , there are currently only several documented resistance point mutations to gefitinib and erlotinib , including T790M , L747S and D761Y .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [226, 235], "tok_span": [42, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [248, 253], "tok_span": [48, 52]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [248, 253], "obj_char_span": [226, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "E.g. one study of CTCs from lung cancer patients was able to identify EGFR T790M in CTCs of some patients and progression-free survival was shorter as one might expect in patients with than without T790M on erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [207, 216], "tok_span": [49, 53]}, {"name": "T790M", "ent_type": "variant", "char_span": [75, 80], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [75, 80], "obj_char_span": [207, 216], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "While T790M is found in about half of patients with acquired resistance to erlotinib and gefitinib , the other mechanism of resistance – MET amplification – makes up about 5 % –10 % of these patients .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [75, 84], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [6, 11], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [6, 11], "obj_char_span": [75, 84], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Furthermore , common proteins utilized by erlotinib sensitive and resistant ( T790M EGFR ) could be candidate targets to overcome resistance to EGFR TKI .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [42, 51], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [78, 83], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [78, 83], "obj_char_span": [42, 51], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "On the basis of these results , we reasoned that combined erlotinib and midostaurin could overcome T790M mediated resistance , as erlotinib would target wild-type and exon 19 deletion E746-A750 EGFR activity while midostaurin would inhibit exon 19 deletion E746-A750+T790M EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [58, 67], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [99, 104], "tok_span": [23, 27]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [130, 139], "tok_span": [31, 35]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [99, 104], "obj_char_span": [58, 67], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 27], "obj_tok_span": [12, 16]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [99, 104], "obj_char_span": [130, 139], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 27], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated EGFR ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [12, 21], "tok_span": [2, 6]}, {"name": "L858R", "ent_type": "variant", "char_span": [180, 185], "tok_span": [49, 53]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [123, 132], "tok_span": [29, 33]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [213, 222], "tok_span": [59, 63]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [180, 185], "obj_char_span": [12, 21], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [2, 6]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [180, 185], "obj_char_span": [123, 132], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [29, 33]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [180, 185], "obj_char_span": [213, 222], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [59, 63]}], "umls_entity_list": []}, {"text": "Three of the 4 patients with T790M status ascertained from an archival biopsy initiated dacomitinib more than 90 days after discontinuing from erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [29, 34], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [29, 34], "obj_char_span": [143, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "The T790M mutation in exon 20 of the kinase domain is relatively rare in untreated patients but occurs in up to 50 % of patients with acquired resistance to erlotinib or gefitinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [157, 166], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [157, 166], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "The increased inhibition potency for Erlotinib against the oncogenic EGFR L858R mutant ( over the EGFR WT protein ) correlates with decreased global connectivity of the hub residues ( Arg-958 , Glu-884 , Gln-894 and Asp-896 ) in the mutant ( – wild type , – L858R mutant ) .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [5, 8]}, {"name": "L858R", "ent_type": "variant", "char_span": [74, 79], "tok_span": [12, 16]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [74, 79], "obj_char_span": [37, 46], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "The subsequent decrease in potency for Erlotinib against the oncogenic EGFR L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues ( – wild type , – L858R + E884K mutant ) .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [39, 48], "tok_span": [6, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [76, 81], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [76, 81], "obj_char_span": [39, 48], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "These results suggest that the addition of CX-4945 to EGFR-TKI may overcome T790M mediated resistance through the increased activity of EGFR-TKI to suppress EGFR signals by the down-regulation of EGFR . 10.1371/journal.pone.0114000.g004Addition of CX-4945 to EGFR-TKIs substantially suppressed the EGFR signaling pathway in gefitinib/erlotinib-resistant , PC-9 cells .", "entity_list": [{"name": "gefitinib/erlotinib-resistant", "ent_type": "drug", "char_span": [324, 353], "tok_span": [80, 91]}, {"name": "T790M", "ent_type": "variant", "char_span": [76, 81], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib-resistant", "sbj_char_span": [76, 81], "obj_char_span": [324, 353], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [80, 91]}], "umls_entity_list": []}, {"text": "The L858R EGFR kinase domain is , however , sensitive to erlotinib and MIG6 inhibition , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [57, 66], "tok_span": [14, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [57, 66], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "The L858R and Δ746–750 tEGFR forms were potently inhibited by erlotinib with apparent Kis in the range of 0.1–0.4 µM , about equal to the apparent Ki of erlotinib for WT tEGFR complexed with EGF .", "entity_list": [{"name": "by erlotinib", "ent_type": "drug", "char_span": [59, 71], "tok_span": [19, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}, {"name": "Ki of erlotinib", "ent_type": "drug", "char_span": [147, 162], "tok_span": [46, 52]}], "relation_list": [{"subject": "L858R", "object": "by erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [59, 71], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [19, 24]}, {"subject": "L858R", "object": "Ki of erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [147, 162], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [46, 52]}], "umls_entity_list": []}, {"text": "( c ) Western blot analysis of the expression levels of WT , L858R , and Δ746–750 tEGFRs in the presence and absence of the EGFR inhibitor erlotinib .", "entity_list": [{"name": "inhibitor erlotinib", "ent_type": "drug", "char_span": [129, 148], "tok_span": [35, 40]}, {"name": "L858R", "ent_type": "variant", "char_span": [61, 66], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "inhibitor erlotinib", "sbj_char_span": [61, 66], "obj_char_span": [129, 148], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [35, 40]}], "umls_entity_list": []}, {"text": "HEK293 GnTi− cells were transfected with the plasmid DNA encoding tEGFR , and cultured in the presence and absence of 50 nM erlotinib . ( d ) Coomassie blue stained SDS-PAGE analysis of the purified L858R tEGFR and Δ746–750 tEGFR with either EGF or Cetuximab ( Cetux ) as ligand .", "entity_list": [{"name": "nM erlotinib", "ent_type": "drug", "char_span": [121, 133], "tok_span": [26, 31]}, {"name": "L858R", "ent_type": "variant", "char_span": [199, 204], "tok_span": [48, 52]}], "relation_list": [{"subject": "L858R", "object": "nM erlotinib", "sbj_char_span": [199, 204], "obj_char_span": [121, 133], "rel_type": "sensitivity", "sbj_tok_span": [48, 52], "obj_tok_span": [26, 31]}], "umls_entity_list": []}, {"text": "Inhibitory effects of erlotinib and lapatinib on WT , Δ746–750 , L858R , and L858R I706Q tEGFRs with EGF or Cetuximab as ligand .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [22, 31], "tok_span": [4, 8]}, {"name": ", L858R", "ent_type": "variant", "char_span": [63, 70], "tok_span": [20, 25]}], "relation_list": [{"subject": ", L858R", "object": "erlotinib", "sbj_char_span": [63, 70], "obj_char_span": [22, 31], "rel_type": "sensitivity", "sbj_tok_span": [20, 25], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "( A ) The T790M secondary mutation in exon 20 of EGFR is present in 50 % –70 % of NSCLC patients who acquire resistance to EGFR-TKIs , such as gefitinib or erlotinib .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [153, 165], "tok_span": [41, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [10, 15], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "or erlotinib", "sbj_char_span": [10, 15], "obj_char_span": [153, 165], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [41, 46]}], "umls_entity_list": []}, {"text": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( T315I ) following imatinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [387, 396], "tok_span": [79, 83]}, {"name": "T790M", "ent_type": "variant", "char_span": [369, 374], "tok_span": [73, 77]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [369, 374], "obj_char_span": [387, 396], "rel_type": "resistance or non-response", "sbj_tok_span": [73, 77], "obj_tok_span": [79, 83]}], "umls_entity_list": []}, {"text": "However , in patients with acquired resistance , tumor cells bearing EGFR T790M represented a minority of cells , and as such , part of the tumor may remain responsive to erlotinib or gefitinib. , The other signal pathway related EGFR followed the same principles .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [171, 180], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [74, 79], "obj_char_span": [171, 180], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [211, 220], "tok_span": [53, 57]}, {"name": "L858R", "ent_type": "variant", "char_span": [38, 43], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [109, 114], "tok_span": [27, 31]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [38, 43], "obj_char_span": [211, 220], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [53, 57]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [109, 114], "obj_char_span": [211, 220], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [53, 57]}], "umls_entity_list": []}, {"text": "Alternatively , the selective resistance hypothesis suggests that the T790M mutation might exist in patients as small clones prior to treatment ; these resistant clones may proliferate after exposed to gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [215, 224], "tok_span": [39, 43]}, {"name": "T790M", "ent_type": "variant", "char_span": [70, 75], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [70, 75], "obj_char_span": [215, 224], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 13], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "Case Age Sex Genotype Histology Stage Time on erlotinib* Response # 1 59 Female Exon 19 del Adeno IIIB 6months PR 2 67 Female L858R Adeno IIIA 12 months PR 3 44 Female L858R Adeno IIIB 13 months PR 4 49 Female L858R Adeno IIIB 7 months PR 5 72 Male Exon 19 del Adeno IIB 17 months PR 6 72 Male L858R Adeno IIIA 15 months PR 7 61 Female Exon 19 del Adeno IIIB 21 months PR 8 62 Female Exon 19 del Adeno IIIB 19 months CR 9 68 Female Exon 19 del Adeno IIIB 8 months SD 10 57 Female Exon 19 del Adeno IIIB 6 months PR 11 59 Female L858R Adeno IIIA 16 months PR 12 64 Female Exon 19 del Adeno IIIB 16 months PR 13 65 Female L858R Adeno IIIB 18 months PR", "entity_list": [{"name": "erlotinib*", "ent_type": "drug", "char_span": [46, 56], "tok_span": [10, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [126, 131], "tok_span": [35, 39]}], "relation_list": [{"subject": "L858R", "object": "erlotinib*", "sbj_char_span": [126, 131], "obj_char_span": [46, 56], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [10, 15]}], "umls_entity_list": []}, {"text": "Yamauchi M , et al also found N-cadherin expression was significantly upregulated in gefitinib-resistant PC9/ZD cells harboring the acquired resistant mutation T790M in the EGFR gene , other cells expressing N-cadherin were found resistant to erlotinib ( A549 , H157 , and H322 ) and that inhibition of N-cadherin expression using siRNA led to a significant decrease in viability in A549 and H322 cells .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [243, 252], "tok_span": [57, 61]}, {"name": "T790M", "ent_type": "variant", "char_span": [160, 165], "tok_span": [36, 40]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [160, 165], "obj_char_span": [243, 252], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [57, 61]}], "umls_entity_list": []}, {"text": "Changes in dasatinib and erlotinib ( 2 ) induced cell viability were assessed in PC9 cells stably expressing either a mutant drug sensitive EGFR allele ( L858R ) or a drug resistant allele ( L858R/T790M ) ( ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [5, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [154, 159], "tok_span": [31, 35]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [154, 159], "obj_char_span": [25, 34], "rel_type": "sensitivity", "sbj_tok_span": [31, 35], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "PC9 cells expressing either L858R EGFR or L858R/T790M EGFR were exposed to indicated concentrations of dasatinib ( D ) or erlotinib ( E ) for 120 hr and cell viability was accessed .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [122, 131], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [28, 33], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [28, 33], "obj_char_span": [122, 131], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "B PC9 cells expressing either L858R EGFR ( left panel ) or L858R/T790M EGFR ( right panel ) were exposed to indicated concentrations of erlotinib ( E ) or dasatinib ( D ) for 24 hr. ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [136, 145], "tok_span": [36, 40]}, {"name": "L858R", "ent_type": "variant", "char_span": [30, 35], "tok_span": [6, 10]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [30, 35], "obj_char_span": [136, 145], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "A small molecule Met inhibitor combined with an EGFR TKI has proven to be a reasonable strategy to overcome erlotinib-resistant T790M NSCLC .", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [108, 127], "tok_span": [20, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [128, 133], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "erlotinib-resistant", "sbj_char_span": [128, 133], "obj_char_span": [108, 127], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [20, 26]}], "umls_entity_list": []}, {"text": "Erlotinib EGFR EGFR protein expression positive EGFR exon 19 deletion or exon 21 substitution ( L858R ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies Everolimus ERBB2 HER2 protein overexpression negative Indications and usage , boxed warning , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [96, 101], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [96, 101], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [30, 34]}, {"name": "L858R", "ent_type": "variant", "char_span": [370, 375], "tok_span": [75, 79]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [370, 375], "obj_char_span": [143, 152], "rel_type": "sensitivity", "sbj_tok_span": [75, 79], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "XL647 has also showed to be active against cells containing the T790M mutation , which have been associated with emerging resistance to first-generation EGFR TKIs such as gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [184, 193], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [64, 69], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [64, 69], "obj_char_span": [184, 193], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "The EGF receptor tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and erlotinib have shown marked therapeutic effects against NSCLCs with EGFR activating mutations , such as exon 19 deletions and L858R point mutations . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [72, 81], "tok_span": [17, 21]}, {"name": "L858R", "ent_type": "variant", "char_span": [198, 203], "tok_span": [40, 44]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [198, 203], "obj_char_span": [72, 81], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and BMX ) , demonstrated preclinical efficacy against T790M mutant at eightfold lower doses compared to afatinib . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [243, 248], "tok_span": [58, 62]}, {"name": "afatinib", "ent_type": "drug", "char_span": [293, 301], "tok_span": [70, 72]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [243, 248], "obj_char_span": [293, 301], "rel_type": "response", "sbj_tok_span": [58, 62], "obj_tok_span": [70, 72]}], "umls_entity_list": []}, {"text": "Tyrosine kinase inhibitors ( TKIs ) targeting the epidermal growth factor receptor (EGFR) , such as gefitinib and erlotinib , have shown remarkable activity in the patients with NSCLC , and particularly these TKIs are more effective to NSCLC with EGFR mutations in 19 exon ( in-frame deletions ) and exon 21 ( L858R point mutation ) , which are found to be more prevalent in Asian patients .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [114, 123], "tok_span": [25, 29]}, {"name": "L858R", "ent_type": "variant", "char_span": [310, 315], "tok_span": [66, 70]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [310, 315], "obj_char_span": [114, 123], "rel_type": "sensitivity", "sbj_tok_span": [66, 70], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Many evidences showed that patients with advanced lung adenocarcinomas harbor EGFR mutations , L858R missense mutations at exon 21 or deletions in exon 19 were more sensitive to the EGFR-TKI erlotinib or gefitinib , , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [191, 200], "tok_span": [38, 42]}, {"name": "L858R", "ent_type": "variant", "char_span": [95, 100], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [95, 100], "obj_char_span": [191, 200], "rel_type": "sensitivity", "sbj_tok_span": [14, 18], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "The drug resistance mutation T790M was detected in CTCs collected from patients with EGFR mutations that had received tyrosine kinase inhibitors Gefitinib ( Iressa ) or Erlotinib ( Tarceva ) .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [169, 178], "tok_span": [34, 37]}, {"name": "T790M", "ent_type": "variant", "char_span": [29, 34], "tok_span": [4, 8]}, {"name": "Tarceva", "ent_type": "drug", "char_span": [181, 188], "tok_span": [38, 41]}], "relation_list": [{"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [29, 34], "obj_char_span": [169, 178], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [34, 37]}, {"subject": "T790M", "object": "Tarceva", "sbj_char_span": [29, 34], "obj_char_span": [181, 188], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "Although the sequence analysis of EGFR might be necessary for clinical trials using TKI such as gefitinib or erlotinib , these simple methods established in this study for detection of exon 19 deletion and exon 21 L858R mutation are very useful for screening .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [109, 118], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [214, 219], "tok_span": [43, 47]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [214, 219], "obj_char_span": [109, 118], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Third , Montagut et al. reported that EGFR S492R ectodomain mutation prevents cetuximab binding and confers resistance to cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [78, 87], "tok_span": [20, 24]}, {"name": "S492R", "ent_type": "variant", "char_span": [43, 48], "tok_span": [11, 15]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [122, 131], "tok_span": [29, 33]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [43, 48], "obj_char_span": [78, 87], "rel_type": "resistance", "sbj_tok_span": [11, 15], "obj_tok_span": [20, 24]}, {"subject": "S492R", "object": "cetuximab", "sbj_char_span": [43, 48], "obj_char_span": [122, 131], "rel_type": "resistance", "sbj_tok_span": [11, 15], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , Gefitinib T790M gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) – Colorectal cancer ( metastatic ) Rare , Overexpression , copy number increase Cetuximab , Panitumumab K-ras– , B-raf , PIK3CA , PTEN mutations", "entity_list": [{"name": "Cetuximab", "ent_type": "drug", "char_span": [292, 301], "tok_span": [72, 75]}, {"name": "T790M", "ent_type": "variant", "char_span": [134, 139], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "Cetuximab", "sbj_char_span": [134, 139], "obj_char_span": [292, 301], "rel_type": "response", "sbj_tok_span": [30, 34], "obj_tok_span": [72, 75]}], "umls_entity_list": []}, {"text": "These second-generation EGFR inhibitors have also been shown to drive drug resistance through the acquisition of T790M in both preclinical and clinical settings , suggesting low potency against T790M. , As a potential solution , afatinib was combined with the EGFR antibody cetuximab in a Phase IIB study , which demonstrated an impressive response rate of 32 % in patients with EGFR mutant lung cancers resistant to first-generation EGFR inhibitors .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [274, 283], "tok_span": [52, 56]}, {"name": "T790M", "ent_type": "variant", "char_span": [113, 118], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [113, 118], "obj_char_span": [274, 283], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [52, 56]}], "umls_entity_list": []}, {"text": "As the second-generation , irreversible EGFR-TKIs , such as afatinib and dacomitinib , failed to overcome the resistance caused by T790M , , other measures , such as EGFR dual targeting with cetuximab and afatinib and third-geneneration , mutant-selective EGFR-TKIs – are being actively evaluated .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [191, 200], "tok_span": [44, 48]}, {"name": "T790M", "ent_type": "variant", "char_span": [131, 136], "tok_span": [29, 33]}, {"name": "afatinib", "ent_type": "drug", "char_span": [60, 68], "tok_span": [14, 16]}, {"name": "afatinib", "ent_type": "drug", "char_span": [205, 213], "tok_span": [49, 51]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [131, 136], "obj_char_span": [191, 200], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [44, 48]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [131, 136], "obj_char_span": [60, 68], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [14, 16]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [131, 136], "obj_char_span": [205, 213], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [49, 51]}], "umls_entity_list": []}, {"text": "One common hypothesis of Cetuximab-resistance is EGFR or downstream molecular mutation within tumor cells , such as acquired EGFR ectodomain mutation S492R .", "entity_list": [{"name": "Cetuximab-resistance", "ent_type": "drug", "char_span": [25, 45], "tok_span": [4, 9]}, {"name": "S492R", "ent_type": "variant", "char_span": [150, 155], "tok_span": [27, 31]}], "relation_list": [{"subject": "S492R", "object": "Cetuximab-resistance", "sbj_char_span": [150, 155], "obj_char_span": [25, 45], "rel_type": "resistance", "sbj_tok_span": [27, 31], "obj_tok_span": [4, 9]}], "umls_entity_list": []}, {"text": "Several preclinical reports showed that other agents , such as the anti-EGFR monoclonal Ab cetuximab or PI3K/mTOR inhibitors combined with irreversible EGFR inhibitors hold promise to overcome resistance mediated by T790M .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [91, 100], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [216, 221], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [216, 221], "obj_char_span": [91, 100], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "In this case , novel tyrosine kinase inhibitor such as nilotinib and dasatinib ( also called the second-generation of tyrosine kinase inhibitor ) have been shown activity against Gleevec-resistant patients bearing some point mutations but the “gate-keeper” mutations ( e.g. , T315I Bcr-Abl , T674I PDGFRα ) .", "entity_list": [{"name": "Gleevec-resistant", "ent_type": "drug", "char_span": [179, 196], "tok_span": [33, 38]}, {"name": ", T674I", "ent_type": "variant", "char_span": [290, 297], "tok_span": [67, 72]}], "relation_list": [{"subject": ", T674I", "object": "Gleevec-resistant", "sbj_char_span": [290, 297], "obj_char_span": [179, 196], "rel_type": "resistance", "sbj_tok_span": [67, 72], "obj_tok_span": [33, 38]}], "umls_entity_list": []}, {"text": "Pan J et al reported that EXEL-0862 is effective against Gleevec-resistant D816V KIT and T674I PDGFRα ( 2007 ) .", "entity_list": [{"name": "Gleevec-resistant", "ent_type": "drug", "char_span": [57, 74], "tok_span": [14, 19]}, {"name": "T674I", "ent_type": "variant", "char_span": [89, 94], "tok_span": [26, 30]}], "relation_list": [{"subject": "T674I", "object": "Gleevec-resistant", "sbj_char_span": [89, 94], "obj_char_span": [57, 74], "rel_type": "resistance", "sbj_tok_span": [26, 30], "obj_tok_span": [14, 19]}], "umls_entity_list": []}, {"text": "However , the secondary mutation T674I FIP1L1-PDGFRα in its kinase domain has been found in imatinib-refractory HES or CEL .", "entity_list": [{"name": "in imatinib-refractory", "ent_type": "drug", "char_span": [89, 111], "tok_span": [25, 30]}, {"name": "T674I", "ent_type": "variant", "char_span": [33, 38], "tok_span": [5, 9]}], "relation_list": [{"subject": "T674I", "object": "in imatinib-refractory", "sbj_char_span": [33, 38], "obj_char_span": [89, 111], "rel_type": "resistance", "sbj_tok_span": [5, 9], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "Because the FIP1L1-PDGFRα T674I mutant in HES mainly contributes to the imatinib-resistance , , we explored whether DCC-2036 could inhibit PDGFRα in FIP1L1-PDGFRα positive cells regardless of the mutational status .", "entity_list": [{"name": "the imatinib-resistance", "ent_type": "drug", "char_span": [68, 91], "tok_span": [22, 27]}, {"name": "FIP1L1-PDGFRα T674I", "ent_type": "variant", "char_span": [12, 31], "tok_span": [2, 15]}], "relation_list": [{"subject": "FIP1L1-PDGFRα T674I", "object": "the imatinib-resistance", "sbj_char_span": [12, 31], "obj_char_span": [68, 91], "rel_type": "resistance", "sbj_tok_span": [2, 15], "obj_tok_span": [22, 27]}], "umls_entity_list": []}, {"text": "Because tyrosine kinase inhibitor sorafenib was effective for imatinib-resistant FIP1L1-PDGFRα T674I mutation cells , we also compared the inhibitory effect of DCC-2036 with sorafenib in the BaF3-T674I cells .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [62, 80], "tok_span": [9, 13]}, {"name": "FIP1L1-PDGFRα T674I", "ent_type": "variant", "char_span": [81, 100], "tok_span": [13, 26]}], "relation_list": [{"subject": "FIP1L1-PDGFRα T674I", "object": "imatinib-resistant", "sbj_char_span": [81, 100], "obj_char_span": [62, 80], "rel_type": "resistance", "sbj_tok_span": [13, 26], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "International guidelines were adapted to incorporate 3 years of adjuvant imatinib as the gold standard , except for known imatinib resistant mutations , such as PDGFR D842V mutated GIST .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [73, 81], "tok_span": [10, 12]}, {"name": "D842V", "ent_type": "variant", "char_span": [167, 172], "tok_span": [29, 33]}, {"name": "imatinib", "ent_type": "drug", "char_span": [122, 130], "tok_span": [20, 22]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [167, 172], "obj_char_span": [73, 81], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [10, 12]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [167, 172], "obj_char_span": [122, 130], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "BT474 lapatinib-resistant cells acquire E542K PIK3CA mutation .", "entity_list": [{"name": "lapatinib-resistant", "ent_type": "drug", "char_span": [6, 25], "tok_span": [3, 8]}, {"name": "E542K", "ent_type": "variant", "char_span": [40, 45], "tok_span": [10, 14]}], "relation_list": [{"subject": "E542K", "object": "lapatinib-resistant", "sbj_char_span": [40, 45], "obj_char_span": [6, 25], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [3, 8]}], "umls_entity_list": []}, {"text": "After treatment of cells with increasing doses of lapatinib , we observed a similar inhibition of HER2 phosphorylation in parental and resistant cells , but the resistant cells with an acquired E542K mutation showed only very limited inhibition of PI3K signaling as measured by Akt and S6 phosphorylation ( Figure C ) .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [8, 11]}, {"name": "E542K", "ent_type": "variant", "char_span": [194, 199], "tok_span": [34, 38]}], "relation_list": [{"subject": "E542K", "object": "lapatinib", "sbj_char_span": [194, 199], "obj_char_span": [50, 59], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Similarly to BT474 LR cells with acquired E542K mutation , cells with the other hotspot mutations showed a blunted inhibitor response of PI3K signaling to lapatinib with persistent PI3K-Akt signaling ( Figure A ) .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [155, 164], "tok_span": [35, 38]}, {"name": "E542K", "ent_type": "variant", "char_span": [42, 47], "tok_span": [9, 13]}], "relation_list": [{"subject": "E542K", "object": "lapatinib", "sbj_char_span": [42, 47], "obj_char_span": [155, 164], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [35, 38]}], "umls_entity_list": []}, {"text": "Acquired E542K mutation in BT474 lapatinib resistant cells shifts the lapatinib half-maximal inhibitory concentration ( IC50 ) for phosphoinositide 3-kinase signaling .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [33, 42], "tok_span": [11, 14]}, {"name": "E542K", "ent_type": "variant", "char_span": [9, 14], "tok_span": [2, 6]}, {"name": "lapatinib", "ent_type": "drug", "char_span": [70, 79], "tok_span": [18, 21]}], "relation_list": [{"subject": "E542K", "object": "lapatinib", "sbj_char_span": [9, 14], "obj_char_span": [33, 42], "rel_type": "sensitivity", "sbj_tok_span": [2, 6], "obj_tok_span": [11, 14]}, {"subject": "E542K", "object": "lapatinib", "sbj_char_span": [9, 14], "obj_char_span": [70, 79], "rel_type": "sensitivity", "sbj_tok_span": [2, 6], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "First , GIST mutational status appears to be important , and there is a consensus that patients with the imatinib-insensitive D842V mutation of PDGFRA should not receive adjuvant imatinib .", "entity_list": [{"name": "imatinib-insensitive", "ent_type": "drug", "char_span": [105, 125], "tok_span": [21, 25]}, {"name": "D842V", "ent_type": "variant", "char_span": [126, 131], "tok_span": [25, 29]}, {"name": "imatinib", "ent_type": "drug", "char_span": [179, 187], "tok_span": [37, 39]}], "relation_list": [{"subject": "D842V", "object": "imatinib-insensitive", "sbj_char_span": [126, 131], "obj_char_span": [105, 125], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [21, 25]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [126, 131], "obj_char_span": [179, 187], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "Preoperative biopsy should be utilized not only to confirm the diagnosis of GIST but also to ensure that the imatinib-resistant D842V mutation is not present .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [109, 127], "tok_span": [21, 25]}, {"name": "D842V", "ent_type": "variant", "char_span": [128, 133], "tok_span": [25, 29]}], "relation_list": [{"subject": "D842V", "object": "imatinib-resistant", "sbj_char_span": [128, 133], "obj_char_span": [109, 127], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "UT-7/Epo , BaF-3 hKit WT and BaF-3 hKit T670I cultivated with Epo ( 1 UI/ml ) or IL3 ( 1 ng/ml ) were incubated 4 h with 2 µM Imatinib or 5 µM sorafenib or vehicle or stimulated 10 minutes with 50 ng/mL SCF .", "entity_list": [{"name": "µM Imatinib", "ent_type": "drug", "char_span": [123, 134], "tok_span": [52, 55]}, {"name": "T670I", "ent_type": "variant", "char_span": [40, 45], "tok_span": [23, 27]}], "relation_list": [{"subject": "T670I", "object": "µM Imatinib", "sbj_char_span": [40, 45], "obj_char_span": [123, 134], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [52, 55]}], "umls_entity_list": []}, {"text": "We used the T670I mutant c-Kit unable to bind imatinib and responsible for myeloproliferative disorder in mice and imatinib-resistant GIST in humans , .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [46, 54], "tok_span": [14, 16]}, {"name": "T670I", "ent_type": "variant", "char_span": [12, 17], "tok_span": [3, 7]}, {"name": "imatinib-resistant", "ent_type": "drug", "char_span": [115, 133], "tok_span": [26, 30]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [12, 17], "obj_char_span": [46, 54], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 16]}, {"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [12, 17], "obj_char_span": [115, 133], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Indeed , up to 10 µM imatinib was ineffective to block T670I mutant –driven cell proliferation , while kinase inhibitor sorafenib , which inhibits wt c-Kit at a concentration of 5 µM efficiently reduced this proliferation .", "entity_list": [{"name": "µM imatinib", "ent_type": "drug", "char_span": [18, 29], "tok_span": [5, 8]}, {"name": "block T670I", "ent_type": "variant", "char_span": [49, 60], "tok_span": [11, 16]}], "relation_list": [{"subject": "block T670I", "object": "µM imatinib", "sbj_char_span": [49, 60], "obj_char_span": [18, 29], "rel_type": "resistance", "sbj_tok_span": [11, 16], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "For example , GIST patients with the D842V mutation in PDGFRA exon 18 are known to be unresponsive to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [102, 110], "tok_span": [26, 28]}, {"name": "D842V", "ent_type": "variant", "char_span": [37, 42], "tok_span": [8, 12]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [37, 42], "obj_char_span": [102, 110], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 12], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "In a recent report , the c-KIT mutation L576P was associated with resistance to multiple KIT inhibitors including imatinib , nilotinib , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [114, 122], "tok_span": [25, 27]}, {"name": "L576P", "ent_type": "variant", "char_span": [40, 45], "tok_span": [11, 15]}, {"name": "nilotinib", "ent_type": "drug", "char_span": [125, 134], "tok_span": [28, 31]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [40, 45], "obj_char_span": [114, 122], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [25, 27]}, {"subject": "L576P", "object": "nilotinib", "sbj_char_span": [40, 45], "obj_char_span": [125, 134], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "The BRAF V600E mutation has been described as a predictor of tumor aggressiveness in metastatic disease and also of low RRs to cetuximab and panitumumab .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [141, 152], "tok_span": [31, 34]}, {"name": "V600E", "ent_type": "variant", "char_span": [9, 14], "tok_span": [2, 5]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [9, 14], "obj_char_span": [141, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [2, 5], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "Indeed , Montagut et al. identified the S492R mutation in 2 out of 10 tumors from patients with cetuximab resistance , and those 2 tumors showed good response to panitumumab .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [162, 173], "tok_span": [38, 41]}, {"name": "S492R", "ent_type": "variant", "char_span": [40, 45], "tok_span": [10, 14]}], "relation_list": [{"subject": "S492R", "object": "panitumumab", "sbj_char_span": [40, 45], "obj_char_span": [162, 173], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "Moreover , the presence of the V600E mutation in the BRAF gene is more and more frequently taken into consideration before patient targeted therapy qualification , because wild-type BRAF is required for a response to panitumumab or cetuximab .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [217, 228], "tok_span": [40, 43]}, {"name": "V600E", "ent_type": "variant", "char_span": [31, 36], "tok_span": [6, 9]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [31, 36], "obj_char_span": [217, 228], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 9], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "L1196M EML-ALKpm Gatekeeper residue mutation blocks crizotinib binding", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [52, 62], "tok_span": [16, 20]}, {"name": "L1196M", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [52, 62], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "G1202R EML-ALKpm A mutation-specific strong H-bond pulls crizotinib out of the position found in the non-crizotinib resistant EML-ALK fusion gene 1151Tins Thr insertion is predicted to alter ATP binding to ALK", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [57, 67], "tok_span": [20, 24]}, {"name": "G1202R", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}, {"name": "non-crizotinib", "ent_type": "drug", "char_span": [101, 115], "tok_span": [31, 37]}], "relation_list": [{"subject": "G1202R", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [57, 67], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [20, 24]}, {"subject": "G1202R", "object": "non-crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [101, 115], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [31, 37]}], "umls_entity_list": []}, {"text": "L1152R EML-ALKpm Mutation resistant to crizotinib and the structurally unrelated compound TAE684", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [39, 49], "tok_span": [13, 17]}, {"name": "L1152R", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}], "relation_list": [{"subject": "L1152R", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [39, 49], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Mutant F1174L complex exhibited the least binding affinity towards crizotinib , which was confirmed by the docking score of 5432 and ACE value of −144.17 .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [67, 77], "tok_span": [13, 17]}, {"name": "F1174L", "ent_type": "variant", "char_span": [7, 13], "tok_span": [2, 6]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [7, 13], "obj_char_span": [67, 77], "rel_type": "resistance", "sbj_tok_span": [2, 6], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "This suggests that F1174L mutation affects the binding of crizotinib and makes the backbone more flexible to move . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [58, 68], "tok_span": [12, 16]}, {"name": "F1174L", "ent_type": "variant", "char_span": [19, 25], "tok_span": [3, 7]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [19, 25], "obj_char_span": [58, 68], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "The two mutations were shown to independently induce crizotinib resistance in Ba/F3 cells engineered to express the L1196M and C1156Y mutations . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [53, 63], "tok_span": [8, 12]}, {"name": "L1196M", "ent_type": "variant", "char_span": [116, 122], "tok_span": [23, 27]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [127, 133], "tok_span": [28, 32]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [116, 122], "obj_char_span": [53, 63], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [8, 12]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [127, 133], "obj_char_span": [53, 63], "rel_type": "resistance", "sbj_tok_span": [28, 32], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Sasaki et al. reported that cells derived from pleural effusions of patients with EML4-ALK lung cancer who developed acquired resistance to crizotinib displayed the gatekeeper L1196M mutation and high levels of expression of EGFR ligands ( EGF and amphiregulin ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [140, 150], "tok_span": [30, 34]}, {"name": "L1196M", "ent_type": "variant", "char_span": [176, 182], "tok_span": [39, 43]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [176, 182], "obj_char_span": [140, 150], "rel_type": "resistance", "sbj_tok_span": [39, 43], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "The reversible dual ALK/EGFR inhibitor AP26113 is a more potent ALK inhibitor than crizotinib and demonstrates preclinical activity against various secondary mutations resistant to crizotinib , including L1196 and G1269A .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [83, 93], "tok_span": [19, 23]}, {"name": "G1269A", "ent_type": "variant", "char_span": [214, 220], "tok_span": [43, 47]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [181, 191], "tok_span": [33, 37]}], "relation_list": [{"subject": "G1269A", "object": "crizotinib", "sbj_char_span": [214, 220], "obj_char_span": [83, 93], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [19, 23]}, {"subject": "G1269A", "object": "crizotinib", "sbj_char_span": [214, 220], "obj_char_span": [181, 191], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "L1196M mutant cells were more resistant to crizotinib than C1156Y mutant cells .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [43, 53], "tok_span": [10, 14]}, {"name": "L1196M", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [59, 65], "tok_span": [15, 19]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [43, 53], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 14]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [59, 65], "obj_char_span": [43, 53], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "In the xenograft model of mice , the combination of cetuximab and afatinib can lead to a significant reduction of erlotinib-resistant tumor harboring T790M , compared to gefitinib plus cetuximab .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [66, 74], "tok_span": [16, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [150, 155], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [150, 155], "obj_char_span": [66, 74], "rel_type": "response", "sbj_tok_span": [33, 37], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "In a subset of patients with exon 19 and L858R mutations , the median PFS was 13.6 months for afatinib , compared with 6.9 months for chemotherapy ( HR = 0.47 , 95 % CI 0.34–0.65 , P & lt ; 0.0001 ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [94, 102], "tok_span": [24, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [41, 46], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [41, 46], "obj_char_span": [94, 102], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Afatinib is considered as a second-generation TKI that binds irreversibly to EGFR as well as receptors carrying the T790M mutation .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "T790M", "ent_type": "variant", "char_span": [116, 121], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "Afatinib", "sbj_char_span": [116, 121], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [23, 27], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Even knock-down of the T790M transcript by siRNAs , when combined with afatinib , was efficacious in controlling T790M-mutant , lung cancer cells .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [71, 79], "tok_span": [18, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [23, 28], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [23, 28], "obj_char_span": [71, 79], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 L858R point mutation ) in LUX-3 , LUX-6 , and combined cohorts Patient cohort Afatinib ( median OS ) Platinum based chemotherapy ( median OS ) Hazard ratio ( 95 % confidence interval )", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [176, 184], "tok_span": [40, 42]}, {"name": "L858R", "ent_type": "variant", "char_span": [98, 103], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "Afatinib", "sbj_char_span": [98, 103], "obj_char_span": [176, 184], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [40, 42]}], "umls_entity_list": []}, {"text": "Afatinib EGFR EGFR exon 19 deletion or exon 21 substitution ( L858R ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "L858R", "ent_type": "variant", "char_span": [62, 67], "tok_span": [12, 16]}], "relation_list": [{"subject": "L858R", "object": "Afatinib", "sbj_char_span": [62, 67], "obj_char_span": [0, 8], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "In addition , 2nd generation EGFR TKI ( afatinib ) aiming to overcome the EGFR T790M mutation has failed to show the expected clinical efficacy .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [40, 48], "tok_span": [10, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [79, 84], "obj_char_span": [40, 48], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Also in third line , bosutinib was able to overcome all types of mutations ( including mutations resistant to dasatinib and nilotinib , with the most frequent being F317L , T351I , G250E and Y253H ) , except T315I . ", "entity_list": [{"name": "bosutinib", "ent_type": "drug", "char_span": [21, 30], "tok_span": [5, 8]}, {"name": "Y253H", "ent_type": "variant", "char_span": [191, 196], "tok_span": [47, 51]}], "relation_list": [{"subject": "Y253H", "object": "bosutinib", "sbj_char_span": [191, 196], "obj_char_span": [21, 30], "rel_type": "response", "sbj_tok_span": [47, 51], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "However , for some patients , especially those possessing the T315I kinase domain mutation , ponatinib ( Iclusig® ) will be the ideal TKI .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [93, 102], "tok_span": [18, 22]}, {"name": "T315I", "ent_type": "variant", "char_span": [62, 67], "tok_span": [10, 14]}, {"name": "Iclusig®", "ent_type": "drug", "char_span": [105, 113], "tok_span": [23, 28]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [62, 67], "obj_char_span": [93, 102], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [18, 22]}, {"subject": "T315I", "object": "Iclusig®", "sbj_char_span": [62, 67], "obj_char_span": [105, 113], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [23, 28]}], "umls_entity_list": []}, {"text": "A molecule such as ponatinib , which was shown to inhibit all clinically important kinase domain mutations including T315I during preclinical evaluation , has the potential to achieve this feat .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [19, 28], "tok_span": [4, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [117, 122], "tok_span": [21, 25]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [117, 122], "obj_char_span": [19, 28], "rel_type": "response", "sbj_tok_span": [21, 25], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Overcoming both losses of an active-site hydrogen bond and the steric hindrance caused by the T315I mutation were the main focus during the design process of ponatinib . ", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [158, 167], "tok_span": [34, 38]}, {"name": "T315I", "ent_type": "variant", "char_span": [94, 99], "tok_span": [20, 24]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [94, 99], "obj_char_span": [158, 167], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "Ponatinib has since been put back on the market for a narrowed patient population : treatment of adults with T315I positive CML ( any phase ) and Ph+ALL , and treatment of adult patients for whom no other TKI therapy is indicated .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [109, 114], "tok_span": [21, 25]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [109, 114], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [21, 25], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Ponatinib is currently FDA approved for T315I positive CML ( in any phase ) and T315I positive Ph+ALL , or any phase of CML or Ph+ALL for which no other TKIs are indicated .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [40, 45], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [40, 45], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "A third generation inhibitor was recently tested in resistant/intolerant CML patients : ponatinib is a potent , synthetic , oral multi-target pan-BCR/ABL inhibitor able to block native and mutated BCR/ABL , including T315I mutation , resistant to dasatinib and nilotinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [88, 97], "tok_span": [16, 20]}, {"name": "T315I", "ent_type": "variant", "char_span": [217, 222], "tok_span": [49, 53]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [217, 222], "obj_char_span": [88, 97], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The PACE trial ( Ponatinib Ph+ ALL and CML Evaluation ) , a phase 2 open-label trial , tested ponatinib 45 mg QD in 449 patients resistant or intolerant to dasatinib or nilotinib or with T315I mutation in different phases of the disease .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [17, 26], "tok_span": [5, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [187, 192], "tok_span": [49, 53]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [94, 103], "tok_span": [24, 28]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [187, 192], "obj_char_span": [17, 26], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [5, 7]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [187, 192], "obj_char_span": [94, 103], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Further clinical studies of ponatinib are ongoing , most notably a single-arm phase 2 study in patients with CML or Ph+ acute lymphoblastic leukemia ( ALL ) who either are resistant or intolerant to either dasatinib or nilotinib , or who harbor the T315I mutation ( Ponatinib Ph+ ALL and CML evaluation [PACE ] ; NCT01207440 ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [28, 37], "tok_span": [4, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [249, 254], "tok_span": [55, 59]}, {"name": "Ponatinib", "ent_type": "drug", "char_span": [266, 275], "tok_span": [61, 63]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [249, 254], "obj_char_span": [28, 37], "rel_type": "response", "sbj_tok_span": [55, 59], "obj_tok_span": [4, 8]}, {"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [249, 254], "obj_char_span": [266, 275], "rel_type": "response", "sbj_tok_span": [55, 59], "obj_tok_span": [61, 63]}], "umls_entity_list": []}, {"text": "In addition , the recently approved ponatinib is active against the most common mutation that causes resistance to both first and second generation ABL TKIs , the “gatekeeper” T315I mutation ( Table ; Figure ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [36, 45], "tok_span": [6, 10]}, {"name": "“gatekeeper” T315I", "ent_type": "variant", "char_span": [163, 181], "tok_span": [32, 41]}], "relation_list": [{"subject": "“gatekeeper” T315I", "object": "ponatinib", "sbj_char_span": [163, 181], "obj_char_span": [36, 45], "rel_type": "response", "sbj_tok_span": [32, 41], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Targeting the T315I mutation : Ponatinib", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [31, 40], "tok_span": [9, 11]}, {"name": "T315I", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [14, 19], "obj_char_span": [31, 40], "rel_type": "response", "sbj_tok_span": [3, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Irrespective of its potential use in TKI-naïve CML and Ph+ ALL patients , the impressive activity against the T315I BCR–ABL1 will likely make ponatinib a crucial second line agent for patients with this mutation .", "entity_list": [{"name": "make ponatinib", "ent_type": "drug", "char_span": [137, 151], "tok_span": [34, 39]}, {"name": "the T315I", "ent_type": "variant", "char_span": [106, 115], "tok_span": [22, 27]}], "relation_list": [{"subject": "the T315I", "object": "make ponatinib", "sbj_char_span": [106, 115], "obj_char_span": [137, 151], "rel_type": "response", "sbj_tok_span": [22, 27], "obj_tok_span": [34, 39]}], "umls_entity_list": []}, {"text": "Ponatinib ( AP24534 ) was developed to interact with the inactive ABL conformation at multiple sites and with the T315I mutation , providing high affinity and efficacy .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [114, 119], "tok_span": [24, 28]}, {"name": "AP24534", "ent_type": "drug", "char_span": [12, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [114, 119], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [24, 28], "obj_tok_span": [0, 2]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [114, 119], "obj_char_span": [12, 19], "rel_type": "response", "sbj_tok_span": [24, 28], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "It was demonstrated that ponatinib is effective on CML cells harboring different mutations in BCR/ABL , including highly multiresistant T315I .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [4, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [136, 141], "tok_span": [26, 30]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [136, 141], "obj_char_span": [25, 34], "rel_type": "response", "sbj_tok_span": [26, 30], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "For instance , median survival of patients with blast phase ( BP ) CML who are refractory or intolerant to imatinib is 3 to 9 months. , Of particular concern is the ABL T315I ‘gatekeeper ' mutation , which renders leukemia cells resistant to all commercially available tyrosine kinase inhibitors other than ponatinib. ,", "entity_list": [{"name": "than ponatinib.", "ent_type": "drug", "char_span": [302, 317], "tok_span": [62, 68]}, {"name": "T315I", "ent_type": "variant", "char_span": [169, 174], "tok_span": [38, 42]}], "relation_list": [{"subject": "T315I", "object": "than ponatinib.", "sbj_char_span": [169, 174], "obj_char_span": [302, 317], "rel_type": "response", "sbj_tok_span": [38, 42], "obj_tok_span": [62, 68]}], "umls_entity_list": []}, {"text": "Finally , the third line inhibitor ponatinib has been developed and shown to exhibit substantial efficacy in patients with CML in whom the polyresistant BCR-ABL1 T315I mutation is expressed in leukemic cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [35, 44], "tok_span": [6, 10]}, {"name": "T315I", "ent_type": "variant", "char_span": [162, 167], "tok_span": [33, 37]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [162, 167], "obj_char_span": [35, 44], "rel_type": "response", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "In addition , other new ATP-competitive inhibitors capable of inhibiting T315I Bcr-Abl have been reported in conjunction with co-crystal structures : PPY-A , SGX393 , and PHA-739358 , AP24163 , DSA series compounds , HG-7-85-01 and AP24534 ; see also .", "entity_list": [{"name": "AP24534", "ent_type": "drug", "char_span": [232, 239], "tok_span": [68, 72]}, {"name": "T315I", "ent_type": "variant", "char_span": [73, 78], "tok_span": [12, 16]}], "relation_list": [{"subject": "T315I", "object": "AP24534", "sbj_char_span": [73, 78], "obj_char_span": [232, 239], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [68, 72]}], "umls_entity_list": []}, {"text": "The remarkable association between certain EGFR mutations , especially exon 19 deletions or L858R mutation in exon 21 and clinical benefit in patients with NSCLC treated with EGFR tyrosine kinase inhibitors ( TKIs ) , such as Gefitinib and Erlotinib , is well established .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [240, 249], "tok_span": [45, 48]}, {"name": "L858R", "ent_type": "variant", "char_span": [92, 97], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [92, 97], "obj_char_span": [240, 249], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [45, 48]}], "umls_entity_list": []}, {"text": "Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) – mainly either deletion at exon 19 or L858R mutation at exon 21 – respond to small molecule tyrosine kinase inhibitors ( gefitinib and erlotinib ) , , , with a recently reported median survival to gefitinib of 17.5 months .", "entity_list": [{"name": "and erlotinib", "ent_type": "drug", "char_span": [223, 236], "tok_span": [44, 49]}, {"name": "or L858R", "ent_type": "variant", "char_span": [127, 135], "tok_span": [22, 27]}], "relation_list": [{"subject": "or L858R", "object": "and erlotinib", "sbj_char_span": [127, 135], "obj_char_span": [223, 236], "rel_type": "sensitivity", "sbj_tok_span": [22, 27], "obj_tok_span": [44, 49]}], "umls_entity_list": []}, {"text": "Patients with EGFR mutations – either the exon 19 deletion or the L858R mutation – received 150 mg of daily oral erlotinib continuously until progression or intolerable adverse effects .", "entity_list": [{"name": "oral erlotinib", "ent_type": "drug", "char_span": [108, 122], "tok_span": [23, 28]}, {"name": "the L858R", "ent_type": "variant", "char_span": [62, 71], "tok_span": [11, 16]}], "relation_list": [{"subject": "the L858R", "object": "oral erlotinib", "sbj_char_span": [62, 71], "obj_char_span": [108, 122], "rel_type": "sensitivity", "sbj_tok_span": [11, 16], "obj_tok_span": [23, 28]}], "umls_entity_list": []}, {"text": "Doody and colleagues studied the activity of cetuximab with NSCLC lines bearing both wild-type EGFR and those with activating mutations in the intracellular kinase domain : not only those known to confer sensitivity to gefitinib and erlotinib ( L858R and delL747-T753insS ) but also the TKI-resistant mutation T790M .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [233, 242], "tok_span": [45, 49]}, {"name": "L858R", "ent_type": "variant", "char_span": [245, 250], "tok_span": [50, 54]}, {"name": "T790M", "ent_type": "variant", "char_span": [310, 315], "tok_span": [74, 78]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [245, 250], "obj_char_span": [233, 242], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [45, 49]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [310, 315], "obj_char_span": [233, 242], "rel_type": "resistance or non-response", "sbj_tok_span": [74, 78], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "In the EGFR gene , for example , we detected L858R ( in II-18 and H1975 ) and E746_A750del mutations ( in PC-9 and H1650 ) , which are known to be sensitive to the anti-cancer drugs , gefitinib and erlotinib . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [198, 207], "tok_span": [63, 67]}, {"name": "L858R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [45, 50], "obj_char_span": [198, 207], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [63, 67]}], "umls_entity_list": []}, {"text": "More recently , ponatinib , considered as a pan-BCR-ABL1 inhibitor , was shown to be active against T315I mutants .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [16, 25], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [100, 105], "tok_span": [26, 30]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [100, 105], "obj_char_span": [16, 25], "rel_type": "response", "sbj_tok_span": [26, 30], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "The present strategy highlighted a potential role of the stromal niche in the acquired resistance of T315I mutants towards ponatinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [123, 132], "tok_span": [22, 26]}, {"name": "T315I", "ent_type": "variant", "char_span": [101, 106], "tok_span": [16, 20]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [101, 106], "obj_char_span": [123, 132], "rel_type": "response", "sbj_tok_span": [16, 20], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Our assay was based on human UT-7 cell lines ( expressing non mutated or T315I mutated BCR-ABL1 ) , mutagenized with ENU ( N-ethyl-N-nitrosourea ) and cultured with or without murine MS-5 stromal cells in the presence of imatinib , dasatinib , nilotinib , or ponatinib ( ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [259, 268], "tok_span": [70, 74]}, {"name": "T315I", "ent_type": "variant", "char_span": [73, 78], "tok_span": [16, 20]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [73, 78], "obj_char_span": [259, 268], "rel_type": "response", "sbj_tok_span": [16, 20], "obj_tok_span": [70, 74]}], "umls_entity_list": []}, {"text": "The constant detection of T315I mutation in the UT-7-11/ponatinib/with MS-5 screening strengthened this hypothesis ( Table , exp. 5 ) .", "entity_list": [{"name": "UT-7-11/ponatinib/with", "ent_type": "drug", "char_span": [48, 70], "tok_span": [11, 23]}, {"name": "T315I", "ent_type": "variant", "char_span": [26, 31], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "UT-7-11/ponatinib/with", "sbj_char_span": [26, 31], "obj_char_span": [48, 70], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [11, 23]}], "umls_entity_list": []}, {"text": "To examine the role of the MS-5 niche , we first analyzed by array-CGH ( 1 ) two imatinib-resistant UT-7-11 clones harboring the E255K mutation compared with UT-7-11 control that did not undergo ENU mutagenesis , and ( 2 ) two ponatinib-resistant UT-7-315 clones with the T315I mutation alone compared with non mutagenized UT-7-315 control ( Fig. ) .", "entity_list": [{"name": "ponatinib-resistant", "ent_type": "drug", "char_span": [227, 246], "tok_span": [60, 66]}, {"name": "T315I", "ent_type": "variant", "char_span": [272, 277], "tok_span": [74, 78]}], "relation_list": [{"subject": "T315I", "object": "ponatinib-resistant", "sbj_char_span": [272, 277], "obj_char_span": [227, 246], "rel_type": "response", "sbj_tok_span": [74, 78], "obj_tok_span": [60, 66]}], "umls_entity_list": []}, {"text": "Potential MS-5 effects were analyzed in ( 1 ) two imatinib-resistant UT-7-11 clones harboring the E255K mutation compared with non mutagenized UT-7-11 control and in ( 2 ) two ponatinib-resistant UT-7-315 clones harboring the T315I mutation alone compared with non mutagenized UT-7-315 control .", "entity_list": [{"name": "ponatinib-resistant", "ent_type": "drug", "char_span": [176, 195], "tok_span": [45, 51]}, {"name": "T315I", "ent_type": "variant", "char_span": [226, 231], "tok_span": [59, 63]}], "relation_list": [{"subject": "T315I", "object": "ponatinib-resistant", "sbj_char_span": [226, 231], "obj_char_span": [176, 195], "rel_type": "response", "sbj_tok_span": [59, 63], "obj_tok_span": [45, 51]}], "umls_entity_list": []}, {"text": "Second , in the presence of the MS-5 microenvironment , UT-7 cells harboring the T315I mutation alone could survive ponatinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [116, 125], "tok_span": [27, 31]}, {"name": "T315I", "ent_type": "variant", "char_span": [81, 86], "tok_span": [19, 23]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [81, 86], "obj_char_span": [116, 125], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "In this model , T315I mutation and stromal niche could jointly play a crucial role in the acquisition of ponatinib resistance .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [22, 26]}, {"name": "T315I", "ent_type": "variant", "char_span": [16, 21], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [16, 21], "obj_char_span": [105, 114], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "However , ponatinib has been shown to be active against BCR-ABL1 mutants ( in particular the T315I mutant ) in vitro as well as in vivo .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [10, 19], "tok_span": [2, 6]}, {"name": "T315I", "ent_type": "variant", "char_span": [93, 98], "tok_span": [23, 27]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [93, 98], "obj_char_span": [10, 19], "rel_type": "response", "sbj_tok_span": [23, 27], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Altered BCR-ABL1 signaling potentially due to the T315I mutation , associated with a stroma mediated influence on these particular signaling pathways , could represent an explanation for ponatinib escape .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [187, 196], "tok_span": [35, 39]}, {"name": "T315I", "ent_type": "variant", "char_span": [50, 55], "tok_span": [12, 16]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [50, 55], "obj_char_span": [187, 196], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Based on IC50 values , it is noticeable that T315I show an intermediate resistance to ponatinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [86, 95], "tok_span": [19, 23]}, {"name": "T315I", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [45, 50], "obj_char_span": [86, 95], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Overall , these data suggest that T315I mutants , supported by a stromal niche , could survive ponatinib through interactions mediated by direct contact or soluble factors .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [20, 24]}, {"name": "T315I", "ent_type": "variant", "char_span": [34, 39], "tok_span": [6, 10]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [34, 39], "obj_char_span": [95, 104], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "In WJTOG3405 , 177 chemotherapy-naïve patients diagnosed with advanced NSCLC harboring sensitive EGFR mutations ( either deletion in the exon 19 or L858R point mutation in exon 21 ) were randomly assigned to receive either oral gefitinib or intravenous cisplatin plus docetaxel chemotherapy .", "entity_list": [{"name": "oral gefitinib", "ent_type": "drug", "char_span": [223, 237], "tok_span": [44, 49]}, {"name": "or L858R", "ent_type": "variant", "char_span": [145, 153], "tok_span": [27, 32]}], "relation_list": [{"subject": "or L858R", "object": "oral gefitinib", "sbj_char_span": [145, 153], "obj_char_span": [223, 237], "rel_type": "sensitivity", "sbj_tok_span": [27, 32], "obj_tok_span": [44, 49]}], "umls_entity_list": []}, {"text": "However , we found that gefitinib treatment of these cells did not result in dephosphorylation of ERK1/2 (A) or substantial apoptosis ( B ) , presumably due to the presence of the additional ( T790M ) mutation , known to reduce the kinase activity of EGFR , rendering it effectively wild type .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [24, 33], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [193, 198], "tok_span": [46, 50]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [193, 198], "obj_char_span": [24, 33], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "The NSCLC cell lines H358 ( WT EGFR ) , H1650 , HCC827 ( Del E746A750 deletions ) and H3255 ( L858R mutation ) were chosen for initial studies on the effects of gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [161, 170], "tok_span": [49, 53]}, {"name": "L858R", "ent_type": "variant", "char_span": [94, 99], "tok_span": [34, 38]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [94, 99], "obj_char_span": [161, 170], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "In addition , acquired resistance caused by a second site substitution , T790M in exon 20 , results in poorly gefitinib activity , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [110, 119], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [73, 78], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [73, 78], "obj_char_span": [110, 119], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "In addition , recent studies showed the pharmacogenomic issues in EGFR determine the limitation of gefitinib in clinical applications : Activating mutations of the in-frame deletions ( ΔE746-A750 ) in exon 19 and the L858R point mutation in exon 21 of the EGFR tyrosine kinase domain in NSCLC are highly correlated with gefitinib sensitivity , , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [99, 108], "tok_span": [17, 21]}, {"name": "the L858R", "ent_type": "variant", "char_span": [213, 222], "tok_span": [48, 53]}, {"name": "with gefitinib", "ent_type": "drug", "char_span": [315, 329], "tok_span": [69, 74]}], "relation_list": [{"subject": "the L858R", "object": "gefitinib", "sbj_char_span": [213, 222], "obj_char_span": [99, 108], "rel_type": "sensitivity", "sbj_tok_span": [48, 53], "obj_tok_span": [17, 21]}, {"subject": "the L858R", "object": "with gefitinib", "sbj_char_span": [213, 222], "obj_char_span": [315, 329], "rel_type": "sensitivity", "sbj_tok_span": [48, 53], "obj_tok_span": [69, 74]}], "umls_entity_list": []}, {"text": "If an increase in BIM expression is important for gefitinib induced apoptosis , it should be suppressed upon treatment of cell lines expressing the resistant T790M EGFR mutation with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [158, 163], "tok_span": [29, 33]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [183, 192], "tok_span": [36, 40]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [158, 163], "obj_char_span": [50, 59], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [158, 163], "obj_char_span": [183, 192], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "These results confirm that up-regulation of BIM correlates with effective TKI induced apoptosis and that T790M suppresses this process in gefitinib treated cells .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [138, 147], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [105, 110], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [105, 110], "obj_char_span": [138, 147], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Our in vitro studies demonstrated that both of the secondary mutations initially identified in our lab ( T790M and L747S ) confer varying degrees of resistance to the apoptotic signals initiated by gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [198, 207], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [105, 110], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [105, 110], "obj_char_span": [198, 207], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "EGFR , AKT , and ERK1/2 were not inhibited in our T790M gefitinib treated models .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [56, 65], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [50, 55], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [50, 55], "obj_char_span": [56, 65], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "At the time of this writing , phase II trials in which patients with advanced NSCLC are included on the basis of presence of the two most common EGFR mutations ( either exon 19 deletions or the exon 21 arginine-for-leucine substitution at amino acid 858 , or L858R ) and are given gefitinib as first-line treatment show radiographic response rates that exceed 75 % .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [281, 290], "tok_span": [60, 64]}, {"name": "L858R", "ent_type": "variant", "char_span": [259, 264], "tok_span": [52, 56]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [259, 264], "obj_char_span": [281, 290], "rel_type": "sensitivity", "sbj_tok_span": [52, 56], "obj_tok_span": [60, 64]}], "umls_entity_list": []}, {"text": "Bottom : Expression of EGFR in Ba/F3 cells expressing L858R , L858R-L747S #1–4 , or L858R-T790M . ( E ) Gefitinib release assay .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [104, 113], "tok_span": [47, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [54, 59], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [54, 59], "obj_char_span": [104, 113], "rel_type": "sensitivity", "sbj_tok_span": [14, 18], "obj_tok_span": [47, 50]}], "umls_entity_list": []}, {"text": "BIM expression correlated with the amount of apoptosis in L858R , L858R-L747S , and L858R-T790M cells . ( B ) Modulation of signaling following gefitinib treatment in Ba/F3 cells expressing EGFR mutants .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [144, 153], "tok_span": [45, 49]}, {"name": "L858R", "ent_type": "variant", "char_span": [58, 63], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [58, 63], "obj_char_span": [144, 153], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Time course of gefitinib treatment in L858R (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [15, 24], "tok_span": [3, 7]}, {"name": "L858R", "ent_type": "variant", "char_span": [38, 43], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [38, 43], "obj_char_span": [15, 24], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Our group has undertaken a randomized phase 3 trial to compare gefitinib plus carboplatin plus pemetrexed with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an L858R , G719X , or L861Q EGFR mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry number , UMIN000006340 ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [63, 72], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [188, 193], "tok_span": [41, 45]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [111, 120], "tok_span": [25, 29]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [188, 193], "obj_char_span": [63, 72], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [11, 15]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [188, 193], "obj_char_span": [111, 120], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "For example , HCC827 cells undergo MET amplification and AXL induction upon adaption to gefitinib , , , and PC9 cells acquire the T790M mutation in EGFR that confers resistance to erlotinib and gefitinib . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [88, 97], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [130, 135], "tok_span": [31, 35]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [194, 203], "tok_span": [47, 51]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [130, 135], "obj_char_span": [88, 97], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 35], "obj_tok_span": [18, 22]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [130, 135], "obj_char_span": [194, 203], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 35], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "Most NSCLC patients who harbor activating EGFR mutations , including deletions in exon 19 or the point mutation L858R in exon 21 , experience an initial marked response to the EGFR-TKIs gefitinib or erlotinib . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [186, 195], "tok_span": [37, 41]}, {"name": "L858R", "ent_type": "variant", "char_span": [112, 117], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [112, 117], "obj_char_span": [186, 195], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Age ( years ) Gender Smoking Histology EGFR mutation status Response to gefitinib 62 F Never Ad E747_P753insS PR 58 F Never Ad E746_A750del PR 80 F Never Ad E746_A750del PR 61 M Never Ad E746_A750del PR 65 M Former Ad E746_A750del PR 60 M Current Ad E746_A750del PR 66 F Never Ad E747_T750del PR 76 F Never Ad Wild SD 57 F Former Ad Wild SD 40 F Never Ad Wild SD 72 F Never Ad Wild SD 58 F Former Ad Wild SD 66 F Never Ad Wild SD 65 F Former Ad L858R SD 39 F Never Ad Wild PD 69 M Former Ad Wild PD 72 F Never Ad Wild PD 74 F Never Ad Wild PD 67 M Former Ad Wild PD 62 M Former SCC Wild PD 59 F Current Ad Wild PD 77 M Current Ad Wild PD 82 F Never Ad Wild PD 66 F Never Ad Wild PD 56 M Current Ad Wild PD 61 M Former Ad Wild PD 65 M Former Ad Wild PD", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [72, 81], "tok_span": [14, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [445, 450], "tok_span": [154, 158]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [445, 450], "obj_char_span": [72, 81], "rel_type": "sensitivity", "sbj_tok_span": [154, 158], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [123, 132], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [21, 25]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [74, 79], "obj_char_span": [123, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [35, 39]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [123, 132], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Kim and colleagues demonstrated that the combination of lapatinib with cetuximab overcame gefitinib resistance due to the secondary T790M mutation in NSCLC by inducing enhanced cytotoxicity both in vitro and in vivo .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [132, 137], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [132, 137], "obj_char_span": [90, 99], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Gefitinib has been registered for the therapy of advanced NSCLC harbouring activating EGFR mutations in the tyrosine kinase domain , the most frequent being L858R in exon 21 and Del ( 746–750 ) in exon 19 .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [157, 162], "tok_span": [28, 32]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [157, 162], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "In particular , the L858R mutant is 10- to 100-fold more sensitive to erlotinib and gefitinib than the wild-type kinase , ,, and significantly more sensitive than the G719S mutant .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [24, 28]}, {"name": "G719S", "ent_type": "variant", "char_span": [167, 172], "tok_span": [43, 47]}, {"name": "L858R", "ent_type": "variant", "char_span": [20, 25], "tok_span": [4, 8]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [70, 79], "tok_span": [19, 23]}], "relation_list": [{"subject": "G719S", "object": "gefitinib", "sbj_char_span": [167, 172], "obj_char_span": [84, 93], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [24, 28]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [20, 25], "obj_char_span": [84, 93], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [24, 28]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [20, 25], "obj_char_span": [70, 79], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "The bulkier methionine residue T790M changes the ATP binding pocket of the tyrosine kinase domain , leading to the blockade of gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [127, 136], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [31, 36], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [31, 36], "obj_char_span": [127, 136], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "However , it was demonstrated recently that T790M increased the affinity of ATP to the EGFR tyrosine kinase domain ; thus , it decreased the binding of gefitinib and erlotinib , because they are ATP-competitive agents .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [152, 161], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [44, 49], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [44, 49], "obj_char_span": [152, 161], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "In preclinical models , dacomitinib was highly potent in inhibiting the HER domain and anti-cancer activity in gefitinib-resistant cell lines and xenograft with HER2 and T790M mutation NSCLC models .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [111, 130], "tok_span": [22, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [170, 175], "tok_span": [37, 41]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [170, 175], "obj_char_span": [111, 130], "rel_type": "resistance or non-response", "sbj_tok_span": [37, 41], "obj_tok_span": [22, 28]}], "umls_entity_list": []}, {"text": "In the xenograft model of mice , the combination of cetuximab and afatinib can lead to a significant reduction of erlotinib-resistant tumor harboring T790M , compared to gefitinib plus cetuximab .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [170, 179], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [150, 155], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [150, 155], "obj_char_span": [170, 179], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "PFS was 4.4 months , whereas median overall survival was 19 months ; two patients with acquired T790M mutations had SD for 9 months and 1 month , respectively The most common afatinib related toxicities were diarrhea in all patients and rash/acne in 91.9 % of patients LUX-Lung 7 , NCT01466660 IIb Yes First-line Afatinib versus gefitinib PFS ; DCR – –", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [329, 338], "tok_span": [80, 84]}, {"name": "T790M", "ent_type": "variant", "char_span": [96, 101], "tok_span": [19, 23]}, {"name": "afatinib", "ent_type": "drug", "char_span": [175, 183], "tok_span": [37, 39]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [96, 101], "obj_char_span": [329, 338], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [80, 84]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [96, 101], "obj_char_span": [175, 183], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "Moreover , the OS pooled analysis indicated the differential activity for afatinib by a specific EGFR mutant allele , indicating that for future analyses , outcomes of exon 19 deletion patients and L858R in studies of EGFR TKIs should not be pooled . ", "entity_list": [{"name": "L858R", "ent_type": "variant", "char_span": [198, 203], "tok_span": [33, 37]}, {"name": "afatinib", "ent_type": "drug", "char_span": [74, 82], "tok_span": [11, 13]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [198, 203], "obj_char_span": [74, 82], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Moreover , the second-generation irreversible EGFR inhibitors were shown in preclinical models to be more potent targeting T790M mutation than gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [123, 128], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [123, 128], "obj_char_span": [143, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Cytology showed the development of right pleural effusion after gefitinib treatment , and a second mutation of T790M was found in the primary lesion .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [64, 73], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [111, 116], "obj_char_span": [64, 73], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "In addition , the case indicates that extended gefitinib exposure in the systemic lung cancer sites was associated with the development of a systemic T790M resistance mutation , whereas CNS metastases did not undergo this secondary change .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [150, 155], "tok_span": [27, 31]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [150, 155], "obj_char_span": [47, 56], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "NSCLC patients harboring exon 19 deletion or exon 21 L858R somatic mutations experience significant tumor regression when prescribed the reversible small molecular tyrosine kinase inhibitors ( TKIs ) such as gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [208, 217], "tok_span": [34, 38]}, {"name": "L858R", "ent_type": "variant", "char_span": [53, 58], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [53, 58], "obj_char_span": [208, 217], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "A secondary point mutation in exon 20 of EGFR ( T790M ) is associated with acquired resistance to gefitinib or Erlotinib , but this can be overcome by the irreversible EGFR-tyrosine kinase inhibitor BIBW2992 ( BIBW ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [48, 53], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [48, 53], "obj_char_span": [98, 107], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "The T790M mutation in exon 20 of the kinase domain is relatively rare in untreated patients but occurs in up to 50 % of patients with acquired resistance to erlotinib or gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [170, 179], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [170, 179], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Patient nos. 18 and 20 who received gefitinib before metachronous metastasis developed metastatic tumours , which were either wild type in respect to EGFR mutation status ( no. 18 ) or had acquired resistance because of the T790M EGFR mutation ( no. 20 ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [36, 45], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [224, 229], "tok_span": [45, 49]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [224, 229], "obj_char_span": [36, 45], "rel_type": "resistance or non-response", "sbj_tok_span": [45, 49], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "The H1975 and H820 cell lines had EGFR T790M mutations in exon 20 , associated with gefitinib and erlotinib resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [39, 44], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [39, 44], "obj_char_span": [84, 93], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Activating mutations such as exon 21 missense point mutation L858R and in-frame deletions in exon 19 are the most commonly studied predictive biomarkers of response to EGFR-TKIs ( gefitinib and erlotinib ) , . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [180, 189], "tok_span": [38, 42]}, {"name": "L858R", "ent_type": "variant", "char_span": [61, 66], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [61, 66], "obj_char_span": [180, 189], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "For tyrosine kinase inhibitors ( TKIs ) , mutations within the ATP pocket of the kinase domain may affect the interaction of the drug with its target : for example , the single amino acid mutation tyrosine/methionine ( T790M ) in the ATP binding pocket of the EGFR mediates secondary resistance to the EGFR TKIs erlotinib and gefitinib in non-small cell lung cancer ( NSCLC ) . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [326, 335], "tok_span": [67, 71]}, {"name": "T790M", "ent_type": "variant", "char_span": [219, 224], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [219, 224], "obj_char_span": [326, 335], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 45], "obj_tok_span": [67, 71]}], "umls_entity_list": []}, {"text": "Through this approach , they showed that Src Family Kinases (SFKs) , as well as EGFR , are relevant targets for the Src inhibitor dasatinib and that acquired T790M mutations render cells resistant not only to erlotinib and gefitinib , but also to dasatinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [223, 232], "tok_span": [49, 53]}, {"name": "T790M", "ent_type": "variant", "char_span": [158, 163], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [158, 163], "obj_char_span": [223, 232], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "The T790M mutation is known to mediate secondary resistance to EGFR TKIs , yet there is evidence that it can be detected even before treatment with erlotinib or gefitinib when a high sensitivity method of detection is applied .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [161, 170], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [161, 170], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Alternatively , the selective resistance hypothesis suggests that the T790M mutation might exist in patients as small clones prior to treatment ; these resistant clones may proliferate after exposed to gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [202, 211], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [70, 75], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [70, 75], "obj_char_span": [202, 211], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 13], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "In addition , other EGFR mutations have also demonstrated contribution to the development of drug resistance to erlotinib and gefitinib , including secondary EGFR kinase mutations , L858R mutations , and secondary D761Y point mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [126, 135], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [182, 187], "tok_span": [33, 37]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [112, 121], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [182, 187], "obj_char_span": [126, 135], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [22, 26]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [182, 187], "obj_char_span": [112, 121], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Second-generation TKIs that irreversibly inhibit the EGFR TKI domain may offer the potential for overcoming the resistance of T790M mutation to erlotinib and gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [158, 167], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [126, 131], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [126, 131], "obj_char_span": [158, 167], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Similarly , the T790M point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib , which are used to treat non-small cell lung cancer .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [142, 151], "tok_span": [26, 30]}, {"name": "T790M", "ent_type": "variant", "char_span": [16, 21], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [16, 21], "obj_char_span": [142, 151], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Of these , 2 patients , with L858R and 746-deletion separately , were treated with gefitinib after operation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [83, 92], "tok_span": [21, 25]}, {"name": "L858R", "ent_type": "variant", "char_span": [29, 34], "tok_span": [7, 11]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [29, 34], "obj_char_span": [83, 92], "rel_type": "sensitivity", "sbj_tok_span": [7, 11], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Tyrosine kinase inhibitors ( TKIs ) targeting the epidermal growth factor receptor (EGFR) , such as gefitinib and erlotinib , have shown remarkable activity in the patients with NSCLC , and particularly these TKIs are more effective to NSCLC with EGFR mutations in 19 exon ( in-frame deletions ) and exon 21 ( L858R point mutation ) , which are found to be more prevalent in Asian patients .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [100, 109], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [310, 315], "tok_span": [66, 70]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [310, 315], "obj_char_span": [100, 109], "rel_type": "sensitivity", "sbj_tok_span": [66, 70], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "By contrast , we showed that other EGFR mutants are oncogenic without the requirement for dimerization , including the gefitinib-resistant exon 20 insertion mutant and the T790M mutant . ", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [119, 138], "tok_span": [20, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [172, 177], "tok_span": [32, 36]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [172, 177], "obj_char_span": [119, 138], "rel_type": "resistance or non-response", "sbj_tok_span": [32, 36], "obj_tok_span": [20, 26]}], "umls_entity_list": []}, {"text": "Indeed , in non-small cell lung cancers treated with gefitinib or erlotinib , sensitive patients have the EGFR T790M mutation in only a few cells , whereas resistant patients exhibit EGFR T790M in the majority of the tumour cells ( ; ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [53, 62], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [111, 116], "obj_char_span": [53, 62], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Yamauchi M , et al also found N-cadherin expression was significantly upregulated in gefitinib-resistant PC9/ZD cells harboring the acquired resistant mutation T790M in the EGFR gene , other cells expressing N-cadherin were found resistant to erlotinib ( A549 , H157 , and H322 ) and that inhibition of N-cadherin expression using siRNA led to a significant decrease in viability in A549 and H322 cells .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [85, 104], "tok_span": [19, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [160, 165], "tok_span": [36, 40]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [160, 165], "obj_char_span": [85, 104], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [19, 25]}], "umls_entity_list": []}, {"text": "Moreover , serial genotyping of circulating lung cancer cells during gefitinib therapy demonstrated the emergence of the kinase inhibitor resistance–associated mutation T790M at increasing allelic ratios , coinciding with clinical relapse .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [69, 78], "tok_span": [10, 14]}, {"name": "mutation T790M", "ent_type": "variant", "char_span": [160, 174], "tok_span": [25, 30]}], "relation_list": [{"subject": "mutation T790M", "object": "gefitinib", "sbj_char_span": [160, 174], "obj_char_span": [69, 78], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 30], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Acquired resistance , including EGFR secondary mutations ( T790M and other rare mutations ) , MET gene amplification , PTEN gene downregulation , high-level hepatocyte growth factor expression , epithelial–mesenchymal transition , and conversion to small cell lung cancer , – continues to restrict the durable long-term outcomes of erlotinib .", "entity_list": [{"name": "of erlotinib", "ent_type": "drug", "char_span": [329, 341], "tok_span": [60, 65]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "of erlotinib", "sbj_char_span": [59, 64], "obj_char_span": [329, 341], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 13], "obj_tok_span": [60, 65]}], "umls_entity_list": []}, {"text": "The second-generation TKIs may overcome resistance to the treatment of erlotinib or gefitinib via the T790M gatekeeper mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [102, 107], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [102, 107], "obj_char_span": [71, 80], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Phase II XL647 41 patients with relapsed or recurrent advanced NSCLC who progressed after ≥ 12 weeks of stable disease or response to erlotinib or gefitinib and/or those patients with a documented EGFR T790M Objective RR The objective RR was 3 % , 67 % of the patients harbored T790M had progression of disease , while14 % of those without this mutation , 11 patients ( 28 % ) had a dose reduction due to toxicity .", "entity_list": [{"name": "to erlotinib", "ent_type": "drug", "char_span": [131, 143], "tok_span": [25, 30]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [197, 207], "tok_span": [43, 48]}], "relation_list": [{"subject": "EGFR T790M", "object": "to erlotinib", "sbj_char_span": [197, 207], "obj_char_span": [131, 143], "rel_type": "resistance or non-response", "sbj_tok_span": [43, 48], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "The RR with erlotinib was 70.6 % , 12.2 % presented complete responses and a better outcome was associated with the exon 19 deletion than with the L858R mutation ( odds ratio 3.08 ; P = 0.001 ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [12, 21], "tok_span": [3, 7]}, {"name": "L858R", "ent_type": "variant", "char_span": [147, 152], "tok_span": [34, 38]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [147, 152], "obj_char_span": [12, 21], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "MTS assay was used to evaluate the effects of erlotinib ( a ) , bevacizumab ( c ) , and combination of erlotinib and bevacizumab ( d ) on the growth of NSCLC cell lines , which included cell lines with EGFR mutations : PC9 ( EGFR exon 19 deletion ) , 11–18 ( EGFR L858 ) , H1975 ( EGFR L858R and T790 M mutations ) and EGFR wild-type cell lines : H157 , H460 and A549 .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [46, 55], "tok_span": [10, 14]}, {"name": "EGFR L858R", "ent_type": "variant", "char_span": [281, 291], "tok_span": [76, 81]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [103, 112], "tok_span": [27, 31]}], "relation_list": [{"subject": "EGFR L858R", "object": "erlotinib", "sbj_char_span": [281, 291], "obj_char_span": [46, 55], "rel_type": "sensitivity", "sbj_tok_span": [76, 81], "obj_tok_span": [10, 14]}, {"subject": "EGFR L858R", "object": "erlotinib", "sbj_char_span": [281, 291], "obj_char_span": [103, 112], "rel_type": "sensitivity", "sbj_tok_span": [76, 81], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "A recent study demonstrated that using a combination of erlotinib and cetuximab reversed the drug resistance in NSCLC in T790M and L858R mutation lung cancer cell lines ( Wang et al. , ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [56, 65], "tok_span": [9, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [131, 136], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [121, 126], "tok_span": [25, 29]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [70, 79], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [131, 136], "obj_char_span": [56, 65], "rel_type": "sensitivity", "sbj_tok_span": [30, 34], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [121, 126], "obj_char_span": [56, 65], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "cetuximab", "sbj_char_span": [121, 126], "obj_char_span": [70, 79], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "This has been reported by several prospective trials of gefitinib and erlotinib in EGFR mutated NSCLC , which showed RRs exceeding 70 % in tumors with exon 19 deletions or the L858R mutation , with PFS intervals of 6-14 months and OS times beyond 20-24 months- .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [70, 79], "tok_span": [14, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [176, 181], "tok_span": [38, 42]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [176, 181], "obj_char_span": [70, 79], "rel_type": "sensitivity", "sbj_tok_span": [38, 42], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "For example , in glioblastoma and non-small-cell lung carcinoma ( NSCLC ) patients the presence of EGFRvIII or T790M EGFR was found to be associated with resistance to treatment with gefitinib and erlotinib , respectively ( ; ; ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [197, 206], "tok_span": [45, 49]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [111, 116], "obj_char_span": [197, 206], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Apoptotic effects of erlotinib on EGFR-sensitive cell lines in comparison to the T790M mutant H1975 ( B ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [21, 30], "tok_span": [4, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [81, 86], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [81, 86], "obj_char_span": [21, 30], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "On the basis of this study , in May 2013 the U.S Food and Drug Administration ( FDA ) approved erlotinib for use in patients with lung cancers harboring EGFR exon 19 deletions and EGFR L858R substitutions . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [185, 190], "tok_span": [40, 44]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [185, 190], "obj_char_span": [95, 104], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Afatinib exhibits superior anticancer activity in lung cancer patients harboring gefitinib/erlotinib-resistant mutant EGFR ( including T790M , exon 20 insertion , and T790M/L858R double mutation ) .", "entity_list": [{"name": "gefitinib/erlotinib-resistant", "ent_type": "drug", "char_span": [81, 110], "tok_span": [11, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [135, 140], "tok_span": [26, 30]}, {"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib-resistant", "sbj_char_span": [135, 140], "obj_char_span": [81, 110], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [11, 22]}, {"subject": "T790M", "object": "Afatinib", "sbj_char_span": [135, 140], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [26, 30], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Finally , a recent study shows not only that EGFR mutations are statistically associated with Asian ethnicity and never-smoker status , but also that patients with EGFR exon 19 deletions have significantly longer median survival than patients with EGFR L858R mutation ( 34 vs. 8 months , p=0.01 ) after treatment with gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [331, 340], "tok_span": [68, 72]}, {"name": "L858R", "ent_type": "variant", "char_span": [253, 258], "tok_span": [42, 46]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [253, 258], "obj_char_span": [331, 340], "rel_type": "sensitivity", "sbj_tok_span": [42, 46], "obj_tok_span": [68, 72]}], "umls_entity_list": []}, {"text": "First , a secondary mutation in exon 20 , leading to a substitution of methionine for threonine at position 790 ( T790M ) in the kinase domain , is reported in 2 of 5 patients with acquired resistance to gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [217, 226], "tok_span": [49, 53]}, {"name": "T790M", "ent_type": "variant", "char_span": [114, 119], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [114, 119], "obj_char_span": [217, 226], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 27], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "For example , the LUX-Lung 5 and LUX-Lung 6 trials are studying the role of BIBW2992 in patients who have failed erlotinib/gefinitib , and those with EGFR activating mutations respectively . 3 ) Neratinib Neratinib is an irreversible pan-ErbB TKI that is being studied as an agent that among other things may potentially overcome resistance due to T790M mutations .", "entity_list": [{"name": "erlotinib/gefinitib", "ent_type": "drug", "char_span": [113, 132], "tok_span": [30, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [348, 353], "tok_span": [84, 88]}], "relation_list": [{"subject": "T790M", "object": "erlotinib/gefinitib", "sbj_char_span": [348, 353], "obj_char_span": [113, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [84, 88], "obj_tok_span": [30, 39]}], "umls_entity_list": []}, {"text": "In terms of EGFR targeted therapy , resistant mechanisms ( eg , EGFR T790M mutation and MET amplification ) emerge as a result of the tumor evolution after EGFR inhibition by gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [188, 197], "tok_span": [39, 43]}, {"name": "T790M", "ent_type": "variant", "char_span": [69, 74], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [69, 74], "obj_char_span": [188, 197], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "Because they also harbor the L858R mutation of EGFR associated with sensitivity to EGFR tyrosine kinase inhibitors like erlotinib , we next investigated interactions between IGF-1R and EGFR in the cells treated under various conditions .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [120, 129], "tok_span": [21, 25]}, {"name": "L858R", "ent_type": "variant", "char_span": [29, 34], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [29, 34], "obj_char_span": [120, 129], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "For example , 11–18 cells , which harbor an erlotinib-sensitive EGFR mutation ( L858R ) , undergo only G1 arrest in response to erlotinib but undergo apoptosis when co-treated with R1507 and erlotinib .", "entity_list": [{"name": "an erlotinib-sensitive", "ent_type": "drug", "char_span": [41, 63], "tok_span": [10, 17]}, {"name": "( L858R", "ent_type": "variant", "char_span": [78, 85], "tok_span": [19, 24]}, {"name": "to erlotinib", "ent_type": "drug", "char_span": [125, 137], "tok_span": [33, 38]}, {"name": "and erlotinib", "ent_type": "drug", "char_span": [187, 200], "tok_span": [49, 54]}], "relation_list": [{"subject": "( L858R", "object": "an erlotinib-sensitive", "sbj_char_span": [78, 85], "obj_char_span": [41, 63], "rel_type": "sensitivity", "sbj_tok_span": [19, 24], "obj_tok_span": [10, 17]}, {"subject": "( L858R", "object": "to erlotinib", "sbj_char_span": [78, 85], "obj_char_span": [125, 137], "rel_type": "sensitivity", "sbj_tok_span": [19, 24], "obj_tok_span": [33, 38]}, {"subject": "( L858R", "object": "and erlotinib", "sbj_char_span": [78, 85], "obj_char_span": [187, 200], "rel_type": "sensitivity", "sbj_tok_span": [19, 24], "obj_tok_span": [49, 54]}], "umls_entity_list": []}, {"text": "Two EGFR mutations ( exon 19 deletion and exon 21 L858R substitution ) that cluster around the adenosine-5′-triphosphate binding pocket of the EGFR tyrosine kinase ( TK ) domain are highly responsive to EGFR TK inhibitors ( TKIs ) like gefitinib or erlotinib .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [246, 258], "tok_span": [57, 62]}, {"name": "L858R", "ent_type": "variant", "char_span": [50, 55], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "or erlotinib", "sbj_char_span": [50, 55], "obj_char_span": [246, 258], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [57, 62]}], "umls_entity_list": []}, {"text": "EGFR mutations ( 51 patients screened ) del 19 7 13.7 L858R 2 3.9 Total 9 17.6 K-ras mutations ( 56 patients screened ) 10 17.8 First-line therapy Chemotherapy 52 Erlotinib 7 Chemotherapy + erlotinib 1", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [163, 172], "tok_span": [47, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [54, 59], "tok_span": [13, 17]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [190, 199], "tok_span": [54, 58]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [54, 59], "obj_char_span": [163, 172], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [47, 50]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [54, 59], "obj_char_span": [190, 199], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [54, 58]}], "umls_entity_list": []}, {"text": "Several studies have reported that advanced NSCLC patients with EGFR exon 19 deletion had a longer overall survival ( OS ) and/or progression-free survival ( PFS ) following treatment with gefitinib or erlotinib compared with those with the L858R mutation , , , but this result has not been shown in all reports , , , , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [202, 211], "tok_span": [39, 43]}, {"name": "L858R", "ent_type": "variant", "char_span": [241, 246], "tok_span": [48, 52]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [241, 246], "obj_char_span": [202, 211], "rel_type": "sensitivity", "sbj_tok_span": [48, 52], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "As previously demonstrated , cells with the deletion mutant and the point mutation L858R were inhibited by the TKIs gefitinib and erlotinib , while the exon 20 insertion mutation was resistant . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [130, 139], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [83, 88], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [83, 88], "obj_char_span": [130, 139], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Indeed , concomitant inhibition of MET and EGFR in erlotinib-resistant cells harboring the T790M mutation significantly increases lung cancer cytotoxicity above MET targeted therapy alone in both in vitro and in vivo settings.", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [51, 70], "tok_span": [9, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [91, 96], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "erlotinib-resistant", "sbj_char_span": [91, 96], "obj_char_span": [51, 70], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [9, 15]}], "umls_entity_list": []}, {"text": "Interestingly , four EGFR FISH+ patients with KRAS mutations ( G12V in one case , G12D in another one , G13D in the remaining two cases ) responded to cetuximab therapy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [151, 160], "tok_span": [37, 41]}, {"name": "G12D", "ent_type": "variant", "char_span": [82, 86], "tok_span": [19, 22]}, {"name": "G13D", "ent_type": "variant", "char_span": [104, 108], "tok_span": [26, 29]}], "relation_list": [{"subject": "G12D", "object": "cetuximab", "sbj_char_span": [82, 86], "obj_char_span": [151, 160], "rel_type": "sensitivity", "sbj_tok_span": [19, 22], "obj_tok_span": [37, 41]}, {"subject": "G13D", "object": "cetuximab", "sbj_char_span": [104, 108], "obj_char_span": [151, 160], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 29], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Di Nicolantonio et al. ( ) also demonstrated that introduction of the BRAF V600E allele could confer resistance to either cetuximab or panitumumab in wild-type BRAF colorectal cancer cells .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [122, 131], "tok_span": [27, 31]}, {"name": "V600E", "ent_type": "variant", "char_span": [75, 80], "tok_span": [18, 21]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [75, 80], "obj_char_span": [122, 131], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Loupakis et al. analyzed 87 patients with KRAS WT tumors for the BRAF V600E mutation who were receiving irinotecan and cetuximab for refractory metastatic CRC .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [119, 128], "tok_span": [30, 34]}, {"name": "V600E", "ent_type": "variant", "char_span": [70, 75], "tok_span": [18, 21]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [70, 75], "obj_char_span": [119, 128], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "While almost all of the known K-RAS mutations at codons 12 are associated with lack of benefit from cetuximab or panitumumab , a specific mutation at codon 13 , i.e. , G13D may be an exception .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [100, 109], "tok_span": [20, 24]}, {"name": "G13D", "ent_type": "variant", "char_span": [168, 172], "tok_span": [41, 44]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [168, 172], "obj_char_span": [100, 109], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 44], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Thus , in two trials , administration of cetuximab to patients with this mutation was associated with a significantly better outcome than that seen in patients with other types of K-RAS mutations. , Indeed , patients with the G13D mutation appeared to benefit to approximately the same extent as patients with K-RAS wild-type tumors from the addition of cetuximab to first-line chemotherapy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [41, 50], "tok_span": [8, 12]}, {"name": "G13D", "ent_type": "variant", "char_span": [226, 230], "tok_span": [44, 47]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [354, 363], "tok_span": [70, 74]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [226, 230], "obj_char_span": [41, 50], "rel_type": "resistance or non-response", "sbj_tok_span": [44, 47], "obj_tok_span": [8, 12]}, {"subject": "G13D", "object": "cetuximab", "sbj_char_span": [226, 230], "obj_char_span": [354, 363], "rel_type": "resistance or non-response", "sbj_tok_span": [44, 47], "obj_tok_span": [70, 74]}], "umls_entity_list": []}, {"text": "Patients with the G13D mutation may however , benefit from combined cetuximab and chemotherapy but this remains to be confirmed .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [68, 77], "tok_span": [13, 17]}, {"name": "G13D", "ent_type": "variant", "char_span": [18, 22], "tok_span": [3, 6]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [18, 22], "obj_char_span": [68, 77], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 6], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Intermittent , high-dose afatinib ( NCT01647711 ) I Must have known T790M mutation 2nd/3rd line after progression on 1st-generation EGFR-TKI Afatinib at pulsatile , high doses MTD None , trial ongoing Afatinib + cetuximab ( NCT01090011 ) lb/II Not required 2nd/3rd line after progression on 1st-generation EGFR-TKI Afatinib + biweekly cetuximab DLT Janjigian et al", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [212, 221], "tok_span": [61, 65]}, {"name": "T790M", "ent_type": "variant", "char_span": [68, 73], "tok_span": [22, 26]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [335, 344], "tok_span": [100, 104]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [68, 73], "obj_char_span": [212, 221], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [61, 65]}, {"subject": "T790M", "object": "cetuximab", "sbj_char_span": [68, 73], "obj_char_span": [335, 344], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [100, 104]}], "umls_entity_list": []}, {"text": "In an abstract recently published in the 2011 ASCO Annual Meeting Proceedings , Tejpar et al. retrospectively analyzed the influence of KRAS G13D mutations on the efficacy of treatment with cetuximab as the first-line systemic therapy and compared it with the pooled results of randomized studies CRYSTAL and OPUS .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [190, 199], "tok_span": [37, 41]}, {"name": "G13D", "ent_type": "variant", "char_span": [141, 145], "tok_span": [27, 30]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [141, 145], "obj_char_span": [190, 199], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 30], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "While it has been proven that cetuximab is not active in patients bearing KRAS mutant tumours , even if a recent analysis suggests that this could not be true for G13D mutations , up today there are no predictive biomarkers of bevacizumab efficacy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [30, 39], "tok_span": [6, 10]}, {"name": "G13D", "ent_type": "variant", "char_span": [163, 167], "tok_span": [34, 37]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [163, 167], "obj_char_span": [30, 39], "rel_type": "resistance or non-response", "sbj_tok_span": [34, 37], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "In this study , we engineer the T670I mutation into the mouse c-kit locus , an allele originally identified in GIST patients with refractory responses to imatinib , and bred the strain onto the NOD background to generate imatinib-resistant c-Kit mice that develop T1D .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [154, 162], "tok_span": [32, 34]}, {"name": "T670I", "ent_type": "variant", "char_span": [32, 37], "tok_span": [7, 11]}, {"name": "imatinib-resistant", "ent_type": "drug", "char_span": [221, 239], "tok_span": [46, 50]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [32, 37], "obj_char_span": [154, 162], "rel_type": "resistance", "sbj_tok_span": [7, 11], "obj_tok_span": [32, 34]}, {"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [32, 37], "obj_char_span": [221, 239], "rel_type": "resistance", "sbj_tok_span": [7, 11], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "We characterize the imatinib response of diabetic NOD mice expressing wild-type or T670I mutant c-kit alleles and ask whether inhibition of c-Kit is required for efficacy of imatinib in this model .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [20, 28], "tok_span": [3, 5]}, {"name": "T670I", "ent_type": "variant", "char_span": [83, 88], "tok_span": [15, 19]}, {"name": "imatinib", "ent_type": "drug", "char_span": [174, 182], "tok_span": [37, 39]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [83, 88], "obj_char_span": [20, 28], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [3, 5]}, {"subject": "T670I", "object": "imatinib", "sbj_char_span": [83, 88], "obj_char_span": [174, 182], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "The T670I allele of c-Kit is a mutation originally identified in GIST patients with refractory responses to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [108, 116], "tok_span": [23, 25]}, {"name": "T670I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [4, 9], "obj_char_span": [108, 116], "rel_type": "resistance", "sbj_tok_span": [1, 5], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "To develop imatinib-resistant c-Kit NOD mice , we generated mice that carried the c-kit T670I mutation ( ) , and then bred this allele onto the NOD background for 10 generations and until known genomic insulin dependent diabetes (Idd) loci were fixed .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [11, 29], "tok_span": [2, 6]}, {"name": "T670I", "ent_type": "variant", "char_span": [88, 93], "tok_span": [21, 25]}], "relation_list": [{"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [88, 93], "obj_char_span": [11, 29], "rel_type": "resistance", "sbj_tok_span": [21, 25], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Henceforth , mice homozygous for the T670I allele will be referred to as NOD .c-KitT670I mice , while control littermates homozygous for the wild-type allele will be referred to as NOD .c-Kitwt mice . 10.1371/journal.pone.0084900.g001NOD.c-KitT670I mice are imatinib resistant and develop diabetes .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [258, 266], "tok_span": [81, 83]}, {"name": "T670I", "ent_type": "variant", "char_span": [37, 42], "tok_span": [7, 11]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [37, 42], "obj_char_span": [258, 266], "rel_type": "resistance", "sbj_tok_span": [7, 11], "obj_tok_span": [81, 83]}], "umls_entity_list": []}, {"text": "Approximately 5 % to 7 % of GIST harbour oncogenic mutations in PDGFRA , typically in the juxtamembrane domain ( exon 12 ) or activation loop ( exon 18 ) ; the D842V substitution in exon 18 , is highly resistant to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [215, 223], "tok_span": [52, 54]}, {"name": "D842V", "ent_type": "variant", "char_span": [160, 165], "tok_span": [39, 43]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [160, 165], "obj_char_span": [215, 223], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [52, 54]}], "umls_entity_list": []}, {"text": "The second-line treatment , after imatinib failure , is provided by less specific kinase inhibitors , such as sunitinib that shows potency against imatinib-resistant KIT mutated in the ATP binding pocket ( V654A and T670I ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [34, 42], "tok_span": [7, 9]}, {"name": "V654A", "ent_type": "variant", "char_span": [206, 211], "tok_span": [41, 45]}, {"name": "imatinib-resistant", "ent_type": "drug", "char_span": [147, 165], "tok_span": [28, 32]}, {"name": "T670I", "ent_type": "variant", "char_span": [216, 221], "tok_span": [46, 50]}], "relation_list": [{"subject": "V654A", "object": "imatinib", "sbj_char_span": [206, 211], "obj_char_span": [34, 42], "rel_type": "resistance", "sbj_tok_span": [41, 45], "obj_tok_span": [7, 9]}, {"subject": "V654A", "object": "imatinib-resistant", "sbj_char_span": [206, 211], "obj_char_span": [147, 165], "rel_type": "resistance", "sbj_tok_span": [41, 45], "obj_tok_span": [28, 32]}, {"subject": "T670I", "object": "imatinib", "sbj_char_span": [216, 221], "obj_char_span": [34, 42], "rel_type": "resistance", "sbj_tok_span": [46, 50], "obj_tok_span": [7, 9]}, {"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [216, 221], "obj_char_span": [147, 165], "rel_type": "resistance", "sbj_tok_span": [46, 50], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and KIT ( T670I ) that confer resistance to imatinib ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors . ", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [251, 259], "tok_span": [58, 60]}, {"name": "T670I", "ent_type": "variant", "char_span": [217, 222], "tok_span": [49, 53]}, {"name": "Gleevec", "ent_type": "drug", "char_span": [262, 269], "tok_span": [61, 64]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [217, 222], "obj_char_span": [251, 259], "rel_type": "resistance", "sbj_tok_span": [49, 53], "obj_tok_span": [58, 60]}, {"subject": "T670I", "object": "Gleevec", "sbj_char_span": [217, 222], "obj_char_span": [262, 269], "rel_type": "resistance", "sbj_tok_span": [49, 53], "obj_tok_span": [61, 64]}], "umls_entity_list": []}, {"text": "Further , although approximately 70 % of c-Kit mutations in melanoma and GIST occur in exon 11 , there is a preponderance of the activating L576P , exon 11 variant in melanoma ( ~34 % of c-Kit mutations ) and this mutation shows poor imatinib sensitivity in GIST , and variable sensitivity in melanoma . ", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [234, 242], "tok_span": [55, 57]}, {"name": "L576P", "ent_type": "variant", "char_span": [140, 145], "tok_span": [30, 34]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [140, 145], "obj_char_span": [234, 242], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [55, 57]}], "umls_entity_list": []}, {"text": "Cells with an A829P c-Kit mutation are resistant to imatinib but are still sensitive to the tyrosine kinase inhibitors nilotinib and dasatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [52, 60], "tok_span": [14, 16]}, {"name": "A829P", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "A829P", "object": "imatinib", "sbj_char_span": [14, 19], "obj_char_span": [52, 60], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Additionally , the T670I c-Kit mutation mediates resistance to imatinib , nilotinib , and dasatinib but remains sensitive to sunitinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [63, 71], "tok_span": [14, 16]}, {"name": "T670I", "ent_type": "variant", "char_span": [19, 24], "tok_span": [3, 7]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [19, 24], "obj_char_span": [63, 71], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "In vitro analyses identified three point mutations , L755S , L755P , and T798M to confer resistance to lapatinib ( Kancha et al. , ) .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [103, 112], "tok_span": [27, 30]}, {"name": "L755S", "ent_type": "variant", "char_span": [53, 58], "tok_span": [8, 12]}], "relation_list": [{"subject": "L755S", "object": "lapatinib", "sbj_char_span": [53, 58], "obj_char_span": [103, 112], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 12], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": ", Concerning PDGFRA mutations , concordant in vitro data and clinical results support that the D842V substitution and other mutations within the kinase domain activation loop ( exon 18 ) are predictive of primary resistance to imatinib , whereas it is efficient in cases of juxtamembrane domain mutations. , ,", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [227, 235], "tok_span": [41, 43]}, {"name": "D842V", "ent_type": "variant", "char_span": [95, 100], "tok_span": [17, 21]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [95, 100], "obj_char_span": [227, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [41, 43]}], "umls_entity_list": []}, {"text": "In short , almost all GIST with exon 11 mutations responded to imatinib , patients with exon 9 mutations should receive a 800 mg daily dose of imatinib , and D842V PDGFRA mutation is predictive of primary resistance .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [63, 71], "tok_span": [13, 15]}, {"name": "D842V", "ent_type": "variant", "char_span": [158, 163], "tok_span": [33, 37]}, {"name": "imatinib", "ent_type": "drug", "char_span": [143, 151], "tok_span": [29, 31]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [158, 163], "obj_char_span": [63, 71], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [13, 15]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [158, 163], "obj_char_span": [143, 151], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Some PDGFRA mutant GISTs show at least partial response to imatinib ; however , the most common PDGFRA mutation in GISTs ( D842V ) confers a complete resistance to the drug. , In KIT mutant GISTs , a mutation in exon 11 was associated with a higher response rate ( 67 % –83 % ) than a mutation in exon 9 ( 35 % –48 % ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [59, 67], "tok_span": [12, 14]}, {"name": "D842V", "ent_type": "variant", "char_span": [123, 128], "tok_span": [27, 31]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [123, 128], "obj_char_span": [59, 67], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Histology Immunohistochemistry Mutations KIT CD34 S100 SMA Desmin Gene Site 15 Spindle Positive + - - - C-kit Exon11 , MS 16 Spindle Positive + - - - C-kit Exon11 , IFD 17 Spindle Positive + - - - C-kit Exon11 , MS 18 Spindle Positive + - - - C-kit Exon11 , MS 19 Spindle Positive + - Weak - C-kit Exon11 , IFD 22 Myxoid epithelioid Weak + - + - PDGFRA Exon18 del D842V 23 Epithelioid Weak - - - - PDGFRA Exon18 DIMH842-845 26 Epithelioid Weak + NA NA NA PDGFRA Exon18 28 Myxoid epithelioid Weak + - - - PDGFRA Exon12 , V561D MS : miss sense , IFD : in-frame deletion , NA : not available Because of possible relapse even after complete resection of omental GISTs and the objective response rate of 67 % of Imatinib to the mutation in PDGFRA exon 12 , our patient received daily oral administration of 300 mg Glevec® , ( we applied 15 % reduced dose , referring to a report by Cormier , et al. after took account of a smaller average of Japanese build than American ) .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [707, 715], "tok_span": [216, 218]}, {"name": "D842V", "ent_type": "variant", "char_span": [364, 369], "tok_span": [116, 120]}], "relation_list": [{"subject": "D842V", "object": "Imatinib", "sbj_char_span": [364, 369], "obj_char_span": [707, 715], "rel_type": "resistance or non-response", "sbj_tok_span": [116, 120], "obj_tok_span": [216, 218]}], "umls_entity_list": []}, {"text": "Panitumumab can still bind to an EGFR mutant S492R to which cetuximab can not bind to .", "entity_list": [{"name": "Panitumumab", "ent_type": "drug", "char_span": [0, 11], "tok_span": [0, 3]}, {"name": "S492R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "S492R", "object": "Panitumumab", "sbj_char_span": [45, 50], "obj_char_span": [0, 11], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Similarly , a patient developed resistance to crizotinib after 5 months of treatment and molecular analyses revealed the resistant tumor harbored two acquired but independent mutations within the kinase domain of EML4-ALK , C1156Y , and the gatekeeper mutation L1196M .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [46, 56], "tok_span": [7, 11]}, {"name": "L1196M", "ent_type": "variant", "char_span": [261, 267], "tok_span": [53, 57]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [224, 230], "tok_span": [42, 46]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [261, 267], "obj_char_span": [46, 56], "rel_type": "resistance", "sbj_tok_span": [53, 57], "obj_tok_span": [7, 11]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [224, 230], "obj_char_span": [46, 56], "rel_type": "resistance", "sbj_tok_span": [42, 46], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "In vitro assays have also identified the L1196M gatekeeper mutation to be the major mechanism of resistance to crizotinib .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [111, 121], "tok_span": [23, 27]}, {"name": "L1196M", "ent_type": "variant", "char_span": [41, 47], "tok_span": [7, 11]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [41, 47], "obj_char_span": [111, 121], "rel_type": "resistance", "sbj_tok_span": [7, 11], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "In light of the identification of the gatekeeper mutation before crizotinib is approved , many “second-generation” ALK inhibitors are now or soon to be entered into early clinical development to try to overcome crizotinib resistance , especially the L1196M gatekeeper mutation .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [65, 75], "tok_span": [12, 16]}, {"name": "the L1196M", "ent_type": "variant", "char_span": [246, 256], "tok_span": [50, 55]}, {"name": "overcome crizotinib", "ent_type": "drug", "char_span": [202, 221], "tok_span": [42, 47]}], "relation_list": [{"subject": "the L1196M", "object": "crizotinib", "sbj_char_span": [246, 256], "obj_char_span": [65, 75], "rel_type": "resistance", "sbj_tok_span": [50, 55], "obj_tok_span": [12, 16]}, {"subject": "the L1196M", "object": "overcome crizotinib", "sbj_char_span": [246, 256], "obj_char_span": [202, 221], "rel_type": "resistance", "sbj_tok_span": [50, 55], "obj_tok_span": [42, 47]}], "umls_entity_list": []}, {"text": "Of note , AP26113 is not only ten times more active than crizotinib in inhibiting wild-type ALK but is a hundred times more potent than crizotinib in inhibiting the L1196M gatekeeper mutation .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [57, 67], "tok_span": [14, 18]}, {"name": "L1196M", "ent_type": "variant", "char_span": [165, 171], "tok_span": [40, 44]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [136, 146], "tok_span": [33, 37]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [165, 171], "obj_char_span": [57, 67], "rel_type": "resistance", "sbj_tok_span": [40, 44], "obj_tok_span": [14, 18]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [165, 171], "obj_char_span": [136, 146], "rel_type": "resistance", "sbj_tok_span": [40, 44], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "However , to date , the number of patients reported with identified resistance mechanisms to crizotinib remains extremely small ( less than four so far ) and therefore it is premature to say that the L1196M gate-keeper mutation will be the most important mechanism of acquired resistance to crizotinib than other mechanisms that can bypass the ALK signaling pathway .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [93, 103], "tok_span": [15, 19]}, {"name": "L1196M", "ent_type": "variant", "char_span": [200, 206], "tok_span": [38, 42]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [291, 301], "tok_span": [57, 61]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [200, 206], "obj_char_span": [93, 103], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [15, 19]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [200, 206], "obj_char_span": [291, 301], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [57, 61]}], "umls_entity_list": []}, {"text": "Most importantly , Hsp90 inhibitors lead to cell death in both crizotinib-sensitive and crizotinib-resistant ALK dependent cell lines , , including NSCLC cell lines harboring the ALK L1196M gatekeeper mutation which provides another alternate pathway to overcome resistance to crizotinib .", "entity_list": [{"name": "crizotinib-sensitive", "ent_type": "drug", "char_span": [63, 83], "tok_span": [12, 18]}, {"name": "L1196M", "ent_type": "variant", "char_span": [183, 189], "tok_span": [40, 44]}, {"name": "crizotinib-resistant", "ent_type": "drug", "char_span": [88, 108], "tok_span": [19, 25]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [277, 287], "tok_span": [57, 61]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib-sensitive", "sbj_char_span": [183, 189], "obj_char_span": [63, 83], "rel_type": "resistance", "sbj_tok_span": [40, 44], "obj_tok_span": [12, 18]}, {"subject": "L1196M", "object": "crizotinib-resistant", "sbj_char_span": [183, 189], "obj_char_span": [88, 108], "rel_type": "resistance", "sbj_tok_span": [40, 44], "obj_tok_span": [19, 25]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [183, 189], "obj_char_span": [277, 287], "rel_type": "resistance", "sbj_tok_span": [40, 44], "obj_tok_span": [57, 61]}], "umls_entity_list": []}, {"text": "Comparison of Ki between crizotinib and AP26113 for wild-type ALK and ALK with LII96M gate-keeper mutation Ki ( nM ) ALK wild-type ALK ( L1196M )", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [25, 35], "tok_span": [4, 8]}, {"name": "L1196M", "ent_type": "variant", "char_span": [137, 143], "tok_span": [43, 47]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [137, 143], "obj_char_span": [25, 35], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "A recent report of a G2032R mutation in the ROS1 TK domain leading to crizotinib resistance has also been identified ( ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [70, 80], "tok_span": [18, 22]}, {"name": "G2032R", "ent_type": "variant", "char_span": [21, 27], "tok_span": [5, 9]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [21, 27], "obj_char_span": [70, 80], "rel_type": "resistance", "sbj_tok_span": [5, 9], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Drug Company Activity against Activity against Ongoing trials Study phase Previous treatment other kinases L1196M mutation LDK378 ( ceritinib ) Novartis IFG-1R Yes NCT01772797 Phase I None c-MET NCT02040870 Phase I/II Crizotinib/chemotherapy NCT01685138 Phase II 0-3 lines of chemotherapy NCT01685060 Phase II Crizotinib or 1-3 lines of chemotherapy NCT01947608 Phase II Crizotinib NCT01964157 Phase II 1 line of chemotherapy NCT01828099 Phase III None NCT01828112 Phase III Crizotinib", "entity_list": [{"name": "Crizotinib/chemotherapy", "ent_type": "drug", "char_span": [218, 241], "tok_span": [60, 66]}, {"name": "L1196M", "ent_type": "variant", "char_span": [107, 113], "tok_span": [15, 19]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [310, 320], "tok_span": [87, 91]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [371, 381], "tok_span": [106, 110]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [475, 485], "tok_span": [138, 142]}], "relation_list": [{"subject": "L1196M", "object": "Crizotinib/chemotherapy", "sbj_char_span": [107, 113], "obj_char_span": [218, 241], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [60, 66]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [310, 320], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [87, 91]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [371, 381], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [106, 110]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [475, 485], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [138, 142]}], "umls_entity_list": []}, {"text": "The effect of the C1156Y mutation is unclear , although it may have an indirect effect on crizotinib binding , and further studies will be required to establish its mechanism . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [90, 100], "tok_span": [20, 24]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [18, 24], "tok_span": [4, 8]}], "relation_list": [{"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [18, 24], "obj_char_span": [90, 100], "rel_type": "resistance", "sbj_tok_span": [4, 8], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "One of these is AP26113 from Ariad , which inhibits the growth of crizotinib-resistant H3122 cell lines and xenograft mouse models that carry the L1196M EML4–ALK mutation ( ) .", "entity_list": [{"name": "crizotinib-resistant", "ent_type": "drug", "char_span": [66, 86], "tok_span": [17, 23]}, {"name": "L1196M", "ent_type": "variant", "char_span": [146, 152], "tok_span": [36, 40]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib-resistant", "sbj_char_span": [146, 152], "obj_char_span": [66, 86], "rel_type": "resistance", "sbj_tok_span": [36, 40], "obj_tok_span": [17, 23]}], "umls_entity_list": []}, {"text": "Other compounds , such as the Hsp90-inhibitor geldenamycin derivatives IPI-504 and 17-AAG , appear to have effects in NSCLC patients with ALK translocations , and this effect appears to extend to ELM4–ALK ( L1196M ) suggesting they may be useful in overcoming crizotinib-resistant tumors .", "entity_list": [{"name": "overcoming crizotinib-resistant", "ent_type": "drug", "char_span": [249, 280], "tok_span": [63, 71]}, {"name": "( L1196M", "ent_type": "variant", "char_span": [205, 213], "tok_span": [51, 56]}], "relation_list": [{"subject": "( L1196M", "object": "overcoming crizotinib-resistant", "sbj_char_span": [205, 213], "obj_char_span": [249, 280], "rel_type": "resistance", "sbj_tok_span": [51, 56], "obj_tok_span": [63, 71]}], "umls_entity_list": []}, {"text": "Overall , this pooled analysis confirmed that first-line afatinib significantly improved OS in patients with advanced NSCLC harboring common EGFR mutations ( Del19 and L858R ) compared with standard chemotherapy .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [57, 65], "tok_span": [10, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [168, 173], "tok_span": [28, 32]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [168, 173], "obj_char_span": [57, 65], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "This review details strategies pursued in circumventing T790M mediated drug resistance to EGFR inhibitors , which is the most common mechanism of acquired resistance , and focuses on the clinical development of second-generation EGFR inhibitors , and in particular afatinib ( BIBW2992 ; Boehringer Ingelheim ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [265, 273], "tok_span": [45, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [56, 61], "tok_span": [8, 12]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [56, 61], "obj_char_span": [265, 273], "rel_type": "response", "sbj_tok_span": [8, 12], "obj_tok_span": [45, 47]}], "umls_entity_list": []}, {"text": "Importantly , preclinical studies suggest that afatinib is more active than first-generation EGFR inhibitors in NSCLC cell lines harboring T790M mutations , whereas in vivo studies have shown the antitumor efficacy of afatinib in EGFR L858R/T790M double-mutant cancers .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [47, 55], "tok_span": [6, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [139, 144], "tok_span": [22, 26]}, {"name": "afatinib", "ent_type": "drug", "char_span": [218, 226], "tok_span": [38, 40]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [139, 144], "obj_char_span": [47, 55], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [6, 8]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [139, 144], "obj_char_span": [218, 226], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [38, 40]}], "umls_entity_list": []}, {"text": "There were , however , no translational studies reported from this trial to validate the activity of afatinib in patients harboring the EGFR T790M allele .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [101, 109], "tok_span": [17, 19]}, {"name": "T790M", "ent_type": "variant", "char_span": [141, 146], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [141, 146], "obj_char_span": [101, 109], "rel_type": "response", "sbj_tok_span": [24, 28], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "These second-generation EGFR inhibitors have also been shown to drive drug resistance through the acquisition of T790M in both preclinical and clinical settings , suggesting low potency against T790M. , As a potential solution , afatinib was combined with the EGFR antibody cetuximab in a Phase IIB study , which demonstrated an impressive response rate of 32 % in patients with EGFR mutant lung cancers resistant to first-generation EGFR inhibitors .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [229, 237], "tok_span": [44, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [113, 118], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [113, 118], "obj_char_span": [229, 237], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "Afatinib ( BIBW 2992 , Boehringer Ingelheim GmbH ) , an irreversible dual inhibitor of EGFR and HER2 kinases , retains some activity in tumors with T790M mutations although at doses that are a log higher than what is needed for cancers with only a sensitizing mutation .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "T790M", "ent_type": "variant", "char_span": [148, 153], "tok_span": [34, 38]}, {"name": "BIBW 2992", "ent_type": "drug", "char_span": [11, 20], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "Afatinib", "sbj_char_span": [148, 153], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [34, 38], "obj_tok_span": [0, 2]}, {"subject": "T790M", "object": "BIBW 2992", "sbj_char_span": [148, 153], "obj_char_span": [11, 20], "rel_type": "response", "sbj_tok_span": [34, 38], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Recently , the addition of cetuximab to afatinib has yielded impressive results in the treatment of EGFR reversible TKI resistant lung cancer due to T790M mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [40, 48], "tok_span": [10, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [149, 154], "tok_span": [29, 33]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [149, 154], "obj_char_span": [40, 48], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Afatinib was more potent than gefitinib , erlotinib , and lapatinib in inducing the cell death of NSCLC cell lines , including those harboring wild-type EGFR , and the erlotinib-resistant T790M mutation .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "T790M", "ent_type": "variant", "char_span": [188, 193], "tok_span": [46, 50]}], "relation_list": [{"subject": "T790M", "object": "Afatinib", "sbj_char_span": [188, 193], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [46, 50], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The combination of afatinib and cetuximab can even overcome resistance due to the T790M mutation both preclinically as well as clinically .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [19, 27], "tok_span": [3, 5]}, {"name": "T790M", "ent_type": "variant", "char_span": [82, 87], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [82, 87], "obj_char_span": [19, 27], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Based on the clinical data of achievable plasma concentrations of continuous daily dosing of neratinib , dacomitinib and afatinib , it is thought that primary resistance to these agents will still be encountered for the EGFR T790M mutation as well as exon 20 insertions and clinical trial results thus far with the second-generation EGFR TKIs had generally supported this prediction with few exceptions ( see below ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [121, 129], "tok_span": [24, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [225, 230], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [225, 230], "obj_char_span": [121, 129], "rel_type": "response", "sbj_tok_span": [43, 47], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Thus , an alternate schedule of drug administration , such as intermittent or pulse high-dose therapy using afatinib to determine its activity against T790M ( NCT01647711 ) , is under investigation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [108, 116], "tok_span": [19, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [151, 156], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [151, 156], "obj_char_span": [108, 116], "rel_type": "response", "sbj_tok_span": [26, 30], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Although afatinib and dacomitinib have been introduced to overcome acquired resistance , they showed limited efficacy in NSCLC with T790M and were more than 100-fold less potent in NSCLC cells with EGFR T790M mutation than in NSCLC cells with EGFR activating mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [9, 17], "tok_span": [1, 3]}, {"name": "T790M", "ent_type": "variant", "char_span": [132, 137], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [132, 137], "obj_char_span": [9, 17], "rel_type": "response", "sbj_tok_span": [23, 27], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Due to their ability to potently inhibit EGFR , both afatinib and neratinib have been assessed in lung cancer that has become resistant to gefitinib and erlotinib due to the T790M point mutation in the kinase domain .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [53, 61], "tok_span": [11, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [174, 179], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [174, 179], "obj_char_span": [53, 61], "rel_type": "response", "sbj_tok_span": [41, 45], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "The new therapy methods , which could be effective in patients with T790M mutation includes irreversible EGFR-TKIs ( afatinib , neratinib ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [117, 125], "tok_span": [24, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [68, 73], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [68, 73], "obj_char_span": [117, 125], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Wu YL ( 2014 ) LUXLUNG6 ( III ) Afatinib 40 mg/d , po Gemcitabine 1000 mg/m2 , d1,8 , iv , q3w + 19 186 ( 124/62 ) 0.20 ( 0.13–0.33 ) cisplatin 75 mg/m2 , d1 , iv , q3w×≤6 cycles 21 138 ( 92/46 ) 0.32 ( 0.19–0.52 ) Exon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [32, 40], "tok_span": [13, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [278, 283], "tok_span": [111, 115]}], "relation_list": [{"subject": "L858R", "object": "Afatinib", "sbj_char_span": [278, 283], "obj_char_span": [32, 40], "rel_type": "sensitivity", "sbj_tok_span": [111, 115], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "AST1306 could potently inhibit the EGFR T790M mutant , exhibiting an IC50 value of 12 ± 2 nmol/L , which is similar to afatinib ( 10 nmol/L ) and approximately 500-fold more potent than lapatinib .", "entity_list": [{"name": "to afatinib", "ent_type": "drug", "char_span": [116, 127], "tok_span": [31, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [40, 45], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "to afatinib", "sbj_char_span": [40, 45], "obj_char_span": [116, 127], "rel_type": "response", "sbj_tok_span": [9, 13], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "EGFR mutation positive NSCLCs which also test positive for mutations associated with primary or , most frequently , secondary resistance to first-generation TKIs ( first of all the T790M substitution ) may respond better to newer agents like afatinib , and dacomitinib , which have demonstrated a greater effectiveness in these clinical situations , but more clinical data are required , ,- .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [242, 250], "tok_span": [45, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [181, 186], "tok_span": [32, 36]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [181, 186], "obj_char_span": [242, 250], "rel_type": "response", "sbj_tok_span": [32, 36], "obj_tok_span": [45, 47]}], "umls_entity_list": []}, {"text": "One approach to circumvent T790M mediated resistance has been the use of irreversible small molecule inhibitors such as afatinib , which has demonstrated activity against T790M mutant cells and tumors in preclinical models .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [120, 128], "tok_span": [21, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [27, 32], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [27, 32], "obj_char_span": [120, 128], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "What is remarkable is that the H1975 cell line harbors the T790M and L858R mutations in the HER1 gene ( information obtained from the Sanger Institute website ) , which confer resistance to HER1 kinase inhibitors , Gefitinib and Erlotinib , responded to the irreversible HER1 kinase inhibitor BIBW-2992 .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [293, 302], "tok_span": [65, 70]}, {"name": "L858R", "ent_type": "variant", "char_span": [69, 74], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "BIBW-2992", "sbj_char_span": [69, 74], "obj_char_span": [293, 302], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [65, 70]}, {"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [59, 64], "obj_char_span": [293, 302], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [65, 70]}], "umls_entity_list": []}, {"text": "Moreover , the irreversible HER1/2 kinase inhibitor , BIBW-2992 , was also able to potently inhibit the growth of the H1975 cell line , which harbored the T790M and L858R mutations in the HER1 gene and thus rendering the cells resistant to Gefitinib and Lapatinib treatment .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [54, 63], "tok_span": [11, 16]}, {"name": "L858R", "ent_type": "variant", "char_span": [165, 170], "tok_span": [43, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [155, 160], "tok_span": [38, 42]}], "relation_list": [{"subject": "L858R", "object": "BIBW-2992", "sbj_char_span": [165, 170], "obj_char_span": [54, 63], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [11, 16]}, {"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [155, 160], "obj_char_span": [54, 63], "rel_type": "response", "sbj_tok_span": [38, 42], "obj_tok_span": [11, 16]}], "umls_entity_list": []}, {"text": "KIT W557R V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "entity_list": [{"name": "Dasatinib", "ent_type": "drug", "char_span": [117, 126], "tok_span": [51, 53]}, {"name": "L576P", "ent_type": "variant", "char_span": [18, 23], "tok_span": [12, 16]}], "relation_list": [{"subject": "L576P", "object": "Dasatinib", "sbj_char_span": [18, 23], "obj_char_span": [117, 126], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [51, 53]}], "umls_entity_list": []}, {"text": "Ponatinib ( AP24534 ) , a third generation pan-BCR-ABL kinase inhibitor generated from the structure guided drug design strategy , is able to inhibit native BCR-ABL kinase , most of the clinically relevant mutants including T315I mutation .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [224, 229], "tok_span": [47, 51]}, {"name": "AP24534", "ent_type": "drug", "char_span": [12, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [224, 229], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [47, 51], "obj_tok_span": [0, 2]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [224, 229], "obj_char_span": [12, 19], "rel_type": "response", "sbj_tok_span": [47, 51], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "The calculated free energies correlate with experimentally measured IC50 values and comparably ponatinib has better binding towards the mutation T315A ( −10.44 kcal/mol ) than T315I ( −10.35 kcal/mol ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [14, 18]}, {"name": "than T315I", "ent_type": "variant", "char_span": [171, 181], "tok_span": [37, 42]}], "relation_list": [{"subject": "than T315I", "object": "ponatinib", "sbj_char_span": [171, 181], "obj_char_span": [95, 104], "rel_type": "response", "sbj_tok_span": [37, 42], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "The free energy of BCR-ABLT315I complexed with imatinib is −9.89 kcal/mol indicating that ponatinib has higher binding towards T315I mutation compared to imatinib .", "entity_list": [{"name": "that ponatinib", "ent_type": "drug", "char_span": [85, 99], "tok_span": [25, 30]}, {"name": "towards T315I", "ent_type": "variant", "char_span": [119, 132], "tok_span": [33, 38]}], "relation_list": [{"subject": "towards T315I", "object": "that ponatinib", "sbj_char_span": [119, 132], "obj_char_span": [85, 99], "rel_type": "response", "sbj_tok_span": [33, 38], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "Figure shows clearly that T315I affinity for ponatinib analogs vary according to variations in their hydrophobic binding interactions .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [45, 54], "tok_span": [10, 14]}, {"name": "T315I", "ent_type": "variant", "char_span": [26, 31], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [26, 31], "obj_char_span": [45, 54], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Recently , in vitro and animal data supported that several novel tyrosine kinase inhibitors including ( but not limited ) AP24534 ( ponatinib ) and DCC-2036 have been demonstrated effective against T315I Bcr-Abl .", "entity_list": [{"name": "AP24534", "ent_type": "drug", "char_span": [122, 129], "tok_span": [20, 24]}, {"name": "T315I", "ent_type": "variant", "char_span": [198, 203], "tok_span": [41, 45]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [132, 141], "tok_span": [25, 29]}], "relation_list": [{"subject": "T315I", "object": "AP24534", "sbj_char_span": [198, 203], "obj_char_span": [122, 129], "rel_type": "response", "sbj_tok_span": [41, 45], "obj_tok_span": [20, 24]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [198, 203], "obj_char_span": [132, 141], "rel_type": "response", "sbj_tok_span": [41, 45], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "It has been speculated that a growing selection pressure in TKI treatment will promote the appearance of T315I mutations.– Novel compounds such as the aurora kinase inhibitors – including danusertib ( formerly PHA-739358 ) , homoharringtonine , and ponatinib – successfully target the T315I mutation .", "entity_list": [{"name": "and ponatinib", "ent_type": "drug", "char_span": [245, 258], "tok_span": [58, 63]}, {"name": "T315I", "ent_type": "variant", "char_span": [105, 110], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "and ponatinib", "sbj_char_span": [105, 110], "obj_char_span": [245, 258], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [58, 63]}], "umls_entity_list": []}, {"text": "Most convincingly , ponatinib demonstrated high efficacy independently of mutational status ( including the highly resistant T315I mutation ) in a Phase II clinical trial with heavily pretreated CP- , AP- , and BC-CML patients as well as patients with Philadelphia chromosome positive acute lymphoblastic leukemia .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [20, 29], "tok_span": [4, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [125, 130], "tok_span": [21, 25]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [125, 130], "obj_char_span": [20, 29], "rel_type": "response", "sbj_tok_span": [21, 25], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Aggoune et al demonstrated that T315I mutants need either compound mutations such as E255K/T315I or a stromal niche to escape from the toxicity of ponatinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [147, 156], "tok_span": [36, 40]}, {"name": "T315I", "ent_type": "variant", "char_span": [32, 37], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [32, 37], "obj_char_span": [147, 156], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "For patients with mutations such as T315I which is known to confer resistance to all TKIs currently approved for first-line treatment of CML , one of the newer agents such as ponatinib ( AP24534 ) which is effective against this mutation and very recently been approved by FDA for TKI-resistant CML , or allogeneic transplantation must be considered .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [175, 184], "tok_span": [37, 41]}, {"name": "T315I", "ent_type": "variant", "char_span": [36, 41], "tok_span": [6, 10]}, {"name": "AP24534", "ent_type": "drug", "char_span": [187, 194], "tok_span": [42, 46]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [36, 41], "obj_char_span": [175, 184], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [37, 41]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [36, 41], "obj_char_span": [187, 194], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "As the T315I mutation is resistant to first and second-generation TKIs , there has been an emerging focus on the effects of the novel third-generation TKI , ponatinib , which has efficacy against the T315I mutant form of BCR-ABL , .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [157, 166], "tok_span": [36, 40]}, {"name": "T315I", "ent_type": "variant", "char_span": [7, 12], "tok_span": [2, 6]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [7, 12], "obj_char_span": [157, 166], "rel_type": "response", "sbj_tok_span": [2, 6], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "Ponatinib is highly active in patients with Ph-positive leukemias , including those with BCR-ABL T315I mutations .", "entity_list": [{"name": "T315I", "ent_type": "variant", "char_span": [97, 102], "tok_span": [21, 25]}, {"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [97, 102], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [21, 25], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The T315I gatekeeper mutation has been the most elusive thus far , and ponatinib is the only effective TKI in patients with this mutation. , The differences between each TKI are fairly clear ; nonetheless , physicians face challenges when choosing which TKI is best for any particular patient .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [19, 23]}, {"name": "T315I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [4, 9], "obj_char_span": [71, 80], "rel_type": "response", "sbj_tok_span": [1, 5], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "It is conceivable that the development of third-generation TKIs such as ponatinib will take care of mutation related resistance , as ponatinib potently inhibits the most feared T315I “gatekeeper” mutation , the single mutation that has sounded the death knell for all treatment options based on TKIs .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [72, 81], "tok_span": [15, 19]}, {"name": "T315I", "ent_type": "variant", "char_span": [177, 182], "tok_span": [39, 43]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [133, 142], "tok_span": [28, 32]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [177, 182], "obj_char_span": [72, 81], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [15, 19]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [177, 182], "obj_char_span": [133, 142], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "In this regard , ponatinib ( formerly AP24534 ) , a multitargeted kinase inhibitor , was shown experimentally to be active against all tested BCR-ABL mutants , including T315I , in vitro .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [17, 26], "tok_span": [4, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [170, 175], "tok_span": [39, 43]}, {"name": "AP24534", "ent_type": "drug", "char_span": [38, 45], "tok_span": [11, 15]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [170, 175], "obj_char_span": [17, 26], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [4, 8]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [170, 175], "obj_char_span": [38, 45], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "However , novel compounds such as the aurora kinase inhibitors , eg , danusertib ( formerly PHA-739358 ) , homoharringtonine , and ponatinib , successfully target the T315I mutation , and clinical trials are currently being carried out , with the first results looking very promising , as reviewed elsewhere .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [131, 140], "tok_span": [37, 41]}, {"name": "T315I", "ent_type": "variant", "char_span": [167, 172], "tok_span": [45, 49]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [167, 172], "obj_char_span": [131, 140], "rel_type": "response", "sbj_tok_span": [45, 49], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Most interestingly , treatment with ponatinib resulted in a complete hematological response in 94 % and a major cytogenetic response in 63 % of the patients in a Phase I clinical trial , with pretreated CML patients including individuals harboring a T315I mutation .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [36, 45], "tok_span": [6, 10]}, {"name": "T315I", "ent_type": "variant", "char_span": [250, 255], "tok_span": [47, 51]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [250, 255], "obj_char_span": [36, 45], "rel_type": "response", "sbj_tok_span": [47, 51], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Initial data at a median follow-up of 57 days suggest that ponatinib has activity in heavily pretreated patients and in patients with the T315I mutation .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [59, 68], "tok_span": [13, 17]}, {"name": "T315I", "ent_type": "variant", "char_span": [138, 143], "tok_span": [28, 32]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [138, 143], "obj_char_span": [59, 68], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Further study is needed to determine the effect of everolimus on T315I mutated leukemia , especially in combination with a T315I inhibitor such as AP24534 ( ponatinib ) .", "entity_list": [{"name": "AP24534", "ent_type": "drug", "char_span": [147, 154], "tok_span": [32, 36]}, {"name": "T315I", "ent_type": "variant", "char_span": [65, 70], "tok_span": [13, 17]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [157, 166], "tok_span": [37, 41]}], "relation_list": [{"subject": "T315I", "object": "AP24534", "sbj_char_span": [65, 70], "obj_char_span": [147, 154], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [32, 36]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [65, 70], "obj_char_span": [157, 166], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Recently , the multi-resistant T315I mutation , which is insensitive to these TKIs , has been circumvented by ponatinib , which is highly effective on both sensitive and resistant CML cell lines , and also on BaF3 murine B cells carrying native Bcr-Abl or T315I mutation .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [110, 119], "tok_span": [25, 29]}, {"name": "T315I", "ent_type": "variant", "char_span": [31, 36], "tok_span": [6, 10]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [31, 36], "obj_char_span": [110, 119], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "T315I is a unique mutation making the CML patient irresponsive to all available TKIs but ponatinib and allografting.–", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [89, 98], "tok_span": [22, 26]}, {"name": "T315I", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [0, 5], "obj_char_span": [89, 98], "rel_type": "response", "sbj_tok_span": [0, 4], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "The clinically most notorious Abl1 mutant is T315I , which is resistant to all KIs except ponatinib ( recently approved in the US and EU ) and rebastinib ( currently studied in clinical trials ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [24, 28]}, {"name": "T315I", "ent_type": "variant", "char_span": [45, 50], "tok_span": [11, 15]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [45, 50], "obj_char_span": [90, 99], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "These include the use of second generation TKIs in case of therapeutic failure or intolerance , e.g. , Dasatinib , Nilotinib , Bosutinib and Ponatinib , the latter particularly used in case of a secondary resistance by T315I mutation ( ) .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [141, 150], "tok_span": [36, 38]}, {"name": "T315I", "ent_type": "variant", "char_span": [219, 224], "tok_span": [50, 54]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [219, 224], "obj_char_span": [141, 150], "rel_type": "response", "sbj_tok_span": [50, 54], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "§This limitation may be overcome by third-generation inhibitors such as ponatinib , which has recently shown promising results against T315I and is currently in late phase II trials .", "entity_list": [{"name": "as ponatinib", "ent_type": "drug", "char_span": [69, 81], "tok_span": [12, 17]}, {"name": "against T315I", "ent_type": "variant", "char_span": [127, 140], "tok_span": [24, 29]}], "relation_list": [{"subject": "against T315I", "object": "as ponatinib", "sbj_char_span": [127, 140], "obj_char_span": [69, 81], "rel_type": "response", "sbj_tok_span": [24, 29], "obj_tok_span": [12, 17]}], "umls_entity_list": []}, {"text": "An L576P mutation in exon 11 of KIT was identified in the clitorectomy specimen and imatinib was commenced at a 400 mg daily dose .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [84, 92], "tok_span": [21, 23]}, {"name": "L576P", "ent_type": "variant", "char_span": [3, 8], "tok_span": [1, 5]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [3, 8], "obj_char_span": [84, 92], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "The convincing clinical response observed in the patient with the L576P mutation in exon 11 ( Case 3 ) is interesting to note in the context of in vitro data demonstrating reduced sensitivity to imatinib compared with other exon 11 mutations ( ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [195, 203], "tok_span": [37, 39]}, {"name": "L576P", "ent_type": "variant", "char_span": [66, 71], "tok_span": [10, 14]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [66, 71], "obj_char_span": [195, 203], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "Three consented to undergo a clinical trial of imatinib , and one patient with an exon 17 ( D820Y ) kinase domain mutation consented to treatment with sorafenib ( off label use ) , because of predicted resistance to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [47, 55], "tok_span": [9, 11]}, {"name": "D820Y", "ent_type": "variant", "char_span": [92, 97], "tok_span": [20, 24]}, {"name": "imatinib", "ent_type": "drug", "char_span": [216, 224], "tok_span": [46, 48]}], "relation_list": [{"subject": "D820Y", "object": "imatinib", "sbj_char_span": [92, 97], "obj_char_span": [47, 55], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [9, 11]}, {"subject": "D820Y", "object": "imatinib", "sbj_char_span": [92, 97], "obj_char_span": [216, 224], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [46, 48]}], "umls_entity_list": []}, {"text": "Imatinib ( Gleevec® ) was the first compound used in therapy , but mutations on TK1 domain , known also ATP binding pocket , ( V654A , T670I gatekeeper mutations of c-kit ) led to reduced effectiveness or ineffectiveness of this treatment .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "( V654A", "ent_type": "variant", "char_span": [125, 132], "tok_span": [29, 34]}, {"name": "Gleevec®", "ent_type": "drug", "char_span": [11, 19], "tok_span": [3, 7]}, {"name": ", T670I", "ent_type": "variant", "char_span": [133, 140], "tok_span": [34, 39]}], "relation_list": [{"subject": "( V654A", "object": "Imatinib", "sbj_char_span": [125, 132], "obj_char_span": [0, 8], "rel_type": "resistance", "sbj_tok_span": [29, 34], "obj_tok_span": [0, 2]}, {"subject": "( V654A", "object": "Gleevec®", "sbj_char_span": [125, 132], "obj_char_span": [11, 19], "rel_type": "resistance", "sbj_tok_span": [29, 34], "obj_tok_span": [3, 7]}, {"subject": ", T670I", "object": "Imatinib", "sbj_char_span": [133, 140], "obj_char_span": [0, 8], "rel_type": "resistance", "sbj_tok_span": [34, 39], "obj_tok_span": [0, 2]}, {"subject": ", T670I", "object": "Gleevec®", "sbj_char_span": [133, 140], "obj_char_span": [11, 19], "rel_type": "resistance", "sbj_tok_span": [34, 39], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "We studied the role of gatekeeper mutations V654A and T670I , which are located into the activation loop ( A-loop of catalytic domain ) , in relation to the binding of therapeutic drugs ( Imatinib , Sunitinib and other important inhibitors ) .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [188, 196], "tok_span": [44, 46]}, {"name": "V654A", "ent_type": "variant", "char_span": [44, 49], "tok_span": [9, 13]}, {"name": "T670I", "ent_type": "variant", "char_span": [54, 59], "tok_span": [14, 18]}], "relation_list": [{"subject": "V654A", "object": "Imatinib", "sbj_char_span": [44, 49], "obj_char_span": [188, 196], "rel_type": "resistance", "sbj_tok_span": [9, 13], "obj_tok_span": [44, 46]}, {"subject": "T670I", "object": "Imatinib", "sbj_char_span": [54, 59], "obj_char_span": [188, 196], "rel_type": "resistance", "sbj_tok_span": [14, 18], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "The mutation T670I determines the loss of one of the H-bond between Imatinib and c-kit , consequently a weaker binding could be the reason of minor effectiveness and therefore could lead to resistance .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [68, 76], "tok_span": [17, 19]}, {"name": "T670I", "ent_type": "variant", "char_span": [13, 18], "tok_span": [2, 6]}], "relation_list": [{"subject": "T670I", "object": "Imatinib", "sbj_char_span": [13, 18], "obj_char_span": [68, 76], "rel_type": "resistance", "sbj_tok_span": [2, 6], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Ba/F3 cells expressing T674I F/P resistant to Imatinib ( IR ) have been described previously .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [46, 54], "tok_span": [15, 17]}, {"name": "T674I", "ent_type": "variant", "char_span": [23, 28], "tok_span": [6, 10]}], "relation_list": [{"subject": "T674I", "object": "Imatinib", "sbj_char_span": [23, 28], "obj_char_span": [46, 54], "rel_type": "resistance", "sbj_tok_span": [6, 10], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "EOL-1 , PC and T674I F/P Imatinib-resistant ( IR ) cells were incubated with 1×10−2 µM of human JAK2 siRNA ( Accell SMARTpool E-003146-00-0005 , Thermo Fisher Scientific , Waltham , MA , USA ) for 48 h , JAK2 mRNA and protein levels were measured using the RT-PCR and immunoblotting assays described above .", "entity_list": [{"name": "Imatinib-resistant", "ent_type": "drug", "char_span": [25, 43], "tok_span": [14, 18]}, {"name": "T674I", "ent_type": "variant", "char_span": [15, 20], "tok_span": [7, 11]}], "relation_list": [{"subject": "T674I", "object": "Imatinib-resistant", "sbj_char_span": [15, 20], "obj_char_span": [25, 43], "rel_type": "resistance", "sbj_tok_span": [7, 11], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "JAK2 inhibition blocks cellular proliferation in EOL-1 , primary F/P ( + ) CEL cells ( PC ) and T674I F/P Imatinib-resistant cells ( IR )", "entity_list": [{"name": "Imatinib-resistant", "ent_type": "drug", "char_span": [106, 124], "tok_span": [33, 37]}, {"name": "T674I", "ent_type": "variant", "char_span": [96, 101], "tok_span": [26, 30]}], "relation_list": [{"subject": "T674I", "object": "Imatinib-resistant", "sbj_char_span": [96, 101], "obj_char_span": [106, 124], "rel_type": "resistance", "sbj_tok_span": [26, 30], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "10.1371/journal.pone.0034912.g004JAK2 inhibition or knock-down by AG490 or transfection of JAK2 siRNA significantly inhibited cellular proliferation in EOL-1 , primary F/P ( + ) cells ( PC ) and T674I F/P Imatinib-resistant cells ( IR ) .", "entity_list": [{"name": "Imatinib-resistant", "ent_type": "drug", "char_span": [205, 223], "tok_span": [64, 68]}, {"name": "T674I", "ent_type": "variant", "char_span": [195, 200], "tok_span": [57, 61]}], "relation_list": [{"subject": "T674I", "object": "Imatinib-resistant", "sbj_char_span": [195, 200], "obj_char_span": [205, 223], "rel_type": "resistance", "sbj_tok_span": [57, 61], "obj_tok_span": [64, 68]}], "umls_entity_list": []}, {"text": "Second , JAK2 inhibition by AG490 or siRNA dramatically inhibited cellular proliferation and induced cellular apoptosis of the EOL-1 , primary F/P ( + ) CEL ( PC ) and T674I F/P Imatinib-resistant CEL ( IR ) cells .", "entity_list": [{"name": "Imatinib-resistant", "ent_type": "drug", "char_span": [178, 196], "tok_span": [46, 50]}, {"name": "T674I", "ent_type": "variant", "char_span": [168, 173], "tok_span": [39, 43]}], "relation_list": [{"subject": "T674I", "object": "Imatinib-resistant", "sbj_char_span": [168, 173], "obj_char_span": [178, 196], "rel_type": "resistance", "sbj_tok_span": [39, 43], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "of patients Treatment outcome c-KIT aberration 2 Complete response L576P exon 11 mutation & amp ; amplification 2 Partial response L576P exon 11 mutation & amp ; exon 13 mutations 6 Stable disease Exon 13 mutations with or without amplification 2 No response Mutations known to cause resistance to Gleevec in GIST", "entity_list": [{"name": "Gleevec", "ent_type": "drug", "char_span": [298, 305], "tok_span": [60, 63]}, {"name": "L576P", "ent_type": "variant", "char_span": [67, 72], "tok_span": [13, 17]}], "relation_list": [{"subject": "L576P", "object": "Gleevec", "sbj_char_span": [67, 72], "obj_char_span": [298, 305], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [60, 63]}], "umls_entity_list": []}, {"text": "BAY-43-9006 has also been reported to inhibit the oncogenic fusion protein of FIP1-like protein and PDGFRα that causes eosinophilic leukemia ; the T674I mutant of this fusion protein is imatinib-resistant . ", "entity_list": [{"name": "is imatinib-resistant", "ent_type": "drug", "char_span": [183, 204], "tok_span": [44, 49]}, {"name": "the T674I", "ent_type": "variant", "char_span": [143, 152], "tok_span": [34, 39]}], "relation_list": [{"subject": "the T674I", "object": "is imatinib-resistant", "sbj_char_span": [143, 152], "obj_char_span": [183, 204], "rel_type": "resistance", "sbj_tok_span": [34, 39], "obj_tok_span": [44, 49]}], "umls_entity_list": []}, {"text": "A PDGFRA mutation ( D842V ) predictive of resistance to imatinib was also identified in one GIST sample .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [56, 64], "tok_span": [14, 16]}, {"name": "D842V", "ent_type": "variant", "char_span": [20, 25], "tok_span": [5, 9]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [20, 25], "obj_char_span": [56, 64], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "More recently , Ashida et al. investigated six acral melanoma cell lines , indicating that sunitinib was better sensitive to c-kit D820Y mutant cells with the secondary resistance to imatinib while the wild type cells did not change .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [183, 191], "tok_span": [39, 41]}, {"name": "D820Y", "ent_type": "variant", "char_span": [131, 136], "tok_span": [28, 32]}], "relation_list": [{"subject": "D820Y", "object": "imatinib", "sbj_char_span": [131, 136], "obj_char_span": [183, 191], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "Work in GIST cell lines suggests that treatment with dasatinib or IPI-504 may provide a therapeutic alternative for GIST patients whose tumors carry the imatinib-resistant PDGR-F ( D842V ) mutant isoform .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [153, 171], "tok_span": [31, 35]}, {"name": "D842V", "ent_type": "variant", "char_span": [181, 186], "tok_span": [40, 44]}, {"name": "dasatinib", "ent_type": "drug", "char_span": [53, 62], "tok_span": [10, 12]}], "relation_list": [{"subject": "D842V", "object": "imatinib-resistant", "sbj_char_span": [181, 186], "obj_char_span": [153, 171], "rel_type": "resistance or non-response", "sbj_tok_span": [40, 44], "obj_tok_span": [31, 35]}, {"subject": "D842V", "object": "dasatinib", "sbj_char_span": [181, 186], "obj_char_span": [53, 62], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes SD 4.0 cetuximab , sirolimus SD 4 7 Adenocarcinoma L858R ( exon 21 ) Sensitive PIK3CA : No KRAS : No TP53 : Not done Yes PR 8.1 erlotinib , bortezomib SD 2 8 Adenocarcinoma T790M ( exon 20 ) , deletion in exon 19 Resistant , Sensitive PIK3CA : Not done", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [27, 36], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [193, 198], "tok_span": [67, 71]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [193, 198], "obj_char_span": [27, 36], "rel_type": "response", "sbj_tok_span": [67, 71], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes PR 8.1 erlotinib , bortezomib SD 2 8 Adenocarcinoma T790M ( exon 20 ) , deletion in exon 19 Resistant , Sensitive PIK3CA : Not done KRAS : No TP53 : Not done Yes PR1.9 erlotinib , cetuximab PD2 9 Adenocarcinoma L858R ( exon 21 ) Sensitive PIK3CA : No", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [200, 209], "tok_span": [69, 73]}, {"name": "T790M", "ent_type": "variant", "char_span": [72, 77], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [72, 77], "obj_char_span": [200, 209], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [69, 73]}], "umls_entity_list": []}, {"text": "A second patient ( case # 5 , Table ) with two known EGFR-sensitive mutations ( L858R and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) had a PR ( 55 % decrease ; duration=9+ months ) on erlotinib/cetuximab/bevacizumab .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [202, 233], "tok_span": [62, 74]}, {"name": "E542K", "ent_type": "variant", "char_span": [133, 138], "tok_span": [39, 43]}], "relation_list": [{"subject": "E542K", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [133, 138], "obj_char_span": [202, 233], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [62, 74]}], "umls_entity_list": []}, {"text": "Computed tomography ( CT ) scans of a NSCLC patient ( case # 5 , Table ) with two sensitive EGFR mutations ( L858R in exon 21 and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) a ) CT at baseline , and b ) CT taken 5 months after treatment initiation with erlotinib/cetuximab/bevacizumab demonstrating a PR ( -55 % ) .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [270, 301], "tok_span": [73, 85]}, {"name": "E542K", "ent_type": "variant", "char_span": [173, 178], "tok_span": [48, 52]}], "relation_list": [{"subject": "E542K", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [173, 178], "obj_char_span": [270, 301], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [73, 85]}], "umls_entity_list": []}, {"text": "Of the two EGFR mutation positive patients with a simultaneous PIK3CA mutation , one patient ( case # 5 , Table ) with an E542K mutation in exon 9 of the PIK3CA gene in addition to two sensitive EGFR mutations ( L858R and G873E in exon 21 ) , achieved a PR ( -55 % ) for 9+ months on erlotinib/cetuximab/bevacizumab .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [284, 315], "tok_span": [77, 89]}, {"name": "E542K", "ent_type": "variant", "char_span": [122, 127], "tok_span": [27, 31]}], "relation_list": [{"subject": "E542K", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [122, 127], "obj_char_span": [284, 315], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [77, 89]}], "umls_entity_list": []}, {"text": "A recently published experience found a correlation between BRAF V600E activating mutation , mutually exclusive with KRAS ones , and resistance to the treatment with cetuximab and panitumumab administered alone or in combination with chemotherapy ( ) .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [166, 175], "tok_span": [28, 32]}, {"name": "V600E", "ent_type": "variant", "char_span": [65, 70], "tok_span": [9, 12]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [65, 70], "obj_char_span": [166, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 12], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "To optimise the selection of patients who are more likely to benefit from anti-EGFR we investigated in a cohort of patients treated with the combination of cetuximab and irinotecan and bearing KRAS codons 12 and 13 wild-type tumours , the association of KRAS codons 61 and 146 mutations and BRAF V600E mutation with clinical outcomes .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [156, 165], "tok_span": [29, 33]}, {"name": "V600E", "ent_type": "variant", "char_span": [296, 301], "tok_span": [63, 66]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [296, 301], "obj_char_span": [156, 165], "rel_type": "resistance or non-response", "sbj_tok_span": [63, 66], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "We and others have recently demonstrated that the V600E mutation can also preclude responsiveness to panitumumab or cetuximab in mCRC patients and cellular models of CRC . ", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [116, 125], "tok_span": [22, 26]}, {"name": "V600E", "ent_type": "variant", "char_span": [50, 55], "tok_span": [8, 11]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [50, 55], "obj_char_span": [116, 125], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 11], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Doody and colleagues studied the activity of cetuximab with NSCLC lines bearing both wild-type EGFR and those with activating mutations in the intracellular kinase domain : not only those known to confer sensitivity to gefitinib and erlotinib ( L858R and delL747-T753insS ) but also the TKI-resistant mutation T790M .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [45, 54], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [310, 315], "tok_span": [74, 78]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [310, 315], "obj_char_span": [45, 54], "rel_type": "response", "sbj_tok_span": [74, 78], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "They found that ligand independent phosphorylation of the T790M lines was unaffected by cetuximab ( as measured by assays for phosphorylated EGFR , and downstream phosphorylated molecules Akt and MAPK ) and cellular proliferation was inhibited .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [88, 97], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [58, 63], "tok_span": [8, 12]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [58, 63], "obj_char_span": [88, 97], "rel_type": "response", "sbj_tok_span": [8, 12], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The identification of the mutations located in codons 12 and 13 , for example , 90 % of KRAS mutations in accordance with European KRAS Quality Assurance Program , is also a point to focus , according to recent studies suggesting that patients with KRAS G13D mutated tumors could benefits of cetuximab therapy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [292, 301], "tok_span": [57, 61]}, {"name": "G13D", "ent_type": "variant", "char_span": [254, 258], "tok_span": [49, 52]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [254, 258], "obj_char_span": [292, 301], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 52], "obj_tok_span": [57, 61]}], "umls_entity_list": []}, {"text": "More recently , a combination of afatinib and cetuximab , allowing for a complete EGFR blockade , has shown clinical benefit with a 36 % partial response ( PR ) rate overall and a 29 % PR rate in confirmed T790M mutations .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [46, 55], "tok_span": [9, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [206, 211], "tok_span": [44, 48]}, {"name": "afatinib", "ent_type": "drug", "char_span": [33, 41], "tok_span": [6, 8]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [206, 211], "obj_char_span": [46, 55], "rel_type": "response", "sbj_tok_span": [44, 48], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [206, 211], "obj_char_span": [33, 41], "rel_type": "response", "sbj_tok_span": [44, 48], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Furthermore , Chen et al. showed that the knockdown of T790M transcript by siRNAs , recovered the sensitivity of T790M mutant cells to TKIs , decreasing cell growth and inducing apoptosis of T790M mutant NSCLC cell line H1975 treated with TKIs , or cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [249, 258], "tok_span": [58, 62]}, {"name": "T790M", "ent_type": "variant", "char_span": [55, 60], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [55, 60], "obj_char_span": [249, 258], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [58, 62]}], "umls_entity_list": []}, {"text": "Two patients whose melanomas harbored L576P responded to dasatinib .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [57, 66], "tok_span": [13, 15]}, {"name": "L576P", "ent_type": "variant", "char_span": [38, 43], "tok_span": [7, 11]}], "relation_list": [{"subject": "L576P", "object": "dasatinib", "sbj_char_span": [38, 43], "obj_char_span": [57, 66], "rel_type": "sensitivity", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "A patient with a KIT L576P vaginal mucosal melanoma and extensive metastases to lymph nodes demonstrated a dramatic reduction in metabolic activity with Sprycel .", "entity_list": [{"name": "Sprycel", "ent_type": "drug", "char_span": [153, 160], "tok_span": [27, 30]}, {"name": "L576P", "ent_type": "variant", "char_span": [21, 26], "tok_span": [6, 10]}], "relation_list": [{"subject": "L576P", "object": "Sprycel", "sbj_char_span": [21, 26], "obj_char_span": [153, 160], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "Known mechanisms for resistance to crizotinib include the gatekeeper L1196M mutation , other secondary ALK gene mutations ( F1174L , C1156Y , G1202R , S1206Y , 1151-T-ins , and G1269A ) , ALK amplification , and activation of bypass signals via activation of other receptors ( KIT amplification and epidermal growth factor receptor (EGFR) autophosphorylation ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [35, 45], "tok_span": [6, 10]}, {"name": "F1174L", "ent_type": "variant", "char_span": [124, 130], "tok_span": [28, 32]}, {"name": "S1206Y", "ent_type": "variant", "char_span": [151, 157], "tok_span": [43, 47]}, {"name": "L1196M", "ent_type": "variant", "char_span": [69, 75], "tok_span": [15, 19]}, {"name": "G1202R", "ent_type": "variant", "char_span": [142, 148], "tok_span": [38, 42]}, {"name": "G1269A", "ent_type": "variant", "char_span": [177, 183], "tok_span": [56, 60]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [133, 139], "tok_span": [33, 37]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [124, 130], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [28, 32], "obj_tok_span": [6, 10]}, {"subject": "S1206Y", "object": "crizotinib", "sbj_char_span": [151, 157], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [6, 10]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [69, 75], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [6, 10]}, {"subject": "G1202R", "object": "crizotinib", "sbj_char_span": [142, 148], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [6, 10]}, {"subject": "G1269A", "object": "crizotinib", "sbj_char_span": [177, 183], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [56, 60], "obj_tok_span": [6, 10]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [133, 139], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Hsp90 inhibitors have been reported to overcome crizotinib resistance caused by several mechanisms , including ALK amplification , L1196M gatekeeper ALK mutation , other secondary ALK mutations ( including F1174L ) , and epithelial to mesenchymal transition .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [48, 58], "tok_span": [8, 12]}, {"name": "F1174L", "ent_type": "variant", "char_span": [206, 212], "tok_span": [41, 45]}, {"name": "L1196M", "ent_type": "variant", "char_span": [131, 137], "tok_span": [23, 27]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [206, 212], "obj_char_span": [48, 58], "rel_type": "resistance", "sbj_tok_span": [41, 45], "obj_tok_span": [8, 12]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [131, 137], "obj_char_span": [48, 58], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Since the ALK F1174L mutation has been shown to be resistant to crizotinib we then treated MYCN/KI AlkF1178L mice with vandetanib .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [64, 74], "tok_span": [16, 20]}, {"name": "F1174L", "ent_type": "variant", "char_span": [14, 20], "tok_span": [4, 8]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [14, 20], "obj_char_span": [64, 74], "rel_type": "resistance", "sbj_tok_span": [4, 8], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Our demonstration that crizotinib is active in vivo in a relevant model of NB corresponding to the R1275Q mutation is of high clinical interest .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [23, 33], "tok_span": [3, 7]}, {"name": "R1275Q", "ent_type": "variant", "char_span": [99, 105], "tok_span": [20, 24]}], "relation_list": [{"subject": "R1275Q", "object": "crizotinib", "sbj_char_span": [99, 105], "obj_char_span": [23, 33], "rel_type": "sensitivity", "sbj_tok_span": [20, 24], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Resistance to crizotinib in a patient with CD74-ROS1 fusion was already reported , apparently as a consequence of a de novo mutation of G2032R in the ROS1-kinase domain .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [14, 24], "tok_span": [2, 6]}, {"name": "G2032R", "ent_type": "variant", "char_span": [136, 142], "tok_span": [30, 34]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [136, 142], "obj_char_span": [14, 24], "rel_type": "resistance", "sbj_tok_span": [30, 34], "obj_tok_span": [2, 6]}], "umls_entity_list": []}]